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ABSTRACT
Cachexia is the unintentional loss of body weight secondary to chronic disease and is 
prevalent is roughly 50% of cancer patients. The loss of body weight and skeletal muscle 
mass is reduced functional capacity associated with reduced life quality. The etiology of 
cachexia is multimodal and complex; however, cachexia has been linked to several 
systemic (e.g. chronic inflammation, hypogonadism, anemia, insulin resistance) and 
behavioral (e.g. anorexia, inactivity) changes that can compound to accelerate muscle mass 
and body weight loss. While several inflammatory cytokines are associated with cachexia’s 
disease progression, our laboratory has established that Interleukin-6 (IL-6) is a key 
regulator of skeletal muscle mass maintenance in tumor-bearing ApcMin/+ (MIN) mice. 
Additionally, we have shown that reduced volitional activity and increased skeletal muscle 
fatigue occurs prior to significant wasting and exercise training is able to prevent IL-6-
induced cachexia in the MIN without affecting muscle inflammatory signaling. 
Furthermore, repeated muscle contractions were able to attenuate myofibrillar atrophy, and 
increase muscle oxidative metabolism without effecting the tumor environment. While the 
efficacy of exercise to improve skeletal muscle’s metabolic health during aging and disease 
has been well described, the effects of volitional activity on cancer-induced skeletal muscle 
fatigue, oxidative metabolism, and muscle inflammatory signaling is not well understood. 
The overall purpose of this study is to determine the regulation of skeletal muscle fatigue 
by activity and muscle inflammatory signaling during the progression of cachexia. Our 
central hypothesis is that cancer-induced skeletal muscle fatigue develops prior to 
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significant weight loss concomitant with decreased muscle use and disrupted muscle 
oxidative metabolism which occurs through chronically activated muscle gp130 signaling. 
Our results suggest that the onset of skeletal muscle fatigue developed prior to significant 
weight loss in MIN mice. Furthermore, elevated circulating IL-6 accelerated skeletal 
muscle fatigue and reduced muscle oxidative metabolism through muscle gp130 signaling; 
however, loss of muscle gp130 signaling was unable to improve skeletal muscle fatigue in 
MIN mice. Last, we demonstrate that there is a direct relationship between activity and 
skeletal muscle fatigability in healthy and tumor-bearing mice. Together, these results 
suggest that fatigue develops independent of weight loss and while elevated IL-6 
contributes to skeletal muscle fatigue, cancer-induced fatigue was not solely regulated by 
IL-6/muscle gp130 signaling. 
vi 
TABLE OF CONTENTS
Acknowledgements ............................................................................................................ iii 
Abstract .............................................................................................................................. iv 
List of Tables ................................................................................................................... viii 
List of Figures .................................................................................................................... ix 
List of Symbols .................................................................................................................. xi 
List of Abbreviations ........................................................................................................ xii 
Chapter 1: Review of the Literature .....................................................................................1 
 1.1: Cancer Cachexia ..................................................................................................1 
 1.2: IL-6 Family of Cytokines, Muscle gp130 Signaling, and Cancer Cachexia .......8 
 1.3: Skeletal Muscle Metabolism .............................................................................14 
 1.4: Skeletal Muscle Function ..................................................................................21 
 1.5: Skeletal Muscle Use and Cancer Cachexia .......................................................39 
Chapter 2: The impact of cachexia progression on the development of skeletal muscle 
fatigue in tumor-bearing mice ............................................................................................45 
 2.1: Abstract .............................................................................................................45 
 2.2: Introduction .......................................................................................................46 
 2.3: Methods .............................................................................................................50 
 2.4: Results ...............................................................................................................53 
 2.5: Discussion .........................................................................................................58 
Chapter 3: The role of muscle gp130 signaling in skeletal muscle fatigue during the 
progression of cachexia......................................................................................................78 
vii 
 3.1: Abstract .............................................................................................................78 
 3.2: Introduction .......................................................................................................79 
 3.3: Methods .............................................................................................................83 
 3.4: Results ...............................................................................................................90 
 3.5: Discussion .........................................................................................................94 
Chapter 4: The role of muscle use on skeletal muscle fatigue during 
cachexia progression ........................................................................................................115 
 4.1: Abstract ...........................................................................................................115 
 4.2: Introduction .....................................................................................................116 
 4.3: Methods ...........................................................................................................119 
 4.4: Results .............................................................................................................124 
 4.5: Discussion .......................................................................................................129 
Chapter 5: Overall Discussion .........................................................................................147 
 5.1: Skeletal muscle dysfunction during cachexia progression ..............................147 
 5.2: Skeletal muscle oxidative metabolism during cachexia progression ..............151 
 5.3: Summary .........................................................................................................154 
References ........................................................................................................................156 
Appendix A: Detailed Protocols ......................................................................................201 
Appendix B: Proposal ......................................................................................................223 
Appendix C: Raw Data ....................................................................................................271 
viii 
LIST OF TABLES
Table 2.1. Characteristic data of ~20-week-old male MIN and WT mice ........................63 
Table 2.2. Characteristic data of male MIN mice stratified by body weight loss..............64 
Table 2.3. Relationship between body weight loss, muscle mass, and cachexia indices in 
~20-week-old male MIN mice ...........................................................................................65 
Table 2.4. Relationship between the force and fatigability of the tibialis anterior and indices 
of cachexia in ~20-week-old male MIN mice ...................................................................66 
Table 2.5. Regression analysis of force and fatigability of the tibialis anterior and indices 
of cachexia in ~20-week old male MIN mice ....................................................................67 
Table 2.6. Relationship between the twitch properties of the tibialis anterior and indices of 
cachexia in ~20-week-old male MIN mice ........................................................................68 
Table 2.7. Regression analysis of twitch properties of the tibialis anterior and indices of 
cachexia in ~20-week old male MIN mice ........................................................................69 
Table 3.1. Characteristic data of male gp130 KO and WT with elevated IL-6..................98 
Table 3.2. The effect of elevated IL-6 on skeletal muscle’s contractile properties ...........99 
Table 3.3. The effect of elevated IL-6 on muscle fiber-type distribution ........................100 
Table 3.4. Animal characteristics of male skeletal muscle specific gp130 KO ApcMin/+ 
mice ..................................................................................................................................101 
Table 3.5 The role of the muscle gp130 receptor in cancer-induced skeletal muscle 
contractile dysfunction .....................................................................................................102
Table 4.1. Mouse body composition pre- and post-wheel access ....................................134 
Table 4.2. Behavioral and functional characteristics pre- and post-wheel access ...........135 
Table 4.3. The effect of wheel access on the characteristic data of MIN and B6 mice ...136 
Table 4.4. The effect of wheel access on skeletal muscle’s contractile properties in the MIN 
and B6 ..............................................................................................................................137 
ix 
LIST OF FIGURES
Figure 2.1. Indices of cachexia in MIN mice .....................................................................70 
Figure 2.2. The effect of cachexia on whole body and muscle specific fatigue ................72 
Figure 2.3. The effect of cachexia on maximal tetanic force .............................................73 
Figure 2.4. The effect of cachexia on specific tetanic force ..............................................74 
Figure 2.5. The effect of cachexia on the muscle force rates ............................................75 
Figure 2.6. The effect of cachexia on calcium handling gene expression .........................76 
Figure 3.1. The effect of IL-6 on skeletal muscle mitochondrial function ......................103 
Figure 3.2. The effect of IL-6 on muscle mitochondrial content .....................................104 
Figure 3.3. The effect of IL-6 on skeletal muscle force production ................................105 
Figure 3.4. The effect of IL-6 on submaximal contraction-induced skeletal muscle 
fatigability ........................................................................................................................107 
Figure 3.5. Indices of cachexia in gp130 KO MIN mice .................................................108 
Figure 3.6. The role of the muscle gp130 receptor on cancer-induced 
muscle weakness ..............................................................................................................110 
Figure 3.7. The role of the muscle gp130 receptor on cancer-induced 
muscle fatigability ............................................................................................................111 
Figure 3.8. The effect of muscle gp130 loss on mitochondrial content, function, and quality 
control in MIN mice.........................................................................................................112 
Figure 4.1 The effect of wheel access on body weight, polyp size, and plasma IL-6 .....138 
Figure 4.2 The effect of free wheel access on skeletal muscle force production in the male 
MIN ..................................................................................................................................140 
Figure 4.3 The effect of free wheel access on skeletal muscle fatigability 
in the male MIN ...............................................................................................................142 
x 
Figure 4.4 The effect of wheel access on skeletal muscle mitochondrial content in isolated 
skeletal muscle mitochondria in male MIN .....................................................................144 
Figure 4.5 The effect of wheel access on skeletal muscle mitochondrial function in the male 
MIN ..................................................................................................................................145
xi 
LIST OF SYMBOLS
Po Skeletal muscle maximal tetanic force 
 
sPo Skeletal muscle maximal specific force 
 
Lo Optimal length 
 
Lf Fiber Length 
 
± Plus or Minus 
 
α Alpha 
 
β Beta 
 
κ Kappa 
 
º Degrees 
 
p Probability of type 1 error 
 
% Percent 
xii 
LIST OF ABBREVIATIONS
Akt.............................................................................................................. Protein Kinase B 
AMP ........................................................................................... Adenosine Monophosphate 
AMPK .................................................................................. AMP-activated Protein Kinase 
ANOVA ............................................................................................... Analysis of Variance 
APC ......................................................................................... Adenomatous Polyposis Coli 
ATP ................................................................................................ Adenosine Triphosphate 
BCL ............................................................................................................. B-cell Lyphoma 
Bnip ............................................................................................... BCL2 interacting protein  
BW ................................................................................................................... Body Weight 
C ................................................................................................................................ Control 
C/EBPβ ......................................................................... CCAAT Enhancer Binding Protein 
C-26...................................................................................................... Colon-26 Carcinoma 
CHF ............................................................................................... Congestive Heart Failure 
CLC .......................................................................................... Cardiotrophin-like Cytokine 
CNTF .......................................................................................... Ciliary Neurotropic Factor 
COPD .................................................................... Chronic Obstruction Pulmonary Disease 
CSA ...................................................................................................... Cross Sectional Area 
CT-1 ............................................................................................................. Cardiotrophin 1 
CX .......................................................................................................................... Cachectic 
DHPR .......................................................................................... Dihydropyridine Receptor 
DNA .................................................................................................. Deoxyribonucleic acid 
xiii 
+dP/dt ................................................ Change in Force/Change in Time during Contraction 
-dP/dt .................................................. Change in Force/Change in Time during Relaxation 
DRP ...............................................................................................Dynamin-Related Protein 
EC ..................................................................................................... Excitation Contraction 
ECM ...................................................................................................... Extracellular Matrix 
EDL ........................................................................................... Extensor Digitorum Longus 
Erk 1/2 .......................................................................... Extracellular signal-related Kinases 
FAP .................................................................................. Familial Adenomatous Polyposis 
FDA.............................................................................................. Federal Drug Association 
Fis .................................................................................................................. Fission Protein 
FOXO .......................................................................................................... Forkhead Box O 
g................................................................................................................................... Grams 
GAPDH ........................................................... Glyceraldehyde 3-phosphate dehydrogenase 
gp130......................................................................................................... Glycoprotein 130 
GRIM ................................................ Genes Associated with Retinoid-interferon Mortality 
GTP ................................................................................................ Guanosine Triphosphate 
H+ ................................................................................................................... Hydrogen ion 
HA ................................................................................................................... High Activity 
HSA............................................................................................ Human alpha-skeletal actin 
IFN .........................................................................................................................Interferon 
iKO ..........................................................................................................Inducible knockout 
IL-6 ................................................................................................................... Interleukin 6 
iNOS .................................................................................. Inducible Nitric Oxide Synthase 
JAK ...................................................................................................................Janus Kinase 
kN/m2 ................................................................................................... Kilonewtons/meters2 
xiv 
KO .......................................................................................................................... Knockout 
LA .................................................................................................................... Low Activity 
LC3 ................................................. Microtubule-associated proteins 1A/1B light chain 3B 
LIF............................................................................................. Leukemia Inhibitory Factor 
LLC .................................................................................................. Lewis Lung Carcinoma 
LPS ........................................................................................................ Lipo-polysaccharide 
MAPK ........................................................................... Mitogen Activated Protein Kinases 
Mfn ....................................................................................................................... Mitofusion 
mg ........................................................................................................................ Milligrams 
MHC ................................................................................................... Myosin Heavy Chain 
MIN .......................................................................................................................... ApcMin/+ 
MLC ...................................................................................................... Myosin Light Chain 
MMP ............................................................................................. Matrix Metalloproteinase 
mN.................................................................................................................... Millinewtons 
mRNA ..................................................................................... Messenger Ribonucleic Acid 
ms ...................................................................................................................... Milliseconds 
mTORC ........................................................... Mechanistic Target of Rapamycin Complex 
NFAT ............................................................................ Nuclear Factor of Activated T cells 
NF-κB ..................................................................................................... Nuclear Factor κ B 
NMJ................................................................................................ Neuromuscular Junction 
NOS.................................................................................................... Nitric Oxide Synthase 
NRF ............................................................................................... Nuclear Response Factor 
OPA.................................................................................................... Optic Atrophy Protein 
OSM ................................................................................................................. Oncostatin M 
p..................................................................................................................... Phosphorylated 
xv 
PBS ............................................................................................. Phosphate Buffered Saline 
PCr .............................................................................................................. Phosphocreatine 
PGC-1 ........................... Peroxisome-Proliferator Gamma-Activated Receptor Coactivator 
ROS ............................................................................................... Reactive Oxygen Species 
RT ............................................................................................................... Relaxation Time 
RT-PCR................................................................... Real Time Polymerase Chain Reaction 
RvR ....................................................................................................... Ryanodine Receptor 
SD ...........................................................................................................Standard Deviation 
SDH.............................................................................................. Succinate Dehydrogenase 
SEM ........................................................................................... Standard Error of the Mean 
SERCA ..................................................... Sacro(endo)plasmic Reticulum Calcium ATPase 
skm ............................................................................................................... Skeletal Muscle 
Smad3 .......................................................... Mothers Against Decapentaplegic Homolog 3 
SR ......................................................................................... Sarco(endo)plasmic Reticulum 
STAT3..................................................Signal Transducer and Activator of Transcription 3 
t ..................................................................................................................................... Total 
TA ............................................................................................................... Tibialis Anterior 
TBST .................................................................................... Tris Buffered Saline-Tween 20 
TFAM ....................................................................... Mitochondrial Transcription Factor A 
TGF ......................................................................................... Transforming Growth Factor 
TNF .................................................................................................. Tumor Necrosis Factor 
TPT ...................................................................................................... Time to Peak Twitch 
WA .................................................................................................................. Wheel Access 
WS................................................................................................................... Weight Stable 
 1 
CHAPTER 1
REVIEW OF THE LITERATURE 
1.1 – Cancer Cachexia 
Overview 
Cachexia is a complex wasting disorder characterized by the unintentional loss of 
body weight and muscle mass secondary to chronic disease (Evans et al. 2008). While 
cachexia can develop in patients with renal failure, human immunodeficiency virus and 
acquired immune deficiency syndrome, heart failure, and chronic obstructive pulmonary 
disease (Dahele and Fearon 2004; Deans and Wigmore 2005; Evans et al. 2008), cachexia 
affects roughly 80% of cancer patients and is responsible for over 20% of all cancer-related 
deaths (Argiles 2012; Tisdale 2002; Fearon 2008). The prevalence and severity of cachexia 
is largely dependent on the cancer type, with the highest prevalence in head and neck, lung, 
and gastrointestinal cancers (esophageal, pancreatic, colon, etc.) and the lowest prevalence 
in breast cancers (Deans and Wigmore 2005; Evans et al. 2008; von Haehling and Anker 
2014; Vigano et al. 2000; Fearon 2008). Additionally, the etiology and progression of 
cachexia are unique within different cancer types and can present differently with each 
patient (Monitto et al. 2001). Cancer patients that experience significant weight loss are 
less likely to be functionally independent, have a low tolerance to chemotherapeutic 
interventions, and have a low life quality, which all negatively impact disease prognosis 
(Vigano et al. 2000; Winningham et al. 1994; Stene et al. 2015; O'Gorman, McMillan, and 
McArdle 1999; Montazeri 2009; Tisdale 2002). Currently, there are no FDA approved 
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treatments for cachexia, likely due to the disparity across cancer types as well as the 
complexity and multimodal nature of the disease. 
Cachexia is associated with systemic disruptions including chronic inflammation, 
anemia, hypogonadism, and insulin resistance (Evans et al. 2008). Cachectic patients also 
demonstrate behavioral changes including anorexia and physical inactivity; however, 
whether these behavioral changes are causal, or consequence of cachexia progression and 
the systemic disruptions remains inconclusive (Evans et al. 2008; Muscaritoli et al. 2010). 
Each of these systemic and behavioral changes can both independently and synergistically 
affect the mass, metabolism, and functional properties of skeletal muscle (Evans et al. 
2008). The maintenance of skeletal muscle mass, metabolism, and function have 
established roles in physiological and pathological conditions including obesity, ageing, 
and chronic disease (Wolfe 2006; Romanello and Sandri 2015; Carson, Hardee, and 
VanderVeen 2016). While cachexia’s etiology continues to be unearthed, the loss of 
muscle mass and functional quality are thought to develop primarily through disruptions 
to muscle metabolic homeostasis (Tisdale 2009). Disruptions to muscle protein turnover 
(i.e. accelerated muscle protein catabolism and suppressed anabolism) has been a primary 
target for cancer-cachexia therapeutics; however, several therapies have failed in clinical 
trials due to the inability to improve skeletal muscle function (al-Majid and McCarthy 
2001a; Christensen et al. 2014; Aversa, Costelli, and Muscaritoli 2017; Biolo, Cederholm, 
and Muscaritoli 2014; Dobs et al. 2013; Ramage and Skipworth 2018). 
Cachexia-induced skeletal muscle mass loss is associated with the reduced ability 
to perform activities of daily living which eventually leads to a loss of functional 
independence and markedly reduces life quality (Vigano et al. 2000; Evans et al. 2008; 
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Moses et al. 2004; Fearon KC 2006; Argiles 2014; Amano et al. 2017). Chronic 
inflammation, anemia, and hypogonadism, hallmarks of cancer-cachexia, can each lead to 
functional decrements without necessarily affecting muscle mass (Argiles et al. 2009; 
Fearon 2008; Evans et al. 2008; Tisdale 2002; Muscaritoli et al. 2010). Cancer patients, 
regardless of cachexia diagnosis, have increased perceived (central) fatigue and decreased 
functional independence which are negatively associated with life quality and survival (al-
Majid and McCarthy 2001a; Stone et al. 1999; O'Gorman, McMillan, and McArdle 1999; 
von Haehling and Anker 2014; Christensen et al. 2014; Winningham et al. 1994; 
Muscaritoli et al. 2010). While there are no treatments currently approved for cancer 
cachexia, improving our mechanistic understanding of cachexia-induced muscle wasting, 
metabolic dysfunction, and more recently contractile dysfunction, should provide vital 
insight necessary for the development of successful therapeutic interventions (Dahele and 
Fearon 2004). The overall goal of this literature review is to outline our current 
understanding of cancer-induced skeletal muscle metabolic and contractile dysfunction and 
their regulatory mechanisms during the progression of cachexia. Additionally, the efficacy 
for exercise to prevent and/or treat cancer-induced skeletal muscle metabolic and 
contractile dysfunction will be discussed. 
 
Pre-clinical Models of Cancer Cachexia 
The high prevalence of cachexia in cancer patients and strong relationship between 
muscle mass loss and morbidity/mortality with disease progression provides significant 
rationale to investigate the molecular mechanisms of this complex disorder aimed at 
identifying successful therapeutic targets and improve patient life quality and survival 
 4 
(Tisdale 2002; Fearon KC 2006). There are inherent difficulties to examining the 
mechanisms of a comorbidity like cachexia. Clinically, patients are treated first for the 
primary disease and these treatments often affect the comorbidities which serves as a 
consistent barrier to understanding the comorbidities underlying mechanisms alone (Penna, 
Busquets, and Argiles 2016). As previously stated, the development of cachexia is not 
ubiquitous across cancer types, nor does every patient within a certain cancer type develop 
cachexia in the same fashion (Fearon KC 2006). Additionally, patients often suffer from 
weight loss prior to cancer diagnosis, making it difficult to understand the progression of 
the disease (Bruera 1997; Tisdale 2002; Kritchevsky et al. 1991). Lastly, upon cancer 
diagnosis, patients are prescribed a specific and tightly regulated treatment regimen that 
often involve radiation, chemotherapy, and/or surgery, all of which can negatively impact 
body weight, muscle mass, and muscle function (Barreto et al. 2016; Barreiro et al. 2002). 
To elude these existing barriers, several preclinical models have been developed to 
understand the progression and underlying mechanism of cancer-induced cachexia 
(Deboer 2009; Penna, Busquets, and Argiles 2016). While there are inherent limitations to 
animal pre-clinical models, significant progress has been made in our understanding of the 
disease largely in part due to the development of genetic and tumor implant rodent models. 
Furthermore, mechanistic investigations with the use of in vitro strategies involving tumor 
cell-cultured media and specific cachectic factors further our understanding of the signaling 
pathways associated with muscle wasting. The following 2 sections will review the mouse 
and rat models that have been commonly used in cancer cachexia studies.  
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Tumor Implant Models of Cancer Cachexia  
Over the last few decades, several mechanistic investigations of cachexia have 
utilized tumor-implant models (Puppa, Gao, et al. 2014; Monitto et al. 2001; Judge et al. 
2014; Ekman et al. 1982; Jaweed et al. 1983; Talbert et al. 2014). These models are cost 
and time effective and provide several distinct advantages to understanding cancer induced 
muscle wasting. Two commonly used tumor cell lines that induce a cachectic phenotype 
are Lewis Lung Carcinoma (LLC) cells implanted into a mouse with a C57BL/6 genetic 
background, and the Colon-26 carcinoma (C-26) implanted into mice with either a Balb/c 
or CD2F1 genetic background (Talbert et al. 2014; Puppa, Gao, et al. 2014). While the 
LLC and C-26 are the most commonly used models, several other tumor cell lines have 
been developed to model cancer cachexia using a tumor implantation including the Walker 
256, MAC16, AH-130, and B16 melanoma lines (Deboer 2009; Penna, Busquets, and 
Argiles 2016). All these implant models involve the tumor cells to be isolated and cultured 
in vitro and then injected into the flank of the mouse with the appropriate genetic 
background. Only a few days after tumor cell implantation, a mass is palpable at the 
injection site and significant wasting can be achieved within 14 days with the C-26 and 28 
days with the LLC (Penna, Busquets, and Argiles 2016; Deboer 2009; Gao and Carson 
2016; Puppa, Gao, et al. 2014; Seto, Kandarian, and Jackman 2015). In addition to the 
different rates of cachexia development between LLC and C-26, their etiologies are 
distinct. For example, C-26 induced muscle wasting appears to be associated with the 
interleukin-6 (IL-6) family of cytokine members, IL-6 and leukemia inhibitory factor 
(LIF), while tumor necrosis factor (TNF) and IL-6 levels have been linked to LLC induced 
cachexia progression (Carson and Baltgalvis 2010; Gao and Carson 2016; Seto, Kandarian, 
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and Jackman 2015). Several tumor implant models have also been developed for analysis 
in rat models of cancer induced wasting which have their own distinct advantages and 
disadvantages when compared to the mouse. Rat tumor implant models primarily include 
the methylcholanthrene sarcoma cells (Ekman et al. 1982) and Yoshida AH-130 hepatoma 
(Busquets et al. 2000). The rat tumor implant models demonstrate significant body weight 
and muscle mass loss after only seven days of tumor implantation. However, the use of rat 
models is advantageous for several models of exercise intervention/prevention. 
Additionally, there is the added benefit of significantly greater blood volume and tissue 
size compared to the mouse with allows for the analysis of several cachexia-associated 
targets within one cohort of animals. 
A distinct advantage of the LLC mouse model of cancer cachexia is the ease of 
incorporating genetically modified knockout mice using C57BL/6 mice. This allows the 
investigator to examine the role of certain cachectic factors in the wasting process with 
relative ease (Pin et al. 2015; Puppa, Gao, et al. 2014; Zhang, Jin, and Li 2011). While rat 
models and the C-26 tumor implant model provides a shorter duration of cachexia 
progression, these models lack the ease of genetic manipulation through breeding. 
However, to elude these disadvantages, significant progress has been made in the 
developments of plasmid electroporation or an adeno-associated virus to mechanistically 
understand the wasting of C-26 and rat models (Cornwell et al. 2014; Seto, Kandarian, and 
Jackman 2015; Judge et al. 2014). Together, these tumor implant models have dramatically 
improved our mechanistic understanding of skeletal muscle wasting with cancer. 
While preclinical models cannot perfectly mirror the human condition, LLC and C-
26 tumor bearing mice exhibit body weight, muscle mass, and adipose tissue loss 
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associated with high levels of systemic inflammation and disrupted whole-body and muscle 
metabolism similar to cancer patients (Deboer 2009). While the presence of systemic 
inflammation remains consistent across cachexia models, their individual inflammatory 
cytokine profiles are distinct. While initially this may appear to be a limitation, the diversity 
between models is translatable as cancer patients have a similar range in inflammatory 
cytokine profiles depending on the cancer type and host genome (Argiles et al. 2009). 
 
Genetically Modified Mouse Models of Cancer Cachexia 
The ApcMin/+ (MIN) mouse is an established model of colorectal cancer, or more 
specifically, familial adenomatous polyposis (FAP) (Moser, Pitot, and Dove 1990). MIN 
mice have a nonsense germline mutation in the Adenomatous polyposis coli (Apc) gene 
which predisposes mice to multiple intestinal neoplasia resulting in the development of 
intestinal polyps. Polyps develop at as early as 4 weeks of age and the number of polyps 
plateau by approximately 12 weeks of age while polyp size continues to increase (Moser, 
Pitot, and Dove 1990; McClellan et al. 2012). Depending on the size and number of 
intestinal polyps, mice will initiate body weight loss around 16 weeks and significant body 
weight loss is present between 18-26 weeks (Baltgalvis 2010). The MIN mouse has been 
commonly used in cancer/tumor-cell biology since its discovery in 1990. This model is 
advantageous as ~70% of FAP patients have a similar mutation to the Apc gene that 
predisposes them to several polyps in the colon which can become malignant over time 
(Moser, Pitot, and Dove 1990; Aihara, Kumar, and Thompson 2014). While there are 
inherent differences between the MIN mouse and FAP patients, our laboratory and others 
have demonstrated significant body weight loss, muscle and fat mass loss, high systemic 
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inflammation, hypogonadism, and fatigue similar to that observed in colorectal cancer 
patients that experience cachexia (Baltgalvis et al. 2008; Baltgalvis et al. 2009; Baltgalvis 
2010; Ravasco, Monteiro-Grillo, and Camilo 2007).  
The MIN mouse provides an advantage for therapeutic investigations as the onset 
and progression of cachexia occurs over several weeks compared to the rapid wasting that 
occurs with tumor-implant models (Baltgalvis 2010). As previously stated, the progression 
and severity of cachexia in the MIN mouse is related to the tumor number and size; 
however, our laboratory has demonstrated the cachexia in the MIN mouse is dependent on 
circulating IL-6 levels (Baltgalvis et al. 2008; White, Baltgalvis, et al. 2011). The loss of 
body weight over time is associated with both muscle and fat mass loss in addition to loss 
of testes and seminal vesicle mass in males (White JP 2013; Hardee, Counts, et al. 2018). 
Interestingly, the initiation and progression of cachexia in male and female MIN mice are 
unique. While IL-6 was sufficient to accelerate cachexia progression in the male MIN 
mouse, IL-6 was not correlated to wasting in the female and IL-6 over expression had no 
effect on body weight of muscle mass (Hetzler et al. 2015). These sex differences are an 
intriguing area of investigation that requires additional work. Additionally, the MIN mouse 
is bread on the C57BL/6 background which, similar to the LLC mouse, provides the 
advantage of readily available genetic knockouts. 
 
1.2 – IL-6 Family of Cytokines, Muscle gp130 Signaling, and Cancer Cachexia 
Inflammation Overview 
Inflammation is broadly defined as a physiological immune response that results in 
the accumulation of immune cells, plasma proteins, and fluid in a target tissue; however, 
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chronic or pathological, often low-grade, inflammation is associated with increased 
morbidity and mortality with aging and disease (Abbas, Lichtman, and Pillai 2015; 
Franceschi et al. 2000; Franceschi and Campisi 2014). Chronically elevated systemic 
inflammation is one of the established drivers of cachexia development across several 
chronic diseases (Evans et al. 2008). While understanding broad, general inflammation 
provides some mechanistic insight into the cachectic condition, several inflammatory 
mediators, namely cytokines, have established roles in muscle mass loss in both cancer 
patients and pre-clinical cachexia models (Argiles et al. 2009; Belizario et al. 2016; Carson 
and Baltgalvis 2010). Out of the numerous pro-inflammatory cytokines that exist, the 
interferon (IFN), transforming growth factor (TGF), TNF, IL-1 and 6 superfamilies’ have 
emerged as critical regulators of muscle mass and metabolism during cachexia progression 
(Carson and Baltgalvis 2010; Chen et al. 2016; Loumaye et al. 2015; Mueller et al. 2016; 
Onesti and Guttridge 2014; Patel and Patel 2017; Pal, Febbraio, and Whitham 2014; Reid 
and Li 2001; Rodriguez et al. 2014; Sandri 2008). 
 
IL-6 Family of Cytokines and Muscle gp130 Signaling 
Circulating pro-inflammatory cytokines affect several physiological processes 
through binding to either a soluble or membrane bound receptor to stimulate intracellular 
signaling in numerous target tissues (Argiles et al. 2009; Glass 2005; Rose-John 2018; 
Argiles, Busquets, and Lopez-Soriano 2005; Puigserver et al. 2001). Indeed, several 
inflammatory mediators, including the IL-6 family of cytokines, have been widely 
investigated in skeletal muscle physiology and pathophysiology for its role in the 
regulation of muscle mass, recovery/regeneration, and metabolic homeostasis during 
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exercise, aging, and disease (Carson and Baltgalvis 2010; Flint et al. 2016; Zimmers, 
Fishel, and Bonetto 2016; Narsale and Carson 2014; Pedersen 2012; Febbraio et al. 2004; 
Puigserver et al. 2001). The IL-6 family of cytokines includes IL-6, IL-11, IL-27, LIF, 
ciliary neurotropic factor (CNTF), oncostatin M (OSM), cardiotrophin 1 (CT-1), and 
cardiotrophin-like cytokine (CLC) (Rose-John 2018). Apart from the rest, elevated 
circulating levels of IL-6, LIF, and CNTF have been demonstrated in cancer patients and 
preclinical cachexia models and therefore will be the primary focus of this review (Argiles 
et al. 2009). It is important to note, however, that there is considerable overlap between 
inflammatory cytokine families as to the intracellular inflammatory signaling proteins that 
can be activated (Argiles et al. 2009; De Paepe and De Bleecker 2013; Spate and Schulze 
2004). Therefore, when the direct role of IL-6 is not well understood, evidence garnered 
from other inflammatory mediators will be discussed as rationale for further investigation. 
IL-6 has been described as a pleiotropic cytokine and has been implicated as a 
critical regulator of inflammation-induced skeletal muscle remodeling during and 
following exercise (Washington TA 2011; White JP 2009; Mihara M 2012; Febbraio and 
Pedersen 2002) as well as contributes to skeletal muscle (and fat) wasting during chronic 
disease (Pal, Febbraio, and Whitham 2014; Mihara M 2012; Carson and Baltgalvis 2010). 
The IL-6 family of cytokines bind to their respective receptors (e.g. IL-6R, LIFR, CNTFR) 
which allows for heterodimerization with the ubiquitously expressed glycoprotein 130 
(gp130) receptor (Schwantner et al. 2004). The IL-6 and gp130 receptors are 
transmembrane receptors that have no protein kinase activity; however, are constitutively 
associated with the tyrosine kinase, Janus kinase (JAK) (Schwantner et al. 2004; Rose-
John 2018). Specific to skeletal muscle, once the cytokine binds and the gp130 receptor 
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heterodimerizes, JAK phosphorylates immediate downstream target signal transducer and 
activator of transcription 3 (STAT3). Once activated, STAT3 can translocate to the nucleus 
and initiate the transcription of several target genes (Schwantner et al. 2004; Carson and 
Baltgalvis 2010). In addition to STAT3, IL-6 family of cytokines signaling through gp130 
has been demonstrated to activate protein kinase B (Akt) and mitogen activated protein 
kinases (MAPK), which include extracellular signal-related kinases (Erk 1/2) and p38 
(Bonetto A 2012; Carson and Baltgalvis 2010; Gao et al. 2017). Intracellular signaling 
through STAT3, Akt, and MAPK modulate skeletal muscle mass and metabolism through 
the regulation of protein synthesis, mitochondrial dynamics, and cell proliferation (Gao et 
al. 2017; Fix et al. 2018). 
 
IL-6 Family of Cytokines, Muscle gp130 Signaling, and Cancer Cachexia 
Both systemic inflammation and muscle inflammatory signaling have been 
extensively examined for their regulation of muscle wasting with cancer (Tisdale 2002; 
Evans et al. 2008; Carson and Baltgalvis 2010; VanderVeen, Fix, and Carson 2017; Argiles 
et al. 2009; Argiles 2014; Deans and Wigmore 2005; Sandri 2008; Onesti and Guttridge 
2014). Chronic inflammation has been linked to disrupted muscle protein turnover and 
oxidative metabolism, which are both integral to the pathology of muscle mass loss during 
cachexia progression (White, Baltgalvis, et al. 2011; Carson, Hardee, and VanderVeen 
2016; Argiles et al. 2009; White, Baynes, et al. 2011; Deans and Wigmore 2005; Seto, 
Kandarian, and Jackman 2015; Cannon TY 2007; Onesti and Guttridge 2014; Fearon, 
Glass, and Guttridge 2012). Although many systemic mediators of cancer cachexia appear 
to be associated with specific preclinical models and cancer types, IL-6 has been implicated 
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as a driver of cachexia in cancer patients and preclinical models including the MIN and C-
26 mouse (Carson and Baltgalvis 2010). To this end, elevated circulating IL-6 can be 
observed in cachectic cancer patients and pre-clinical models alike and is strongly 
correlated to body weight and muscle mass loss (Fortunati et al. 2007; Baltgalvis et al. 
2009; Seto, Kandarian, and Jackman 2015). Systemic overexpression of IL-6 in the MIN 
mouse is sufficient to accelerate the cachectic phenotype, while IL-6 null MIN mice had 
no significant muscle mass loss (Baltgalvis et al. 2008). Additionally, administration of an 
IL-6 receptor antibody in C-26 mice attenuated muscle mass loss associated with reduced 
ubiquitin-dependent proteolytic pathways (Fujita et al. 1996). Recent evidence suggests 
LIF, another member of the IL-6 family, modulates cachexia progression in both LLC and 
C-26 tumor-bearing mice (Jackman et al. 2017; Seto, Kandarian, and Jackman 2015; Mori 
et al. 1991; Gao and Carson 2016; Kandarian et al. 2018). 
Downstream muscle gp130 signaling through STAT3 and MAPK have received 
significant mechanistic investigation for their roles in cancer cachexia. Loss of the muscle 
gp130 receptor in LLC tumor-bearing mice had suppressed muscle STAT3 and p38 
activation associated with improved muscle mass. Constitutively active muscle specific 
STAT3 was sufficient to induce skeletal muscle mass loss in both tumor-bearing and 
tumor-free mice, while STAT3 inhibition attenuated body weight and muscle mass loss in 
tumor bearing mice (White, Baynes, et al. 2011; Bonetto A 2012; Miller et al. 2016). 
Furthermore, IL-6 null MIN mice did not lose body weight or muscle mass and had 
suppressed muscle STAT3 activation; however, STAT3 did not return to the expression 
level of healthy controls (Baltgalvis et al. 2008). Interestingly, elevated muscle protein 
degradation was still present in both gp130 loss in the LLC and the IL-6 null MIN mouse 
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(Puppa, Gao, et al. 2014). These results suggest that IL-6 and muscle gp130 signaling are 
not the sole regulators of the cachectic condition and other inflammatory mediators’ 
compound with IL-6 to exacerbate the cachectic condition (Baltgalvis et al. 2008; 
Baltgalvis et al. 2009). 
The role of MAPK signaling in cancer-induced muscle wasting has received 
significant investigation; however, the role of MAPK signaling in cancer-induced muscle 
wasting appears dependent on tumor type and the treatment vehicle. The induction of 
protein degradation through the E3 ligase, Atrogin-1, during LLC-induced cachexia is 
regulated by the p38-MAPK-C/EBPβ (CCAAT enhancer binding protein) signaling axis 
and loss of muscle C/EBPβ attenuated muscle mass loss through suppressed proteasomal 
proteolysis (Zhang, Jin, and Li 2011). While administration of the MAPK inhibitor, 
PD98059, to C-26 tumor bearing mice attenuated muscle mass loss associated with 
improved muscle myogenesis (Penna et al. 2010), the MAPK inhibitor, Selumetinib, had 
no effect on muscle mass in LLC tumor-bearing mice (Au et al. 2016). Lastly, 
administration of the MAPK inhibitor, MEK162, attenuated muscle mass loss concomitant 
with reduced atrophy associated genes (Talbert et al. 2017). 
The role of muscle inflammatory signaling in cachexia-induced muscle wasting 
continues to be an active area of investigation. The IL-6 family of cytokines and associated 
muscle gp130 signaling through STAT3 and MAPK appear to regulate skeletal muscle 
mass during cachexia progression through modulation of muscle metabolism and protein 
turnover. Due to the complexity of the disease and diversity in cancer types, additional 
work is needed to determine the efficacy of treatments targeting these signaling pathways. 
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1.3 – Skeletal Muscle Metabolism 
Overview 
Skeletal muscle metabolism is the net chemical reactions that occur within skeletal 
muscle; however, the current review refers to skeletal muscle metabolism in regard to the 
fuel metabolism necessary to produce ATP to meet the energy demand of skeletal muscle. 
Holistically, skeletal muscle metabolism has a vital role in the maintenance of 
physiological health and metabolic homeostasis in several disease conditions including 
obesity, ageing, and chronic disease (Wolfe 2006; Romanello and Sandri 2015). 
Additionally, skeletal muscle makes up roughly 40% of total body weight in a healthy adult 
and accounts for 20-30% of whole-body resting energy expenditure (Zurlo et al. 1990). 
While skeletal muscle can serve as an amino acid reservoir during energy stress, skeletal 
muscle is also a glucose sink. Skeletal muscle is the primary site of insulin stimulated 
glucose transport and is a key regulator of whole-body glucose homeostasis (Kummitha et 
al. 2014; Wolfe 2006). Along with its role in glucose homeostasis, at rest and low-intensity 
activity skeletal muscle relies on beta-oxidation of fatty acids as a primary a fuel source 
(Kummitha et al. 2014). As the duration and intensity of activity increases, skeletal 
muscle’s primary fuel source shifts towards glycolytic pathways although still account for 
as much as 90% of whole body oxygen uptake during high-intensity activity (Zurlo et al. 
1990). The modulation and disruption of these phenomena remains an active area of 
investigation across several physiological and pathological conditions. 
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Skeletal Muscle Oxidative Metabolism 
Skeletal muscle oxidative metabolism is determined by the muscle’s mitochondria 
content and ATP production efficiency, which along with free radical production, defines 
mitochondrial function. In addition to oxidative metabolism, mitochondria have an 
established role the regulation of muscle apoptosis, autophagy, and protein turnover 
(Romanello and Sandri 2013). The relative content and function of the muscle’s 
mitochondria align with the muscle’s contractile phenotype and myosin heavy chain 
isoform expression which are described in later sections (Schiaffino and Reggiani 1996). 
The unique plasticity of skeletal muscle allows for mitochondrial content and function to 
be modulated by several different stimuli including muscle use, systemic inflammation, 
and circulating hormones (Holloszy and Coyle 1984; Thomason and Booth 1990). 
Furthermore, this plasticity involves the regulation of mitochondrial content and function 
through the modulation of mitochondrial dynamics, mitophagy, and biogenesis regulation, 
which collectively define mitochondrial quality control (Deng and Haynes 2017; Picca et 
al. 2017). 
The regulation of mitochondrial dynamics involves the coordination of 
mitochondrial fission and fusion, or the addition and fragmentation of a mitochondrion to 
and from the mitochondrial network, respectively (Romanello and Sandri 2015; Youle and 
van der Bliek 2012; Iqbal et al. 2013; Drake, Wilson, and Yan 2016). Mitochondrial fusion 
is regulated by the GTPases Mitofusin 1 and 2 (MFN-1, MFN-2) and optic atrophy protein 
1 (OPA1) (Drake, Wilson, and Yan 2016; Yan, Lira, and Greene 2012). While MFN-1 and 
MFN-2 have a similar structure, MFN-1 plays a greater role in the fusion of the outer 
mitochondrial membrane and MFN-2 regulates GTP hydrolysis required for this dynamic 
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process (Romanello and Sandri 2015; Iqbal and Hood 2015; Carson, Hardee, and 
VanderVeen 2016). Mitochondrial fission machinery is controlled by the GTPase cytosolic 
dynamin-related protein 1 (DRP-1) which can translocate to the outer mitochondrial 
membrane and develop active fission sites (Jheng et al. 2012; Romanello et al. 2010; 
Romanello and Sandri 2015; Wu et al. 2011; Youle and van der Bliek 2012; Iqbal and 
Hood 2015). Fission protein 1 (FIS1) is required for mitochondrial division by signaling 
DRP-1 to translocate the outer mitochondrial membrane (Iqbal and Hood 2015). 
Disruptions to mitochondrial dynamics through accelerated fission and/or reduced fusion 
results in a relative increase in isolated mitochondria from the network which reduces 
mitochondrial ATP production efficiency (Youle and van der Bliek 2012).  
Mitochondrial biogenesis is a critical process necessary for maintaining an 
adequate abundance of skeletal muscle mitochondria in order to sustain the energy 
demands of the cell (Baar 2004; Garnier et al. 2005; Romanello and Sandri 2015; Wu et 
al. 1999). The peroxisome-proliferator gamma-activated receptor coactivator (PGC-1) has 
been extensively examined as the critical regulator of skeletal muscle mitochondrial 
biogenesis (Puigserver and Spiegelman 2003). PGC-1 and  isoforms have been 
demonstrated to regulate oxidative metabolism independently. PGC-1 can regulate 
myosin heavy-chain isoform expression, and increased expression by transgenic 
overexpression induced an oxidative muscle phenotype (Arany et al. 2007). PGC-1 can 
induce nuclear response factors (NRF-1,2) and mitochondrial transcription factor A (Tfam) 
transcription, which both transcriptionally regulate the expression of mitochondrial 
associated genes (Wu et al. 1999; Lin et al. 2002; Puigserver and Spiegelman 2003; Baar 
2004). Moreover, the stimulation of mitochondrial biogenesis by PGC-1 can increase 
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mitochondrial content and the loss of PGC-1 results in decreased relative muscle 
mitochondrial content and suppressed muscle ATP production (Joseph et al. 2006; Lira et 
al. 2010; Vainshtein et al. 2015). 
The autophagic removal of damaged and dysfunctional mitochondria is termed 
mitophagy (Jokl and Blanco 2016; Kimura et al. 2007; Carson, Hardee, and VanderVeen 
2016). Autophagy can be described as both general or specific, wherein specific organelles, 
including mitochondria, can be targeted for degradation. The induction of p62, B-cell 
Lyphoma (BCL2) interacting protein 3 (Bnip3), and microtubule-associated proteins 
1A/1B light chain 3B (LC3)-interacting domains are responsible for the intracellular 
degradation of organelles (Luo et al. 2014; Romanello and Sandri 2015; Youle and van der 
Bliek 2012). The autophagic removal of damaged and dysfunctional mitochondria, termed 
mitophagy, is critical for the maintenance of a healthy network of mitochondria (Drake and 
Yan 2017). Failure of these processes can lead to an accumulation of damaged 
mitochondria which can negatively regulate metabolism and mass (Romanello and Sandri 
2015; Sandri 2010; Penna et al. 2013). 
 
Cachectic Skeletal Muscle Oxidative Metabolism 
Several chronic diseases are associated with disrupted skeletal muscle oxidative 
metabolism and mitochondrial dysfunction (Deng and Haynes 2017; Prasai 2017; Bordi, 
Nazio, and Campello 2017; Romanello and Sandri 2015; Boland, Chourasia, and Macleod 
2013; Carson, Hardee, and VanderVeen 2016). Furthermore, the regulation of oxidative 
metabolism has emerged as a biological target of cancer-induced muscle wasting (Carson, 
Hardee, and VanderVeen 2016). Loss of mitochondria content and associated reductions 
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in ATP production have been reported in several preclinical models of cachexia (White, 
Baltgalvis, et al. 2011; Brown et al. 2017). Although skeletal muscle with a greater 
abundance of oxidative muscle fibers differ in mitochondria content and reliance on 
oxidative metabolism when compared to primarily glycolytic muscles, reductions in 
mitochondrial content is observed in both muscle types in the mouse hindlimb from 
severely cachectic mice (White, Baltgalvis, et al. 2011). 
Increased mitochondrial fission is a hallmark of mitochondrial dysfunction in 
inflammatory diseases (White, Baltgalvis, et al. 2011; White et al. 2012; Wu et al. 2011; 
Carson, Hardee, and VanderVeen 2016); however, mitochondrial fission is required for the 
removal of old or damaged mitochondria and blocking these processes can result in 
mitochondrial dysfunction and muscle atrophy (Romanello et al. 2010; White et al. 2012; 
Wu et al. 2011). Furthermore, the loss of mitochondrial fusion proteins MFN1 and 2 results 
in reduced mitochondrial DNA and significant muscle mass loss (Lee et al. 2014). While 
the regulation of these processes in cachectic skeletal muscle is only beginning to be 
described, suppressed MFN1 and 2 in skeletal muscle has been reported early in cachexia 
progression in the MIN mouse (White et al. 2012). While increased FIS1 expression is 
observable only in severely cachectic skeletal muscle in LLC tumor bearing mice, there is 
a significant reduction in OPA1 prior to muscle mass loss (White, Baltgalvis, et al. 2011; 
Brown et al. 2017).  
Aberrations of skeletal muscle mitophagy can contribute to skeletal muscle 
mitochondrial dysfunction leading to mass loss (Aversa et al. 2016; White et al. 2012; 
Penna et al. 2011). Several indices of accelerated mitophagy has been reported in skeletal 
muscle from cancer patients and pre-clinical models (Cosper and Leinwand 2011; Ding et 
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al. 2016; Fritzen et al. 2016; McClung et al. 2010; Talbert et al. 2014; White et al. 2012).  
Muscle mitophagy is dependent on the adenosine monophosphate (AMP) activated protein 
kinase (AMPK), Forkhead Box O (FOXO), and mechanistic target of rapamycin complex 
1 (mTORC1) signaling axis, and when disrupted can negatively regulate muscle mass and 
metabolism (Fritzen et al. 2016; Sanchez et al. 2012; Sandri 2010). Additionally, increased 
activation of non-selective autophagy has been reported in cachectic muscle and bearing 
mice (Tessitore et al. 1993; Penna et al. 2013); however additional work is needed to 
identify the regulation of mitophagy during cachexia progression (Mayers et al. 2014). 
 
IL-6 Family of Cytokines, Muscle gp130 Signaling, and Skeletal Muscle Oxidative 
Metabolism 
Manipulating systemic IL-6 can affect the disruption of muscle oxidative 
metabolism during cancer cachexia; however, a direct mechanistic link in skeletal muscle 
has not been described. Systemic IL-6 over-expression can reduce protein expression of 
muscle mitochondrial biogenesis and dynamics proteins in tumor bearing mice (White et 
al. 2012), while IL-6 receptor antibody negates these disruptions and prevents the loss of 
muscle oxidative metabolism (White, Baltgalvis, et al. 2011; White et al. 2013; Fujita et 
al. 1996). Recently, mitochondrial STAT3 localization has been implicated as a regulator 
of basal cellular respiration, and it has been hypothesized that the accumulation of 
mitochondrial STAT3 disrupts efficiency of the electron transport chain and induces 
mitochondrial ROS production (Smith et al. 2014; Wegrzyn et al. 2009). A role for STAT3 
in the disruption of skeletal muscle oxidative metabolism with cancer cachexia has yet to 
be established. 
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Inflammatory signaling has been linked to cancer-induced mitochondrial 
dysfunction in skeletal muscle (Carson, Hardee, and VanderVeen 2016). Specifically, 
activation of either nuclear factor κ B (NF-κB), STAT3, or mothers against 
decapentaplegic homolog 3 (Smad3) signaling have been associated with cancer-induced 
muscle mitochondria dysfunction in tumor bearing mice (VanderVeen, Fix, and Carson 
2017). In vivo and in vitro analysis of LLC driven cachexia demonstrated decreased muscle 
ATP synthesis rates and decreased electron transport chain efficiency with associative 
increases in TNF-α (Constantinou et al. 2011; McLean, Moylan, and Andrade 2014). 
Furthermore, inhibiting direct TNF-α downstream target, NF-κB, improved diaphragm 
mitochondrial respiration in mice bearing P07 lung derived tumors (Fermoselle et al. 
2013). While STAT3’s role in skeletal muscle mitochondrial homeostasis has not been 
clearly defined, examination of liver and heart mitochondria demonstrate that STAT3 
accumulation disrupts genes associated with retinoid-interferon mortality (GRIM 19) 
(Wegrzyn et al. 2009). Lastly, elevated Smad3 signaling was associated with reduced 
enzymatic activity in isolated skeletal muscle mitochondria, however, a mechanistic link 
requires further investigations (Padrao et al. 2013). Currently, our mechanistic 
understanding of mitochondrial quality control and mitochondrial respiration in skeletal 
muscle during cachexia progression is extremely limited due to the dearth of published 
studies and the heterogeneity of the preclinical cancer cachexia models used in these 
investigations. 
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1.4 – Skeletal Muscle Function 
Overview 
Skeletal muscle function is classically defined as the muscle’s force production, 
fatigue properties, and twitch characteristics (Close 1972; Fitts and Holloszy 1977; Fitts et 
al. 1984; Brooks and Faulkner 1988; Close 1964). Examination of these functional 
outcomes provides a distinct physiological window into the functional quality of the 
muscle that may be affected by several physiological and pathological conditions (Allen, 
Lamb, and Westerblad 2008; Westerblad and Allen 2003). Skeletal muscle’s contractile 
phenotype is classically categorized by its myofiber twitch rates and fatigue properties (e.g. 
fast-fatigable, fast-fatigue resistant, and slow-fatigue resistant) and/or their metabolic 
profile (e.g. fast-glycolytic, fast-oxidative/glycolytic, and slow-oxidative) (Fitts and 
Holloszy 1977; Close 1972; Fitts et al. 1984; Allen, Lamb, and Westerblad 2008). Each 
skeletal muscle has a heterogenous mix of several fiber-types, however a muscle can be 
categorized based on the relative abundance of a particular fiber-type (Close 1972; Fitts et 
al. 1980). While central, peripheral, and systemic factors can influence muscle function, 
this section will discuss the intrinsic properties of the muscle that directly impact force, 
fatigue, and contractile quality. This section will outline the functional properties of 
skeletal muscle and the known disruptions to skeletal muscle function in cachectic cancer 
patients and preclinical cachexia models. 
 
Skeletal Muscle Function Analysis Techniques 
There are several modalities of examining skeletal muscle function in both humans 
and preclinical models (Fitts et al. 1980; Thompson et al. 1992; Segal, White, and Faulkner 
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1986; Brooks and Faulkner 1988; Bonetto, Andersson, and Waning 2015; Altenburg et al. 
2007; Widrick et al. 1997). While significant technological advancements have 
dramatically improved our understanding of skeletal muscle function in humans, 
mechanistic investigations of skeletal muscle function are primarily done in animal models 
(Bonetto, Andersson, and Waning 2015). The analysis of whole-body muscle function 
through grip strength, daily activity, and time to exercise-induced exhaustion provides 
physiological relevance; however, whole-body functional assessments are not specific to 
skeletal muscle as well as lacks mechanistic depth. Analysis of skeletal muscle in vitro, or 
often termed ex vivo, allows for analysis of a whole muscle in a highly controlled system 
(Brooks and Faulkner 1988). This technique provides mechanistic advantages; however, 
the controlled system is limited in its physiological relevance. Analysis of skeletal muscle 
in situ allows for analysis of a single muscle while maintaining the host nerve and blood 
supply (Murphy et al. 2012; Schiaffino and Reggiani 1996). This technique provides 
physiological advantages, however, limits mechanistic specificity to the muscle as changes 
in circulation of neural stimulation can affect force output. Additionally, in situ muscle 
function allows for analysis of larger muscles (primary movers), while ex vivo muscle 
function is primarily done in smaller muscles with 2 teasable tendons. To study the 
contractile properties of a single fiber-type the analysis of isolated single myofibers is the 
most advantageous technique (Widrick et al. 1997; Schiaffino and Reggiani 1996). Similar 
to ex vivo analysis, isolated myofibers are difficult to dissect and have lower physiological 
relevance, however, provides significant mechanistic insight. Lastly, skinned myofibers 
allow for precise mechanistic investigation into muscle contractile properties and fatigue, 
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specifically calcium kinetics and metabolic changes that affect fatigue (Widrick et al. 2001; 
Kandarian and Williams 1993). 
 
Skeletal Muscle Contractile Properties 
Examination of the skeletal muscle’s contractile properties provides important 
information regarding skeletal muscle function and metabolic phenotype changes with 
aging, disease, and disuse (Fitts and Holloszy 1977; Fitts et al. 1984; Brooks and Faulkner 
1988; Barreiro and Gea 2015; Berchtold, Brinkmeier, and Muntener 2000; Widrick et al. 
2001; Wolfe 2006). Skeletal muscle twitch characteristics depend on neural excitation, 
sarcomeric structure, calcium handling, and myosin ATPase isoform expression (Close 
1972; Schiaffino and Reggiani 1996; Khodabukus and Baar 2015). A fundamental 
characteristic of skeletal muscle is the capacity to produce force and the contractile 
properties of the muscle is a strong indicator of the muscle’s maximal capacity to produce 
force (Close 1972). Skeletal muscles produce force through the interaction of contractile 
proteins actin and myosin. Actin and myosin are intermyofibrillar filaments which undergo 
tightly coordinated rapid conformation changes that result in shortening the distance 
between the sarcomere’s z-lines (Burkholder et al. 1994). 
The initiation of a single muscle contraction, or twitch, begins in the neuron where 
a change in the resting membrane potential above threshold results in an action potential 
(Schneider and Chandler 1973). During an action potential voltage gated-ion channels open 
allowing for the rapid exchange of sodium and potassium resulting in the propagation of 
the action potential down the axon until it reaches the synapse between the nerve and the 
muscle, termed the neuromuscular junction (NMJ) (Gonzalez-Freire et al. 2014). At the 
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NMJ the nerve releases acetylcholine to bind to the acetylcholine receptor to continue the 
action potential along the sarcolemma to initiate Excitation-Contraction (EC) coupling 
(Franzini-Armstrong and Jorgensen 1994; Bannister 2016; Sandow 1965). This leads to a 
release of calcium from the sacro(endo)plasmic reticulum (SR) into the cytosol by the 
interaction between the Ryanodine Receptor (RyR) and Dihydropyridine Receptor 
(DHPR) (Franzini-Armstrong and Jorgensen 1994; Kandarian and Williams 1993). 
Calcium then binds to troponin which causes a conformational shift in tropomyosin to 
expose the myosin binding site on actin (Winegrad 1965). Once the myosin binding site is 
exposed myosin binds to actin forming the crossbridge. After formation of the crossbridge, 
myosin ATPase causes ATP to be released from the myosin head causing a ‘powerstroke’ 
to initiate a contraction (Sweeney and Hammers 2018). After the contraction the muscle 
relaxes by releasing calcium binding from troponin and get sequestered back to the SR by 
the sacro(endo)plasmic reticulum calcium ATPase (SERCA) (MacLennan, Asahi, and 
Tupling 2003). A single stimulus large enough to stimulate a single action potential can 
stimulate a single muscle contraction, or a muscle twitch. 
The rate of twitch rise and relaxation is a strong prognosticator for the muscle’s 
contractile phenotype and contractile quality (Close 1972; Fitts and Holloszy 1977; Brooks 
and Faulkner 1988). The rate of contractile rise and relaxation depends primarily on the 
muscle’s myosin heavy chain (MHC) and SERCA isoform expression, respectively (Fitts 
et al. 1980; Close 1964; Brooks and Faulkner 1988; Burkholder et al. 1994). Muscle fibers 
expressing type I MHC isoform have the slowest myosin ATPase activity resulting in the 
slowest contractile speed. Furthermore, the slower contractile speeds are associated with 
low force production (Khodabukus et al. 2015; Khodabukus and Baar 2015). Muscle fibers 
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expressing type II MHC isoform have faster myosin ATPase activity and thus have faster 
contraction speeds (Fitts et al. 1980). Type II muscle fiber however can be further divided 
into type IIa, IIx, or IIb, each of which have distinct metabolic profiles and increase in 
contraction speeds from IIa to IIx, to IIb (Fitts et al. 1984). The rate of muscle relaxation 
relies on the rate that calcium is sequestered back to the SR by the SERCA to release 
calcium binding from troponin (Khodabukus and Baar 2015). Skeletal muscle’s that are 
primarily slow-twitch have similar expression levels of SERCA1a and SERCA2a isoforms, 
while skeletal muscle’s that are primarily fast-twitch are almost exclusively comprised of 
SERCA2a (Kandarian and Williams 1993). The slow-twitch muscles have a reduced or 
prolonged relaxation time, while fast-twitch muscles have a rapid relaxation time. 
 
Cachectic Skeletal Muscle Contractile Properties 
Recently, specific decrements to skeletal muscle’s contractile quality have been 
identified in cachectic patients and tumor bearing mice (Christensen et al. 2014; Gorselink 
et al. 2006; Murphy et al. 2012; Roberts, Frye, et al. 2013; Jaweed et al. 1983). Slower 
twitch rise and relaxation have been reported in AC-33 tumor bearing rats, however the 
effect of cachexia on the twitch properties of skeletal muscle isolated from C-26 tumor 
bearing mice remains inconclusive (Jaweed et al. 1983; Murphy et al. 2012; Roberts, Frye, 
et al. 2013). Roberts et. al showed slower 1/2 relaxation time (RT) and time to peak twitch 
(TPT) in the extensor digitorum longus (EDL) and soleus (Roberts, Frye, et al. 2013); 
however, both Murphy et. al and Gorselink et. al report no change in twitch rates in the 
tibialis anterior (TA) and EDL, respectively (Murphy et al. 2012; Gorselink et al. 2006).  
One potential explanation for the slower twitch properties could be a shift in fiber-type 
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distribution (Toth et al. 2016). It is generally accepted that preferential atrophy of type II 
muscle fibers occurs during cachexia, particularly at the early stages of wasting. 
Interestingly, muscle mass loss is associated with reduced myofiber cross sectional area 
(CSA) in all fiber-types (IIb, IIx, and IIa) from the TA, EDL, and soleus in cachectic mice 
(Hardee et al. 2016). Thus, the loss of fiber atrophy and metabolic dysfunction could 
contribute to the disrupted contractile phenotype during severe cachexia and should be 
explored in future investigations.  
Classically, twitch relaxation is dependent on the rate of calcium reuptake by 
SERCA after stimulation (Close 1972; Berchtold, Brinkmeier, and Muntener 2000). 
Modifications to SERCA expression and function by cachexia remains a largely untapped 
area of study. Previous reports have shown increased expression of SERCA1 and SERCA2 
in the gastrocnemius and EDL, respectively, which was hypothesized to be indicative of 
leaky calcium channels resulting in aberrant calcium handling thought to contribute to 
mitochondrial dysfunction, EC uncoupling, and fatigue (Debold 2016; Fontes-Oliveira et 
al. 2013; Carson, Hardee, and VanderVeen 2016). Consistent with this notion, 1/2 RT is 
increased in the EDL and soleus in tumor-bearing mice (Roberts, Frye, et al. 2013; Jaweed 
et al. 1983). These results provide a strong rationale for investigating calcium release and 
reuptake by the SR in cachectic muscle and its role in disrupted muscle function. 
 
IL-6 Family of Cytokines, Muscle gp130 Signaling, and Skeletal Muscle Contractile 
Properties 
 While the mechanisms regulating cachexia-induced skeletal muscle contractile 
dysfunction have not been well described, skeletal muscle contractile dysfunction is 
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commonly reported across several inflammatory diseases including Chronic Obstruction 
Pulmonary Disease (COPD), Congestive Heart Failure (CHF), sepsis, and cancer (Hussain 
1998; Hussain and Sandri 2013; Pieske et al. 1996). Injection of lipo-polysaccharide (LPS) 
is a preclinical model of sepsis and induces a robust inflammatory response. Administration 
of LPS markedly reduces force and contractile function through disrupting sarcolemma 
function, EC coupling, and disruptions to the contractile machinery (Comtois et al. 2001; 
Lin et al. 1998). One prevailing hypothesis is that high levels of inflammation and/or 
inflammatory cytokines induce oxidative stress which disrupts skeletal muscle contractility 
(Barreiro et al. 2002; Reid, Lannergren, and Westerblad 2002). While elevated levels of 
the IL-6 family of cytokines have been reported with LPS, results from these studies have 
led investigators to understand the role of TNFα in contractile dysfunction. 
Interestingly, the deleterious effects of TNFα on skeletal muscle contractility have 
been demonstrated to occur through the induction of oxidative stress, namely nitrous oxide 
systems (NOS) and reactive oxygen species (ROS) (Hardin et al. 2008; Reid, Lannergren, 
and Westerblad 2002). Recently, IL-6 has been shown to regulate nitric oxide synthase 
dependent signaling associated with a reduction in cardiac myocyte post-rest potentiation 
indicative of disrupted calcium transiency (Yu, Kennedy, and Liu 2003; Yu et al. 2005). 
Increased inducible NOS (iNOS) with IL-6 was associated with increases in STAT3 and 
Erk 1/2 signaling; however, inhibition of STAT3, not Erk 1/2, mitigated the IL-6 induction 
of iNOS and was sufficient to rescue myocyte contractility (Yu, Kennedy, and Liu 2003). 
IL-6 alone has also been demonstrated to reduce caffeine stimulated calcium release from 
the SR further demonstrating a role for IL-6 in the disruption of calcium transiency and 
muscle contractile quality (Yu et al. 2005). 
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Skeletal Muscle Force Production 
The mechanisms of muscle force production during an isolated muscle twitch were 
previously described in the Skeletal Muscle Contractile Properties section. While the 
twitch characteristics provide insight into the force producing capabilities of the muscle, 
analysis of maximal skeletal muscle force production provides greater physiological 
relevance. The ‘all or none’ principal of skeletal muscle contraction describes the 
phenomena that if the motor neuron membrane potential exceeds threshold, a single action 
potential will occur regardless of the strength of the stimulus (Fitts et al. 1980). As 
previously described, this single action potential will elicit a muscle twitch and if the 
muscle is able to completely reach relaxation, a second stimulus will simply induce a 
second twitch. If the frequency of the stimulus is great enough, where complete relaxation 
does not occur, the second stimulus will increase muscle force greater than observed with 
a single twitch (Bannister 2016; Schneider and Chandler 1973; Gonzalez-Freire et al. 
2014). This property of skeletal muscle function is termed ‘summation’ and the loss of 
muscle relaxation time is termed ‘tetanus’. To this end, there is a positive sigmoidal 
relationship between the stimulation frequency and muscle force production. Based on the 
summation principle of skeletal muscle, it is simple to surmise that muscles that are 
predominately made up of slow-twitch muscle fibers (slow 1/2 RT and TPT) will reach 
maximal tetanic force (Po) at a lower simulation frequency than muscles with a greater 
abundance of fast-twitch fibers (fast 1/2 RT and TPT). Furthermore, in association with 
reaching Po earlier, analysis of isolated slow-twitch muscle fibers identified muscles that 
are predominately made up of slow-twitch muscle fibers produce significantly less force 
when compared to muscles with a greater abundance of fast-twitch fibers. 
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While analysis of isolated muscle fibers is mechanistically advantageous, the key 
contributors to force production by whole muscles are the size of the muscle fibers 
innervated by the motor neuron, the number of muscle fibers within the motor unit, the 
muscle fiber-type distribution, and relative amount of non-contractile tissue within the 
muscle (Close 1972; Bodine et al. 1987; Brooks and Faulkner 1988; Bonetto, Andersson, 
and Waning 2015). Intrinsic to the muscle, skeletal muscle force can be modulated by 
myofiber CSA (sarcomeres in parallel), percent non-contractile tissue (fibrosis), and 
relative myosin heavy chain isoform expression (fiber-type). Changes in any of these 
structural or biochemical aspects of skeletal muscle will alter its functional properties 
(Brooks and Faulkner 1988; Fitts et al. 1984; Friden and Lieber 1992; Holloszy and Booth 
1976; Segal, White, and Faulkner 1986). 
 
Cachectic Skeletal Muscle Force Production 
Skeletal muscle specific tetanic force (sPo), or force produced per unit area, has 
been a principal parameter for establishing muscle’s structural integrity with aging and 
disease (Burkholder et al. 1994; Brooks and Faulkner 1988; Barreiro and Gea 2015). Often 
skeletal muscle weakness can be explained by a loss of muscle weight and muscle CSA; 
however, if the structural integrity of the muscle is compromised, or there is increased 
fibrosis/non-contractile tissue, the loss of muscle strength will be compounded (Siegel 
1989). While decreased Po has been demonstrated in cancer patients and preclinical 
models, whether there is a decrease in sPo with cachexia remains inconclusive. The 
disparity in results is likely related to the muscle tested, degree and duration of cachexia, 
and heterogeneity of the disease related to the animal model and tumor type. Interestingly, 
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reductions in absolute (grams of force) and relative (grams of force/kilograms of body 
weight) grip strength was demonstrated in C-26 mice with both mild and severe body 
weight loss (Murphy et al. 2012). While ex vivo diaphragm sPo was reduced in cachectic 
C-26 mice, there was not a significant reduction of in situ TA sPo (Murphy et al. 2012). 
These results were supplemented with reductions in muscle mass and CSA. Ex vivo 
examination of the soleus and EDL from C-26 mice showed reductions in both absolute 
and specific tension concomitant with decreased myofiber CSA and a shift towards a more 
glycolytic phenotype with increased percentage of type IIb/x in the EDL and an increased 
type IIa and IIb/x in the soleus (Roberts, Frye, et al. 2013). 
Specific tension can be negatively impacted by expansion of the extracellular 
matrix (ECM), which involves connective tissue deposition and/or edema. Our lab has 
previously reported increased non-contractile tissue in cachectic MIN mice, which did not 
appear to be associated with regeneration or degeneration (Hardee et al. 2016). Matrix 
metalloproteinases (MMP) are key ECM remodeling proteins that degrade the collagen in 
the ECM, as well as play a role in the synthesis and deposition of new collagen (Spinale 
2007). MMP-2, MMP-3, and MMP-9 are the primary isoforms in skeletal muscle and when 
elevated can indicate increased ECM remodeling (Zhang et al. 2014; Mehan et al. 2011). 
Elevated expression of MMP-2 and MMP-3 has been reported in the diaphragm, EDL, and 
soleus from C-26 tumor bearing mice (Devine et al. 2015). The regulation of ECM 
remodeling with cachexia and its contribution to skeletal muscle weakness is not well 
understood, however several inflammatory cytokines and immune cells have direct roles 
in ECM remodeling and the stimulation of fibroblast proliferation. 
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IL-6 Family of Cytokines, Muscle gp130 Signaling, and Skeletal Muscle Force Production 
As previously outlined, systemic inflammation and muscle inflammatory signaling 
play critical roles in cachexia development. While understanding the biochemical 
regulation that drives skeletal muscle wasting is of great importance, decrements in muscle 
force directly impact cancer patient quality of life and health status (Argiles 2012; 
Christensen et al. 2014). Several proposed cancer cachexia therapeutics have failed in 
clinical trials due to their inability to improve overall functional capabilities (Saitoh et al. 
2017; Ramage and Skipworth 2018). Furthermore, our mechanistic understanding of 
cachexia induced muscle weakness is limited and is often left to speculation based on 
changes to muscle mass and CSA. Critical gaps in our knowledge of this regulation are 
likely related to the dearth of studies examining both muscle function and cachectic factors 
in the same cohort of tumor bearing mice. This lack of cohesive integration with these 
measurements has likely contributed to the plethora of unsuccessful cancer cachexia 
treatment paradigms (al-Majid and McCarthy 2001a; Baltgalvis 2010; Christensen et al. 
2014; Murphy et al. 2012; Roberts, Frye, et al. 2013; White, Baltgalvis, et al. 2011; White 
et al. 2012). Our current understanding of cachexia-induced muscle weakness has been 
developed as an extension of mechanistic examinations of muscular dystrophy and cardiac 
dysfunction. 
TNF- overexpression alone has been eloquently demonstrated to decrease 
absolute and specific muscle force. Reductions in diaphragm sPo can be observed as early 
as 1 hour following TNF administration and last up to 24 hours post treatment (Hardin et 
al. 2008). These effects were mediated through the TNFR1, not TNFR2, as TNF had no 
effect on muscle force in muscle lacking TNFR1 (Hardin et al. 2008). Additionally, pre-
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treatment with an antioxidant, Trolox, prevented the TNF induction of muscle weakness, 
implicating a potential role for ROS to induce muscle weakness (Hardin et al. 2008). 
Further investigations into the mechanism of TNF induced muscle weakness demonstrated 
that the activation of MuRF1 through NFκB was required (Adams et al. 2008). Increased 
ROS and elevated expression of MurF1 and NFκB have been reported across several 
preclinical cachexia models and cancer patients alike and can be induced by several 
inflammatory cytokines including the IL-6 family of cytokines; however, additional work 
is needed to elucidate their role in cachexia induced muscle weakness (Mehl KA 2005; 
Williams et al. 1999; Khal et al. 2005; Bossola et al. 2003; Guttridge et al. 2000; Sandri 
2008). 
While the effects of TNF and TNFR signaling on skeletal muscle force are well 
understood, the effect of elevated circulating IL-6 on muscle weakness has not been well 
described. IL-6 overexpression in sedentary MIN demonstrated reduced relative grip 
strength compared to vector and wildtype controls; however, IL-6 overexpression in 
wildtype mice demonstrated an increase in relative grip strength (Puppa et al. 2012). 
Interestingly, in aging and heart failure patients there is an inverse relationship between 
circulating IL-6 and muscle strength (Toth et al. 2006). Cardiac myocytes treated with IL-
6 had decreased contractile function associated with elevated iNOS, which was mediated 
by STAT3 and not Erk1/2 (Yu, Kennedy, and Liu 2003). However, neither systemic IL-6 
nor muscle inflammatory signaling have been directly associated with skeletal muscle 
function decrements during the progression of cancer cachexia. 
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Skeletal Muscle Fatigability 
Skeletal muscle fatigue is a key component of skeletal muscle function and has 
been studied for over 100 years, yet mechanistic investigations of muscle fatigue are still 
in their infancy (Allen, Lamb, and Westerblad 2008). While there is significant overlap 
with force production regulation, skeletal muscle’s fatigability is regulated by several 
physiological processes including the muscle’s blood and nutrient supply, metabolic 
profile, fiber-type distribution, and structural integrity (Holloszy and Booth 1976; Fitts and 
Holloszy 1977; Munkvik, Lunde, and Sejersted 2009; Thompson et al. 1992; Fitts 1994; 
Rutherford, Manning, and Newton 2016). Skeletal muscle fatigue is defined as the inability 
to maintain a given force output over time and is distinct from central or perceived fatigue 
which can contribute to skeletal muscle fatigue independent of the muscle fatigue 
properties (Fitts 1994; Allen, Lamb, and Westerblad 2008). While activity/exercise-
induced fatigue has been studied extensively, difficulty identifying the direct role of several 
contributing factors has served as a significant barrier to understanding fatigue (Westerblad 
and Allen 2003). Additionally, depending on the exercise modality, fatigue may present 
differently (Fitts and Holloszy 1977; Munkvik, Lunde, and Sejersted 2009; Altenburg et 
al. 2007; Coyle et al. 1985; Hagberg et al. 1984; Hagberg et al. 1980; Hargreaves 2000; 
Hurley et al. 1984; Kim et al. 2015). For example, high-intensity exercise recruits each 
fiber-type and relies primarily on anaerobic metabolism; high intensity exercise-induced 
fatigue develops early and is thought to be driven through disruptions to EC coupling, 
disrupted calcium kinetics, and increased intracellular pH (Thompson, Balog, and Fitts 
1992; Murphy and Clausen 2007). In contrast to high-intensity exercise, low-intensity 
endurance exercise primarily recruits type I and type IIa fiber types; the onset of fatigue 
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during low-intensity exercise occurs much later due to its reliance on the high efficiency 
of aerobic metabolism (Fitts 1994). There is considerable debate over the key regulators of 
low-intensity exercised-induced fatigue, however nutrient availability appears to be a key 
contributor. 
To maintain a given force output over time, the muscle’s metabolic demand must 
be met. Since the regulation of circulating and muscle ATP levels is so tightly monitored, 
fatigue develops prior to significant reductions in ATP concentrations, thought to be as a 
protective feedback loop (Fitts 1994). Once the initial ATP stores are used during the first 
few moments of activity causing an increase in ADP/ATP ratio, the phosphocreatine (PCr) 
system supplies enough inorganic phosphate to prop-up ATP levels to maintain force. 
However, the PCr system is not sustainable and at low-intensity exercises skeletal muscle 
recruits the slow twitch fibers and rely primarily on oxidative metabolism as the primary 
fuel source. As intensity and/or duration increases the faster more glycolytic fibers are 
recruited. Therefore, depletion of muscle glycogen is a key indicator of fatigue, however 
as previously stated it is not the only contributor/indicator. It is important to note that 
muscles with a high mitochondrial content, or a slow oxidative contractile phenotype, are 
more fatigue resistant as they are able to rely on oxidative metabolism for a greater duration 
compared to fast glycolytic muscles (Murphy and Clausen 2007). In addition to the 
depletion of fuel sources, the duration of calcium transient, muscle temperature, and build-
up of metabolic byproducts, most notably Hydrogen ions (H+), can induce fatigue (Murphy 
and Clausen 2007). 
In addition to reduced absolute force, fatigue presents with significantly reduced 
peak twitch, slower relaxation (1/2 RT), and slower contraction velocity, TPT (Thompson 
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et al. 1992; Fitts and Holloszy 1978). Interestingly, the slowing of contraction rates occurs 
prior to the increase in metabolic byproducts; however, their causal relationship remains 
unknown (Thompson et al. 1992; Westerblad and Allen 2003). These contractile 
dysfunctions are thought to develop by decreased amplitude of calcium transient; however, 
disrupted calcium kinetics can occur through several mechanisms (Debold 2016; Allen, 
Lamb, and Westerblad 2008). Whether this dysfunction occurs at the NMJ, t-tubule, or 
SERCA, it is clear that calcium release and reuptake contribute to fatigue demonstrated by 
direct release of calcium by caffeine returns force to its pre-fatigued levels. 
Historically, the root causes of fatigue were thought to be attributed to the 
accumulation of lactate and H+ in the blood, as at physiological pH, lactic acid 
disassociates rapidly (Fitts 1994). The production of lactate and H+ occurs in anaerobic 
catabolism of glucose and/or glycogen and both lactate and H+ have strong inverse 
relationships with force in a fatiguing muscle (Westerblad and Allen 2003; Thompson, 
Balog, and Fitts 1992). Administration of lactate to an isolated muscle fiber had no effect 
on muscle force, demonstrating that lactate does not directly induce fatigue, but rather it is 
H+ that depresses force (Westerblad and Allen 2003). With high intensity exercise the pH 
of skeletal muscle can fall from physiological 7.0 to 6.2 which can be attributed to both 
increased H+ production and a reduction in cell buffer capacity (Allen, Lamb, and 
Westerblad 2008). Interestingly, lactate transporter inhibition accelerated fatigue and 
reduced pH, indicating that lactate serves as an H+ buffer to prevent fatigue rather than 
cause it. In addition to H+, the metabolic byproduct inorganic phosphate, can depress force 
through disrupting cross bridge formation and the power stroke, as well as disrupt calcium 
binding to troponin (Fitts 1994; Westerblad and Allen 2003). 
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While biochemical changes that occur during activity can result in fatigue, 
ultrastructural changes and muscle damage during contraction can negatively impact force 
production over time (Cooke 2007). While isometric and concentric muscle contractions 
do not typically induce muscle damage, extreme exercise durations as well as extremely 
high intensities can induce muscle damage and depress force (Choi and Widrick 2009). 
Whether the damage occurs to the myofibrils, mitochondrial membrane, T-tubule, or SR 
depends on the exercise modality and severity of the muscle damage; however, changes in 
the ultrastructure of any of these aspects can negatively impact muscle force during 
exercise. 
 
Cachectic Skeletal Muscle Fatigability 
Cancer patients with decreased functional ability and increased fatigue, regardless 
of cachexia diagnosis, experience decreased quality of life and a poorer prognosis 
(O'Gorman, McMillan, and McArdle 1999; al-Majid and McCarthy 2001a). Fatigue is the 
most frequently reported symptom by cancer patients (al-Majid and McCarthy 2001a). 
Cachectic patients and preclinical cachexia models exhibit decreased volitional activity and 
increased fatigue that precedes significant weight loss (Baltgalvis 2010; Murphy et al. 
2012; Roberts, Frye, et al. 2013; Toth et al. 2016; Puppa, Gao, et al. 2014). Determining 
whether this fatigue is due to neural, humoral, or musculoskeletal alterations remains a 
consistent barrier in cancer and cachexia research. Recently, specific decrements to skeletal 
muscle’s contractile quality have been identified in cachectic patients and tumor bearing 
mice (Christensen et al. 2014; Gorselink et al. 2006; Murphy et al. 2012; Roberts, Frye, et 
al. 2013; Jaweed et al. 1983); however, the drivers of these functional deficits in skeletal 
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muscle have not been clearly defined (Op den Kamp et al. 2012; Christensen et al. 2014; 
Biolo, Cederholm, and Muscaritoli 2014). 
Along with muscle mass, fatigue is a strong predictor of survival in cancer patients 
(Vigano et al. 2000; Christensen et al. 2014). Cachectic skeletal muscle has been reported 
to have disrupted metabolic homeostasis, specifically disrupted oxidative metabolism and 
decreased mitochondrial content which directly impact muscle fatigue resistance. 
Additionally, disrupted mitochondrial quality control (decreased content and biogenesis, 
disrupted dynamics, etc.) and increased ROS in cachectic muscle (White et al. 2012; 
Carson, Hardee, and VanderVeen 2016) coincides with decreased physical activity 
(Baltgalvis 2010). Decrements in mitochondrial biogenesis and mitochondrial content have 
been strongly associated with increased fatigue in skeletal muscle (Lin et al. 2002; Brown 
et al. 2017), however a direct mechanistic link with cachexia-induced fatigue has not been 
identified. Ex vivo muscle function has also demonstrated increased fatigability in C-26 
mice in the soleus (Roberts, Frye, et al. 2013), but the fatigue properties of the EDL and 
the relationship with weight loss or established indices of cachexia was not determined. 
The functional and metabolic impairments that occur in cachectic C-26 mice was well 
described and demonstrated reduced volitional activity and reductions in carbohydrate and 
fat oxidation concomitant with reduced energy expenditure (Murphy et al. 2012). 
Interestingly, while disrupted oxidative metabolism has been reported with C-26 induced 
cachexia, mild and severely cachectic C-26 tumor bearing mice had a greater reliance on 
fat oxidation relative to total body energy expenditure associated with reduced TA and 
diaphragm force output throughout the duration of an intermittent fatigue protocol (Murphy 
et al. 2012). 
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The current understanding of cancer induced fatigue is limited and has been 
excluded from several studies examining cancer- and cachexia-induced metabolic 
dysfunction. Substantial work is needed to determine if several contributing factors of 
fatigue are altered with cancer and cancer-cachexia. Additionally, further work is needed 
to determine the contribution of alterations to the NMJ and muscle blood flow to functional 
decrements with cachexia, as these can also occur with aging and chronic disease (Rudolf, 
Deschenes, and Sandri 2016). 
 
IL-6 Family of Cytokines, Muscle gp130 Signaling, and Skeletal Muscle Fatigability 
While the role of IL-6 and muscle gp130 signaling in skeletal muscle fatigue during 
chronic disease remains largely unknown, the role of systemic IL-6 and muscle 
inflammatory signaling during exercise and activity has been well described (Pedersen 
2012; Munoz-Canoves et al. 2013; Pedersen, Steensberg, and Schjerling 2001). While there 
is a marked induction of plasma IL-6 with both endurance and high intensity exercise, there 
is evidence to suggest that the elevation of circulating IL-6 depends on the exercise 
intensity/duration and muscle mass recruited to perform the activity (Pedersen and Fischer 
2007; Pedersen 2012). In contrast to plasma IL-6, IL-6 mRNA transcription is rapidly 
induced after the onset of exercise (Fischer 2006). Interestingly, there is significant 
evidence that suggests the induction of IL-6 transcription occurs through intracellular 
calcium following muscle contraction. It is well established that intracellular calcium 
regulates a myriad of cellular signaling; however, it has been hypothesized that calcium 
stimulation of nuclear factor of activated T cells (NFAT) regulates IL-6 transcription 
(Febbraio and Pedersen 2002). While the role of calcium and NFAT signaling in muscle 
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fatigue has received significant attention, the link between IL-6 and calcium regulated 
fatigue has not been well established. 
While IL-6 transcription is initiated early during exercise, it appears IL-6 remains 
in the muscle until energy sources become depleted (Febbraio and Pedersen 2002). The 
role of oxidative metabolism, muscle glycogen, and glycogen depletion during exercise-
induced fatigue was described above. Interestingly, there was a strong association with the 
release of IL-6 into circulation and muscle glycogen depletion during exercise. Moreover, 
skeletal muscles with low glycogen content had increased IL-6 transcription compared to 
high-glycogen muscle. IL-6 transcription may be regulated by calcium in the low glycogen 
state; however, it has been hypothesized that IL-6 is release in the plasma due to energy 
stress to activate liver glycogenolysis in order to restore muscle glycogen. In this 
hypothesis, IL-6 would serve to trigger a negative feedback loop to reduce muscle 
contraction and allow glucose uptake by the muscle and subsequent glycogen storage. If 
this were to occur, high levels of IL-6, during physiological exercise or pathological 
disease, could induce systemic and intramuscular alterations that directly impact skeletal 
muscle fatigability. 
 
1.5 – Skeletal Muscle Use and Cancer Cachexia 
Skeletal Muscle Use and Skeletal Muscle Function 
Several aspects of skeletal muscle force production are affected by increased and 
decreased muscle use with exercise and unloading, respectively (Fitts et al. 1984; Holloszy 
and Booth 1976; Holloszy and Coyle 1984; Fitts and Holloszy 1977; Thomason and Booth 
1990; Widrick et al. 2001). The nature of skeletal muscle plasticity allows for adaptations 
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to both metabolic and structural aspects of muscle to occur in response to increased and 
decreased use (Fitts and Holloszy 1977; Holloszy and Booth 1976; Holloszy and Coyle 
1984; Hargreaves 2000). A shift to a slower, more oxidative, contractile phenotype is an 
established adaptation to exercise training (Fitts and Holloszy 1977). This contractile 
phenotype is associated with a shift to a slower fiber type as well as an increase in 
mitochondrial content (Holloszy and Coyle 1984; Kandarian and Williams 1993). The 
effect of exercise training on force production largely depends on the exercise modality. 
Endurance exercise training will have little effect on muscle force in healthy adults; 
however, endurance exercise may prevent the loss of strength with aging and disease 
(Coyle et al. 1985). Contrary to endurance exercise, resistance exercise has potent effects 
on absolute and relative force concomitant with increased muscle protein synthesis and 
increased muscle CSA (Kandarian and Williams 1993). While resistance and endurance 
exercise have similar effects on muscle’s contractile phenotype and fiber type, resistance 
exercise results in increased sarcomeres in parallel which improve overall force production 
capacity. 
 
Muscle Use and Cancer Cachexia 
Both endurance and resistance exercise have been proposed as promising 
preventative and therapeutic interventions for skeletal muscle mass and strength loss with 
cancer cachexia (Cheema et al. 2008; Peddle-McIntyre et al. 2012; McNeely et al. 2015; 
Lonbro et al. 2013; Alves et al. 2015; Lira et al. 2015; al-Majid and McCarthy 2001a; 
Argiles 2012). Whether the plasticity of skeletal muscle remains intact in cancer patients 
is an active area of investigation, however cancer patients that underwent an endurance 
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exercise training regimen displayed increased oxygen consumption and improved life 
quality scores compared to baseline and sedentary controls. These results have been 
recapitulated by rodent models of cachexia showing endurance exercise training can 
improve muscle protein synthesis and muscle to body weight ratio, however skeletal 
muscle function was not directly measured in these studies (al-Majid and McCarthy 2001a; 
Puppa et al. 2012). Consequent of severe disease, exercise intolerance serves as a critical 
barrier to understanding the effects of endurance exercise as a therapeutic in preclinical 
cancer cachexia models. Cachectic muscle was, however, able to respond to an acute bout 
of low-frequency induced concentric muscle contractions, shown by increased 
transcription of several oxidative metabolism genes (Puppa, Murphy, et al. 2014). 
Additionally, endurance exercise prior to the onset of cachexia prevented significant body 
weight and muscle mass loss, however skeletal muscle strength was not directly measured 
(Puppa et al. 2012). Our lab has previously demonstrated that repeated bouts of eccentric 
muscle contraction, a model of resistance exercise, can attenuate the loss of muscle mass 
and myofiber CSA as well as prevent the induction of muscle non-contractile tissue in MIN 
mice that had initiated wasting (Hardee et al. 2016). Interestingly, cachectic muscle was 
able to stimulate protein synthesis and activate anabolic signaling in response to an acute 
bout of eccentric muscle contraction demonstrating that skeletal muscle plasticity remains 
intact (Hardee, Counts, et al. 2018). The culmination of these studies provides significant 
rationale to investigate the effect of exercise on skeletal muscle function prior to and after 
the onset of cachexia.  
The capacity to regenerate from injury and adapt to altered use are defining features 
of skeletal muscle that also provide optimism for therapeutic interventions for cachectic 
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muscle. Exercise has been shown to be beneficial in diabetes, COPD, CHF, and continues 
to show beneficial results in cancer patients as well (Grande et al. 2014; Booth, Roberts, 
and Laye 2012). Volitional activity level in addition to regimented exercise paradigms can 
dramatically impact skeletal muscle mass and metabolism (Holloszy and Coyle 1984; Yan, 
Lira, and Greene 2012). Increased muscle activity induced a more oxidative muscle 
phenotype by increasing mitochondria content and function (Drake, Wilson, and Yan 2016; 
Holloszy 2004; Holloszy 1982; Hood 2001). Increased muscle use can positively impact 
muscle mass, and the extent of this change is dependent on the exercise type, intensity, 
duration, and frequency (al-Majid and McCarthy 2001a, 2001b). The metabolic plasticity 
of muscle is reinforced by the dramatic alterations that occur to skeletal muscle after an 
acute bout of exercise (Holloszy 2004; Holloszy and Coyle 1984; Yan, Lira, and Greene 
2012). Increasing the muscle metabolic demand with exercise can stimulate mitochondrial 
biogenesis to increase mitochondrial content and function (Lira et al. 2010; Vainshtein et 
al. 2015; Wright et al. 2007). Cachectic muscle from tumor bearing mice subjected to an 
acute bout of low frequency electrical stimulation maintained the capacity to activate genes 
responsible for mitochondrial biogenesis, PGC-1, NRF-1, and Tfam (Puppa, Murphy, et 
al. 2014). However, cachectic muscle had deficits in the acute activation of protein 
expression after a single bout of stimulated concentric contractions, which could be rescued 
by systemic inhibition of inflammatory signaling (Puppa, Murphy, et al. 2014). 
Decreased muscle use, either by unloading or extreme sedentary behavior, can 
induce a shift to a more glycolytic phenotype, coinciding with decreased mitochondrial 
content and function, and muscle atrophy (Booth, Roberts, and Laye 2012). Cancer patients 
commonly suffer from excessive fatigue prior to and during chemotherapeutic treatments 
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(al-Majid and McCarthy 2001a; Stewart, Skipworth, and Fearon 2006; Stone et al. 1999). 
This fatigue is accompanied by a dramatic decrease in volitional activity and the reduced 
ability to perform activities of daily living (Ferriolli et al. 2012; al-Majid and McCarthy 
2001a; Farkas J 2013; Montazeri 2009). Preclinical cancer models also have shown that 
cachectic mice undergo limited volitional activity as disease progression worsens (Murphy 
et al. 2012; Baltgalvis 2010). However, minimizing sedentary time and using alternative 
muscle contraction methods may serve as a first line of action to attenuate cachexia-
induced decrements to muscle mitochondria (Booth and Chakravarthy 2006; Dahele et al. 
2007; Gratas-Delamarche et al. 2014; Thyfault and Booth 2011). To this end, IL-6 over-
expression in tumor bearing mice was not able to induce muscle mass loss and metabolic 
changes in mice that were regularly exercised on a treadmill (Puppa et al. 2012). It is 
interesting to speculate if disuse alters the muscle sensitivity to the cachectic environment, 
causing a more rapid decline in muscle metabolic function and mass. Conversely, research 
is needed to determine if muscle contraction or exercise serves to desensitize the muscle to 
the cachectic environment. 
 
Muscle Use and Cachectic Skeletal Muscle Metabolism 
Exercise also regulates mitochondrial dynamics, increasing both fission and fusion. 
This is thought to aid in mitochondrial turnover and improve ATP production efficiency. 
Endurance exercise pre-training was protective again IL-6 induced muscle mass loss and 
metabolic dysfunction in the MIN mouse (Puppa et al. 2012). Additionally, cachectic 
muscle retains the capacity to respond to repeated bouts of stimulated eccentric 
contractions. Cachectic muscle in MIN mice that underwent 7 bouts of eccentric 
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contractions increased muscle succinate dehydrogenase (SDH) activity and decreased 
AMPK signaling (Hardee et al. 2016). Exercise training is implicated as a potential 
therapeutic to either prevent or reverse muscle wasting. It is evident from preclinical 
studies that cachectic muscle maintains the ability to robustly respond to an acute bout of 
exercise or contraction. Further work is needed to determine if repeated bouts of exercise 
can confer the metabolic health benefits of exercise after the development of cancer 
cachexia (Vainshtein et al. 2015; Sheldon, Booth, and Kirby 1993). 
Physical activity and contraction has been established as a potent regulator of 
mitophagy and may possess the potential to correct or attenuate dysfunction mitophagy 
processes in cachectic muscle (Lira et al. 2013; Sanchez 2016; Sanchez et al. 2014; 
Schwalm et al. 2015; Vainshtein et al. 2014; Yan, Lira, and Greene 2012; Pigna et al. 
2016). In C-26 tumor implanted mice, voluntary wheel running attenuated cachexia 
induced p62 and LC3 II/I accumulation indicating improved mitophagy (Pigna et al. 2016). 
Additionally, AMPK activation via AICAR suppressed p62 accumulation through 
promotion of mitophagy and accelerating the turnover of p62 accumulation in cachectic 
muscle (Pigna et al. 2016). While there is growing evidence for mitophagic processes in 
the regulation of cancer cachexia, additional studies are warranted to establish a direct role 
for inflammation in the regulation of these processes. Additionally, the role of exercise 
and/or muscle contraction in the regulation of mitophagy in diseased or chronically 
inflamed muscle may prove to be a powerful therapeutic for the restoration of mitophagic 
balance in cachectic muscle. Clearly, further research is warranted to examine the complex 
interaction between cancer-induced inflammation, muscle contraction, and muscle disuse 
for maintenance or improvement of cachectic muscle oxidative metabolism. 
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CHAPTER 2
THE IMPACT OF CACHEXIA PROGRESSION ON THE DEVELOPMENT OF SKELETAL 
MUSCLE FATIGUE IN TUMOR-BEARING MICE 
 
2.1 – Abstract 
While cancer-induced skeletal muscle wasting has been widely investigated, the 
drivers of cancer-induced muscle functional decrements are only beginning to be 
understood. Decreased muscle function impacts cancer patient quality of life and health 
status, and several potential therapeutics have failed in clinical trials due to a lack of 
functional improvement. Furthermore, systemic inflammation and intrinsic inflammatory 
signaling’s role in the cachectic disruption of muscle function requires further 
investigation. We examined skeletal muscle functional properties during cancer cachexia 
and determined their relationship to systemic and intrinsic cachexia indices. Male ApcMin/+ 
(MIN) mice were stratified by percent body weight loss into weight stable (WS; <5% loss) 
or cachectic (CX; >5% loss). Age-matched C57BL/6 (WT) littermates served as controls. 
Tibialis anterior (TA) twitch properties, tetanic force, and fatigability were examined in 
situ. TA protein and mRNA expression were examined in the non-stimulated leg. CX 
decreased muscle mass, tetanic force (Po), and specific tetanic force (sPo). Whole body and 
muscle fatigability were increased in WS and CX. CX had slower contraction rates, +dP/dt 
and –dP/dt, which were inversely associated to muscle STAT3 and P65 activation. STAT3 
and P65 activation were also inversely associated with Po. However, STAT3 was not 
related to sPo or fatigue. Muscle SOCS3 mRNA expression was negatively associated with 
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TA weight, Po, and sPo, but not fatigue. Our study demonstrates that multiple functional 
deficits that occur with cancer cachexia are associated with increased muscle inflammatory 
signaling. Notably, muscle fatigability is increased in the MIN mouse before cachexia 
development. 
 
2.2 – Introduction 
Cachexia is a complex wasting disorder characterized by unintentional body weight 
loss secondary to chronic disease (Dahele and Fearon 2004; Deans and Wigmore 2005; 
Evans et al. 2008). Cachexia affects roughly 80% of cancer patients and is responsible for 
over 20% of all cancer-related deaths (Argiles 2012; Tisdale 2002). Cachexia-induced 
skeletal muscle mass loss is associated with reduced ability to perform basic daily tasks 
leading to a loss of functional independence (Vigano et al. 2000; Evans et al. 2008; Moses 
et al. 2004; Fearon KC 2006; Argiles 2014; Amano et al. 2017). More clinically relevant, 
cancer patients with decreased functional ability and increased fatigue, regardless of 
cachexia diagnosis, experience decreased quality of life and a poorer prognosis (O'Gorman, 
McMillan, and McArdle 1999; al-Majid and McCarthy 2001a). Cachectic patients and 
preclinical cachexia models exhibit decreased volitional activity, whole body weakness, 
and fatigue (Baltgalvis 2010; Puppa 2014; Murphy et al. 2012; Roberts, Frye, et al. 2013; 
Toth et al. 2016). Recently, specific decrements to skeletal muscle’s contractile quality 
have been identified in cachectic patients and tumor bearing mice (Christensen et al. 2014; 
Gorselink et al. 2006; Murphy et al. 2012; Roberts, Frye, et al. 2013; Jaweed et al. 1983). 
However, the drivers of these functional deficits in skeletal muscle have not been clearly 
defined (Op den Kamp et al. 2012; Christensen et al. 2014; Biolo, Cederholm, and 
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Muscaritoli 2014). To this end, several proposed cancer cachexia therapeutics have failed 
in clinical trials due to their inability to improve overall patient function (Dobs et al. 2013; 
Aversa, Costelli, and Muscaritoli 2017; Biolo, Cederholm, and Muscaritoli 2014). This 
inability of potential therapeutics to improve muscle function illustrates our lack of 
understanding related to the cachectic factors that induce these deficits. Critical gaps in our 
knowledge of this regulation are likely related to the dearth of studies examining both 
muscle function and cachectic factors in the same cohort of tumor bearing mice. This lack 
of cohesive integration with these measurements has likely contributed to the plethora of 
unsuccessful cancer cachexia treatment paradigms (al-Majid and McCarthy 2001a; 
Baltgalvis 2010; Christensen et al. 2014; Murphy et al. 2012; Roberts, Frye, et al. 2013; 
White, Baltgalvis, et al. 2011; White et al. 2012). 
Disrupted proteostasis and oxidative metabolism, linked to chronic inflammation, 
are integral to the pathology of cachectic skeletal muscle (White, Baltgalvis, et al. 2011; 
Carson, Hardee, and VanderVeen 2016; Argiles et al. 2009). Both systemic and muscle 
inflammation have been extensively examined for their regulation of muscle wasting with 
cancer (Tisdale 2002; Evans et al. 2008; Carson and Baltgalvis 2010; VanderVeen, Fix, 
and Carson 2017; Argiles et al. 2009; Argiles 2014; Deans and Wigmore 2005; Sandri 
2008; Onesti and Guttridge 2014). Widely examined systemic mediators of muscle wasting 
include pro-inflammatory cytokines Interleukin-6 (IL-6), Tumor Necrosis Factor- 
(TNF), Transforming Growth Factor , (TGF), Interferon  (IFN), and others 
(VanderVeen, Fix, and Carson 2017; Carson and Baltgalvis 2010; Kumar, Bhatnagar, and 
Paul 2012; Loumaye et al. 2015; Patel and Patel 2017; Onesti and Guttridge 2014). 
Although many systemic mediators of cancer cachexia appear to be associated with 
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specific preclinical models, IL-6 has been implicated as a driver of cachexia in cancer 
patients and preclinical models (Carson and Baltgalvis 2010). Interestingly, there is a 
significant inverse relationship between circulating IL-6 and muscle strength in heart 
failure patients and sarcopenia (Toth et al. 2006). Disrupted protein turnover and metabolic 
homeostasis in the ApcMin/+ (MIN) mouse, an established cancer cachexia model, is 
dependent on elevated circulating IL-6 (Carson and Baltgalvis 2010; White, Baynes, et al. 
2011; van Hall et al. 2008; White et al. 2012; White, Baltgalvis, et al. 2011; White et al. 
2013). Muscle inflammatory signaling has also be investigated for the disruption of protein 
turnover and metabolism induced by cancer (Zhou et al. 2016; Acharyya and Guttridge 
2007; Argiles et al. 2005; Sandri 2008). Chronic activation of signal transducer and 
activator of transcription (STAT3), nuclear factor B (P65), mitogen activated protein 
kinases (P38 and Erk1/2), and protein kinase B (Akt) signaling in skeletal muscle are all 
associated with muscle wasting (Bonetto A 2012; Carson and Baltgalvis 2010; Argiles et 
al. 2009; Zhou et al. 2016; Klasing and Johnstone 1991). Interestingly, each of these 
signaling pathways can regulate muscle mass in healthy and atrophic conditions (Bonetto 
A 2012; Guttridge et al. 2000; Zhang, Jin, and Li 2011; White et al. 2013). Moreover, 
STAT3 can disrupt cardiac myocyte contractility (Yu, Kennedy, and Liu 2003; Yu et al. 
2005). However, neither systemic IL-6 nor muscle inflammatory signaling have been 
directly associated with skeletal muscle function decrements during the progression of 
cancer cachexia. 
Muscle force production, fatigue, and twitch characteristics are functional 
properties that define skeletal muscle quality. Life quality associated with aging, muscular 
dystrophy, COPD, and cancer patients is directly related to these muscle parameters (Wolfe 
 49 
2006; Siegel 1989; Winningham et al. 1994; Barreiro and Gea 2015; al-Majid and 
McCarthy 2001a). Furthermore, muscle fatigability (distinct from central fatigue), 
myofibrillar protein expression, and calcium handling characteristics are used to define a 
muscle’s phenotype (Close 1972; Schiaffino and Reggiani 1996; Khodabukus and Baar 
2015). A myofibers response to catabolic stimuli have been shown to be regulated by 
phenotype; slow-oxidative fibers are more susceptible to disuse atrophy, while fast-
glycolytic muscles are more sensitive to cachectic stimuli (Widrick et al. 2001; Brooks and 
Faulkner 1988; Roberts, Frye, et al. 2013; Acharyya and Guttridge 2007). While 
understanding the biochemical regulation that drives skeletal muscle wasting is of great 
importance, decrements in muscle function directly impact cancer patient quality of life 
and health status (Argiles 2012; Christensen et al. 2014), and several proposed cancer 
cachexia therapeutics have failed in clinical trials due to their inability to improve muscle 
function (Saitoh et al. 2017). Therefore, determining the regulation of impaired muscle 
function during cancer cachexia progression is imperative to understanding this complex 
wasting disorder. We have found that ApcMin/+ (MIN) mice, an established preclinical 
model of cancer cachexia, demonstrate decreased voluntary wheel running and cage 
activity prior to significant weight loss (Baltgalvis 2010). However, it is not known if this 
decreased volitional activity is associated with decrements in skeletal muscle function. To 
this end, we examined skeletal muscle functional properties during cancer cachexia and 
determined their relationship to systemic and intrinsic cachexia indices. We hypothesized 
that cachectic skeletal muscle would exhibit decreased strength and increased fatigability 
when compared to weight stable and healthy controls, and that these decrements would be 
inversely related to increased muscle inflammatory signaling. To test this hypothesis, male 
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MIN mice were stratified by percent body weight loss into weight stable (MIN-WS; <5% 
BW loss) or cachectic (MIN-CX; >5% BW loss). Age-matched male C57BL/6 (WT) 
littermates served as controls. The tibialis anterior (TA) was stimulated in situ and analyzed 
for properties of muscle function. Protein and mRNA expression related to the cachectic 
phenotype were determined from the contra-lateral TA to determine relationships to muscle 
function. 
 
2.3 – Methods 
Animals 
Male WT and MIN mice were purchased from Jackson Laboratories and were bred 
at the University of South Carolina’s Animal Resources Facility. All animals were group 
housed and kept on a 12:12-h light-dark cycle. Body weights were measured weekly, and 
animals were monitored for signs of distress. Animals were given food and water ad libitum 
throughout the duration of the study. All animals were fasted 5 hours prior to tissue 
collection. Mice were anesthetized with a ketamine-xylazine-acepromazine cocktail, and 
hindlimb muscles and select organs were carefully dissected and snap frozen in liquid 
nitrogen and stored at -80⁰C until further analysis. All animal experiments were approved 
by the University of South Carolina’s Institutional Animal Care and Use Committee. 
Analysis of Muscle Function 
At ~20 weeks of age, mice were anesthetized with 2% isoflurane inhalation and 
kept anesthetized at 1.5 % isoflurane throughout the duration of the procedure (~1 hour). 
Muscle function analysis of the TA in situ, which maintains the host nerve and blood 
supply, has been previously described (Murphy et al. 2012; Bonetto, Andersson, and 
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Waning 2015; Dellorusso et al. 2001). Briefly, the distal tendon of the right TA was isolated 
and tied to a force transducer (Aurora Scientific, Ontario, Canada) using 5-0 silk sutures. 
The mouse was place on the apparatus maintained at 37C throughout the entirety of the 
procedure (Bonetto, Andersson, and Waning 2015). The sciatic nerve was exposed 
proximal to the knee and maintained using warmed mineral oil. The sciatic nerve was then 
subjected to a single stimulus to determine the optimal length (Lo). Once Lo was obtained, 
a force-frequency curve was generated, and maximal tetanic force was determined. After 
a 5-minute rest the TA was subjected to a 4-minute intermittent fatigue protocol consisting 
of 1 second maximal stimulation every 4 seconds (Murphy et al. 2012). Maximal tension 
was again measured 5 and 10 minutes after completion of the fatigue protocol. Specific 
tension was determined using TA muscle CSA calculated by muscle mass/(Lf x 1.06), 
where Lf represents fiber length determined by multiplying Lo by 0.6, the predetermined 
TA muscle length to fiber length ratio, and 1.06 represents the skeletal muscle density 
(Brooks and Faulkner 1988). 
Western blot analysis 
Western blot analysis was performed as described previously (Puppa 2014). 
Briefly, the left proximal TA was homogenized, and protein concentration was determined 
using the standard Bradford protein assay. Homogenates were fractionated on 7-10% SDS-
polyacrylamide gels and transferred to a polyvinylidene difluoride membrane. Primary 
antibodies for phosphorylated (p) and total (t) P65, STAT3, P38, and Erk1/2 (Cell 
Signaling Technology) were incubated 1:1000 overnight at 4⁰C in 5% TBST milk. Anti-
rabbit IgG-conjugated secondary antibodies (cell signaling) were incubated 1:2000 for 1 
hour at room temperature in 5% TBST milk. Enhanced Chemiluminescence was used to 
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visualize antibody-antigen interaction and captured using the Syngene: G-Box. Blots were 
analyzed by determining the integrated optical density of each band using ImageJ (NIH 
software). 
RNA isolation and RT-PCR 
RNA isolation, cDNA synthesis, and real-time PCR were performed as previously 
described (Narsale et al. 2016) using reagents from Applied Biosystems (Foster City, CA, 
USA). Primers for GAPDH, IL-6, IL-1, TNF-, SOCS3, SERCA1, RyR1, and 
Calsequestrin were purchased from IDT (Coralville, Iowa, USA) and run using SYBR 
green PCR buffer (Narsale et al. 2016). Data were analyzed using the 2-ΔΔCT method. 
Cytochrome C Oxidase Activity  
Extensor Digitorum Longus (EDL) muscle samples were homogenized in 
extraction buffer (0.1 M KH2P04/Na2HP04, 2 mM EDTA, pH 7.2). Cytochrome-c oxidase 
(COX) activity was determined by measuring the rate of oxidation of fully reduced 
cytochrome c at 550nm using (CYTOCOX1) Sigma Aldrich Kit and spectrophotometer 
(Eppendorf) (Iqbal and Hood 2015). 
Treadmill Run to Fatigue 
A separate cohort of WT (n=6) and MIN (n=15) mice was run on a treadmill to 
examine time to exhaustion as a measure of whole body fatigue, as previously described 
(Velazquez et al. 2014). Three days prior to the fatigue test, mice were acclimated to the 
treadmill by running at a 5% grade for a total of 20 minutes, with 5 m/min incremental 
increases in speed starting at 5m/min and finishing at 20m/min. After acclimation, the mice 
were run on a treadmill until complete exhaustion, determined by 2 minutes of resistance 
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to hand prodding. The fatigue test consisted of 5 minutes at 5m/min, 10 m/min, 15 m/min, 
and 30 minutes at 20 m/min and then increased to the final speed of 25 m/min. 
Statistical analysis 
Values are presented as means ± standard error of the mean (SEM). Student t-tests 
were performed to determine differences between genotypes. A one-way ANOVA was 
used to determine differences in muscle function and inflammatory signaling when MIN 
mice were stratified by age or body weight loss. Post hoc analyses were performed with 
student Newman-Keuls methods. A Bartlett’s test was used to determine significantly 
different standard deviations (p<0.05). If a significant difference was observed between 
group standard deviations, a non-parametric Kruskal-Wallis one-way ANOVA was used. 
A Pearson correlation was used to determine correlations between inflammatory genes and 
proteins with muscle function properties in MIN mice. Stepwise linear regression models 
were used to identify predictors (cachexia indices) of the 8 measured outcomes related to 
skeletal muscle function. Significance was set at p<0.05. 
 
2.4 – Results 
MIN-CX had increased plasma IL-6 levels compared to MIN-WS and WT mice 
(Figure 2.1a). MIN-CX had significantly reduced TA weight (35%) compared to MIN-WS 
(Figure 2.1b). We then examined intrinsic muscle inflammatory signaling proteins in the 
non-stimulated TA (Figure 2.1c, d). Activation of signaling proteins was determined from 
the phosphorylated to total ratio of the expressed protein in muscle. STAT3 activation 
increased 24-fold in MIN-CX compared to MIN-WS and 19-fold compared to WT. P65 
activation increased 1.5-fold in MIN-CX compared to MIN-WS and 1.6-fold compared to 
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WT. Erk1/2 activation increased 3.4-fold in MIN-CX compared to MIN-WS and 3.3-fold 
compared to WT. P38 activation was increased 2.2-fold in MIN-CX compared to MIN-WS 
and 2.0-fold compared to WT. We then examined muscle inflammatory gene expression 
in the non-stimulated TA (Figure 2.1e). IL-6 mRNA was increased in MIN-CX 9.1-fold 
compared to MIN-WS and 9.0-fold compared to WT. SOCS3 mRNA was increased in 
MIN-CX 15-fold compared to MIN-WS and 16-fold compared to WT. IL-1 mRNA was 
increased in MIN-CX 7.1-fold compared to MIN-WS and 4.8-fold compared to WT. 
Lastly, TNF-α mRNA was increased in MIN-CX 1.3-fold compared to MIN-WS, but was 
not different from WT. Extensor digitorum longus (EDL) cytochrome C oxidase (COX) 
enzyme activity was reduced 50% in MIN-CX compared to MIN-WS and 52% compared 
to WT (Figure 2.1f). There was a negative relationship between STAT3 activation and TA 
weight in all MIN mice (Figure 2.1g). Similarly, a negative relationship was observed with 
SOCS3 mRNA and TA weight (Figure 2.1h). Many indices of cachexia had a negative 
relationship with body weight loss in all MIN mice (Table 2.3); SOCS3 expression and 
STAT3 activation exhibited strong negative relationships with percent body weight loss. 
Interestingly, only P38 activation and COX activity were related to muscle mass in all MIN 
mice. 
Whole-body fatigability in tumor-bearing mice 
We have previously reported decreased voluntary wheel running and grip strength 
throughout the progression of cachexia in MIN mice (Baltgalvis 2010). We have extended 
these prior findings by measuring time to exhaustion as a measure of whole-body 
fatigability using a graded treadmill exercise test in MIN and age matched WT mice. Both 
MIN-CX (>5% BW loss, n=7) and MIN-WS (<5% BW loss, n=5) had decreased (77% and 
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43%, respectively) exercise capacity compared to WT controls (Figure 2.2a). There was 
no difference between 12-week ApcMin/+ (MIN-12) mice and age-matched WT, indicating 
the deficit in fatigue was not inherent to the genotype (Figure 2.2a). 
Skeletal muscle fatigability in tumor-bearing mice 
TA muscle fatigability was determined using an intermittent fatigue protocol in 
situ. TA fatigability was increased in the MIN compared to WT (Figure 2.2b). Interestingly, 
when MIN mice were stratified by body weight loss no difference was observed in muscle 
fatigability between MIN-CX and MIN-WS mice (Figure 2.2b). We also observed no 
difference in muscle fatigability between MIN-12 and age-matched WT, indicating the 
deficit in muscle fatigability was not to the genotype. Plasma IL-6 demonstrated a trend 
(p=0.07) for a relationship with muscle fatigue in all MIN mice; however, muscle 
fatigability was not significantly related to any other measured cachexia indices (Table 2.4, 
2.5). Interestingly, COX activity, a surrogate for oxidative metabolism, was not related to 
skeletal muscle fatigability indicating fatigue may be present prior to decrements in muscle 
oxidative metabolism. However, it should be noted that COX activity analysis was 
performed in the EDL instead of the TA. 
Skeletal muscle force through the progression of cachexia 
TA maximal tension (Po) was reduced 41% in MIN-CX compared to MIN-WS and 
42% compared to WT (Figure 2.3c). Interestingly, a loss in force production was observed 
at lower frequencies (e.g., 80 Hz) (Figure 2.3a). Furthermore, there was an increase in the 
percent maximal tetanic force at 10, 30 and 50 Hz, which is indicative of a slower 
contractile phenotype in MIN-CX (Figure 2.3b). The reduction in Po was related strongly 
to STAT3 activation in MIN mice (Figure 2.3d). Po also had a strong relationship with 
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SOCS3 mRNA in MIN mice (Figure 2.3e). Due to the loss of muscle mass, we examined 
specific tension (sPo) to correct for alterations in muscle size. sPo was reduced 14% in MIN-
CX compared to MIN-WS and 21% compared to WT (Figure 2.4c). MIN-CX also 
displayed alterations in sPo at both low (50 Hz) and higher stimulation frequencies (200-
300 Hz) (Figure 2.4a). Similar to Po, % of maximal specific tetanic force was increased at 
10, 30 and 50Hz in MIN-CX (Figure 2.4b). The negative relationship between STAT3 
activation and Po was not present when adjusted for muscle CSA (Figure 2.4d); however, 
the negative relationship between SOCS3 and Po remained when adjusting for muscle CSA 
(Figure 2.4e). 
We then examined the relationship between indices of cachexia and maximal force 
(Table 2.4). We observed a strong relationship between body weight loss and both Po and 
sPo, as well as a strong relationship between testes mass (White JP 2013) and Po, but this 
was lost when we corrected for muscle CSA. In addition to the relationships between Po 
with STAT3 activation and SOCS3 mRNA, Po was negatively related to P65 and P38 
activation, TNF- mRNA, and EDL COX activity (Table 2.4). Notably, the negative 
correlation between P65 activation and sPo was strengthened when corrected for muscle 
CSA (Table 2.4). While several indices of cachexia had strong relationships to reduced Po 
(Table 2.4), stepwise regression analysis determined that percentage body weight loss and 
the relative TA mass were both significant predictors of reduced Po in MIN mice (Table 
2.5). Interestingly, stepwise regression analysis also identified P65 activation as a 
significant predictor for reduced sPo in MIN mice (Table 2.5). 
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Cachectic skeletal muscle contractile properties 
Twitch and tetanic contractile characteristics were examined to better determine 
cachectic skeletal muscle contractile phenotype. One-half (1/2) relaxation time (1/2 RT) 
was increased 19% in Min-CX compared to MIN-WS and 19% compared to WT (Figure 
2.5a). Furthermore, the rate of relaxation from tetanus, -dP/dt, was reduced 49% in MIN-
CX compared to MIN-WS and 67% compared to WT (Figure 2.5c). There was a trend for 
a relationship between ½ RT and STAT3 activation (p=0.07) in all MIN mice (Table 2.6). 
Interestingly, SOCS3 mRNA expression was not related to ½ RT (Table 2.6). Stepwise 
regression analysis demonstrated that percent body weight loss and SOCS3 mRNA 
expression were significant predictors of reduced ½ RT in MIN mice. There was a strong 
negative relationship with –dP/dt and STAT3 as well as SOCS3 (Table 2.4); however, 
percent body weight loss was the only significant predictor of reduced –dP/dt (Table 2.5). 
Time to peak twitch (TPT) was increased 15% in MIN-CX compared to MIN-WS and 15% 
compared to WT (Figure 2.5b). TPT was related to STAT3 activation (Table 2.6); however, 
only TNF- emerged as the only predictor for the decrements to TPT (Table 2.7). The rate 
of rise to tetanus, +dP/dt, was reduced 35% in MIN-CX compared to MIN-WS and 55% 
compared to WT (Figure 2.5d). A negative relationship existed between +dP/dt and STAT3 
activation (Table 2.4) as well as SOCS3 mRNA expression (Table 2.4). Stepwise 
regression analysis identified TA weight as a significant predictor of reduced +dP/dt in 
MIN mice (Table 2.5). We found no difference in twitch tension (tPo) between any groups 
(Figure 2.7a). Similarly, neither STAT3 activation nor SOCS3 mRNA was related to tPo 
(Table 2.6). 
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Calcium handling gene expression 
Based on the observations demonstrating a slower contractile phenotype (Figures 
2.3c, 2.4c, 2.5a, 2.5b, 2.6a, and 2.6b), we investigated the gene expression of key calcium 
handling proteins, Sarco(endo)plasmic Reticulum Calcium ATPase (SERCA) 1, 
Ryanodine Receptor (RyR) 1, and Calsequestrin (Figure 2.6). SERCA1 gene expression 
was increased 1.4-fold in MIN-CX muscle compared to both MIN-WS and WT. RyR1 
gene expression was increased 1.3-fold in MIN-CX compared to MIN-WS and 1.6-fold 
compared to WT. Lastly, Calsequestrin gene expression was increased in MIN-CX (3.1-
fold) and MIN-WS (2.2-fold) compared to WT; however, no significant difference between 
MIN-CX and MIN-WS was found. 
 
2.5 – Discussion 
The current study aimed to improve our understanding of cachectic muscle’s 
functional decrements and illuminate potential contributing factors. While cachectic 
skeletal muscle force, fatigability, and inflammatory signaling have all been studied, the 
lack of a cohesive integration of these measurements has limited the possible conclusions 
to a role in the pathogenesis of muscle dysfunction with cancer (al-Majid and McCarthy 
2001a; Baltgalvis 2010; Christensen et al. 2014; Murphy et al. 2012; Roberts, Frye, et al. 
2013; White, Baltgalvis, et al. 2011; White et al. 2012). Therefore, the primary goal of this 
study was to examine the functional properties of skeletal muscle during the development 
of cachexia and determine their relationship to the systemic and intrinsic regulators of the 
cachectic muscle phenotype. This study demonstrates that a slow-fatigable contractile 
phenotype develops during the progression of cachexia similar to what has been previously 
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reported in other cachexia models (Jaweed et al. 1983; Murphy et al. 2012; Roberts, Frye, 
et al. 2013; Gorselink et al. 2006). However, we have extended these findings by 
demonstrating functional changes have a strong relationship with intrinsic muscle 
inflammatory signaling. We also report the novel finding that muscle fatigability was 
increased before significant cachexia development. Unexpectedly, we found no 
relationship between increased muscle fatigability and systemic IL-6 levels in male MIN 
mice. 
Along with muscle mass, fatigue is a strong predictor of survival in cancer patients 
(Vigano et al. 2000; Christensen et al. 2014). Determining whether this fatigue is due to 
neural, humoral, or musculoskeletal alterations remains a consistent barrier in cancer and 
cachexia research. The present study provides evidence to support a direct role for skeletal 
muscle in cancer fatigue development before the onset of cachexia. Cachectic skeletal 
muscle has been reported to have disrupted metabolic homeostasis, which may contribute 
to muscle-specific fatigue. Our lab has previously found disrupted mitochondrial quality 
control (decreased content and biogenesis, disrupted dynamics, etc.) in MIN muscle (White 
et al. 2012; Carson, Hardee, and VanderVeen 2016), which coincides with decreased 
physical activity (Baltgalvis 2010). Decrements in mitochondrial biogenesis and 
mitochondrial content have been strongly associated with increased fatigue in skeletal 
muscle (Lin et al. 2002; Brown et al. 2017). The results of this study further extend this 
work by showing decreased COX activity in cachectic MIN muscle. Unexpectedly, MIN 
mice that were not cachectic exhibited increased whole body and muscle fatigue that 
preceded elevated inflammatory signaling. Ex vivo muscle function has also demonstrated 
increased fatigability in C26 mice (Roberts, Frye, et al. 2013), but the relationship with 
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weight loss or inflammation was not determined. However, additional research is needed 
to determine the contribution of alterations in the neuromuscular junction and muscle blood 
flow to functional decrements with cachexia, as these can occur with aging and chronic 
disease (Rudolf, Deschenes, and Sandri 2016). To this end, we demonstrated that tumor-
bearing mice, independent of weight loss, experienced increased fatigue measured by 
whole body exercise and in situ muscle function, which was not related to elevated 
circulating IL-6, activated muscle inflammatory signaling, or COX activity. 
Examining skeletal muscle’s contractile properties provides important information 
on alterations to muscle function and phenotype with aging, disease, and disuse (Fitts and 
Holloszy 1977; Fitts et al. 1984; Brooks and Faulkner 1988; Barreiro and Gea 2015; 
Berchtold, Brinkmeier, and Muntener 2000; Widrick et al. 2001; Wolfe 2006). Skeletal 
muscle twitch characteristics depend on neural excitation, sarcomeric structure, calcium 
handling, and myosin isoform expression (Close 1972; Schiaffino and Reggiani 1996; 
Khodabukus and Baar 2015). One potential explanation for the slower twitch properties 
could be a shift in fiber-type distribution. It is generally accepted that preferential atrophy 
of type II occurs during cachexia, particularly at the early stages of wasting. Interestingly, 
we have previously demonstrated a loss of fiber-types (IIB , IIX, and IIA) in the TA of 
cachectic MIN mice, which coincided with the percent of myofibers with high succinate 
dehydrogenase enzyme activity (Hardee et al. 2016). Thus, the loss of fiber atrophy and 
metabolic dysfunction could contribute to the disrupted contractile phenotype during 
severe cachexia and should be explored in future investigations. Classically, twitch 
relaxation is dependent on the rate of calcium reuptake by the Sarcoplasmic Reticulum 
Calcium ATPase (SERCA) after stimulation (Close 1972; Berchtold, Brinkmeier, and 
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Muntener 2000). The modifications of SERCA expression and function by cachexia remain 
a largely untapped area of study. Previous reports have shown increased expression of 
SERCA1 and SERCA2 in the gastrocnemius and EDL, respectively, which was 
hypothesized to be indicative of leaky calcium channels resulting in aberrant calcium 
handling thought to contribute to mitochondrial dysfunction, EC uncoupling, and fatigue 
(Debold 2016; Fontes-Oliveira et al. 2013; Carson, Hardee, and VanderVeen 2016). 
Consistent with this notion, ½ relaxation time (RT) is increased in the EDL and soleus in 
tumor-bearing mice (Roberts, Frye, et al. 2013; Jaweed et al. 1983). We extend these 
findings by demonstrating that the decreased rate of relaxation (-dP/dt) was related to the 
development of cachexia. Moreover, the decline in -dP/dt was associated with body weight 
loss, muscle mass, and the activation of STAT3 and P38. Lastly, we also found disrupted 
expression of key proteins related to skeletal muscle calcium release and uptake. The 
results from this study identify a strong rationale for investigating calcium release and 
reuptake by the SR in cachectic muscle and its role in disrupted muscle function. 
A fundamental characteristic of skeletal muscle is the capacity to produce force, 
which is related to muscle size and cross-sectional area (Close 1972; Bodine et al. 1987; 
Brooks and Faulkner 1988). The specific tension produced by muscle, force per unit area, 
has been a principal parameter for establishing muscle structural integrity (Burkholder et 
al. 1994; Brooks and Faulkner 1988; Barreiro and Gea 2015). While reduced specific 
tension has been reported previously in cachectic muscle from LLC tumor-bearing mice 
(Roberts, Frye, et al. 2013), others have reported no change in C-26 tumor-bearing mice 
(Murphy et al. 2012). These equivocal results are likely related to the muscle tested, degree 
and duration of cachexia, and heterogeneity related to the model and tumor type. Specific 
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tension can be negatively impacted by expansion of the extracellular matrix, which 
involves connective tissue deposition and/or edema. We have previously reported 
increased non-contractile tissue in MIN-CX, which did not appear to be associated with 
regeneration or degeneration (Hardee et al. 2016). Additionally, edema serves to decrease 
muscle protein concentration, which has not been found in MIN-CX mice (Mehl KA 2005). 
However, we found that indices of muscle inflammation were associated with reduced 
specific tension in cachectic muscle. Circulating inflammatory factors are widely 
investigated for their role in cancer cachexia; however, in non-tumor-bearing mice TNF- 
overexpression was demonstrated to decrease muscle force through the activation of 
MuRF1 through P65 (Adams et al. 2008). While elevated MurF1 and P65 have been 
reported, elevated circulating TNF- has not been shown in the MIN (Mehl KA 2005). 
Furthermore, we have previously demonstrated that repeated bouts of eccentric muscle 
contraction can attenuate the induction of muscle non-contractile tissue in MIN mice that 
have initiated wasting (Hardee et al. 2016). There is a strong justification for further 
examination of muscle inflammatory signaling’s role in the induction of non-contractile 
tissue to decrease force independent of mass in the cachectic muscle and to further 
understand the beneficial effects of muscle contractions or physical activity on these 
processes. 
In summary, our study demonstrates that multiple functional deficits that occur with 
cancer cachexia are associated with increased muscle inflammatory signaling, and this 
includes the development of a slow-fatigable contractile phenotype. Although the 
mechanistic regulators of this phenotype require further investigation, our findings provide 
a rationale for examining specific inflammatory signaling pathway regulation of muscle 
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function. Notably, muscle fatigability is increased in the MIN mouse before cachexia 
development. Additional research extending our mechanistic understanding of the 
underpinnings of cachectic muscle’s functional decrements should provide valuable 
information for the development of efficacious treatments for this wasting syndrome.
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Table 2.1. Characteristic data of ~20-week-old male MIN and WT mice.  
  WT  MIN  
n  10  16  
Age  20.3 ± 0.8  20.9 ± 0.5            
Peak Body Weight (g)  26.7 ± 0.5  25.4 ± 0.5  
Final Body Weight (g)  26.7 ± 0.5  22.8 ± 1.0  
BW Change from Peak (%)  0.0 ± 0.0  -10.6 ± 2.3^            
Hindlimb Muscle (mg)  206 ± 5  161 ± 11^  
Testes (mg)  196 ± 5.0  152 ± 12^  
Epididymal Fat (mg)  396 ± 18  93 ± 29^  
Spleen (mg)  67 ± 3  423 ± 34^  
Tibia Length (mm)  16.8 ± 0.1  16.9 ± 0.0  
Values are means ± SE. Body weights given in grams (g). Percent (%) loss 
determined from peak weight to weight prior to sacrifice. All tissue 
weights expressed in milligrams (mg). C57BL/6 (WT). ApcMin/+ (MIN).  
^Significant from WT. p<0.05 (t-test).  
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Table 2.2. Characteristic data of male MIN mice stratified by body weight loss.  
  MIN-WS  MIN-CX  
n  7  9  
Age  21.8 ± 0.6  20.0 ± 0.6            
Peak Body Weight (g)  27.0 ± 0.6  24.1 ± 0.4*  
Final Body Weight (g)  26.8 ± 0.6  19.7 ± 0.4*  
BW Change from Peak (%)  -0.9 ± 0.4  -18.3 ± 0.9*            
Hindlimb Muscle (mg)  201 ± 5  127 ± 9*  
Testes (mg)  194 ± 5  118 ± 13*  
Epididymal Fat (mg)  212 ± 20  0 ± 0*  
Spleen (mg)  384 ± 65  453 ± 21  
Tibia Length (mm)  16.9 ± 0.0  16.8 ± 0.1  
Values are means ± SE. Body weights given in grams (g). % loss determined 
from Peak weight to weight prior to sacrifice. All tissue weights expressed in 
milligrams (mg). Male ApcMin/+ mice were stratified by weight loss, 0-5% loss 
(MIN-WS), 5-20% loss (MIN-CX).  *Significant from MIN-WS. p<0.05 (t-
test).  
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Table 2.3. Relationship between body weight 
loss, muscle mass, and cachexia indices in ~20-
week-old male MIN mice. 
Cachexia Indices  TA weight  BW loss 
Plasma IL-6  -0.53  -0.46 
STAT3  -  -0.78* 
P65  -0.44  -0.55* 
Erk 1/2  -0.49  -0.47* 
P38  -0.77*  -0.74* 
SOCS3 mRNA  -  -0.76* 
IL-6 mRNA  -0.28  -0.44 
IL-1β mRNA  -0.41  -0.42 
TNF-α mRNA  -0.37  -0.52* 
COX Activity^  0.68*  0.64* 
Values are Pearson's correlation (R). Values 
used for STAT3, P65, Erk 1/2, and P38 are ratios 
of phosphorylated to total protein expression. 
†analysis done in the Extensor Digitorum 
Longus *Significant correlation p<0.05. Tibialis 
anterior (TA). Body weight (BW). 
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Table 2.4. Relationship between the force and fatigability of the tibialis 
anterior and indices of cachexia in ~20-week-old male MIN mice. 
Cachexia Indices Fatigue Po  sPo  -dP/dt  +dP/dt 
Plasma IL-6  -0.56  -0.48 
 -0.10  -0.39  -0.33 
BW Loss  0.01  0.93* 
 0.60*  0.86*  0.87* 
Spleen/BW  0.26  -0.62* 
 -0.36  -0.48  -0.64* 
TA/BW  -0.18  0.72* 
 0.01  0.63  0.66* 
Testes  0.11  0.85* 
 0.21  0.75*  0.85* 
Cachexia Indices 
in Skeletal Muscle 
  
 
   
    
STAT3  -  - 
 -  -0.64*  -0.73* 
P65  0.28  -0.62* 
 -0.71*  -0.66*  -0.51* 
Erk 1/2  -0.48  -0.44 
 -0.09  -0.35  -0.42 
P38  0.05  -0.73* 
 -0.34  -0.62*  -0.73* 
IL-6 mRNA  -0.08  -0.41 
 -0.48  -0.41  -0.26 
SOCS3 mRNA  -  - 
 -  -0.72*  -0.58* 
IL-1β mRNA  0.01  -0.41 
 -0.14  -0.43  -0.20 
TNF-α mRNA  -0.03  -0.47* 
 -0.41  -0.47  -0.46* 
COX Activity†   -0.08   0.65*   0.20   0.54*   0.63* 
Values are Pearson's correlation (R). Values used for STAT3, P65, Erk 1/2, 
and P38 are ratios of phosphorylated to total protein expression. †analysis 
done in the Extensor Digitorum Longus *Significant correlation p<0.05. 
Absolute Force (Po). Specific Force (sPo). Rate of Relaxation (-dP/dt). Rate 
of Rise (+dP/dt). Tibialis anterior (TA). Body weight (BW). 
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Table 2.5. Regression analysis of force and fatigability of the tibialis anterior and indices 
of cachexia in ~20-week old male MIN mice. 
  β  SE  Partial R2  Model R2  P value 
           
Fatigue (%)           
-  -  -  -  -  - 
           
Po (mN)           
BW Loss (%)  2850  340.8  0.87  0.87  <0.001 
TA/ BW (mg/g)  498  158.1  0.06  0.93  0.008 
           
sPo (kN/m
2)           
P65  -51.2  13.5  0.51  0.51  0.002 
           
-dP/dt (mN/ms)           
BW Loss (%)  38462  6189  0.73  0.73  <0.001 
           
+dP/dt (mN/ms)           
TA Weight (mg)  324  47.9  0.77  0.77  <0.001 
β is the estimated regression coefficient. Standard Error of β (SE). Body weight (BW). 
Tibialis anterior (TA). Phosphorylated to total ratio of P65 (P65). Absolute force (Po). 
Specific force (sPo). Rate of relaxation (-dP/dt). Rate of rise (+dP/dt). Functional 
outcomes (dependent variable) are italicized. Significant (p<0.05) predictors 
(independent variables) obtained from stepwise linear regression models that included 16 
variables are shown in bold for each functional outcome. Other variables that were not 
significant were removed from the model 
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Table 2.6. Relationship between the twitch properties of 
the tibialis anterior and indices of cachexia in ~20-week-
old male MIN mice. 
Cachexia Indices  1/2 RT  TPT 
 
tPo 
Plasma IL-6  0.27  0.44  0.27 
BW Loss  -0.52*  -0.63*  -0.52* 
Spleen/BW  0.34  0.49*  0.34 
TA/BW  -.22  -0.18  -0.22 
Testes  -0.44  -0.43  0.24 
Cachexia Indices 
in Skeletal Muscle 
    
 
 
STAT3  0.45  0.57*  -0.35 
P65  0.22  0.43  0.22 
Erk 1/2  0.26  0.32  0.26 
P38  0.37  0.48  0.37 
IL-6 mRNA  -0.25  -0.15  -0.25 
SOCS3 mRNA  0.02  0.19  -0.44 
IL-1β mRNA  -0.13  0.04  -0.13 
TNF-α mRNA  0.38  0.64*  0.38 
COX Activity†  -0.04  -0.23  0.51* 
Values are Pearson's correlation (R). Values used for 
STAT3, P65, Erk 1/2, and P38 are ratios of 
phosphorylated to total protein expression. †analysis 
done in the Extensor Digitorum Longus *Significant 
correlation p<0.05. 1/2 Relaxation Time (1/2 RT). Time 
to Peak Twitch (TPT). Peak twitch (tPo) Tibialis anterior 
(TA). Body weight (BW).           
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Table 2.7. Regression analysis of twitch properties of the tibialis anterior and indices 
of cachexia in ~20-week old male MIN mice. 
  β  SE  Partial R2  Model R2  P value 
           
1/2 RT (ms)           
BW Loss (%)  -27.8  5.89  0.29  0.29  0.033 
SOCS3 mRNA  -0.19  0.05  0.35  0.63  0.004 
           
TPT (ms)           
TNF-α mRNA  6.90  2.20  0.41  0.41  0.007 
           
tPo (mN)           
COX Activity   17.9   7.99   0.26   0.26   0.042 
β is the estimated regression coefficient. Standard Error of β (SE). Body weight 
(BW). 1/2 Relaxation time (1/2 RT). Time to peak twitch (TPT). Peak twitch (tPo). 
Functional outcomes (dependent variable) are italicized. Significant (p<0.05) 
predictors (independent variables) obtained from stepwise linear regression models 
that included 16 variables are shown in bold for each functional outcome.   
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Figure 2.1 Indices of cachexia in MIN mice. (A) Plasma levels of IL-6 in picograms per 
milliliter (pg/mL). B) Tibialis Anterior (TA) weight in milligrams (mg). Grey shading 
represents the SE of WT. C) The ratio of phosphorylated to total protein expression of key 
inflammatory signaling proteins STAT, P65, Erk 1/2, and P38 in the TA from MIN-WS 
and MIN-CX normalized to WT. D) Representative western blot images of phosphorylated 
(p) and total (t) protein expression of inflammatory proteins in the TA. Dotted lines indicate 
where blots were cropped for representation. (E) mRNA expression of IL-6, SOCS3, IL-
1, and TNF- in the TA from MIN-WS and MIN-CX normalized to WT. F) Cytochrome 
C oxidase (COX) activity assay in the Extensor Digitorum Longus. Grey shading 
represents the SE of WT. G) Pearson’s correlation between TA weight and STAT3 
activation in all MIN mice. H) Pearson’s correlation between TA weight and SOCS3 
mRNA in all MIN mice. Values are means ± SE. *Significant from MIN-WS. ^Significant 
from WT. Significance was set at p<0.05 
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Figure 2.2 The effect of cachexia on whole body and muscle specific fatigue. (A) Treadmill 
time to fatigue in MIN-WS, MIN-CX, and MIN-12 compared to WT. (B) In situ muscle 
fatigability shown as % of maximal tension after 2 minutes of an intermittent fatigue 
protocol. (C) Absolute force over the duration of the intermittent fatigue protocol. (D) 
Relative (%) force over the duration of the intermittent fatigue protocol. (E) Pearson’s 
correlation between muscle fatigability and STAT3 activation in all ~20-week-old MIN 
mice. (F) Pearson’s correlation between muscle fatigability and SOCS3 mRNA in all ~20-
week-old MIN mice. Values are means ± SE. *Significant from MIN-WS. ^Significant 
from WT. @Significant from MIN-12.  Significance was set at p<0.05  
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Figure 2.3 The effect of cachexia on maximal tetanic force. (A) In situ force-frequency 
curve of the TA in MIN-WS and MIN-CX. (B) Force-frequency curve relative to maximal 
force. (C) Absolute maximal tetanic force (Po) of the TA in MIN-WS and MIN-CX. (D) 
Pearson’s correlation between Po and STAT3 activation in all ~20-week-old MIN mice. 
(E) Pearson’s correlation between Po and SOCS3 mRNA in all ~20-week-old MIN mice. 
Values are means ± SE. *Significant from MIN-WS. ^Significant from WT. Significance 
was set at p<0.05 
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Figure 2.4 The effect of cachexia on specific tetanic force. (A) In situ force-frequency 
curve of the TA corrected for TA cross-sectional area (CSA) in MIN-WS and MIN-CX 
(kN/m2). (B) Force-frequency curve relative to maximal force. (C) Specific tetanic force 
(sPo) of the TA in MIN-WS and MIN-CX. (D) Pearson’s correlation between sPo and 
STAT3 activation in all ~20-week-old MIN mice. (E) Pearson’s correlation between sPo 
and SOCS3 mRNA in all ~20-week-old MIN mice. Values are means ± SE. *Significant 
from MIN-WS. ^Significant from WT. Significance was set at p<0.05 
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Figure 2.5 The effect of cachexia on the muscle force rates. (A) ½ Relaxation Time (RT) 
of TA muscle twitch at Lo in MIN-WS and MIN-CX. (B) Time to peak twitch (TPT) of TA 
muscle twitch at Lo in MIN-WS and MIN-CX. (C) Rate of relaxation (-dP/dt) of the TA 
muscle at 200 Hz. (D) Rate of rise (+dP/dt) of the TA muscle at 200 Hz. *Significant from 
MIN-WS. ^Significant from WT. Significance was set at p<0.05. 
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Figure 2.6 The effect of cachexia on calcium handling gene expression. mRNA expression 
of Sarco(endo)plasmic reticulum calcium ATPase 1 (SERCA1), Ryanodine Receptor 1 
(RyR1), and Calciquestrin in the TA from MIN-WS and MIN-CX normalized to WT. 
*Significant from MIN-WS. ^Significant from WT. Significance was set at p<0.05. 
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CHAPTER 3
THE ROLE OF MUSCLE GP130 SIGNALING IN SKELETAL MUSCLE FATIGUE 
DURING THE PROGRESSION OF CACHEXIA 
3.1 – Abstract 
Interleukin-6 (IL-6) signaling through the muscle gp130 receptor regulates skeletal 
muscle mass and metabolism in physiological and pathological conditions. Elevated 
circulating IL-6 and associative muscle gp130 signaling have been linked to exercised-
induced fatty-acid oxidation and glucose metabolism as well as cancer-induced metabolic 
dysfunction. Mitochondrial function has emerged as an intriguing regulator of 
inflammation induced skeletal muscle metabolic dysfunction. We have previously shown 
that elevated levels of circulating IL-6 decreased skeletal muscle mitochondrial protein 
expression in tumor-free mice and muscle gp130 signaling can regulate basal 
mitochondrial dynamics. Therefore, we investigated if chronically elevated systemic IL-6 
was sufficient to disrupt skeletal muscle force, fatigue, and oxidative metabolism directly 
through muscle skeletal muscle gp130 signaling. Additionally, we investigated if loss of 
the muscle gp130 receptor could attenuate cancer-induced weakness and fatigue in a 
preclinical model of cancer cachexia. First, an IL-6 overexpression plasmid was 
electroporated into the quadriceps of male wildtype (WT) and skeletal muscle gp130 
knockout (KO) mice. Next, ApcMin/+ (MIN) mice were crossed with KO mice to obtain a 
MIN KO. The functional properties of the tibialis anterior (TA) were assessed in situ. IL-
6 had no effect on body weight, muscle mass, force, or fiber-type in WT and KO mice. 
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Submaximal contraction-induced muscle fatigability was increased by IL-6 in WT but had 
no effect in the KO. IL-6 reduced TA respiration and COX activity associated with 
accelerated submaximal contraction-induced fatigue. MIN mice had reduced 
mitochondrial respiration which was rescued in the MIN KO. MIN mice had reduced 
muscle force and increased muscle fatigability; however, there was no effect of gp130 loss 
on muscle weakness or fatigue in the MIN. These results demonstrate that elevated IL-6 
increased submaximal muscle fatigability and disrupted muscle oxidative metabolism 
through muscle gp130 signaling independent of body weight, skeletal muscle mass, or 
strength; however, the cancer environment does not appear to induce weakness and fatigue 
solely through the muscle gp130 receptor. 
 
3.2 – Introduction 
While cachexia is prevalent in patients with a variety of cancer types, cancer 
patients, independent of weight loss, suffer from functional limitations that negatively 
impact quality of life and survival (Montazeri 2009). Perceived fatigue and disrupted 
metabolic homeostasis occur with many chronic diseases and contribute to reduced life 
quality and poor prognosis (Sin and Man 2003; Deans and Wigmore 2005; Kuller et al. 
2008; Vidt 2006). The difficulty in determining if the fatigue has central, peripheral, or 
musculoskeletal origins has served as a significant barrier to understanding fatigue’s 
etiology. Fatigue remains the most frequently reported symptom in cancer patients (al-
Majid and McCarthy 2001a; Chang et al. 2000; Kilgour RD 2010; Laird et al. 2011; Monga 
et al. 1997; Stewart, Skipworth, and Fearon 2006). Skeletal muscle fatigability, or the 
ability to sustain force over time, relies on several physiological phenomena, most notably, 
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adequate ATP production by mitochondrial respiration and glycolytic pathways and the 
accumulation of their metabolic biproducts (Holloszy and Booth 1976; Fitts and Holloszy 
1977; Munkvik, Lunde, and Sejersted 2009; Thompson et al. 1992; Fitts 1994; Rutherford, 
Manning, and Newton 2016). 
Independent of neural control, skeletal muscle force capacity primarily relies on 
muscle cross-sectional area (CSA, sarcomeres in parallel) and relative presence of non-
contractile tissue (Close 1972). While there is significant overlap between the regulation 
of skeletal muscle force production and fatigability, they can be modulated independent of 
one another. For example, skeletal muscle mitochondrial dysfunction and increased 
fatigability have been demonstrated to occur independent of changes to muscle size and 
strength in tumor-bearing mice suggesting that cancer-induced muscle weakness and 
fatigue have distinct etiologies (VanderVeen et al. 2018; Brown et al. 2017). Classically, 
the contractile properties and fiber-type distribution has been associated with the muscle’s 
fatigue properties; however, changes in mitochondrial respiration may regulate muscle 
function independent of changes in myosin heavy chain expression (Fitts 1994; Allen, 
Lamb, and Westerblad 2008; Westerblad and Allen 2003). The heterogeneity of skeletal 
muscle allows for differential recruitment patterns and functional properties of each fiber 
type (Westerblad and Allen 2003; Fitts and Holloszy 1977; Fitts 1994; Allen, Lamb, and 
Westerblad 2008; Altenburg et al. 2007; Close 1964; Close 1972). Higher percentages of 
type I or type IIa myosin ATPase isoform within a muscle has a slower, more oxidative, 
fatigue resistant phenotype, while higher percentage of type IIb/x myosin ATPase isoform 
results in a fast, more glycolytic, higher force production, fatigable phenotype (Fitts 1994; 
Westerblad and Allen 2003). While type I muscle fibers are susceptible to disuse atrophy 
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(Thomason and Booth 1990; Iqbal et al. 2013; Coyle et al. 1985), chronic inflammatory 
diseases such as cancer-induced muscle wasting have been associated with preferential 
atrophy of type II muscle fibers (Carson, Hardee, and VanderVeen 2016; Wang and Pessin 
2013). The tibialis anterior (TA), which has primarily type II muscle fibers, has been shown 
to have increased muscle fatigability and reduced muscle force in tumor-bearing mice 
(VanderVeen et al. 2018; Murphy et al. 2012). 
While tumor necrosis factor α (TNF-α) has been eloquently shown to disrupt 
skeletal muscle contractile function in vivo and ex vivo (Reid and Moylan 2011; Gilliam et 
al. 2011; Hardin et al. 2008; Reid, Lannergren, and Westerblad 2002; Li et al. 2000; Puppa, 
Gao, et al. 2014), the capacity for other inflammatory cytokines to disrupt skeletal muscle 
function has not been well described. The pleiotropic inflammatory cytokine interleukin-6 
(IL-6) has been shown to be both pro- and anti-inflammatory and regulates several immune 
functions as well as whole-body metabolism during both physiological and pathological 
conditions (Carson and Baltgalvis 2010; Bonetto et al. 2011; Hardee, Counts, et al. 2018; 
Gao et al. 2017; Puppa, Gao, et al. 2014). IL-6 promotes intracellular signaling through 
binding to its receptor (IL-6r) which allows for its β subunit (glycoprotein 130; gp130) to 
homodimerize and activate downstream intracellular signaling (Garbers, Aparicio-
Siegmund, and Rose-John 2015; Schwantner et al. 2004; Rose-John 2018). The anti-
inflammatory nature of IL-6 contributes to the acute phase response and skeletal muscle’s 
exercise adaptations, though chronically elevated IL-6 accelerates inflammation and 
contributes to several disease comorbidities including skeletal muscle wasting (Garbers, 
Aparicio-Siegmund, and Rose-John 2015; Carson and Baltgalvis 2010; Spate and Schulze 
2004). While our understanding of IL-6 in exercise and disease has improved, whether the 
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detrimental effects of chronically elevated circulating IL-6 directly affect skeletal muscle 
through gp130-dependent mechanisms is currently unknown. We have previously shown 
that the TA is susceptible to IL-6 induced muscle wasting (Hardee, Fix, et al. 2018); 
whether IL-6 alone can disrupt the TA skeletal muscle function has not been determined. 
The ApcMin/+ (MIN) mouse is a preclinical model of Familial Adenomatous 
Polyposis in which there is a heterozygous nonsense mutation of the adenomatous 
polyposis coli (apc) gene. When the other copy of the apc gene is lost, they develop 
numerous intestinal polyps, or multiple intestinal neoplasia (Min). These mice initiate the 
devolvement of polyps around 4 weeks of age and continue until roughly 12 weeks of age 
at which the polyps increase in size rather than number. We have previously demonstrated 
that MIN mice initiate weight loss at roughly 16 weeks of age that progresses until 20-26 
weeks of age. The progressive loss of muscle mass can be accelerated by systemic over 
expression of IL-6 and IL-6 null MIN mice did not lose body weight or muscle mass. While 
systemic IL-6’s role in MIN-induced cachexia has been described, whether the tumor-
burden in MIN mice initiates muscle wasting through direct muscle gp130 signaling or 
indirect mechanisms has not been established. 
Systemic IL-6 overexpression can accelerate muscle mass loss in tumor-bearing 
mice, but the effects of IL-6 on skeletal muscle mass and function in tumor-free mice 
remains inconclusive (White et al. 2012; White, Baltgalvis, et al. 2011; Puppa et al. 2012). 
Mitochondrial function has emerged as an intriguing regulator of inflammation-induced 
skeletal muscle metabolic dysfunction (Boland, Chourasia, and Macleod 2013; Brown et 
al. 2017; Hardee et al. 2016; Carson, Hardee, and VanderVeen 2016). We have previously 
shown that 2 weeks of elevated circulating IL-6 decreased skeletal muscle mitochondrial 
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protein expression and loss of muscle gp130 signaling increased mitochondrial fission and 
reduced mitochondrial fusion in basal conditions (Fix et al. 2018; Puppa et al. 2012; Puppa, 
Gao, et al. 2014). Additionally, skeletal muscle fatigability has been demonstrated to occur 
synergistically with elevated muscle IL-6 transcription and increased plasma IL-6 levels 
immediately following exercise; however, a causal role for IL-6 to accelerate skeletal 
muscle fatigue has not been investigated. Furthermore, we have previously shown that 
gp130 expression is greater in the TA compared to the soleus and gastrocnemius suggesting 
greater IL-6 sensitivity in faster muscles (Puppa, Gao, et al. 2014). Interestingly, cancer-
induced skeletal muscle weakness was associated with increased skeletal muscle STAT3 
and SOCS3, two primary downstream targets of IL-6 (VanderVeen et al. 2018). The 
purpose of the current study was to determine if chronically elevated systemic IL-6 for two 
weeks was sufficient to disrupt skeletal muscle force, fatigue, and oxidative metabolism of 
the TA. Additionally, we examined if the muscle gp130 receptor mediates the effects of 
the systemic tumor burden on skeletal muscle. We hypothesized that chronically elevated 
circulating IL-6 can disrupt muscle oxidative metabolism and induce muscle weakness and 
fatigue through the activation of muscle gp130 signaling, and loss of the muscle gp130 
receptor will mitigate the IL-6 and cachectic environments effects on skeletal muscle 
function. 
 
3.3 – Methods 
Animals 
Male C57BL/6 mice were originally purchased from Jackson Laboratories and 
were bred at the University of South Carolina’s Animal Resources Facility. Male mice on 
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a C57BL/6 background were bred with gp130fl/fl mice as previously described (Fix et al. 
2018; Puppa, Gao, et al. 2014; Hardee, Fix, et al. 2018). Gp130fl/fl male mice were bred 
with Cre-expressing mice driven by myosin light chain (MLC), resulting in a skeletal 
muscle floxed gp130 heterozygote cre knockout mouse with a skeletal muscle specific 
deletion of gp130 (KO). An additional cohort was examined to investigate the role of 
muscle gp130 signaling in cancer-induced weakness and fatigue in tumor-bearing mice. 
gp130fl/fl mice were crossed with inducible Cre-expressing mice driven by human alpha 
skeletal actin (HSAcre/+) to develop an inducible gp130 KO mouse (iKO). 
Simultaneously, gp130 fl/fl mice were crossed with ApcMin/+ to produce a gp130 fl/fl 
ApcMin/+ (MIN). The resulting gp130 iKO and MIN were crossed to obtain an iKO-MIN 
mouse. Offspring were genotyped by using tail snips. All animals were group housed (<5 
per cage) and kept on a 12:12-h light-dark cycle. All animals were fasted 5 hours prior to 
tissue collection. Mice were anesthetized with a ketamine-xylazine-acepromazine cocktail, 
and hindlimb muscles and select organs were carefully dissected and snap frozen in liquid 
nitrogen and stored at -80⁰C until further analysis. All animal experiments were approved 
by the University of South Carolina’s Institutional Animal Care and Use Committee. 
IL-6 Overexpression 
In vivo intramuscular electroporation of an IL-6 plasmid was performed to increase 
circulating IL-6 levels in mice as previously described (Hardee, Fix, et al. 2018; Hardee, 
Counts, et al. 2018; White et al. 2012). All mice were subjected to in vivo electroporation 
of the quadriceps muscle. Briefly, mice were electroporated with 50μg of the IL-6 plasmid 
driven by the CMV promoter, or empty control vector, into the quadriceps muscle. To 
accomplish this, mice were anaesthetized with a 2% mixture of isoflurane and oxygen (1 
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l/min), the leg was shaved, and a small incision was made over the quadriceps muscle. Fat 
was dissected away from the muscle, and the plasmid was injected in a 50-μl volume of 
phosphate-buffered saline (PBS). A series of eight 50-ms, 100-V pulses were used to 
promote uptake of the plasmid into myofibers, and then the incision was closed with a 
wound clip. Both vector control and IL-6 groups received the appropriate plasmid starting 
at 11 wk of age, and a second electroporation on the opposite leg was performed at 12 wk 
of age to maintain systemically elevated plasma IL-6 levels. The tibialis anterior (TA) and 
extensor digitorum longus (EDL) muscles used in the study were not subjected to 
electroporation. Mice were euthanized 2 weeks after the initial plasmid electroporation. A 
dose of 50 μg has been shown to increase circulating IL-6 levels similar to what’s been 
observed with tumor-bearing mice (Hardee, Counts, et al. 2018; Puppa et al. 2012; White 
et al. 2012; Baltgalvis et al. 2008). Additionally, two weeks of elevated IL-6 was sufficient 
to accelerate cachexia in tumor-bearing mice and disrupt muscle metabolism in tumor-free 
mice (Puppa et al. 2012). 
Plasma IL-6 
Plasma IL-6 was quantified as previously published (Hardee, Fix, et al. 2018). 
Briefly, blood samples were centrifuged at 10,000 g for 10 min at 4°C. Plasma was 
collected and stored at -80°C until analysis. A commercially available IL-6 enzyme-linked 
immunosorbent assay kit was obtained from BD Biosciences (San Diego, CA). Briefly, a 
Costar clear 96-well plate (Corning, NY) was coated with IL-6 capture antibody and 
allowed to incubate overnight. The plate was then blocked with assay diluent buffer and 
IL-6 standards and plasma samples were added to the plate. The wells were then incubated 
with streptavidinhorseradish peroxidase reagent. After several washes, 3,3,5,5-
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tetramethylbenzidine substrate was added, and the reaction was developed for 20 min. The 
reaction was stopped with sulfuric acid, and absorbance was measured. Samples that fell 
below the curve not reported; however, mice were given a Plasma IL-6 value of 7.8 pg/mL 
(low detection limit) for statistical analysis. All of the mice given the IL-6 plasmid fell 
within the detection limit. 
Analysis of Muscle Function 
In both experiments, mice were anesthetized with 2% isoflurane inhalation and 
anesthesia was maintained at 1.5 % isoflurane throughout the duration of the procedure (~1 
hour). Functional analysis of the TA muscle in situ, which maintains the host nerve and 
blood supply, has been previously described (VanderVeen et al. 2018). After a 5-minute 
rest following a force-frequency response protocol, the TA was subjected to an intermittent 
fatigue protocol consisting of 0.5 second submaximal stimulation (50Hz) every second for 
5 minutes for a total of 300 submaximal contractions. Immediately after the submaximal 
contractions, the TA was subjected to a maximal stimulation (200Hz) to elicit a maximal 
contraction. Fatigue was measure by the % reduction in maximal force following the 5-
minute contraction protocol (Allen, Lamb, and Westerblad 2008; Fitts 1994). Disrupted 
fatigue properties were assessed as change in force throughout the force-time tracing 
(Crilly et al. 2016). 
Immunohistochemistry for myosin heavy chain IIA, IIX, and IIB 
Immunohistochemistry for myosin heavy chain (MHC) type IIa, IIx, and IIb was 
performed as previously described (Goodman et al. 2012). Transverse muscle sections 
(8m) of the TA were blocked in 10% IgG Fab (Jackson Immunology) in PBS (5% BSA 
+ 5% Triton X100) for 1 h at room temperature and then incubated overnight at 4°C with 
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primary antibodies [mouse IgG1 monoclonal anti-type IIa MHC (clone SC-71; 1:100) and 
mouse IgM monoclonal anti-type IIb MHC (clone BF-F3, 1:10). All MHC antibodies were 
obtained from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, 
IA). Secondary antibodies (biotinylated anti-mouse IgG FITC, IgM AMCA; Thermo 
Fischer) were incubated with the sections for 1 hour at RT. Slides were air dried and 
covered in glycerol mounting medium containing DABCO and coverslipped. At least 8 
random, non-overlapping digital images at 20X magnification were taken, and fibers 
stained positive or absent for MHC type IIa, IIx, and IIb were tabulated using imaging 
software (ImageJ; NIH). The analyses were performed by an investigator blinded to the 
treatment groups. 
Cytochrome C Oxidase Activity 
Cytochrome C Oxidase Activity was measured to determine changes in 
mitochondrial content across all groups. Due to tissue availability, the Extensor Digitorum 
Longus (EDL) muscle, a highly glycolytic muscle, was used. The whole EDL was 
homogenized in extraction buffer (0.1 M KH2P04/Na2HP04, 2 mM EDTA, pH 7.2) and 
cytochrome-c oxidase (COX) activity was determined by measuring the rate of oxidation 
of fully reduced cytochrome c at 550nm using  Sigma Aldrich Kit (# CYTOCOX1)and 
spectrophotometer (Eppendorf) as previously described (VanderVeen et al. 2018). 
Respiratory Control Ratio 
Mitochondrial respiration was measured polarographically in a respiration chamber 
(Hansatech Instruments) maintained at 37°C as previously described (Kwon et al. 2015). 
A randomly selected cohort of 4 mice from each treatment group were used for analysis of 
mitochondrial function. A 7-10 mg piece of TA muscle was mechanically tweezed with 
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forceps under a dissecting microscope in ice-cold buffer X (60 mM K-MES, 35 mM KCl, 
7.23 mM K2EGTA, 2.77 mM CaK2EGTA, 20 mM imidazole, 0.5 mM DTT, 20 mM 
taurine, 5.7 mM ATP, 15 mM phosphocreatine, and 6.56 mM MgCl2, pH 7.1). The fiber 
bundle was then incubated in 50uM saponin for 30 minutes and washed 3 times for 5 
minutes in respiration buffer (105mM K-MES, 3mM KCl, 1mM EGTA, 10mM K2HPO4, 
5mM MgCl2, 0.005mM Glutamate, 0.002mM Malate, 0.05% BSA, 20mM Creatine, pH 
7.1). Fiber bundles were then placed into the oxygraph machine in 20mM creatine 
respiration buffer at 37 degrees and provided with 5mM of pyruvate and 2mM of malate. 
Two minutes following pyruvate and malate, 0.25mM of ADP was injected into the 
chamber to induce STATE 3 respiration for a duration of 5 minutes. 10ug/mL of 
Oligomycin was then injected to induce steady STATE 4 respiration for a duration of 10 
minutes.  Respiratory Control Ratio (RCR) was calculated by dividing STATE 3 by 
STATE 4 respirations. 
Polyp counts. 
At sacrifice, the intestines were excised, and intestinal sections were flushed with 
PBS, opened longitudinally, and flattened with a cotton swab. All sections were fixed in 
10% buffered formalin (Fisher) for 24h. Formalin-fixed intestinal sections from all animals 
were rinsed in deionized water, briefly stained in 0.1% methylene blue, and counted by the 
same investigator who was blinded to the treatments. Polyps were counted under a 
dissecting microscope, using tweezers to pick through the intestinal villi and identify 
polyps. Polyps were categorized as <1mm, 1-2 mm, and >2mm for each segment (1-5) 
throughout the intestine. 
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Western blot analysis 
Western blot analysis was performed as previously described (Fix et al. 2018). 
Briefly, the proximal portion of the TA muscle was homogenized, and protein 
concentration was determined using the Bradford standard curve method. Homogenates 
were fractionated on SDS-polyacrylamide gels and transferred to PVDF membrane. After 
the membranes were blocked, antibodies Total OXPHOS Cocktail (Abcam, Cambridge, 
United Kingdom), were incubated at dilutions of 1:5000 overnight at 4°C in 1% TBST 
milk. Anti-rabbit IgG-conjugated secondary antibodies (Cell Signaling Technology) were 
incubated with the membranes at 1:5000 dilutions for 1h in 1% TBST milk. Enhanced 
chemiluminescence developed by autoradiography was used to visualize the antibody–
antigen interactions. Blots were analyzed by measuring the integrated optical density (IOD) 
of each band with ImageJ software (NIH, Bethesda, MD, USA). 
Statistical analysis 
Values are presented as means plus / minus standard error of the mean (SEM).  A 
Bartlett’s test was used to determine significantly different standard deviations (p<0.05). 
First, to understand the effects of IL-6, a pre-planned t-test was performed between WT 
and WT + IL-6. Second, to understand if IL-6 directly affects skeletal muscle, a Two-Way 
ANOVA was performed. If an interaction was observed a Tukey’s multiple comparisons 
test was performed. A Pearson’s correlation was run to determine a relationship between 
several properties of skeletal muscle function and key markers of muscle metabolic health. 
Significance was set at p<0.05. 
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3.4 – Results 
The effect of IL-6 body weight and muscle mass 
Circulating IL-6 was elevated at one- and two-weeks following electroporation in 
WT mice (Table 3.1). KO mice had higher levels of circulating IL-6 at both time points 
when compared to WT+IL-6 (WT+IL-6 range 15.6-371.0 pg/mL; KO+IL-6 range 
99.1pg/mL, high-204.5pg/mL) and vector controls (Below the detection limit, 7.8 pg/mL). 
These levels were comparable to levels of tumor-bearing mice however lower than LPS 
(Copeland et al. 2005). While there was no effect on body weight or muscle weight, there 
was a main effect of IL-6 to reduce tibia length (Table 3.1). There was a main effect of KO 
to increase hindlimb mass by 3% (Table 3.1). There was no effect of IL-6 or KO on muscle 
weight when correcting for reduced tibia length. There was a main effect of IL-6 to increase 
spleen weight. 
The effect of IL-6 on muscle oxidative metabolism  
Mitochondrial function was assessed in a cohort of mice for each treatment group 
(n=4 per group). There was an interaction for WT+IL-6 to have a reduced respiratory 
control ratio (RCR) in the TA compared to all groups (Figure 3.1C). Reduced 
mitochondrial coupling in WT+IL-6 resulted from a reduction in STATE 3 respiration 
compared to all groups (Figure 3.1A), while no differences in STATE 4 respiration existed 
between groups (Figure 3.1B). Similarly, there was an interaction for WT+IL-6 to have 
reduced COX activity of the EDL (n=8 for each group) compared to all groups (Figure 
3.2A). Protein analysis of mitochondrial complexes I-V demonstrated IL-6 reduced 
complex I, II, and IV expression in the TA of WT mice (Figure 3.2C). Interestingly, 
circulating levels of IL-6 demonstrated a strong trend to be negatively associated with COX 
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activity (R= -0.81, p=0.05) in WT+IL-6, but IL-6 was not associated with COX activity 
(R= -0.09, p=0.83) in KO+IL-6 mice. 
The effect of IL-6 on skeletal muscle force production and cross-sectional area    
There was no observed effect of IL-6 on muscle force production across all (10-
200 Hz) frequencies during a force-frequency protocol in WT mice (Figure 3.3A). 
Furthermore, there was no effect of IL-6 or KO on maximal tetanic force (Po; Table 3.2). 
Subsequent analysis of specific tension (sPo) showed no effect of IL-6 on force production 
across all (10-200 Hz) frequencies (Figure 3.3C). Specific tetanic force was reduced by 
muscle gp130 loss (Table 3.2). There was a main effect of KO to reduce sPo by 8.7% 
regardless of IL-6 treatment (Table 3.2). Muscle twitch characteristics were not affected 
by IL-6 (Table 3.2); however, there was a main effect of KO to have 1/2 relaxation time 
reduced by 13.4% and time to peak twitch reduced by 5.6%. Additionally, there was a main 
effect of KO to have rate of contraction (change in force/change in time; +dP/dt) increased 
by 10.9% (Table 3.2). Fiber type frequency (i.e. type IIa, IIb or IIx) was not affected by 
IL-6 or muscle gp130 loss (Table 3.3). 
The effect of IL-6 on skeletal muscle fatigability 
There were no observed differences in maximal tetanic force following 5 minutes 
of submaximal contraction-induced fatigue; however, a preplanned t-test showed WT+IL-
6 had reduced maximal tetanic force (mN) by 7% following 5 minutes of the submaximal 
contraction-induced fatigue compared to WT (Figure 3.4C). There was an interaction for 
WT+IL-6 to have reduced relative force by 18.5% and 18.0% following 90 seconds of a 
submaximal contraction-induced fatigue protocol compared to WT and KO+IL-6, 
respectively (Figure 3.4D). 
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The effect of gp130 loss on cachexia indices in tumor bearing mice  
Our lab has previously shown that deletion of the muscle gp130 receptor in LLC 
tumor bearing mice was able to spare muscle mass without affecting tumor-burden (Puppa, 
Gao, et al. 2014). Deletion of the muscle gp130 receptor (Figure 3.5F) had no effect on 
plasma IL-6 levels in the MIN (Figure 3.5A). Additionally, there was no effect of KO on 
polyp number and size in the MIN (Figure 3.5B, C). There was no difference in body 
weight between all groups; however, there was a 2.4% difference in body weight loss 
between MIN Flox and Flox controls (Table 3.4). There was no difference in hindlimb 
mass between all groups (Table 3.4), but epididymal fat was reduced 77% in MIN Flox 
and 73% in MIN KO compared to Flox controls (Table 3.4). 
The effect of gp130 loss on skeletal muscle function in tumor bearing mice 
 MIN mice have been demonstrated to exhibit skeletal muscle weakness, increased 
fatigability and disrupted twitch and contraction rates (VanderVeen et al. 2018). There was 
no difference in twitch 1/2 RT or TPT across all groups; however, rate of contraction 
(+dP/dt) was reduced 16% in MIN Flox and 13% in MIN KO compared to Flox controls 
(Table 3.5). Rate of relaxation (-dP/dt) was reduced 34% in MIN Flox and 29% in MIN 
KO compared to Flox controls (Table 3.5). As expected, MIN Flox mice had reduced 
maximal force by 21% (Figure 3.6B) compared to healthy Flox mice (Figure 3.6B). MIN 
KO was not different from MIN Flox but was reduced 17% compared to healthy Flox mice 
(Figure 3.6B). There was a trend (p=0.10) for specific force to be reduced by 11% in the 
MIN Flox compared to healthy Flox. There was no difference in specific force between 
MIN KO and all groups (Figure 3.6D). There was a 48%, 53%, and 64% reduction in 
maximal force following 300 submaximal contractions in Flox, MIN flox, and MIN KO, 
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respectively (Figure 3.7B). Comparatively, maximal force following fatigue is reduced by 
29% and 44% in MIN flox and MIN KO, respectively, compared to Flox controls (Figure 
3.7B). There was a 65%, 70%, and 76% reduction in maximal force following both 300 
submaximal contractions and 300 maximal contractions in Flox, MIN flox, and MIN KO, 
respectively (Figure 3.7C). Comparatively, maximal force following fatigue is reduced by 
30% and 41% in MIN flox and MIN KO, respectively, compared to Flox controls (Figure 
3.7C). 
The effect of gp130 loss on skeletal muscle mitochondria content, function, and quality 
control in tumor bearing mice 
 A key contributor to muscle fatigability and muscle mass maintenance with chronic 
disease is mitochondrial content, function, and quality control. There was no difference 
across all groups in muscle protein p/t AMPK, a key muscle energy stress sensor (Figure 
3.8A). There was a 29% and 44% increase in muscle protein BNIP3 expression compared 
to Flox controls; however, there was no difference in Parkin or p62 expression (Figure 
3.8B). There was a 24% reduction in PGC1α protein expression in MIN Flox compared to 
healthy Flox controls (Figure 3.8C). There was no difference in between MIN KO PGC1α 
protein expression and all groups. There was a 23% and 22% increase in DRP1 protein 
expression in MIN Flox and MIN KO, respectively, compared to Flox controls (Figure 
3.8C). There was no difference in FIS1 protein expression between MIN Flox and all 
groups; however, FIS1 was reduced 24% in MIN KO compared to Flox controls (Figure 
3.8C). There was no difference in MNF1 protein expression between MIN Flox and all 
groups; however, MFN1 protein expression was increased 18% in MIN KO compared to 
MIN Flox (Figure 3.8C). There was a 73% reduction in COXIV protein expression 
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compared to Flox controls (Figure 3.8E). COXIV protein expression was increased 2.6 fold 
in MIN KO compared to MIN Flox and was not significantly different from healthy Flox 
controls (Figure 3.8E). Surprisingly, cytochrome c protein expression was increased 46% 
and 32% in MIN Flox and MIN KO, respectively, compared to healthy Flox mice (Figure 
3.8E). Lastly, there was a 40% reduction in RCR compared to Flox controls (Figure 3.8F). 
RCR was increased 69% increase in MIN KO compared to MIN Flox and was not 
significantly different from healthy Flox controls (Figure 3.8F). 
 
3.5 – Discussion 
 IL-6 has an established role in exercise- and disease-induced changes to systemic 
and skeletal muscle metabolism (Wolf, Rose-John, and Garbers 2014; Lightfoot and 
Cooper 2016; Febbraio et al. 2004; Febbraio and Pedersen 2002). Although two weeks of 
IL-6 has been shown to accelerate cachexia in tumor-bearing mice and disrupt muscle 
metabolism in tumor-free mice (White et al. 2012), whether IL-6 disrupts mitochondrial 
function and muscle fatigability has not been measured. The current study investigated if 
chronically elevated systemic IL-6 was sufficient to disrupt skeletal muscle force, fatigue, 
and oxidative metabolism directly through muscle skeletal muscle gp130 signaling. Our 
results demonstrate that 2 weeks of elevated circulating IL-6 accelerated submaximal 
contraction-induced skeletal muscle fatigue of the TA muscle. Conversely, IL-6 was unable 
to induced submaximal fatigue in gp130 KO mice suggesting that IL-6 induced fatigue 
occurred through direct skeletal muscle gp130 activation. Additionally, our results 
demonstrated that 2 weeks of elevated IL-6 was sufficient to disrupt skeletal muscle 
oxidative metabolism and decrease mitochondrial content through gp130-dependent 
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signaling, mirroring the submaximal fatigue findings. While IL-6 was able to accelerate 
fatigue, the cancer environment does not appear to work through muscle gp130 signaling 
to induce weakness and fatigue, however cancer-induced muscle mitochondrial 
dysfunction was muscle gp130 receptor dependent. 
While chronic inflammation is a nonspecific immune response, cytokines are 
inflammatory mediators that have been implicated in the progression of several diseases 
and associated comorbidities (Lightfoot and Cooper 2016; Deans and Wigmore 2005; 
Fearon, Glass, and Guttridge 2012; Zhou et al. 2016). In addition to tumor growth and 
development, elevated circulating IL-6 has been linked to disrupted protein turnover 
associated with cancer-induced muscle wasting (Cron, Allen, and Febbraio 2016; Carson 
and Baltgalvis 2010; Narsale and Carson 2014). IL-6 has been shown to regulate skeletal 
muscle metabolism through the activation of GLUT4 translocation and accelerated 
lipolysis (Cron, Allen, and Febbraio 2016). We have previously reported that IL-6 can 
reduce mitochondrial content in both tumor-free and tumor-bearing mice (Puppa et al. 
2012). The current study extends these findings to suggest that elevated circulating IL-6 
accelerates submaximal contraction-induced skeletal muscle fatigue. A potential 
mechanism for IL-6 regulation of fatigue is through the disruption of skeletal muscle 
metabolic homeostasis. Chronic activation of muscle AMPK and suppressed mitochondrial 
biogenesis can occur during cancer-induced muscle wasting (White et al. 2012; White et 
al. 2013). Here we report that elevated circulating IL-6 is sufficient to reduce muscle RCR, 
which is a strong indicator of mitochondrial function (Pettersen et al. 2017). Additionally, 
we found that IL-6 reduced COX activity suggesting a reduction in mitochondrial content. 
A recent study reported that weight stable and cachectic (>5% body weight loss) cancer 
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patients with elevated IL-6, had reduced nuclear factor erythroid 2-related factor 2 (Nrf2) 
expression associated with reduced antioxidant production (Brzeszczynska et al. 2016). 
Furthermore, Crilly et al. found that loss of Nrf2 alone was sufficient to reduce 
gastrocnemius force production during a submaximal contraction-induced fatigue protocol 
(Crilly et al. 2016). 
Signaling through the skeletal muscle gp130 receptor has been an active area of 
investigation in disease-induced muscle wasting (Mihara M 2012; Miller et al. 2016; 
Puppa, Gao, et al. 2014). In this regard, constitutively activated STAT3, a direct 
downstream gp130 target, can inhibit myotube growth in vitro and induce muscle mass 
loss in vivo (Bonetto A 2012). In addition, increased STAT3 signaling can regulate 
mitochondrial respiration by disrupting the electron transport chain and increasing reactive 
oxygen species production (Carson, Hardee, and VanderVeen 2016; Wegrzyn et al. 2009). 
This is important because we recently found that skeletal muscle gp130 signaling can 
regulate protein expression related to basal mitochondria dynamics without affecting 
skeletal muscle fatigability (Fix et al. 2018). We extended these findings to demonstrate 
that the IL-6 disruption of submaximal contraction-induced skeletal muscle fatigue and 
oxidative metabolism are regulated through muscle gp130 signaling. Additionally, we 
show that loss of the muscle gp130 receptor was not able to suppress muscle STAT3 
signaling or rescue skeletal muscle mass. Determining what other factors are contributing 
to increased muscle STAT3 activation and whether chronically elevated IL-6 directly 
effects skeletal muscle mitochondrial function via modulating STAT3 signaling is an 
intriguing area of future investigation. 
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 IL-6 can also regulate the muscle macro- and microenvironment. IL-6 directly 
regulates fibroblast proliferation, liver glucose metabolism, lipolysis, and immune cell 
function (Narsale and Carson 2014; Lightfoot and Cooper 2016; Choi et al. 1994; 
Sundararaj et al. 2009; Cron, Allen, and Febbraio 2016; Febbraio et al. 2004; Pedersen et 
al. 2003). While the IL-6r is predominately expressed in hepatocytes, megakaryocytes, and 
leukocytes, the signal transducing gp130 β-subunit is detectable in every cell type (Wolf, 
Rose-John, and Garbers 2014). Interestingly, we report that the tumor-induced changes to 
submaximal and maximal contraction-induced skeletal muscle fatigability occur 
independent of muscle gp130 signaling. There is an established liver-skeletal muscle 
metabolic cross-talk involving lactate recycling and glucose availability which can alter 
muscle fatigue properties indirectly (Rui 2014). Similar studies examining systemic IL-6 
overexpression showed IL-6 induced hepatic insulin resistance while having no effect on 
skeletal muscle insulin sensitivity (Glund and Krook 2008). 
 The results of the current study found that 2 weeks of systemic IL-6 overexpression 
had no effect on muscle mass or body weight, though regardless of treatment, gp130 loss 
resulted in increased muscle mass. IL-6 can regulate basal muscle protein synthesis and 
suppress the acute induction of protein synthesis by eccentric contraction (Hardee, Counts, 
et al. 2018; Gao et al. 2017); however, we observed no changes in muscle strength or 
contraction rates with IL-6 overexpression. Interestingly skeletal muscle lacking gp130 
showed reduced specific tension, 1/2 RT, and TPT with no apparent effect on muscle 
fatigability which is similar to TNF-α overexpression (Reid, Lannergren, and Westerblad 
2002). IL-6 also increased submaximal contraction-induced fatigue, which was not 
dependent on fiber type distribution or mass changes. Our results found that muscle 
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fatigability, force, and mass can be regulated independently, which points to muscle 
weakness and fatigue with chronic disease having distinct etiologies. 
 In summary, we report that chronically elevated IL-6 increased skeletal muscle 
fatigability and disrupted oxidative metabolism independent of fiber-type and mass 
changes. IL-6 accelerated submaximal fatigue and reduced oxidative metabolism through 
muscle gp130 signaling. While the effect of TNF-α on skeletal muscle function has been 
extensively characterized, to the best of our knowledge this is the first study investigating 
if IL-6 is sufficient to regulate skeletal muscle fatigue and muscle oxidative metabolism. 
Future studies are warranted to establish the mechanisms regulating IL-6 induced maximal 
contraction-induced fatigability and disrupted mitochondrial quality control which 
contribute to submaximal contraction-induced fatigue.
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Table 3.1. Characteristic data of male gp130 KO and WT with elevated IL-6 
  WT  KO 
  Control  IL-6  Control  IL-6 
n  14  15  12  11 
Body Weights (g)                 
Pre  23.3 ± 1.5  23.4 ± 1.9  24.7 ± 2.0  24.0 ± 1.7 
Mid  24.0 ± 1.5  23.4 ± 1.4  24.9 ± 2.0  24.1 ± 1.3 
Post  24.9 ± 2.0  24.0 ± 2.1  25.1 ± 1.3  24.3 ± 1.7 
Plasma IL-6 (pg/mL)                 
Pre  -  -  -  - 
Mid  -  63 ± 52*  -  98 ± 55& 
Post  -  75 ± 43*  -  141 ± 31& 
Tissues at Sacrifice                 
Hindlimb (mg)  207 ± 14  200 ± 14  214 ± 11@  206 ± 14@ 
Hindlimb/Tibia 
(mg/mm) 
 12.2 ± 0.7  12.0 ± 0.7  12.7 ± 0.6  12.3 ± 0.8 
Tibia Length (mm)  17.0 ± 0.3  16.8 ± 0.2#  16.8 ± 0.2  16.7 ± 0.2# 
Epididymal Fat (mg)  362 ± 139  313 ± 96  308 ± 52  290 ± 85 
Spleen (mg)  71 ± 12  122 ± 26#  93 ± 68  199 ± 92# 
Values are means ± SD. Male C57BL/6 (WT) mice. Male skeletal muscle specific gp130 
knockout (KO) mice. Age in weeks (wks). Body weight in grams (g). Plasma interleukin-
6 (IL-6) in picograms/milliliters (pg/mL). All vector controls and pre-IL-6 levels fell 
below the detection limit and therefore weren’t reported. Combined weight of the soleus, 
plantaris, gastrocnemius, and tibialis anterior (hindlimb) in milligrams (mg). Tibia length 
in millimeters (mm). Epididymal fat pad weight in milligrams. Spleen weight in 
milligrams. Significance set at p<0.05 (Two-Way ANOVA). #Significant main effect of 
IL-6. @ Significant main effect of KO. & Significantly different from all groups. * WT-
IL-6 significant interaction from all groups. & KO-IL-6 significant interaction from all 
groups.  
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Table 3.2. The effect of elevated IL-6 on skeletal muscle’s contractile properties 
 WT  KO 
 Control  IL-6  Control 
 IL-6 
TA Weight (mg) 48.4 ± 3.1  46.0 ± 3.4  49.8 ± 3.2@ 
 48.8 ± 3.6@ 
        
 
       
Twitch Properties         
       
1/2 RT (ms) 8.7 ± 1.6  9.0 ± 1.5  7.7 ± 1.2@ 
 7.8 ± 1.7@ 
TPT (ms) 15.7 ± 1.4  16.2 ± 1.4  14.8 ± 0.8@ 
 15.1 ± 1.1@ 
Force Production         
       
Po (mN) 1,655 ± 155 
 1,585 ± 136  1,628 ± 152 
 1,563 ± 100 
sPo (kN/m2) 302 ± 25 
 300 ± 22  276 ± 24@ 
 273 ± 14@ 
Contraction 
Rates 
       
 
       
+ dP/dt (mN/s) 23,233 ± 1675  22,222 ± 3421  25,652 ± 2824@ 
 24,709 ± 2020@ 
- dP/dt (mN/s) 20,221 ± 3222  18,664 ± 3253  19,069 ± 3437 
 20,045 ± 1740 
Values are means ± SD. Male C57BL/6 (WT n=14, WT+IL-6 n=15) mice. Male skeletal 
muscle specific gp130 knockout (KO n=12, KO+IL-6 n=11) mice. Tibialis anterior (TA) 
weight in milligrams (mg). 1/2 Relaxation time (RT) in milliseconds. Time to peak twitch 
(TPT) in milliseconds. Maximal tetanic force (P
o
) in millinewtons. Specific tetanic force 
(sPo) in kilonewtons/meter
2. Rate of contraction at 200 Hz (+dP/dt). Rate of Relaxation 
at 200 Hz (-dP/dt). Significance set at p<0.05 (Two-Way ANOVA). @ Significant main 
effect of KO. 
 
  
 101 
Table 3.3. The effect of elevated IL-6 on muscle fiber-type distribution 
 WT  KO 
 Control  IL-6  Control  IL-6 
Type IIa 10.9 ± 4.7  11.2 ± 6.8  9.5 ± 6.5  6.8 ± 3.1 
Type IIb 38.4 ± 7.1  40.6 ± 4.3  38.9 ± 7.7  35.4 ± 9.2 
Type IIx 50.7 ± 8.5  48.2 ± 5.4  51.8 ± 13.4  58.0 ± 11.3 
Values are % means ± SD. C57BL/6 (WT). Skeletal muscle specific gp130 knockout 
(KO). n=5 for each group  
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Table 3.4. Animal characteristics of male skeletal muscle specific gp130 KO 
ApcMin/+ mice 
  Flox  MIN Flox  MIN KO 
n  7  7  9 
Age (wks)  17.4 ± 0.6  17.0 ± 0.3  17.7 ± 0.2 
             
Peak BW (g)  26.0 ± 0.9  25.2 ± 0.8  26.0 ± 0.7 
Sac BW (g)  26.0 ± 0.9  23.5 ± 1.0  24.9 ± 1.0 
BW Loss (%)  0.0 ± 0.0  6.7 ± 2.4*  4.2 ± 1.9 
             
Hindlimb (mg)  294 ± 12  261 ± 8  277 ± 14 
             
Epi Fat (mg)  326 ± 41  108 ± 30*  119 ± 31* 
             
Spleen (mg)  72 ± 5  398 ± 25*  364 ± 40* 
Testes (mg)  197 ± 4  135 ± 17*  174 ± 13 
Sem Ves (mg)  195 ± 18  76 ± 17*  104 ± 18* 
             
Tibia Length (mm)   17.6 ± 0.1   17.7 ± 0.1   17.8 ± 0.2 
Values are means ± SE. Age given in weeks (wks). Body weights given in 
grams (g). % loss determined from peak weight to weight prior to sacrifice. 
All tissue weights expressed in milligrams (mg). Seminal vesicles (Sem Ves). 
gp130 floxed controls (Flox).  ApcMin/+ mice (MIN). gp130 floxed HSA Cre/+ 
ApcMin/+ (MIN KO). *Significantly different from Flox. p<0.05 (One-way 
ANOVA). 
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Table 3.5. The role of the muscle gp130 receptor in cancer-induced skeletal 
muscle contractile dysfunction 
  Flox  MIN Flox  MIN KO 
Twitch Properties             
1/2 RT (ms)  8.3 ± 0.8  8.7 ± 1.0  9.0 ± 0.8 
TPT (ms)  15.3 ± 0.5  15.4 ± 0.7  15.7 ± 0.3 
Contraction Rates             
+ dP/dt (mN/s)  27506 ± 1477  23070 ± 1979*  24017 ± 1440* 
- dP/dt (mN/s)  18644 ± 1610   12220 ± 1222*   13324 ± 1319* 
Values are means ± SE. Twitch properties 1/2 Relaxation time (RT) and time 
to peak twitch (TPT) given in milliseconds (ms). The rate of maximal 
contraction (+dP/dT) measured from 200Hz given as the ratio of change in 
force over the change in time. The rate of maximal relaxation (-dP/dT) 
measured from 200Hz given as the ratio of change in force over the change 
in time. gp130 floxed controls (Flox).  ApcMin/+ mice (MIN). gp130 floxed 
HSA Cre/+ ApcMin/+ (MIN KO). *Significantly different from Flox. p<0.05 
(One-way ANOVA).  
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Figure 3.1. The effect of IL-6 on skeletal muscle mitochondrial function. Tibialis anterior 
(TA) respiratory control ratio (n=4 per group). Values are means plus / minus standard 
deviation (SD). A) 0.25mM of ADP was injected into the chamber to induce STATE 3 
respiration for a duration of 5 minutes. B) 10ug/mL of Oligomycin was injected to induce 
steady STATE 4 respiration for a duration of 10 minutes. C) Respiratory Control Ratio 
(RCR) was calculated by dividing STATE 3 by STATE 4 respirations. & Significantly 
different from all groups. Significance was set at p<0.05. Two-Way ANOVA. 
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Figure 3.2. The effect of IL-6 on muscle mitochondrial content. A) Extensor digitorum 
longus (EDL) COX activity (WT n=14, WT+IL-6 n=15, KO n=12, KO+IL-6 n=11). B) 
Relative mitochondrial protein expression of Complexes 1-5 in the TA (n=6 per group). 
Representative western blot images are shown to the right of the graph. Values are means 
plus / minus standard error (SEM). C57BL/6 (WT). Skeletal muscle gp130 knockout (KO). 
Interleukin-6 (IL-6). $Significantly different from WT and KO + IL-6. &Significantly 
different from all groups. %Significantly different from KO + IL-6. ^ Significantly different 
from WT. Significance was set at p<0.05. Two-Way ANOVA. 
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Figure 3.3. The effect of IL-6 on skeletal muscle force production. A) Absolute force-
frequency curve of the TA in WT and WT+IL-6 in millinewtons (mN). B) Absolute force-
frequency curve of the TA in KO and KO+IL-6 in mN. C) Specific force-frequency curve 
of the TA in WT and WT+IL-6 in kilonewtons/meters2 (kN/m2). D) Specific force-
frequency curve of the TA in KO and KO+IL-6 in kN/m2. E) Relative force-frequency 
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curve of the TA in WT and WT+IL-6 (% of maximal force). B) Relative force-frequency 
curve of the TA in KO and KO+IL-6 (% of maximal force). WT n=14, WT+IL-6 n=15, 
KO n=12, KO+IL-6 n=11. Values are means plus / minus standard error (SEM). C57BL/6 
(WT). Skeletal muscle gp130 knockout (KO). Interleukin-6 (IL-6). %Significantly 
different from KO + IL-6. Significance was set at p<0.05. Pre-planned t-test. 
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Figure 3.4. The effect of IL-6 on submaximal contraction-induced skeletal muscle 
fatigability. TA muscle’s fatigability during a 5-minute submaximal (50 Hz) fatigue test. 
A) Relative (% of Initial) force-time tracing of the TA muscle’s fatigability during a 5-
minute submaximal (50 Hz) fatigue test from WT and WT + IL-6 mice. B) Relative (% of 
Initial) force-time tracing of the TA muscle’s fatigability during a 5-minute submaximal 
(50 Hz) fatigue test from KO and KO + IL-6 mice. C)  Relative (% of maximal tetanic 
force) force after the 5-minute submaximal contraction-induced fatigue test in all mice. D) 
Relative (% of Initial) force after 90 seconds of a submaximal (50 Hz) fatigue test in all 
mice. WT n=14, WT+IL-6 n=15, KO n=12, KO+IL-6 n=11. Values are means plus / minus 
standard error (SEM). C57BL/6 (WT). Skeletal muscle specific gp130 knockout (KO). 
$Significantly different from WT and KO+IL-6. Significance was set at p<0.05. 
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Figure 3.5 Indices of cachexia in gp130 KO MIN mice. A) Plasma levels of IL-6 in 
picograms per milliliter (pg/mL). B) Number of intestinal polyps in all MIN mice. C) 
Intestinal polyp size distribution in all MIN mice. D) Tibialis Anterior (TA) weight in 
milligrams (mg). E) The ratio of phosphorylated to total protein expression of key 
inflammatory signaling proteins gp130, STAT, P65, Erk 1/2, and P38 in the TA from MIN 
Flox and MIN KO normalized to Flox. F) Representative western blot images of 
phosphorylated (p) and total (t) protein expression of inflammatory proteins in the TA. 
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Values are means ± SE. gp130 floxed controls (Flox).  ApcMin/+ mice (MIN). gp130 floxed 
HSA Cre/+ ApcMin/+ (MIN KO). *Significantly different from Flox. ^ Significant from MIN 
Flox. p<0.05 (One-way ANOVA).  
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Figure 3.6. The role of the muscle gp130 receptor on cancer-induced muscle weakness. A) 
Absolute force-frequency curve of the TA from all groups in millinewtons (mN). B) 
Absolute force-frequency curve of the TA of all groups in mN. C) Specific force-frequency 
curve of the TA of all groups in kilonewtons/meters2 (kN/m2). D) Specific force-frequency 
curve of the TA from all groups in kN/m2. Values are means ± SE. gp130 floxed controls 
(Flox).  ApcMin/+ mice (MIN). gp130 floxed HSA Cre/+ ApcMin/+ (MIN KO). *Significantly 
different from Flox. p<0.05 (One-way ANOVA). 
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Figure 3.7. The role of the muscle gp130 receptor on cancer-induced muscle fatigability. 
TA muscle’s fatigability during a 5-minute submaximal (50 Hz) and 5-minute maximal 
(200hz) fatigue test. A) Relative (% of Initial) force-time tracing of the TA muscle’s 
fatigability during a 5-minute submaximal (50 Hz) and 5-minute maximal (200hz) fatigue 
test from all groups. B) Maximal tetanic force following the 5-minute submaximal 
contraction-induced fatigue test in all mice. C) Maximal tetanic force following both the 
5-minute submaximal and 5-minute maximal contraction-induced fatigue test in all mice. 
Values are means ± SE. gp130 floxed controls (Flox).  ApcMin/+ mice (MIN). gp130 floxed 
HSA Cre/+ ApcMin/+ (MIN KO). *Significantly different from Flox. p<0.05 (One-way 
ANOVA).  
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Figure 3.8. The effect of muscle gp130 loss on mitochondrial content, function, and quality 
control in MIN mice. A) The ratio of phosphorylated to total protein expression of key 
energy stress sensor AMPK in the TA from MIN Flox and MIN KO normalized to Flox. 
B) The total protein expression of mitophagy markers BNIP3, Parkin, and p62 in the TA 
from MIN Flox and MIN KO normalized to Flox. C) The total protein expression of 
mitochondrial quality control markers PGC1α, DRP1, FIS1, and MFN1 in the TA from 
MIN Flox and MIN KO normalized to Flox. D) Representative western blot images of 
protein expression of all mitochondria related proteins. E) The total protein expression of 
mitochondrial content markers COXIV and Cyto C in the TA from MIN Flox and MIN 
KO normalized to Flox. F) Respiratory Control Ratio (RCR) was calculated by dividing 
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STATE 3 by STATE 4 respirations. Values are means ± SE. gp130 floxed controls (Flox).  
ApcMin/+ mice (MIN). gp130 floxed HSA Cre/+ ApcMin/+ (MIN KO). *Significantly 
different from Flox. ^Significant from MIN Flox. p<0.05 (One-way ANOVA).
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CHAPTER 4
THE ROLE OF MUSCLE USE ON SKELETAL MUSCLE FATIGUE DURING CACHEXIA 
PROGRESSION 
4.1 – Abstract 
Weakness and fatigue are among the most commonly reported complaints of cancer 
patients. Whether inactivity and muscle disuse are causal or consequence of muscle 
wasting with cancer, termed cachexia, remains largely unknown. Additionally, significant 
gaps remain in our understanding of the role of physical activity in the regulation of skeletal 
muscle function during cachexia progression. The purpose of the current study was to 
determine the role of physical activity in the development of weakness and fatigue during 
cachexia progression. Thirteen-week-old ApcMin/+ (MIN) and C57BL/6 (B6) mice were 
either given free wheel access (WA) or a locked wheel (C) for 5 weeks. WA had no effect 
on tumor burden (MIN-C 91 ± 8 polyps, MIN-WA 91 ± 4 polyps) or plasma IL-6 (MIN-C 
30 ± 10 pg/mL, MIN-WA 33 ± 8 pg/mL). MINs had reduced muscle force 17% (p=0.0004) 
and increased muscle fatigability 18% (p=0.015) compared to B6; however, fatigue 
recovery was increased 17% (p<0.05) with WA regardless of genotype. There was a direct 
relationship between reduced cage activity and both time to fatigue (R=0.66, p=0.04) and 
in situ skeletal muscle fatigability (R=0.73, p=0.02), which was not present in the MIN-
WA. There was a main effect of WA to increased mitochondrial complex I, II, and V by 
31% (p=0.001), 96% (p<0.0001), and 17% (p=0.0001), respectively, regardless of 
genotype. These results demonstrate that increased activity improved overall functional 
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capacity, skeletal muscle fatigue recovery, and mitochondrial content in tumor-bearing 
mice without affecting tumor-burden or systemic IL-6. 
 
4.2 – Introduction 
Overall weakness and fatigue are among the most commonly reported 
consequences of cancer contributing to lower life quality and poor treatment outcomes 
(Chang et al. 2000; Greene et al. 1994; Stone et al. 1999; Vigano et al. 2000; von Haehling 
and Anker 2014). Patients with low performance scores and reduced physical activity have 
suffer from functional dependence and reduced survival (Barber, Ross, and Fearon 1999; 
Fearon KC 2006; O'Gorman, McMillan, and McArdle 1999; Vigano et al. 2000). Cancer-
related fatigue (CRF) has been defined as subjective tiredness that is disproportional to 
activity which does not ease with rest (Rutherford, Manning, and Newton 2016; Stone et 
al. 1999; Winningham et al. 1994; Berger et al. 2015). While CRF’s definition is inherently 
central, proposed mechanisms include several proinflammatory cytokines and the loss of 
skeletal muscle mass which are hallmarks of cancer-cachexia (Rutherford, Manning, and 
Newton 2016; Berger et al. 2015; Saligan et al. 2015). Cachexia is the progressive loss of 
skeletal muscle mass secondary to chronic disease and is prevalent in 20-80% of cancer 
patients depending on the cancer type (von Haehling and Anker 2014; Evans et al. 2008). 
While our understanding of cachexia progression has improved, identifying whether 
fatigue and inactivity contribute to or are consequence of muscle mass loss with cancer 
requires significant attention. 
Whether CRF has central or peripheral (musculoskeletal) origins have served as a 
significant barrier to understanding fatigue’s etiology (Rutherford, Manning, and Newton 
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2016; Davis 1995). Skeletal muscle fatigue has been classically defined as either the 
inability to maintain a given force output over time (Fitts 1994) or the decrease in maximal 
strength following strenuous or sustained activity which returns after a period of rest 
(Allen, Lamb, and Westerblad 2008). Classically, skeletal muscle’s fatigue properties have 
been characterized but the contractile properties and relative fiber-type distribution (Close 
1972). Skeletal muscle fatigability relies on several physiological phenomena, most 
notably, adequate ATP production by the mitochondria through oxidative metabolism 
(Fitts 1994; Thompson, Balog, and Fitts 1992). Skeletal muscle mitochondria content and 
function is maintained by the regulation of mitochondrial biogenesis, fusion, fission, and 
autophagy (mitophagy), together termed mitochondrial quality control (QC) (Romanello 
and Sandri 2015). The production of new mitochondria through PGC-1α mediated 
mitochondrial biogenesis is stimulated by post-translational modification of the key energy 
sensor 5’ Adenosine monophosphate (AMP)-activated kinase (AMPK) (Reznick and 
Shulman 2006; Puigserver and Spiegelman 2003; Bergeron et al. 2001). AMPK 
phosphorylation is upregulated during energy stress/deprivation concomitant with 
increased reactive oxygen species (ROS) and increased mitochondrial fission proteins, 
DRP-1 and FIS-1, and mitochondrial fusion proteins, MFN-1,2 (Romanello et al. 2010; 
Carling 2017). After the removal of damaged or old mitochondria from the mitochondrial 
network through fission, mitophagic proteins PINK, Parkin-1, and LC3 recycle the 
organelles constituents for reuse. Disrupted mitochondrial content, QC, and oxidative 
capacity has been identified in cachectic muscle and are intriguing therapeutic targets 
(Julienne CM 2012; Brown et al. 2017; Carson, Hardee, and VanderVeen 2016). 
Mitochondrial QC is sensitive to skeletal muscle use (Yan, Lira, and Greene 2012; Hood 
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et al. 2018; Hood et al. 2011); however, the ability for increased activity to attenuate 
cancer-induced fatigue and mitochondrial dysregulation requires further investigation. 
Reduced volitional activity and disputed mitochondrial QC has been identified 
prior to significant wasting in both cancer patients and pre-clinical cachexia models 
(Baltgalvis et al. 2010; Berger et al. 2015). The ApcMin/+ (MIN) is an established pre-
clinical model of cancer-cachexia characterized by the development of intestinal polyps 
and a slow progressive wasting phenotype (Baltgalvis et al. 2008). MIN mice have a 
nonsense germline mutation in the Adenomatous polyposis coli (Apc) gene which 
predisposes mice to multiple intestinal neoplasia (min) resulting in the development of 
intestinal polyps (Moser, Pitot, and Dove 1990). MIN mice begin developing polyps at 4 
weeks of age and polyp number continues to increase until 12-14 weeks at which size 
progressively increases (Puppa et al. 2011). Reduced voluntary wheel activity and reduced 
oxidative metabolism is present ~14-15 weeks of age while body weight is typically 
initiated at 16 weeks (Baltgalvis et al. 2010). We have previously shown the validity for 
exercise to attenuate muscle mass loss in the MIN, but these findings were associated with 
reduced tumor-burden or reduced systemic inflammation (Mehl et al. 2005; Puppa et al. 
2012). Whether increasing volitional activity can attenuate body weight and muscle mass 
loss after full tumor-development has not been investigated. 
Both increased volitional activity and regimented endurance exercise training has 
been positively associated with improved quality of life and survival in cancer patients 
regardless of cachexia diagnosis (Alves et al. 2015; Barbaric et al. 2010; Brown et al. 2012; 
al-Majid and McCarthy 2001a). While changes in physical activity has systemic effects 
that benefit overall health, skeletal muscle is highly sensitive to activity changes (Holloszy 
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2004; Holloszy and Booth 1976; Powers, Kavazis, and DeRuisseau 2005; Zhang, Chen, 
and Fan 2007). Identifying whether fatigue and disuse are causal or consequence of muscle 
wasting with cancer has eluded investigators likely due to the complexity of the syndrome. 
Moreover, several proposed therapeutics have failed in clinical trials due to their inability 
to improve muscle function independent of mass (Ramage and Skipworth 2018). The 
purpose of the current study was to determine if increased volitional activity could 
attenuate the development of weakness and fatigue during cachexia progression in tumor-
bearing mice. We hypothesized that first there would be a direct relationship between cage 
activity and muscle fatigue in the MIN mouse, and second that MIN mice given free access 
to a wheel will have improved fatigue resistance associated with improved mitochondrial 
content and function. To test this hypothesis, B6 and MIN mice were given either free 
access to wheels or a locked wheel for 5 weeks. In order to control for exercise’s effects 
on tumor development, wheel access will be initiated between 13-14 weeks, when MIN 
tumor-number plateaus (Puppa et al. 2011). 
 
4.3 – Methods 
Animals 
Male C57BL/6 (B6) and ApcMin/+ (MIN) mice were originally purchased from 
Jackson Laboratories and were bred at the University of South Carolina’s Animal 
Resources Facility. All animals were group housed and kept on a 12:12-h light-dark cycle. 
Body weights were measured weekly, and animals were monitored for signs of distress. 
Animals were given food and water ad libitum throughout the duration of the study. All 
animals were fasted 5 hours prior to tissue collection. Mice were anesthetized with a 
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ketamine-xylazine-acepromazine cocktail, and hindlimb muscles and select organs were 
carefully dissected and snap frozen in liquid nitrogen and stored at -80⁰C until further 
analysis. All animal experiments were approved by the University of South Carolina’s 
Institutional Animal Care and Use Committee. 
Voluntary Wheel Running 
Voluntary wheel running was used as a marker of volitional physical activity and 
was performed as previously described (Baltgalvis 2010). At 13 weeks of age, B6 and MIN 
mice were individually housed in cages with 9.5-in.-diameter stainless steel wheels 
(MiniMitter, Bend, OR). B6 and MIN mice were randomized into 2 additional groups with 
either a fixed wheel (B6-C and MIN-C) or a free wheel access (B6-WA and MIN-WA). 
Wheel activity was monitored daily from 13 to 18 weeks of age. Bicycle computers 
(Specialized, Morgan Hill, CA) with magnetic sensors measured average speed, distance, 
time, and maximum speed, and the data were recorded daily. 
Analysis of Muscle Function 
At ~19 weeks of age, mice were anesthetized with 2% isoflurane inhalation and 
kept anesthetized at 1.5 % isoflurane for ~1hr throughout the duration of the procedure (~1 
hour). Muscle function analysis of the TA in situ, which maintains the host nerve and blood 
supply, has been previously described (Murphy et al. 2012). Briefly, the distal tendon of 
the left TA was isolated and tied to a force transducer (Aurora Scientific, Ontario, Canada) 
using 5-0 silk sutures. The mouse was place on the apparatus maintained at 37ºC 
throughout the entirety of the procedure. The sciatic nerve was exposed proximal to the 
knee and maintained using warmed mineral oil. The sciatic nerve was then subjected to a 
single stimulus to determine Lo. Once Lo was obtained, a force-frequency curve was 
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generated, and maximal tetanic force was determined. Specific tension was determined 
using TA muscle CSA calculated by muscle mass/(Lf x 1.06), where Lf represents fiber 
length determined by multiplying Lo by 0.6, the predetermined TA muscle length to fiber 
length ratio, and 1.06 represents the skeletal muscle density. After a 5-minute rest the TA 
was subjected to an intermittent fatigue protocol consisting of 0.5 second submaximal 
stimulation (50Hz) every second for 5 minutes. Immediately, after submaximal fatigue the 
TA was subjected to an intermittent fatigue protocol consisting of 0.5 second maximal 
stimulation (200Hz) every second for 5 minutes. The fatiguing properties of skeletal 
muscle were determining be measuring the relative change in force (% of initial 
contraction) throughout the duration of the fatiguing contraction. Absolute muscle fatigue 
was measured as the reduction in maximal force following either the submaximal or 
maximal fatiguing contraction. After the completion of the fatigue protocol the muscle was 
rested for 5 minutes at Lo and then maximally stimulated (200hz) to determine fatigue 
recovery. 
Polyp counts 
At sacrifice, the intestines were excised, and intestinal sections were flushed with 
PBS, opened longitudinally, and flattened with a cotton swab. All sections were fixed in 
10% buffered formalin (Fisher) for 24h. Formalin-fixed intestinal sections from all animals 
were rinsed in deionized water, briefly stained in 0.1% methylene blue, and counted by the 
same investigator who was blinded to the treatments. Polyps were counted under a 
dissecting microscope, using tweezers to pick through the intestinal villi and identify 
polyps. Polyps were categorized as <1mm, 1-2 mm, and >2mm for each segment (1-5) 
throughout the intestine. 
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Western blot analysis 
Western blot analysis was performed as previously described (Fix et al. 2018). 
Protein concentration of the isolated mitochondrial fraction was determined using the 
Bradford standard curve method. Homogenates were fractionated on SDS-polyacrylamide 
gels and transferred to PVDF membrane. After the membranes were blocked, antibodies 
against the Total OXPHOS Cocktail (Abcam, Cambridge, United Kingdom) were 
incubated at dilutions of 1:5000 overnight at 4°C in 1% TBST milk. Anti-rabbit IgG-
conjugated secondary antibodies (Cell Signaling Technology) were incubated with the 
membranes at 1:5000 dilutions for 1 h in 1% TBST milk. Enhanced chemiluminescence 
developed by autoradiography was used to visualize the antibody–antigen interactions. 
Blots were analyzed by measuring the integrated optical density (IOD) of each band with 
ImageJ software (NIH, Bethesda, MD, USA). 
Cytochrome C Oxidase Activity 
TA muscle samples were homogenized in extraction buffer (0.1 M 
KH2P04/Na2HP04, 2 mM EDTA, pH 7.2). Cytochrome-c oxidase (COX) activity was 
determined by measuring the rate of oxidation of fully reduced cytochrome c at 550nm 
using (CYTOCOX1) Sigma Aldrich Kit and spectrophotometer (Eppendorf) (Iqbal and 
Hood 2015). 
Respiratory Control Ratio 
Mitochondrial respiration was measured polarographically in a respiration chamber 
(Hansatech Instruments) maintained at 37°C as previously described (Kwon et al. 2015). 
A 7-10 mg piece of proximal TA muscle was mechanically tweezed with forceps under a 
dissecting microscope in ice-cold buffer X (60 mM K-MES, 35 mM KCl, 7.23 mM 
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K2EGTA, 2.77 mM CaK2EGTA, 20 mM imidazole, 0.5 mM DTT, 20 mM taurine, 5.7 
mM ATP, 15 mM phosphocreatine, and 6.56 mM MgCl2, pH 7.1). The fiber bundle was 
then incubated in 50uM saponin for 30 minutes and washed 3 times for 5 minutes in 
respiration buffer (105mM K-MES, 3mM KCl, 1mM EGTA, 10mM K2HPO4, 5mM 
MgCl2, 0.005mM Glutamate, 0.002mM Malate, 0.05% BSA, 20mM Creatine, pH 7.1). 
Fiber bundles were then placed into the oxygraph machine in 20mM creatine respiration 
buffer at 37 degrees and provided with 5mM of pyruvate and 2mM of malate. Two minutes 
following pyruvate and malate, 0.25mM of ADP was injected into the chamber to induce 
STATE 3 respiration for a duration of 5 minutes. 10ug/mL of Oligomycin was then injected 
to induce steady state 4 respiration for a duration of 10 minutes. Respiratory Control Ratio 
(RCR) was calculated by dividing state 3 by state 4 respirations. 
Skeletal Muscle Enriched Mitochondrial Fraction 
Mitochondrial isolation from the right quadriceps muscle was performed following 
a previously described protocol (Boutagy et al. 2015). Briefly, freshly dissected quadriceps 
muscles were minced and digested for 30 min in isolation buffer 1 (2 M Tris·HCl, 1 M 
KCl, and 0.5 M EDTA/Tris) containing 0.05% trypsin solution. The digested solution was 
spun at 200 g for 3 min, and the pellet was resuspended and homogenized using a Teflon 
pestle. The homogenate was spun at 700 g for 10 min and the supernatant was collected 
and spun at 8,000 g for another 10 min. The supernatant was discarded, and the pellet was 
resuspended in 5 ml of isolation buffer 1 and spun again at 8,000 g for 10 min. The resulting 
pellet was gently resuspended in 50 mL of isolation buffer 2 (0.1 M EGTA/Tris and 1 M 
Tris·HCl) and contained the isolated mitochondrial suspension. The Bradford method was 
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used to determine total mitochondria protein concentration in the purified mitochondrial 
fraction. 
Statistical analysis 
Values are presented as means ± standard error of the mean (SEM).  Student t-tests 
were performed to determine differences between genotypes. A two-way ANOVA was 
used to determine differences in muscle function and oxidative metabolism markers in 
between B6-C, B6-WA, MIN-C, and MIN-WA. Post hoc analyses were performed with 
student Newman-Keuls methods. A Bartlett’s test was used to determine significantly 
different standard deviations (p<0.05). If a significant difference was observed between 
group standard deviations, a non-parametric Kruskal-Wallis one-way ANOVA was used. 
A Pearson correlation was used to determine correlations between inflammatory genes and 
proteins with muscle function properties in MIN mice. Significance was set at p<0.05. 
 
4.4 – Results 
Animal Characteristics 
 After 13 weeks of age, both MIN and B6 mice were given either access to a free or 
fixed wheel. There was a trend for a significant main effect of MIN to have reduced body 
weight at the start of wheel access at 13 weeks of age (23.6 ± 0.2, 23.0 ± 0.3; p=0.068). 
There was no difference in wheel activity between MIN and B6 mice at the first 4 weeks, 
but there was a 50% reduction in wheel running time throughout the 5th week in MIN mice 
(Figure 4.1B). A two-way ANOVA repeated measures showed an effect of time for body 
weight to increase between 12-18 weeks of age in B6-C, B6-WA, and MIN-WA; however, 
there was no increase in body weight over time in the MIN-C (Figure 4.1B). There was a 
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significant main effect of MIN to have 4% body weight loss from peak body weight (Table 
4.1). While this cannot be characterized as cachexia (>5% BW loss), there was 3 MIN-C 
and 2 MIN-WA mice with >5% BW loss, 4 MIN-C and 4 MIN-WA mice between 0% and 
5% BW loss, and 3 MIN-C and 4 MIN-WA with 0% BW loss. Additionally, there were 
significant main effects of MIN to have increased spleen weight, reduced hindlimb mass, 
and reduced testes mass which have been extensively characterized with cachexia and 
cancer progression (Table 4.3). Tumor number in the MIN mouse plateaus at 12 weeks of 
age (Puppa et al. 2011). There was no observed difference in tumor size or number in MIN-
C or MIN-WA after 5 weeks of wheel access (Figure 4.1D, E). Additionally, there was no 
observed difference in plasma IL-6, a key regulator of cachexia development in the MIN 
mouse (Figure 4.1F) (Baltgalvis et al. 2008). 
Body composition 
 There were no observed differences in body weight, bone mineral content, bone 
density, lean mass, fat mass, and body fat % across all groups at 12-13 weeks of age (Table 
4.1). Additionally, there was no difference in daily food intake across all groups at the start 
of the study (Table 4.1). There was a significant main effect of MIN to have reduced bone 
mineral density and bone mineral content at 18 weeks of age (Table 4.1). There was a 
significant main effect of MIN to have reduced lean mass at 18 weeks of age, but there 
were no observed differences in overall fat mass of body fat percentage (Table 4.1). There 
was a significant main effect of MIN in absolute daily food intake, however this effect is 
lost when corrected for body weight (Table 4.1). When measuring the differences within 
individual mice over the duration of the study there was a significant main effect of MIN 
to reduce lean mass, however there was a main effect of Wheel to increase lean mass in 
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both genotypes (Table 4.1). Additionally, there was a significant main effect of MIN to 
reduced BMD and a significant main effect of Wheel to increase bone mineral density 
(Table 4.1). Lastly, there was a significant main effect of Wheel to increase food intake, 
but this effect was lost when corrected for body weight (Table 4.1). 
Whole body function 
 There were no observed differences in cage activity, grip strength, run to fatigue, 
or latency to fall across all groups at 12-13 weeks of age (Table 4.2). There was a 
significant main effect of MIN to have reduced cage activity regardless of wheel access 
(Table 4.2). There was an interaction for MIN-C mice to have reduced relative grip strength 
compared to B6-C and B6-WA by 11% and 9%, respectively (Table 4.2). There was a 
significant main effect of MIN to have reduced time to fatigue, regardless of wheel access; 
however, there was also a significant main effect of wheel to increase time to fatigue 
regardless of genotype (Table 4.2). There were no observed differences in latency to fall 
across all groups. 
Skeletal Muscle Twitch Properties 
 Skeletal muscle function has been classically characterized by the muscle’s twitch 
properties, force production capabilities, and intrinsic fatigability (Close 1972). Similar to 
what has been previously reported in the MIN mouse (VanderVeen et al. 2018), there was 
a significant main effect of MIN to have increase ½ RT and TPT indicating a slower 
contractile phenotype (Table 4.4). There was no effect of wheel in either genotype. There 
was a significant main effect of MIN to have a reduced rate of relaxation (-dx/dt) from 
peak tetanic force; however, rate of peak contraction was not changed (Table 4.4). 
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Additionally, there was no effect of wheel on rate of relaxation or contraction in both 
genotypes (Table 4.4). 
Skeletal Muscle Force Production 
There was a significant main effect of MIN to have reduced absolute force 
production (mN) starting between 80-200 hz during a force frequency protocol (Figure 
4.2). This is recapitulated in a significant main effect of MIN to have reduced absolute 
tetanic force (Po, Figure 4.2B). There were no observed differences across all groups in 
specific force between 10-180hz of the force frequency protocol; however, there was a 
significant interaction for B6-WA to have increased specific force at 200 Hz compared to 
MIN-WA and MIN-C (Figure 4.2C). There was a significant main effect of MIN to have 
reduced maximal specific force (sPo); however, there was also a significant main effect of 
wheel to increase sPo regardless of genotype (Figure 4.2D). Analysis of the relative force 
(% of Po) during the force frequency curve showed as significant interaction for MIN-C to 
have increased relative force compared to B6-C and B6-WA at 50 and 80Hz (Figure 4.2E, 
F). 
Skeletal Muscle Fatigability 
To measure the effects of activity and tumor-burden on submaximal and maximal 
contraction induced TA fatigability, the sciatic nerve was stimulated 1 contraction/second 
for 5 minutes at 50Hz followed by 1 contraction/second for 5 minutes at 200Hz. The 
relative (% of initial) force-time tracing throughout both contraction periods is shown in 
figure 4.3. There was a significant main effect of MIN to have reduced maximal force 
following 5 minutes of repeated submaximal contractions (Figure 4.3B). There was a trend 
(p=0.09) for wheel access to have increased maximal force following the submaximal 
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contractions (Figure 4.3B). Since maximal force was reduced prior to the fatiguing 
protocol, force was corrected for Po and there was a significant main effect of MIN to have 
reduced relative maximal force (% of Po) following the 5 minutes of repeated submaximal 
contractions. There was a significant main effect of MIN to have reduced maximal and 
relative force following the additional 5-minute maximal contraction-induced fatigue 
protocol (Figure 4.3 C). Following for the submaximal and maximal contractions, the 
muscle was allowed to rest at Lo for 5 minutes and maximally stimulated (200Hz) to asses 
fatigue recovery. There was a significant main effect of MIN to have reduced maximal 
force following a fatigue recovery; however, there was a significant main effect of wheel 
to have increased maximal force following fatigue recovery (Figure 4.3D). Again, 
correcting for differences in Po, there was a significant main effect of MIN to have reduced 
fatigue recovery and a significant main effect of wheel to have increased fatigue recovery 
regardless of genotype. 
Skeletal Muscle Mitochondrial Content and Respiration 
  A key contributor to skeletal muscle fatigability and ATP production is the 
mitochondrial content and function. We have previously reported reduction in 
mitochondrial content of the TA and EDL with cachexia progression (VanderVeen et al. 
2018; White et al. 2012). There was a significant main effect of MIN to reduce complex 
IV and II expression in isolated mitochondria (Figure 4.4C, D). There were significant 
main effects of wheel to have increased complex I, II, and V (Figure 4.4A, D, E). There 
was a significant interaction from WT-WA to have increased complex III compared to all 
groups (Figure 4.4B). Additionally, there was a significant main effect of wheel to increase 
cytochrome c protein expression regardless of genotype (Figure 4.4F). To assess muscle 
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mitochondrial function, a 7-10 mg piece of the proximal TA was teased and complex I 
mediated respiration was measured in permeabilized fibers. There were no observed 
differences in State 3 (Figure 4.5A). There was a significant main effect of MIN to increase 
state 4 which resulted in a significant main effect of MIN to have reduced respiratory 
control ratio (RCR, state 3/state 4; Figure 4.5B, C). 
 
4.5 – Discussion 
 The current study sought to further elucidate the role of reduced physical activity 
in increased skeletal muscle fatigue during the early stages of cachexia progression in 
tumor bearing mice. While reduced physical activity has an established role in muscle mass 
maintenance, whether increasing volitional activity prior to significant wasting can 
attenuate the increase in skeletal muscle fatigue during cancer remained largely 
speculative. The current study showed that regardless of tumor presence, increased 
physical activity through volitional wheel running could improve skeletal muscle fatigue 
resistance. Additionally, we showed that wheel running improved mitochondrial quality 
control and content in both healthy and sick mice. While our results show no improvements 
in body weight or hindlimb muscle mass, increased volitional activity may provide a 
protective effect against cancer induced muscle mitochondrial disruptions and fatigue. 
 The loss of volitional activity has previously been considered a side effect of muscle 
mass loss (Evans et al. 2008), though several studies show changes in activity levels and 
increased sedentary behavior prior to, or without, significant weight loss (Baltgalvis et al. 
2010; al-Majid and McCarthy 2001a; Barbaric et al. 2010). Our lab has previously shown 
that if initiated at 4 weeks of age, voluntary wheel running is reduced in prior to weight 
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loss in male MIN mice (Baltgalvis et al. 2010). The current study extends these results by 
showing a reduction in daily cage activity without significant weight loss. Interestingly, 
treadmill training exercise and free wheel access initiated at 4 weeks in the MIN showed 
that only treadmill training reduced total polyp number; however, both exercises reduced 
spleen weight and plasma IL-6 in male MINs (Mehl et al. 2005). To account for this 
potential confounder, the current study initiated wheel access at ~13 weeks of age, after 
tumor development in the MIN plateaus, and showed no effect of wheel on tumor burden 
or plasma IL-6. While MIN-C mice did not increase in body weight from 12-18 weeks, 
free wheel access was able to increase body weight over time which was directly related to 
an increase in lean body mass. While the beneficial effects of exercise on tumor metastasis, 
development, and growth has been studied extensively (Ashcraft et al. 2016), our results 
demonstrate that wheel access was able to improve lean body mass and body weight 
without changing tumor number or size. Low levels of physical activity have been strongly 
linked to the incidence of colon, breast, kidney, and digestive cancers (Barbaric et al. 
2010); however, our results and others suggest that maintaining physical activity levels 
following diagnosis is important in attenuating cancer-related fatigue and cachexia (Knols 
et al. 2005; Schmitz et al. 2005; Finne et al. 2018; Speck et al. 2010). Additionally, further 
work is needed to determine if wheel access improved gut barrier dysfunction which 
develops concurrently with inflammation and tumor-burden in the MIN mouse (Puppa et 
al. 2011). 
Regimented exercise and increased daily physical activity are commonly 
prescribed to cancer patients aimed at improving physical function and quality of life 
(Brown et al. 2012; Speck et al. 2010; Stricker et al. 2004), however our understanding of 
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physical activity’s ability to improve muscle functional capacity during cachexia 
progression is still developing. Furthermore, our understanding of the progression of 
central and musculoskeletal fatigue during cancer remains extremely limited. While a 
cause-effect relationship between central and peripheral fatigue is generally accepted, their 
mechanistic link and causal sequence with aging and chronic disease is not well understood 
(Gandevia 2001). The current study demonstrates that wheel access was unable to improve 
central drive, demonstrated by no difference in cage activity between locked and free wheel 
access MIN mice; however, wheel access improved running time during a treadmill fatigue 
test as well as improved relative grip strength. Increased physical activity has been shown 
to improve physical functioning and improve both physiological and psychological 
outcomes contributing to improved life quality in cancer survivors (Finne et al. 2018; 
Schmitz et al. 2005; Mishra et al. 2012; Juvet et al. 2017). While our results are limited 
regarding central fatigue, our results suggest that wheel access improved several aspects of 
physical function without necessarily improving volitional activity. One potential 
hypothesis for why wheel access was unable to increase activity is the lack of improved 
systemic inflammation and tumor-burden. Chronic inflammation negatively impacts 
central fatigue since several inflammatory cytokines, namely TNF-α, IL-6, and IFNγ, have 
been shown to cross the blood brain barrier and disrupt the hypothalamic-pituitary-adrenal 
(HPA) axis (LaVoy, Fagundes, and Dantzer 2016). Whether activity altered neural 
inflammation of tumor-bearing mice was not determined, however this question serves as 
an intriguing inquiry for further research. 
The regulation of skeletal muscle function during cachexia progression has only 
just begun to be unearthed. Several reports of disrupted skeletal muscle function have been 
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reported (Gorselink et al. 2006; Murphy et al. 2012; Roberts, Ahn, et al. 2013; Roberts, 
Frye, et al. 2013; VanderVeen et al. 2018; Jaweed et al. 1983); however, these studies were 
limited in mechanistic insight and provide contentious findings likely due to the muscle 
measured, tumor model used, and endpoint degree of weight loss. Additionally, a 
disconnect between muscle mass and function has been suggested to contribute to 
unsuccessful treatment outcomes which aimed to improve mass without accounting for 
functional changes in preclinical settings (Ramage and Skipworth 2018). Skeletal muscle 
function analysis has been relegated to the simple assessments of skeletal muscle strength 
without appropriately testing skeletal muscle fatigability. Improved muscle strength 
without improved muscle fatigue resistance has limited translation to cancer patients 
suffering from CRF which affect a large majority of cancer patients (Berger et al. 2015). 
To the best of our knowledge, this is the first study to report both reduced muscle force and 
increased submaximal contraction-induced skeletal muscle fatigue in pre-cachectic tumor-
bearing mice. Furthermore, we provide evidence to suggest a direct relationship between 
inactivity and fatigue which can be mitigated by wheel activity. While increased activity 
was unable to attenuate muscle mass or strength losses, we have previously shown that 
repeated eccentric muscle contractions, a model of resistance exercise, could attenuate the 
loss of muscle CSA in the male MIN mouse (Hardee et al. 2016). Together, increased 
activity and resistance exercise should improve overall functional quality of cancer patients 
through attenuating the deleterious tumor effects on muscle mass, strength, and fatigability. 
Emerging evidence suggests that metabolic dysfunction is a key regulator of the 
loss of muscle mass and function with cancer (Carson, Hardee, and VanderVeen 2016). 
Disrupted oxidative metabolism and mitochondrial dysfunction have been demonstrated in 
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both pre-cachectic and cachectic muscle which may directly disrupt the functional quality 
of skeletal muscle (Brown et al. 2017; VanderVeen, Fix, and Carson 2017). Our lab has 
previously shown that voluntary wheel running is reduced prior to weight loss in male MIN 
mice associated with anemia and decreased muscle citrate synthase (CS) activity 
(Baltgalvis et al. 2010). Regimented treadmill exercise and wheel access initiated at 4 
weeks of age increased CS activity compared to sedentary controls; however, treadmill 
training reduced total polyp number and both exercise types reduced spleen weight and 
plasma IL-6 (Mehl et al. 2005). The current study demonstrated that MIN mice had a 
reduction in cage activity and voluntary wheel running without significant body weight 
loss. While TA muscle respiration was reduced in MINs regardless of treatment, wheel 
access was able to improve mitochondrial content in both healthy and tumor-bearing mice. 
Treadmill exercise training has been shown to be protective against IL-6-induced cachexia 
in the MIN mouse associated with improved triglyceride and glucose metabolism (Puppa 
et al. 2012). While mitochondria are especially susceptible to inflammation-induced 
wasting (VanderVeen, Fix, and Carson 2017; White et al. 2012), exercise has been shown 
to mitigate chronic inflammation, improve mitochondria quality control, and increase 
mitochondrial content (Mathur and Pedersen 2008; Yan, Lira, and Greene 2012). 
The loss of functional independence and the burden of CRF plagues most cancer 
patients and contributes substantially to reduced life quality and survival. Identifying the 
musculoskeletal alteration that occur with disease progression will improve our 
understanding of these functional deficits and improve the efficacy of future therapeutics. 
The current study identified deficits in skeletal muscle mass, strength, and fatigue 
resistance before significant body weight loss occurred. Additionally, these changes 
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occurred concomitant with reduced volitional activity and disrupted mitochondrial 
function and quality control. We provide further evidence to suggest that increased activity 
improved fatigue resistance and mitochondrial content without changing the systemic 
inflammation or tumor burden. While muscle mass loss was not attenuated, increasing 
activity in addition to regimented resistance exercise may improve the functional quality 
of cancer patients in order to improve life quality and survival. 
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 Table 4.1. Mouse body composition pre- and post-wheel access 
   B6  MIN 
   Control  Wheel Access  Control  Wheel Access 
n  10  9  10  10 
                  
Body Weight (g)                 
12wk  23.6 ± 0.3  23.8 ± 0.2  23.3 ± 0.5*  22.6 ± 0.4* 
18wk  25.5 ± 0.5
$
  25.4 ± 0.2
$
  23.6 ± 0.5*  24.4 ± 0.7*
$
 
12 – 18 wks   1.96 ± 0.20  1.58 ± 0.19  0.41 ± 0.71  1.84 ± 0.52 
                  
Lean Mass (g)                 
12wk  17.9 ± 0.3  17.9 ± 0.1  17.9 ± 0.4  17.6 ± 0.3 
18wk  19.3 ± 0.3
$
  19.5 ± 0.1
$
  18.0 ± 0.4*  19.1 ± 0.5*
$
 
12 – 18 wks   1.43 ± 0.08  1.56 ± 0.11^  0.12 ± 0.41*  1.47 ± 0.47*^ 
                  
Fat Mass (g)                 
12wk  2.7 ± 0.1  2.6 ± 0.1  2.5 ± 0.1  2.4 ± 0.1 
18wk  2.8 ± 0.1  2.5 ± 0.1  2.5 ± 0.2  2.5 ± 0.1 
12 – 18 wks   0.14 ± 0.14  -0.18 ± 0.11  0.02 ± 0.25  0.15 ± 0.13 
Values are means ± SEM. All measurements taken at 12 and 18 weeks (wk). Body 
weights (BW) given in grams. Lean mass from DEXA given in grams. Fat mass from 
DEXA given in grams. Change was calculated by the difference between 12 and 18 
weeks. Two-way ANOVA. *Main effect of genotype. ^Main effect of treatment. 
$Paired t-test, effect of time. Significance was set a p<0.05 
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 Table 4.2. Behavioral and functional characteristics pre- and post-wheel access 
   B6  MIN 
   Control  Wheel Access  Control  Wheel Access 
 n  10  9  10  10 
                  
 Behavioral               
 Food Intake (g)                 
 12wk  3.7 ± 0.1  3.7 ± 0.1  3.8 ± 0.2  3.7 ± 0.1 
 18wk  4.0 ± 0.1
$
  4.3 ± 0.2
$
  3.7 ± 0.2*  3.9 ± 0.1* 
 12 – 18 wks   0.3 ± 0.1  0.5 ± 0.2^  -0.2 ± 0.3*  0.2 ± 0.1*^ 
                  
 Cage Activity (counts)                 
 12wk  19453 ± 1319  19622 ± 1381  21999 ± 2747  23433 ± 2765 
 18wk  26389 ± 2003  29827 ± 2622  12633 ± 3437*  14056 ± 1965* 
 12 – 18 wks   6936 ± 2678
$
  10204 ± 2579
$
  -9366 ± 2922
$
*  -9376 ± 3017
$
* 
                  
 Functional               
 Grip Strength (kN/g)                 
 12wk  10.6 ± 0.1  10.3 ± 0.3  10.8 ± 0.3  10.3 ± 0.2 
 18wk  11.3 ± 0.4  11.3 ± 0.1  10.0 ± 0.2*  10.7 ± 0.2* 
 12 – 18 wks   0.7 ± 0.4  0.9 ± 0.3
$
^  -0.8 ± 0.4*  0.4 ± 0.3*^ 
                  
 Fall Latency (s)                 
 12wk  61.5 ± 4.6  62.1 ± 5.9  61.3 ± 4.4  56.4 ± 8.4 
 18wk  76.7 ± 5.7  68.1 ± 5.2  69.0 ± 9.7  72.2 ± 3.4 
 12 – 18 wks   15.2 ± 5.1
$
  6.1 ± 6.2
$
  7.8 ± 9.6
$
  15.8 ± 7.2
$
 
                  
 Time to Fatigue (min)                 
 12wk  77.9 ± 4.1  79.7 ± 6.0  78.8 ± 6.7  74.2 ± 6.1 
 18wk  86.6 ± 3.6  150.3 ± 11.7^  40.8 ± 6.9*  99.9 ± 15.2*^ 
 12 – 18 wks  8.7 ± 4.1  70.7 ± 13.7
$
^  -38 ± 7.3
$
  25.7 ± 15.2*^ 
 Values are means ± SEM. All measurements taken at 12 and 18 weeks (wk). Average food 
intake measured over 3 days in grams. Average daily cage activity measured over 3 days 
in beams crossed. Relative grip strength given in kN force /grams of body weight. Time 
on the rotorod (fall latency) given in seconds. Time to fatigue during a graded exercise 
treadmill test given in minutes. Change was calculated by the difference between 12 and 
18 weeks. Two-way ANOVA. *Main effect of genotype. ^Main effect of treatment.  
$Paired t-test, effect of time. Significance was set a p<0.05 
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Table 4.3. The effect of wheel access on the characteristic data of MIN and B6 mice 
  B6  MIN 
  Control  Wheel Access  Control  Wheel Access 
n  10  9  10  10 
                 
Age (wks)  19.6 ± 0.2  19.8 ± 0.1  19.2 ± 0.4  19.4 ± 0.2 
                 
Peak BW (g)  25.7 ± 0.4  25.7 ± 0.3  24.7 ± 0.3*  25.0 ± 0.4* 
End BW (g)  25.5 ± 0.5
$
 
 25.3 ± 0.2  23.5 ± 0.6*
$
 
 24.4 ± 0.6* 
BW Loss (%)  1.0 ± 0.3  1.4 ± 0.7  4.7 ± 2.0*  2.8 ± 1.4* 
                 
Tibia Length (mm)  17.0 ± 0.0  17.1 ± 0.0  16.8 ± 0.1*  16.9 ± 0.1* 
Hindlimb (mg)  310 ± 6  319 ± 4  266 ± 14*  283 ± 12* 
Hindlimb/Tibia 
Length 
 18.2 ± 0.4  18.6 ± 0.2  15.8 ± 0.8*  16.8 ± 0.7* 
                 
Epi Fat (mg)  255 ± 19  192 ± 16  138 ± 32*  134 ± 20* 
Spleen (mg)  71 ± 3  68 ± 5  313 ± 34*  279 ± 21* 
Testes (mg)  193 ± 4  200 ± 3  179 ± 9*  183 ± 7* 
Sem Ves (mg)  305 ± 8  261 ± 8  152 ± 23*  201 ± 28* 
Values are means ± SEM. Body weights (BW) given in grams (g). Percent body 
weight loss is determined from peak body weight to weight prior to sacrifice. Tissue 
weights given in milligrams (mg). Tibia length given in millimeters (mm). C57BL/6 
(B6). ApcMin/+ (MIN). Two-way ANOVA. *Main effect of genotype. $Paired t-test, 
effect of time. Significance was set a p<0.05 
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Table 4.4. The effect of wheel access on skeletal muscle’s contractile properties in the 
MIN and B6 
  B6  MIN 
  Control  Wheel Access  Control  Wheel Access 
n  10  9  10  10 
TA Weight (mg)  49.0 ± 0.8  48.4 ± 0.8  42.0 ± 1.9*  44.6 ± 1.9* 
 L
o
 (mm)  14.2 ± 0.1  14.3 ± 0.2  13.9 ± 0.2  14.3 ± 0.1 
                 
1/2 RT (ms)  7.3 ± 0.2  7.5 ± 0.1  9.4 ± 0.8*  10.3 ± 1.2* 
TPT (ms)  15.1 ± 0.2  14.8 ± 0.2  16.2 ± 0.4*  17.6 ± 1.3* 
                 
+ dP/dt (mN/s)  24024 ± 873  23197 ± 970  20619 ± 1993  20992 ± 1691 
- dP/dt (mN/s)  17549 ± 1287   19700 ± 977   12538 ± 1313*   13090 ± 1664* 
Values are means ± SEM. Tibialis Anterior (TA) weight given in milligrams (mg). 
Optimal length (Lo) in millimeters (mm), 1/2 relaxation time (RT), and time to peak 
twitch (TPT) determined from isolated twitch contraction. The rate of maximal 
contraction (+dP/dT) and Relaxation (-dP/dT) obtained from 200hz maximal tetanic 
force contraction. C57BL/6 (B6). ApcMin/+ (MIN). Two-way ANOVA. *Main effect of 
genotype. Significance was set a p<0.05 
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Figure 4.1 The effect of free wheel access on body weight, polyp size, and plasma IL-6. A) 
Experimental design. Pre-treatment measurements were performed at 12 weeks (wks) of 
age. Mice were then singled house with either a fixed or free wheel for 5 weeks. Post-
treatment measurements were performed at 18 wks of age. Several properties of skeletal 
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muscle function were assessed at ~19 wks of age is all mice. B) Body weight in grams (g) 
over the duration of the study. C) Time spent on the wheel for mice given free wheel access. 
D) Number of intestinal polyps in all MIN mice. E) Intestinal polyp size distribution in all 
MIN mice. F) Plasma levels of IL-6 in picograms per milliliter (pg/mL) in all mice. Plasma 
IL-6 was not detectable (ND) in all B6 mice. C57BL/6 (B6). ApcMin/+ (MIN). Fixed wheel 
control (C). Free wheel access (WA). Two-way ANOVA. *Main effect of genotype. 
#Significant difference between MIN-C and B6-WA. @Significant difference between 
MIN-C and B6-C. Significance was set a p<0.05 
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Figure 4.2 The effect of free wheel access on skeletal muscle force production in the male 
MIN. A) Absolute force-frequency curve of the TA from all groups in millinewtons (mN). 
B) Maximal tetanic force force-frequency curve of the TA of all groups in mN. C) Specific 
force-frequency curve of the TA of all groups in kilonewtons/meters2 (kN/m2). D) Maximal 
specific force of the TA from all groups in kN/m2. E) Relative (% of maximal tetanic force) 
force-frequency curve of the TA of all groups. D) Relative (% of maximal tetanic force) 
force at 50Hz of the TA of all groups. Values are means ± SE. C57BL/6 (B6). ApcMin/+ 
(MIN). Fixed wheel control (C). Free wheel access (WA). Two-way ANOVA. *Main effect 
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of genotype. #Significant difference between MIN-C and B6-WA. @Significant difference 
between MIN-C and B6-C. Significance was set a p<0.05 
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Figure 4.3 The effect of free wheel access on skeletal muscle fatigability in the male MIN. 
TA muscle’s fatigability during a 5-minute submaximal (50 Hz) and 5-minute maximal 
(200hz) fatigue test. A) Relative (% of Initial) force-time tracing of the TA muscle’s 
fatigability during a 5-minute submaximal (50 Hz) and 5-minute maximal (200hz) fatigue 
test from all groups. B) Maximal tetanic force in millinewtons (mN) following the 5-minute 
submaximal contraction-induced fatigue test in all mice. C) Maximal tetanic force in mN 
following both the 5-minute submaximal and 5-minute maximal contraction-induced 
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fatigue test in all mice. D) Maximal tetanic force in mN following a 5-minute rest after the 
completion of the entire contraction-induced fatigue test in all mice. Values are means ± 
SE. C57BL/6 (B6). ApcMin/+ (MIN). Fixed wheel control (C). Free wheel access (WA). 
Two-way ANOVA. *Main effect of genotype. ^Main effect of treatment. Significance was 
set a p<0.05 
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Figure 4.4 The effect of wheel access on skeletal muscle mitochondrial content in isolated 
skeletal muscle mitochondria in the male MIN. A) The total protein expression of 
mitochondrial complex V (A), III (B), IV (C), II (D), and I (E) relative to B6-C in isolated 
skeletal muscle mitochondria normalized to the loading control, VDAC. F) Representative 
western blot images of protein expression of all mitochondrial complexes. Values are 
means ± SE. C57BL/6 (B6). ApcMin/+ (MIN). Fixed wheel control (C). Free wheel access 
(WA). Two-way ANOVA. *Main effect of genotype. ^Main effect of treatment. & 
Significantly different to all groups. Significance was set a p<0.05   
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Figure 4.5 The effect of wheel access on skeletal muscle mitochondrial function in the male 
MIN. Tibialis anterior (TA) respiratory control ratio. A) 0.25mM of ADP was injected into 
the chamber to induce STATE 3 respiration for a duration of 5 minutes. B) 10ug/mL of 
Oligomycin was injected to induce steady STATE 4 respiration for a duration of 10 
minutes. C) Respiratory Control Ratio (RCR) was calculated by dividing STATE 3 by 
STATE 4 respirations. Values are means ± SE. C57BL/6 (B6). ApcMin/+ (MIN). Fixed 
wheel control (C). Free wheel access (WA). Two-way ANOVA. *Main effect of genotype. 
^Main effect of treatment. & Significantly different to all groups. Significance was set a 
p<0.05
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CHAPTER 5
OVERALL DISCUSSION 
The overall purpose of this dissertation was to determine the development of 
skeletal muscle fatigue in tumor-bearing mice and identify the regulation of skeletal muscle 
fatigue by activity and/or muscle gp130 signaling. We hypothesized that cancer-induced 
skeletal muscle fatigue develops independent of significant weight loss in association with 
decreased muscle use and activated muscle gp130 signaling which disrupts muscle 
oxidative metabolism. We then sought to determine if increased muscle use through 
increased volitional activity could delay the induction of fatigue in tumor-bearing mice. 
Key findings from this dissertation’s experiments demonstrated that (1) cachectic skeletal 
muscle displayed disrupted contractile properties and force production associated with 
increased muscle gp130 signaling, however, disrupted skeletal muscle fatigability develops 
without significant wasting in MIN mice, (2) IL-6 directly disrupted skeletal muscle 
fatigability and mitochondrial function through muscle gp130 signaling, though the loss of 
the gp130 receptor in MIN mice did not rescue skeletal muscle function, and (3) reduced 
activity is associated with skeletal muscle and whole body fatigue in MIN mice which can 
be improved with wheel access. 
 
5.1 – Skeletal muscle dysfunction during cachexia progression 
Cancer patients suffering from progressive body weight loss and low skeletal 
muscle mass have reduced functional independence and life quality contributing to reduced 
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chemotherapy tolerance and a poorer prognosis (Vigano et al. 2000; Evans et al. 2008; 
Moses et al. 2004; Fearon KC 2006; Argiles 2014; Amano et al. 2017; al-Majid and 
McCarthy 2001a; O'Gorman, McMillan, and McArdle 1999). Whether these functional 
deficits are causal or consequence of muscle mass loss with cancer patients remains 
unknown. Additionally, the neural, circulatory, or musculoskeletal contributions to these 
deficits are only beginning to be unearthed (Christensen et al. 2014; Gorselink et al. 2006; 
Murphy et al. 2012; Roberts, Frye, et al. 2013; Jaweed et al. 1983). While cachectic skeletal 
muscle force and fatigability have been studied, our understanding of the progression of 
these deficits and mechanistic explanations remain limited (al-Majid and McCarthy 2001a; 
Baltgalvis 2010; Christensen et al. 2014; Murphy et al. 2012; Roberts, Frye, et al. 2013; 
White, Baltgalvis, et al. 2011; White et al. 2012). Results from the current project 
demonstrate skeletal muscle weakness and contractile dysfunction occurs concomitant 
with body weight and muscle mass loss, while increased skeletal muscle fatigability 
develops prior to the initiation of cachexia. 
Skeletal Muscle Contractile Properties 
Skeletal muscle contractile dysfunction has been demonstrated across several 
chronic diseases (Sin and Man 2003; Deans and Wigmore 2005; Kuller et al. 2008; Vidt 
2006). Whether contraction rates are disrupted during cachexia development has not been 
firmly established. The twitch properties of the TA from LLC and C-26 tumor-bearing 
mice were not different from healthy controls (Murphy et al. 2011; Murphy et al. 2012). 
There was a reduction in twitch force (Gorselink et al. 2006) and slower twitch properties 
(Roberts, Frye, et al. 2013) in the EDL of C-26 mice. The current studies demonstrated that 
twitch properties of the TA from MIN mice were slowed with severe cachexia. 
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Additionally, twitch properties were not affected by IL-6, but the loss of the muscle gp130 
receptor increased the twitch contraction rates. While increased contraction rates are 
associated with reduced skeletal muscle activity, the slowing of cachectic muscle occurs 
concomitant with reduced activity which was not improved with wheel access. Skeletal 
muscle’s contractile properties rely on the coordination of neural excitation, sarcomeric 
structure, calcium handling, and myosin isoform expression (Close 1972; Schiaffino and 
Reggiani 1996; Khodabukus and Baar 2015). Classically, twitch relaxation is dependent 
on the rate of calcium reuptake by the Sarcoplasmic Reticulum Calcium ATPase (SERCA) 
after stimulation (Close 1972; Berchtold, Brinkmeier, and Muntener 2000). Previous 
reports have shown increased expression of SERCA1 and SERCA2 contributing to 
aberrant calcium handling, mitochondrial dysfunction, EC uncoupling, and fatigue (Debold 
2016; Fontes-Oliveira et al. 2013; Carson, Hardee, and VanderVeen 2016). It is generally 
accepted that preferential atrophy of type II occurs during cachexia, particularly at the early 
stages of wasting. Interestingly, we have previously demonstrated a loss of fiber-types (IIB 
, IIX, and IIA) in the TA of cachectic MIN mice, which coincided with the percent of 
myofibers with high succinate dehydrogenase enzyme activity (Hardee et al. 2016). 
Skeletal Muscle Force 
Reduced specific tension has been reported during LLC-induced cachexia (Roberts, 
Frye, et al. 2013), while others have reported a mass dependent loss of muscle force with 
C-26-induced wasting (Murphy et al. 2012; Gorselink et al. 2006). The results from the 
current study demonstrated that 20-week old weight stable male MINs had no disruption 
to absolute or specific skeletal muscle force while severely cachectic MINs had a loss of 
skeletal muscle force that was disproportionate to muscle mass loss. Interestingly, muscle 
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weakness was observed prior to weight loss in MIN mice with a high polyp count 
suggesting that muscle weakness was dependent on tumor-burden which contributes 
significantly to cachexia severity (Baltgalvis et al. 2008). While tumor-burden is strongly 
related to plasma IL-6, elevated levels of IL-6 were not able to induce muscle mass loss or 
weakness in tumor-free mice. Furthermore, loss of the muscle IL-6 receptor β-subunit 
(gp130) was not able to prevent muscle mass loss or muscle weakness in the MIN. Our lab 
has previously shown that IL-6 null MIN mice had spared body and muscle weight loss 
associated with reduced tumor-burden (Baltgalvis et al. 2008), and administration of an IL-
6 antibody to MINs spared muscle mass without affecting tumor-burden (White, Baynes, 
et al. 2011). Together, these results suggest an interaction between circulating IL-6 and the 
tumor-environment to promote skeletal muscle mass loss and may also contribute muscle 
weakness independent of muscle gp130 signaling. Tumor-derived IL-6, IL-6 trans-
signaling, and other members of the IL-6 family of cytokines have been shown to play an 
important role in muscle mass maintenance with cancer (Pettersen et al. 2017; Kandarian 
et al. 2018); however, their role in cancer-induced muscle weakness has not been 
investigated.  
Skeletal muscle fatigue 
Along with lean mass and strength, cancer-related fatigue is a strong predictor of 
survival in cancer patients (Vigano et al. 2000; Christensen et al. 2014). The results of the 
current study support a direct role for skeletal muscle in cancer fatigue development before 
the onset of cachexia. Accelerated skeletal muscle fatigue has been reported in cancer 
patients and preclinical models alike (Stone et al. 1999; Roberts, Frye, et al. 2013); 
however, several reports show do not see a difference in fatigability between tumor-burden 
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and healthy controls (Murphy et al. 2012; Gorselink et al. 2006). Our results demonstrate 
that fatigue develops without significant weight loss and suggests that muscular fatigue 
develops prior to wasting and contributes to muscle mass loss. Interestingly, while TNFα 
administration alone was sufficient to cause weakness and contractile dysfunction, TNFα 
had no effect on skeletal muscle fatigability (Hardin et al. 2008). High levels of IL-6 were 
able to accelerate muscle fatigue in tumor-free mice, but loss of the IL-6 gp130 receptor in 
tumor bearing mice was not sufficient to attenuate cancer-induced muscle fatigue. While 
muscle gp130 loss was unable to prevent cancer-induced fatigue, there is a strong 
relationship between activity and muscle fatigue with cachexia progression, which was 
attenuated by increased activity. These results suggest that activity and chronic 
inflammation can directly cause fatigue, however, may only partially contribute to cancer-
induced fatigues’ etiology. It is important to note, however, that in addition to the 
abundance of mitochondrial derived ATP, skeletal muscle fatigability can be affected by 
nutrient availability, blood supply, pH, and myosin heavy chain isoform expression, which 
were examined in this dissertation. Future inquiry into the regulation and contribution of 
these processes to cancer-induced fatigue are warranted. 
 
5.2 – Skeletal muscle oxidative metabolism during cachexia progression  
Disrupted metabolic homeostasis in skeletal muscle has been demonstrated across 
several chronic diseases (Sin and Man 2003; Deans and Wigmore 2005; Kuller et al. 2008; 
Vidt 2006). Recently, muscle mitochondrial dysfunction and increased fatigability has 
been shown to occur independent of changes to muscle size and strength (VanderVeen et 
al. 2018; Brown et al. 2017).  Additionally, there is a loss of muscle functional quality that 
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is disproportionate to muscle mass demonstrating that muscle weakness and fatigue have 
distinct etiologies (Ramage and Skipworth 2018). IL-6 signaling through muscle gp130 
regulates skeletal muscle mass and metabolic homeostasis during both physiological and 
pathological conditions (Carson and Baltgalvis 2010; Bonetto et al. 2011; Hardee, Counts, 
et al. 2018; Gao et al. 2017; Puppa, Gao, et al. 2014). Furthermore, the mitochondria have 
emerged as an intriguing target for inflammation induced skeletal muscle metabolic 
dysfunction (Boland, Chourasia, and Macleod 2013; Brown et al. 2017; Hardee et al. 2016; 
Carson, Hardee, and VanderVeen 2016). We have previously shown that IL-6 decreases 
mitochondrial protein expression in tumor-free mice and exercise can prevent the IL-6-
induced loss of muscle mass in tumor bearing mice (Puppa et al. 2012). The results from 
the current study extend these findings to show that IL-6/gp130 signaling plays a direct 
role in muscle mitochondrial function and increase volitional activity can improve muscle 
mitochondrial content and fatigability in the tumor bearing mice. 
Skeletal muscle mitochondrial content 
Cachectic skeletal muscle has disrupted metabolic homeostasis thought to 
contribute to aberrant muscle mass maintenance and increased muscle-specific fatigue. We 
have previously found disrupted mitochondrial quality control (decreased content and 
biogenesis, disrupted dynamics, etc.) in MIN muscle (White et al. 2012; Carson, Hardee, 
and VanderVeen 2016), which coincides with decreased physical activity and reduced 
muscle mass (Baltgalvis 2010). Decrements in mitochondrial biogenesis and mitochondrial 
content have been strongly associated with increased fatigue in skeletal muscle (Lin et al. 
2002; Brown et al. 2017). The results from the current study further extend this work by 
showing decreased COX activity in cachectic MIN muscle. Additionally, there was a 
 153 
reduction in several muscle mitochondrial complexes in mitochondrial isolated from pre-
cachectic mouse muscle. We also demonstrated that tumor-bearing mice, independent of 
weight loss, experienced increased fatigue measured by whole body exercise and in situ 
muscle function, which was not related to elevated circulating IL-6, activated muscle 
inflammatory signaling, or COX activity. Interestingly, gpo130 loss was able to partially 
rescue the loss of muscle PGC1α and COXIV protein expression, while increasing MFN1 
and decreased FIS1 protein expression. Increasing physical activity in pre-cachectic MINs 
was able to increase protein expression of isolated mitochondrial complexes concomitant 
with increase run to fatigue time and improved muscle fatigue resistance. 
Skeletal muscle mitochondrial function 
Cancer-induced skeletal muscle mitochondrial dysfunction is currently an active 
area of investigation (Carson, Hardee, and VanderVeen 2016). While more work is needed, 
the activation of either nuclear factor κ B (NF-κB), STAT3, or mothers against 
decapentaplegic homolog 3 (Smad3) signaling have been associated with cancer-induced 
muscle mitochondria dysfunction in tumor bearing mice (VanderVeen, Fix, and Carson 
2017). LLC-tumor cell induced cachexia demonstrated decreased muscle ATP synthesis 
rates and decreased electron transport chain efficiency with associative increases in TNF-
α (Constantinou et al. 2011; McLean, Moylan, and Andrade 2014). Furthermore, blockade 
of NF-κB improved diaphragm mitochondrial respiration in mice bearing P07 lung derived 
tumors (Fermoselle et al. 2013). While our understanding of STAT3’s role in skeletal 
muscle mitochondrial function is in its infancy, the current study demonstrated that IL-6 
can disrupt mitochondrial respiration and through direct activation of muscle gp130 
signaling (Wegrzyn et al. 2009). Additionally, MIN mice lacking the muscle gp130 
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receptor had increased muscle mitochondrial respiration when compare to floxed MINs; 
however, gp130 loss did not improve fatigability in the MIN. Lastly, increased wheel 
activity was able to improve muscle fatigability without improving muscle mitochondrial 
respiration.  
 
5.3 – Summary 
The purpose of this dissertation was to investigate the regulation of skeletal muscle 
fatigue in tumor-bearing mice. The loss of skeletal muscle’s mass and functional quality 
are thought to develop primarily through disruptions to muscle metabolic homeostasis; 
however, what causes these disruptions still remain an active area of investigation (Tisdale 
2009). While accelerated muscle protein catabolism and suppressed anabolism has been a 
primary target for cancer-cachexia therapeutics, several therapeutics have failed to improve 
skeletal muscle function and patient quality of life (al-Majid and McCarthy 2001a; 
Christensen et al. 2014; Aversa, Costelli, and Muscaritoli 2017; Biolo, Cederholm, and 
Muscaritoli 2014; Dobs et al. 2013; Ramage and Skipworth 2018). Recent evidence 
suggests an important role for disrupted oxidative metabolism in cancer-induced wasting, 
specifically, accelerated mitochondrial fission and autophagy in concert with reduced 
mitochondrial biogenesis and fusion contributing to mitochondrial dysfunction. While 
mitochondrial dysfunction contributes to muscle mass loss, results from the current study 
suggest that inflammation-induced mitochondrial dysfunction disrupts skeletal muscle 
fatigability independent of mass. Additionally, disruptions to muscle oxidative metabolism 
early in cachexia progression may contribute to accelerated muscle fatigability observed in 
weight stable and pre-cachectic MIN mice. Lastly, while regimented exercise has 
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established beneficial effects on tumor progression, global metabolism, and muscle 
function, the current study is the first to suggest that increased volitional activity improves 
muscle fatigability and mitochondrial content without affecting tumor-burden or plasma 
IL-6. The current study was limited to investigations of a preclinical model of colorectal 
cancer and cannot necessarily be extrapolated to all cancer types. Additionally, there are 
several factors that contribute to overall and skeletal muscle fatigability that were not 
measure and warrant future investigations. Together the results from the current study, 
however, suggest that cancer-induced skeletal muscle fatigue is distinct from IL-6-induced 
skeletal muscle fatigue and skeletal muscle fatigability occurs independent of body weight 
loss which can be improved with increased volitional activity. 
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APPENDIX A
DETAILED PROTOCOLS 
Tissue Homogenization 
1. Materials and Reagents 
a. Mueller Buffer 
 
Mueller Buffer 
Stock 
Solution 
Desired 
Concentration 
Volume of stock 
needed(ul) 
HEPES 500mM 50mM 600 
Triton-X100 100% 0.10% 6 
EGTA (pH 8.0) 500mM 4mM 48 
EDTA (pH 8.0) 500mM 10mM 120 
Na4P2O7 100mM 15mM 900 
β-glycerophosphate 2M 100mM 300 
NaF 500mM 25mM 300 
NaVO4 1M 5mM 50 
dH2O - - 3585 
Protease Inhibitor - - 60 
b. Mueller Diluent: 
 
Mueller Diluent 
Stock 
Solution 
Desired 
Concentration 
Volume of stock 
needed (ul) 
Glycerol 100% 50% 1500 
Na4P2O7 100mM 50mM 1500 
EGTA (pH 8.0) 500mM 2.5mM 15 
β-mercaptoethanol 500mM 1mM 6 
Protease Inhibitor - - 30 
2. Procedure 
a. Weigh out the samples to be used and place weighted portion into an 
Eppendorf tube labeled with the sample and M. 
b. Add 10ul/mg tissue of Mueller buffer to the homogenization tube and add 
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sample. 
c. Homogenize in glass on glass tissue homogenizer keeping the sample in 
ice while homogenizing. (homogenize ~30s check sample repeat if 
needed) 
d. Wash glass tissue homogenizer 3 times by dH2O between two samples. 
e. Transfer tissue homogenate back to Eppendorf tube. 
f. Spin samples at 13,000rpm for 10min at 4°C. 
g. Transfer supernatant to clean Eppendorf tube labeled with sample and D, 
discard the pellet. 
h. Add 5ul/mg tissue of Diluent buffer to the D tube and vortex. 
i. Run protein assay (Bradford). 
j. Dilute samples down to a working concentration in a new tube labeled 
with the sample and the working concentration. Keep both D tube and 
diluted samples in -80°C. 
 
Protein Assay (Bradford) 
1. Materials and Reagents 
a. Bradford Reagent (Bio-Rad, Catalog #: 5000006) 
b. Make a stock of 1mg/ml BSA in PBS, store aliquot in -20°C. 
c. Costar 96 well plate 
2. Procedure 
a. In a clear flat bottom 96 well plate create a standard curve with the 1ug/ul 
BSA solution from 0-14ug in duplicate or triplicate 
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b. Dilute samples 1:5 in a new tube with water (5ul sample: 20ul dH20) 
c. Add 5ul of the diluted samples to the wells of the plate being sure to run 
them in duplicate or triplicate  
d. Make a 1:5 dilution of Bradford reagent. You will need enough for 
300ul/well. Be sure to clean the glassware well before you use it with soap 
and water. 
e. Add 300ul of diluted Bradford reagent to each well. 
f. Let sit in dark drawer for 15 minutes 
g. Read in plate reader at 595nm 
h. Calculate protein concentration based on standard curve 
i. Create curve being sure to subtract out the zero value from both curve and 
samples. 
j. Calculate protein concentration using y=mx+b equation (sample = 
con*slope + intercept -> con=(sample-intercept)/slope) 
 
SDS-PAGE/Western Blot 
1. Materials and Reagents 
a. Acrylamide Solution (38.5% Acrylamide + 1% Bis-Acrylamide) 1.5M Tris-
HCL, pH 8.8 
b. 1.0M Tris-HCL, pH 6.8 
c. 10% SDS 
d. 10% APS 
e. TEMED 
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f. 4×SDS Loading Buffer: 200 mM Tris-Cl (pH 6.8), 400 mM DTT, 8% SDS, 
0.4% bromophenol blue, 40% glycerol  
g. SDS Running Buffer: 25mM Tris, 200mM Glycine, 0.1% SDS Protein 
Ladder (Bio-Rad, Catalog #: 1610373) 
h. Transfer Buffer: 25mM Tris, 200mM Glycine, 20% Methanol 1×TBST: 50 
mM Tris-Cl, 150 mM NaCl, 0.1% Tween-20 5% milk (solved in 1×TBST)  
i. ECL plus (Thermo Scientific, Catalog #: 1610373)  
2. Procedure – SDS-PAGE 
a. Make gel. Base the % off of what molecular weight the protein of interest 
is. 
b. Prepare samples 
c. Pipette desired amount of protein into Eppendorf tube 
d. Add correct volume of 4 × SDS loading dye 
e. Vortex and do a quick spin 
f. Heat in heat block at 100°C or in boiling water for 5 minutes 
g. Quick spin 
h. Load 4ul of protein ladder to the 1st lane in the gel 
i. Load all of sample on gel 
j. Run gel at 200V for ~1h or until samples have run 
through the gel  
3. Procedure – Transfer 
a. Prepare 750ml of transfer buffer 
b. Prepare membrane by placing in a small amount of methanol for 1 minute 
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c. Pour methanol into the transfer buffer and wash membranes with the 
transfer buffer 
d. Set up the transfer with the black side of the holder facing down, sponge, 
blotting paper, gel, membrane (be sure there are absolutely no bubbles 
between the gel and the membrane), blotting paper, sponge, white/clear 
side. 
e. Carefully close the sandwich and place in the transfer box black side to 
black side and clear side facing the red side of the transfer box. 
f. Place ice pack in the box and pour remaining transfer buffer into the box. 
g. Transfer either overnight at 70mA or for 200min at 200mA making sure 
to pack well with ice. 
4. Procedure – Probing 
a. Prepare 5% milk in 1×TBST solution 
b. Remove membrane from transfer and place in ponceau solution for 3-5 
minute 
c. Rinse off excess ponceau with dH2O and place membrane in plastic sheet 
and scan into computer 
d. Wash off ponceau with 1×TBST 
e. Block the membrane for 1h in 5% TBST milk solution (made in step 13) 
f. Incubate in primary antibody in milk solution 
g. Wash membranes 3× with 1×TBST for 5 minutes each 
h. Incubate in secondary antibody in milk solution for 1 hour 
i. Wash membranes 3× with 1×TBST for 5 minutes each 
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j. Develop with ECL or ECL quantum. 
 
RNA Isolation 
1. Materials and Reagents  
a. RNase AWAY (Thermo Scientific, Catalog #: 10328011) Trizol Reagents 
(Thermo Scientific, Catalog #: 15596026) Chloroform  
b. Isopropanol Alcohol DEPC H2O  
c. 75% ethanol in DEPC H2O  
2. Procedure 
a. Clean work area thoroughly with alcohol  
b. Label 3 sets of sterile RNAase free 1.5mL eppendorf tubes  
c. Remove cell culture medium, and wash cells once by ice-cold PBS  
d. Remove PBS, add Trizol reagent onto the cell (1ml Trizol for each well of 6-
well plate). 
e. Scrape cell off from cell culture plate gently with rubber scraper, pipette cell 
suspended in 
f. Trizol up and down several times with 1ml pipette to brake cell thoroughly. 
g. Transfer cell homogenate to a sterile 1.5mL tube. 
h. Let samples sit at RT for ~5 minutes. 
i. Add 200ul of chloroform to each tube 
j. Shake tubes (DO NOT VORTEX) for 15-30s (should be the color of pepto 
bismal). 
k. Let samples sit at RT for 2-3min.  
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l. Spin samples at 12000rpm for 15 minutes at 4°C. 
m. Clean gloves and pipette with RNAase AWAY. 
n. Transfer clear supernatant to new tube carefully, Do NOT disturb the 
protein interface (white layer) or organic phase (red/pink colored). 
o. Add 500ul of isopropanol and invert to mix. 
p. Incubate for 20-30 minutes at RT. 
q. Spin samples at 12000rpm for 10 minutes at 4°C, gel like pellet can be 
visualized at the bottom of tube. 
r. Dump the supernatant being careful not to lose the pellet. 
s. Add 1mL 75% EtOH in DEPC to RNA pellet invert to break loose. 
t. Spin at 9500rpm for 5 min at 4°C. 
u. Repeat steps 18-20 once. 
v. Air dry tubes upside down in hood for 10-20 minutes (on towel of 
Kimwipes). 
w. Add ~20-40ul of DEPC water to dissolve pellet, pipette to solve RNA (Keep 
track of the amount of DEPC added). 
x. Read on spec (1-2ul RNA+800ul dH2O) in quartz cuvette/NANO DROP 
and record 260/280/and 230 measurements. (Good quality of RNA samples 
should have 260/280 ratio > 1.8 and 260/230 > 1.8. Do not use samples with 
260/280 below 1.6) 
y. Calculate and Record RNA concentration: RNA= (OD260*40*0.8)/ 
volume RNA added to cuvette. 
z. Store RNA samples in -80°C. 
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cDNA Synthesis 
1. Materials and Reagents: 
a. High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Catalog #: 4368813) 
b. DEPC H2O 
2. Procedure 
a. Prepare reverse transcriptase cocktail as follows and keep on ice. 
Reagent ul/sample 
DEPC 4.2 
10X RT buffer 2.0 
dNTP mix 0.8 
10Xrandom Primers 2.0 
Reverse Transcriptase 1.0 
Total 10.0 
  
b. In a cold block add 3ug of RNA in a 200ul PCR tube and volume to 10ul 
with DEPC water. 
c. Add 10ul of reverse transcriptase cocktail to each tube. 
d. Put in thermocycler on program as follows: 
e. 25°C for 10 min 
f. 42°C for 50 min 
g. 70°C for 15 min 
h. 4°C Hold 
i. Store all samples in -20°C. 
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RT-PCR 
1. Materials and Reagents: 
a. iTaq™ Universal SYBR® Green Supermix (Bio-Rad, Catalog #: 1725121) 
ddH2O 
b. Dilute cDNA samples 1:10 and 1:100 (serial dilution) with ddH2O, keep 
samples on cold block. 
c. Fill out plate template, all samples are in duplicate. 
d. Prepare master mix solutions as follows, keep master mix on ice. 
 
 
Reagent ul/sample 
Syber Green Mix 10.0 
Forward Primer (20uM) 1.0 
Reverse Primer (20uM) 1.0 
Total 12.0 
2. Procedure 
a. Load 8ul of cDNA to each well as per template. 
b. Load 12ul of master mix solution into each well, DO NOT introduce 
bubbles. 
c. Cover plate with plate cover sheet 
d. Spin plate in centrifuge in environmental genomics core 
e. Put plate onto Applied Biosystems 7300 Real-Time PCR System 
f. Add dissociation step and set volume to 20ul. 
g. Start analysis. 
h. Turn OFF machine when finished. 
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IL-6 Electroporations 
1. Prepare plasmids. They are typically at a concentration of 2-3 ug/ul. Dilute to 1 
ug/ul in sterile saline. Need 40 ug of plasmid per injection. 
2. Start anesthesia with Isoflurane at 1-2%/1L O2. (Change percentage of isoflurane 
based on the level of consciousness of the mice.) 
3. Add mice to the anesthesia box. 
4. Place mouse under nose cone. Shave top of quad. Alcohol off skin and betadyne. 
5. Sterilize Scissors with bead sterilizer and alcohol. Make a small vertical snip with 
scissors over quad. 
6. Inject plasmid (50 ug at 1 ug/ul=50 ul) VERY SLOWLY in the middle of the quad 
using insulin syringe. 
7. Electroporate with default setting. 100 mV; 50 ms; 8 pulses. Make sure electrodes 
are under the skin, next to the quad. Touch foot pedal once to start the electrical 
current. 
8. Close the incision with a wound clip. 
9. Return mouse to cage. 
10. Remove wound clip in 7-10 days. 
 
IL-6 ELISA 
1. Materials and Reagents: 
a. Coating Buffer: 100mM Sodium Carbonate, pH 9.5.  
b. Assay Diluent: PBS with 10% FBS 
c. Wash Buffer: PBS with 0.05% Tween-20 
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d. TMB-ELISA Substrate Solution (Thermo Scientific, Catalog #: 34028) 
Stop Solution: 2N H2SO4 
e. Mouse IL-6 ELISA Kit (BD Bioscience, Catalog #: 555240) IL-6 Standard 
(Reconstitute by dH2O to 1ng/ml) 
f. Capture Antibody (Anti-Mouse IL-6 monoclonal antibody, 1:250) 
g. Detection Antibody (Biotinylated Anti-Mouse IL-6 monoclonal 
antibody,1:500) Enzyme 
h. Reagent (Streptavidin-horseradish peroxidase conjugate (SAv-HRP)1:250) 
2. Procedure 
a. Coat microwells with 100 μL per well of Capture Antibody diluted 1:250 
in Coating Buffer. 
b. Seal plate and incubate overnight at 4°C. 
c. Aspirate wells and wash 3 times with ≥ 300 μL/well Wash Buffer. After last 
wash, invert plate and blot on absorbent paper to remove any residual buffer. 
d. Block plates with ≥ 200 μL/well Assay Diluent. Incubate at RT for 1 hour. 
e. Prepare the IL-6 standards. 
f. Prepare a 1000 pg/mL standard from the stock standard. Vortex to mix. 
g. Add 300 μL Assay Diluent to 6 tubes. Label as 500 pg/mL, 250 pg/mL, 
125pg/mL, 62.5 pg/mL, 31.3 pg/mL, and 15.6 pg/mL. 
h. Perform serial dilutions by adding 300 μL of each standard to the next tube 
and vortexing between each transfer. Assay Diluent serves as the zero 
standard (0 pg/mL). 
i. Aspirate/wash as in step 2. 
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j. Pipette 100 μL of each standard, sample, and control into appropriate wells. 
Seal plate and incubate for 2 hours at RT. 
k. Aspirate/ wash as in step 2, but with 5 total washes. 
l. Add 100 μL of Working Detector (1:500 Detection Antibody + 1:250 SAv-
HRP reagent, solved in Assay Diluent) to each well. Seal plate and incubate 
for 1 hour at RT. 
m. Aspirate/ wash as in step 2, but with 7 total washes. 
n. Add 100 μL of TMB-ELISA Substrate Solution to each well. Incubate plate 
(without plate sealer) for 30 minutes at room temperature in the dark. 
o. Add 50 μL of Stop Solution to each well. 
p. Read absorbance at 450 nm within 30 minutes of stopping reaction. 
q. Calculate protein concentration based on standard curve 
r. Create curve being sure to subtract out the zero value from both curve and 
samples. 
s. Calculate protein concentration using y=mx+b equation 
(sample=con*slope+intercept -> con=(sample-intercept)/slope) 
 
Skeletal muscle function – in situ 
1. Materials and Reagents 
a. Aurora scientific force transducer 
b. Heat Therapy Pump (HTP-1500) 
c. Jari monopolar electrodes (25 mm) 
d. Isoflurane 
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e.  Mineral oil 
f. 5-0 silk suture 
2. Procedure 
a. Anesthetize mouse with 2% isoflurane 
b. Shave the entire hindlimb and clean with alcohol 
c. Make a 1 mm incision is made just above the anterior portion of the 
talocrural joint to expose the distal tendon of the TA  
d. Tease the distal tendon of the TA away from surrounding tissue  
e. Tie distal tendon tightly with a 5-0 silk suture and then cut tendon distal to 
knot 
f. Make a 2 mm incision at the midpoint between the lateral aspect of the knee 
and hip to expose the lateral quadriceps 
g. Carefully dissect the muscle to expose the sciatic nerve 
h. Maintain exposed nerve in warmed mineral oil or warmed saline 
i. Place the mouse on the aurora scientific force transducer in situ apparatus 
maintained at 37°C using heat therapy pump  
j. Fix the mouse’s knee to the base plate 
k. Tie the other end of the suture (end that is not tied to the tendon) to the force 
transducer 
l. Delicately place the electrode under the sciatic nerve so that contact is 
maintained throughout the duration of the protocol 
m. Stimulate the sciatic nerve with a single stimulus to elicit a muscle twitch 
n. Slightly lengthen between twitches (>30 seconds apart) the muscle to obtain 
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the optimal length (Lo)  
o. Once Lo was obtained, stimulate the sciatic nerve at 10, 30, 50, 80, 100, 
120, 150, 180, 200, 250, and 300hz (3 minute rest between contractions) to 
produce a force-frequency curve  
p. Rest the muscle for 5-minutes 
q. Stimulate the sciatic nerve for 0.5 second at 50Hz every second for 5 
minutes for a total of 300 submaximal contractions 
r. Immediately after the submaximal contractions, stimulate the sciatic nerve 
for 0.5 second at 200Hz every second for 5 minutes for a total of 300 
additional contractions (600 total) 
s. Rest the muscle for 5 minutes 
t. Stimulate the sciatic nerve at 200 Hz to elicit a maximal contraction 
 
Isolation of skeletal muscle mitochondria 
1. Material and Reagents 
a. 3 single edge razor blades 
b. PFTE pestle 
c. 0.25% Trypsin 
d. Isolation buffer for Mitochondria 1 (IBM1) 
 
IBM1 
Stock 
Solution 
Desired 
Concentration 
Volume of stock 
needed 
Sucrose - 67mM 11.47g 
Tris/HCl (pH 7.4) 2M 50mM 12.5mL 
KCl 1M 50 mM 25mL 
EDTA/Tris (pH 8.0) 0.5M 10mM 10mL 
FA Free BSA - 0.20% 1g 
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e. Isolation buffer for Mitochondria 1 (IBM1) 
 
IBM2 
Stock 
Solution 
Desired 
Concentration 
Volume of stock 
needed 
D-Mannitol - 200mM 10.9g 
Sucrose - 70mM 7.188g 
EGTA/Tris 100mM 5mM 15mL 
Tris/HCl (pH 7.4) 1M 10mM 3mL 
2. Procedure 
a. Excise a piece of muscle 75-100mg from mouse 
b. Place in chilled small cell culture dish containing ~5mL IBM1 
c. Mince tissue for 2 minutes with 3 single edge blades (45s each) 
d. Transfer minced tissue to 15mL tube with 5mL IBM1/0.05 Trypsin 
e. Incubate fore 30 minutes on ice 
f. Spin tube at 200 x g for 3 minutes at 4ºC 
g. Dispose of supernatant 
h. Resuspend pellet in 3mL of ice cold IBM1 (cut tip) 
i. Transfer to 45mL glass homogenizer tube 
j. Rinse 15mL conical tube with 1.5mL of IBM1 (cut tip) 
k. Transfer to the previously mentioned 45mL tube 
l. Place homogenizer tube in a beaker with ice 
m. Homogenize tissue with PFTE pestle (10, 2s passes @ 80 RPM) 
n. Transfer to a new 15mL tube (cut tip) 
o. Rinse glass homogenizer with 6.5 mL of IBM1 
p. Transfer to the previously mentioned 15mL tube containing homogenate 
(cut tip) 
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q. Spin 15mL tube at 700 x g for 10 minutes at 4ºC 
r. Pour supernatant into a new 15mL tube 
s. Spin supernatant at 8,000 x g for 10 minutes at 4ºC 
t. Dispose of supernatant 
u. Resuspend in 0.5mL of IBM2 (cut tip) 
v. Add 4.5mL of IBM2 
w. Spin tube at 8,000 x g for 10 minutes at 4ºC 
x. Dispose of supernatant 
y. Resuspend pellet in 25uL of IBM2 (cut tip) 
 
Respiration 
1. Materials and Reagents 
a. Buffer X 
i. 60 mM K-MES, 35 mM KCl, 7.23 mM K2EGTA, 2.77 mM 
CaK2EGTA, 20 mM imidazole, 0.5 mM DTT, 20 mM taurine, 5.7 
mM ATP, 15 mM phosphocreatine, and 6.56 mM MgCl2, pH 7.1 
b. 50uM Saponin 
c. Respiration buffer 
i. 05mM K-MES, 3mM KCl, 1mM EGTA, 10mM K2HPO4, 5mM 
MgCl2, 0.005mM Glutamate, 0.002mM Malate, 0.05% BSA, 
20mM Creatine, pH 7.1 
d. 20mM Creatine in respiration buffer 
e. 5mM Pyruvate 
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f. 2mM Malate 
g. 0.25mM ADP 
h. Oligomycin 
i. Buffer Z 
i.  
j. Hansatech Oxygraph+ 
2. Procedure  
a. Mechanically tweeze a 7-10 mg piece of muscle with forceps under a 
dissecting microscope in ice-cold buffer X.  
b. Incubate the fiber bundle in 50uM saponin for 30 minutes 
c. Wash 3 times for 5 minutes in respiration buffer 
d. Place fiber bundles into the oxygraph machine in 20mM creatine respiration 
buffer at 37 degrees 
e. Syringe 5mM of pyruvate and 2mM of malate into the chamber 
f. Two minutes following pyruvate and malate, inject 0.25mM of ADP into 
the chamber to induce STATE 3 respiration 
g. Wait 5 minutes 
h. Inject 10ug/mL of Oligomycin to induce steady state 4 respiration 
i. Wait 10 minutes 
j. Respiratory Control Ratio (RCR) was calculated by dividing state 3 by state 
4 respirations. 
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Cytochrome C Oxidase Activity 
1. Materials and Reagents 
a. 20 mM KCN;  MW= 65.12, 13.02 mg/10 ml dH2O 
b. 100 mM KPO4 Buffer (pH 7) 
1. 0.1 M KH2PO4 (pH 5) 
2. 0.1 M K2HPO4.3H2O (pH 8) 
c. 10 mM K-Phosphate Buffer 
d. Extraction Buffer (100 mM Na-K-Phosphate, 2 mM EDTA; pH 7.2) 
1. 500 ml 0.1 M Na2HPO4. 2H2O;  
1. 8.9 g sodium phosphate with 0.372 g EDTA up to 500 ml  
2. 200 ml 0.1 M KH2PO4 
1. 2.7 g potassium phosphate with 0.149 g EDTA up to 200 
ml. 
3. combine both solutions and pH to 7.2      
e. Test Solution (reduced cytochrome c, 2 mg/ml), for 10 ml (enough for 36 
microplate wells); 
1. 20 mg of horse heart cytochrome c (Sigma, C-2506) in a 
scintillation vial 
2. add 1 ml of 10 mM KPO4 buffer and dissolve cytochrome c 
3. make up a small volume of 10 mg/ml sodium dithionite-10 mM 
KPO4 stock solution (make fresh each experiment and use within 
twenty minutes) 
 219 
4. add 40 μl of the dithionite stock solution to the test solution and 
observe red-orange colour change 
5. add 8 ml of ddH2O 
6. add 1 ml of 100 mM KPO4 buffer. 
2. Procedure 
a. Place powdered muscle samples in liquid N2. 
b. Add 50 μl of extraction Buffer to 1.5 ml Eppendorf tubes in the aluminum 
block on ice.  (One Eppendorf per sample).  
c. Add 5-7.5 mg tissue to each tube, recording exact tissue mass.  Mix by 
tapping.  
d. Add the volume of Extraction Buffer required to obtain a 20-fold dilution.   
e. Add a stir bar and mix for 15 min. Make up Test Solution during this time 
and wrap in foil.  
f. Sonicate each tube 3 x 3 seconds, cleaning the probe between samples. 
g. Pipette some of 20-fold sample extract into new Eppendorf tube and add 
volume of Extraction Buffer required to obtain an 80-fold dilution.  (eg. 50 
μl of 20-fold extract + 150 μl Ext. Buffer = 200 μl of 80-fold sample 
extract).  Keep 80-fold sample extract tube on ice for duration of 
experiment 
h. Add 270 μl of Test Solution into 4-8 wells of 96-well microplate and 
incubate at 30°C for 10 minutes to stabilize the temperature and 
absorbance. 
i. Open KC4 plate reader program (on Triton).  Select CONTROL icon, then 
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PRE-HEATING tab, enter 30°C and select ON.  (Do not run assay until 
KC4 temperature has reached 30°C.) 
j. Select WIZARD icon, then READING PARAMETERS icon. 
1. Select Kinetic for Reading Type. 
2. Select Absorbance for Reader and 550 nm for wavelength (drop-
down menu). 
3. Select Sweep for Read Mode. 
4. Select 96 Well Plate (default) for Plate Type. 
5. Enter first and last well to be read (eg. A1 and A4 if reading 4 
samples simultaneously). 
6. Select Yes and Pre-heating and enter 30 for Temperature 
Control. 
7. For Shaking enter 0 for both intensity and duration (shaking is 
not necessary and it will delay the first reading).  
8. Do not select either of the two options for Pre-reading. 
9. Click on the KINETIC… rectangular tile to open the Kinetic 
window. 
10. Enter run time (1 minute is recommended) and select 
MINIMUM for Interval time (under these conditions the 
minimum Interval time should be 3 seconds). 
11. Select Allow Well Zoom During Read to see data in real time 
(optional). 
12. Under Scales, checkmarks should appear for both Auto check 
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boxes.  Do not select Individual Well Auto Scaling. 
13. Press OK to return to Reading Parameters window.  Press OK to 
return to Wizard window.  Press OK.  Do not save the protocols 
k. Set the multipipette to 250 μl and secure 4-8 yellow tips on the white 
projections (make sure they are on tight and all at the same height). 
l. In a second, clean 96 well plate, pipette samples into 4-8 empty wells 
(start with A1).  Recommended volumes: 30 μl of 80-fold extract for 
Mixed Gastroc, 10 μl for Heart.  Adjust volumes according to oxidative 
capacity of the tissue.  (eg.  25 μl for Red Gastrocnemius and 35 μl for 
White Gastrocnemius).  
m. Remove microplate with Test Solution in 4-8 wells from the incubator (as 
long as it has been incubating for 10 minutes).  Place this plate beside the 
plate with the sample extracts in it. 
n. On KC4 program, select the READ icon and press the START READING 
icon, then press the READ PLATE button.  A box will appear that says, 
“Insert plate and start reading”.  Do not press OK yet, but move the mouse 
so that the cursor hovers over the OK button. 
o. Using the multipipette (set to 250 μl) carefully draw up the Test Solution.  
Make sure the volume is equal in all the pipette tips, and that no 
significant air bubbles have entered any of the tips. 
p. Pipette the Test Solution into the wells with the sample extracts (the 
second plate).  As soon as all the Test Solution has been expelled from the 
tips (do not wait for the second push from the multipipette), place the plate 
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onto the tray of the plate reader and with the other hand on the mouse, 
press the OK button.  (Speed at this point is paramount, as there is an 
unavoidable latency period between the time of pressing the OK button 
and the time of the first reading.)  
q. If desired, add 5 μl KCN to one of the wells to measure any absorbance 
changes in the presence of the CYTOX inhibitor. 
r. Once reading is complete, hold the CTRL key on the keyboard, and use 
the mouse to click once on each of the squares corresponding to a well that 
had sample in it.  Once all the desired wells have been highlighted by a 
black square (up to a maximum of 8 wells), let go of the CTRL key and a 
large graph will appear with lines on it representing each sample.   
s. To obtain the rate of change of absorbance over different time periods, 
select Options and enter the amount of time for which you would like a 
rate of change of absorbance to be calculated.  The graph, along with one 
rate (at whichever time interval is selected) for each sample can be printed 
on a single sheet of paper, and the results can be saved. 
t. The delta absorbance will appear in units of mOD/min and the number 
given will be negative.  Convert this to OD/min by dividing by 1000 and 
omit the negative sign in the calculation.  (eg. if Mean V: -394.8 
mOD/mn, then use 0.395 OD/min) 
 223 
APPENDIX B
PROPOSAL 
2.1 – Specific Aims 
Cachexia 
The unintentional loss of body weight with chronic disease, termed cachexia, is 
associated with reduced life quality, poor treatment outcomes, and increased mortality (al-
Majid and McCarthy 2001a; Arthur et al. 2014; Christensen et al. 2014; Evans et al. 2008; 
Deans and Wigmore 2005; Fearon KC 2006; Tisdale 2002; von Haehling and Anker 2014). 
Specifically, cancer-induced cachexia has been associated with nutrient resistance, anemia, 
hypogonadism, and chronic inflammation (Evans et al. 2008; Carson and Baltgalvis 2010; 
Deans and Wigmore 2005; Fearon KC 2006), all of which contribute to weakness, fatigue, 
and physical inactivity resulting in loss of functional independence and increased health 
care costs (Deans and Wigmore 2005; Evans et al. 2008; Christensen et al. 2014; Op den 
Kamp et al. 2012; Roberts, Frye, et al. 2013; Wolfe 2006; Winningham et al. 1994; 
O'Gorman, McMillan, and McArdle 1999; Montazeri 2009; Fearon KC 2006; Arthur et al. 
2014). While our mechanistic understanding of cancer-induced muscle wasting has 
improved, further investigation is needed to understand the regulatory mechanisms of 
functional decrements that occur with cancer and cancer-induced cachexia. 
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Skeletal Muscle Fatigue 
Functional outcomes can be affected by central, peripheral, and muscular 
alterations, and the difficulty delineating their individual roles has hindered our 
mechanistic understanding of the functional decrements the occur with aging and disease 
(Hughes, Wallace, and Baar 2015; Wolfe 2006; Norden et al. 2015). While several cancer-
induced skeletal muscle functional decrements have been described, the regulation of 
skeletal muscle fatigue in cancer patients and preclinical models appears distinct from 
changes to mass and strength which may contribute to the initiation of cachexia 
(Winningham et al. 1994; Roberts, Frye, et al. 2013; Jaweed et al. 1983). We have 
previously shown that tumor-bearing mice had reduced cage activity and increased muscle 
fatigability independent of body weight loss (Roberts, Frye, et al. 2013; Baltgalvis 2010). 
Furthermore, recent evidence suggests that mitochondrial degeneration develops prior to 
significant weight loss demonstrating that fatigue and disrupted oxidative metabolism 
occur early in cachexia progression (Baltgalvis 2010; Brown et al. 2017). While increased 
muscle fatigability and disrupted oxidative metabolism has been reported with cachexia, 
significant gaps remain in our mechanistic understanding of the role of disrupted oxidative 
metabolism in muscle fatigue and when these dysfunctions occur during the progression of 
cachexia. 
 
Skeletal Muscle gp130 Signaling 
Chronic inflammation is a hallmark of cancer and cancer-induced wasting, and 
several inflammatory cytokines have been implicated as drivers of cachexia with chronic 
disease (Deans and Wigmore 2005). Specifically, the interleukin-6 (IL-6) family of 
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cytokines and associated muscle signaling through the membrane gp130 receptor plays a 
role in muscle mass regulation and oxidative metabolism during both physiological and 
pathological conditions (Carson and Baltgalvis 2010). Our lab has demonstrated that loss 
of IL-6 and/or muscle gp130 signaling attenuated muscle mass loss in tumor-bearing mice 
while high levels of IL-6 and muscle gp130 signaling are associated with reduced 
mitochondrial protein expression and disrupted mitochondrial quality control in tumor-
bearing and tumor-free mice (Fix et al. 2018; Baltgalvis et al. 2008; Baltgalvis et al. 2009; 
Puppa, Gao, et al. 2014; Puppa et al. 2012). Additionally, increasing muscle use by 
treadmill exercise or repeated eccentric contractions attenuated the loss of muscle mass and 
succinate dehydrogenase activity with cachexia without affecting downstream muscle 
gp130 signaling targets STAT3 and Erk 1/2 (Hardee et al. 2016). While the role of IL-6 
and associated gp130 signaling in skeletal muscle mass maintenance and metabolic 
homeostasis has received significant attention, their contribution to skeletal muscle fatigue 
during the progression of cachexia remains largely unknown. 
 
Purpose and Hypothesis 
Our long-term goal is to identify the regulatory mechanisms driving cancer-induced 
skeletal muscle dysfunction to better understand the cachectic condition and improve the 
life quality of cancer patients. The overall purpose of the current proposal is to determine 
the regulatory mechanisms of skeletal muscle fatigue in tumor-bearing mice. Our central 
hypothesis is that cancer-induced skeletal muscle fatigue develops prior to cachexia 
development in association with decreased muscle use and activated muscle gp130 
signaling which disrupt muscle oxidative metabolism. Furthermore, increased muscle use 
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through increased volitional activity will delay the induction of fatigue in tumor-bearing 
mice. To test this hypothesis, we will first determine the onset of fatigue in tumor-bearing 
mice and determine its relationship to known cachexia indices including body weight loss, 
systemic inflammation, and muscle inflammatory signaling in tumor-bearing mice. Next, 
we will determine if modulating muscle gp130 signaling alone can regulate skeletal muscle 
fatigue and muscle oxidative metabolism in healthy tumor-bearing mice. Last, we will 
determine if increased muscle use can attenuate the cancer-induced skeletal muscle fatigue 
and improve muscle oxidative metabolism. 
 
Specific Aims 
Using preclinical models of cancer-cachexia, we plan to test our hypothesis using the 
following 3 specific aims: 
Specific Aim 1: Examine the impact of cachexia progression on the 
development of skeletal muscle fatigue in tumor-bearing mice.  
 
Specific Aim 2: Determine the role of muscle gp130 signaling in skeletal muscle 
fatigue during the progression of cachexia.  
 
Specific Aim 3: Determine the effect of muscle use on skeletal muscle fatigue 
during cachexia progression. 
 
Our lab has previously shown that functional decrements occur prior to significant weight 
loss (Baltgalvis 2010). Significant gaps remain in our mechanistic understanding of 
cachexia-induced skeletal muscle dysfunction and whether these decrements are causal, or 
consequent, of weight loss is unknown. The results from this study will extend our current 
understanding of muscle fatigue with cancer and elucidate the mechanisms regulating 
skeletal muscle metabolism which directly impacts skeletal muscle function.  
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Specific Aim 1: Examine the impact of cachexia progression on the development of 
skeletal muscle fatigue in tumor-bearing mice.  
Aim 1.1: Determine the fatigue properties of skeletal muscle in male tumor-bearing 
MIN mice. 
Aim 1.2: Determine the relationship between systemic inflammatory markers, 
muscle gp130 signaling, body weight loss, and skeletal muscle function in weight 
stable and cachectic MIN mice. 
Aim 1.3: Determine the relationship between skeletal muscle oxidative and 
glycolytic metabolism with skeletal muscle fatigue in MIN mice. 
Specific Aim 2: Determine the role of muscle gp130 signaling in skeletal muscle 
fatigue during the progression of cachexia.  
Aim 2.1: Determine if the IL-6 induction of fatigue is through direct activation of 
muscle gp130 signaling in tumor-free mice.  
Aim 2.2: Determine the effect of elevated skeletal muscle gp130 signaling on 
skeletal muscle oxidative and glycolytic metabolism. 
Aim 2.3: Determine the role of skeletal muscle gp130 signaling in cancer induced 
skeletal muscle fatigue in MIN mice. 
Specific Aim 3. Determine the role of muscle use on skeletal muscle fatigue during 
cachexia progression. 
Aim 3.1: Determine the relationship between volitional activity and skeletal muscle 
fatigue during the progression of cachexia. 
Aim 3.2: Determine if 5 weeks of free access to a wheel can prevent the induction 
of skeletal muscle fatigue in MIN mice. 
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Aim 3.3: Determine if 5 weeks of free access to a wheel can prevent the loss of 
muscle oxidative metabolism in MIN mice. 
 
2.2 – Preliminary Results 
The culmination of several published and preliminary findings from our laboratory 
contribute to the premise for the proposed study. Cachexia-induced skeletal muscle mass 
loss is associated with reduced ability to perform basic daily tasks leading to a loss of 
functional independence (Vigano et al. 2000; Evans et al. 2008; Moses et al. 2004; Fearon 
KC 2006; Argiles 2014; Amano et al. 2017). More clinically relevant, cancer patients with 
decreased functional ability and increased fatigue, regardless of cachexia diagnosis, 
experience decreased quality of life and respond poorly to treatment (O'Gorman, 
McMillan, and McArdle 1999; al-Majid and McCarthy 2001a). Cachectic patients and 
preclinical cachexia models exhibit decreased volitional activity, whole body weakness, 
and fatigue (Baltgalvis 2010; Murphy et al. 2012; Roberts, Frye, et al. 2013; Toth et al. 
2016; Puppa, Gao, et al. 2014). Recently, specific decrements to skeletal muscle’s 
contractile quality have been identified in cachectic patients and tumor bearing mice 
(Christensen et al. 2014; Gorselink et al. 2006; Murphy et al. 2012; Roberts, Frye, et al. 
2013; Jaweed et al. 1983). However, the drivers of these functional deficits in skeletal 
muscle have not been clearly defined (Op den Kamp et al. 2012; Christensen et al. 2014; 
Biolo, Cederholm, and Muscaritoli 2014). To this end, several proposed cancer cachexia 
therapeutics have failed in clinical trials due to their inability to improve overall patient 
function (Dobs et al. 2013; Aversa, Costelli, and Muscaritoli 2017; Biolo, Cederholm, and 
Muscaritoli 2014; Ramage and Skipworth 2018). This inability of proposed therapeutics to 
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improve muscle function illustrates our lack of understanding of the cachectic factors that 
induce these functional deficits.  
Critical gaps in our knowledge of this regulation are likely related to the dearth of 
studies examining both muscle function and cachectic factors in the same cohort of tumor 
bearing mice. This lack of cohesive integration with these measurements has likely 
contributed to the plethora of unsuccessful cancer cachexia treatment paradigms (al-Majid 
and McCarthy 2001a; Baltgalvis 2010; Christensen et al. 2014; Murphy et al. 2012; 
Roberts, Frye, et al. 2013; White, Baltgalvis, et al. 2011; White et al. 2012; Ramage and 
Skipworth 2018). We have previously shown that MIN mice demonstrate decreased 
voluntary wheel running and cage activity prior to significant weight loss (Baltgalvis 
2010). However, it is not known if this decreased volitional activity is associated with 
decrements in skeletal muscle function. Our preliminary data suggests that the loss of 
skeletal muscle force occurs in cachectic muscle (Figure 2.2 A, B) which cannot be 
explained by loss of muscle mass alone (Figure 2.2 C, D). Additionally, our preliminary 
examination of whole-body fatigue showed reduced time to exhaustion in weight stable 
MIN mice that is exacerbated by cachexia (Figure 2.3 A). Furthermore, skeletal muscle 
fatigue appears increased in MIN mice regardless of significant body weight loss (Figure 
2.3 B). 
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Figure B.1 Proposed working model of cancer induced fatigue.  The overall purpose of the 
current study is to determine the regulatory mechanisms of skeletal muscle fatigue during 
cachexia progression. Our central hypothesis is that skeletal muscle fatigue develops early 
in cachexia progression in association with disrupted oxidative and glycolytic metabolism. 
Furthermore, we hypothesize that activated muscle gp130 signaling increases volitional 
fatigue through the regulation of muscle oxidative metabolism and increasing skeletal 
muscle use will suppress the induction of cancer-induced fatigue and delay cachexia 
progression. Specific aim 1 will examine the relationship between skeletal muscle function 
and known cachexia indices, including body weight loss, systemic inflammation, and 
muscle inflammatory signaling in tumor bearing mice. Specific aim 2 will directly examine 
the role of muscle gp130 signaling in skeletal muscle fatigue in tumor-free and tumor-
bearing mice. Specific aim 3 will examine the effects of wheel access on the induction of 
fatigue during cachexia progression. 
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Figure B.2 The effect of cachexia on absolute and specific maximal tetanic force. (A) 
Force-frequency curve of the tibialis anterior (TA) absolute force measurements 
(millinewtons) in weight stable ApcMin/+ mice (<5% body weight loss, MIN-WS) and 
cachectic ApcMin/+ mice (>5% body weight loss, MIN-CX) compared to age-matched 
C57BL/6 (WT) mice. Muscle force analysis was assessed using in situ muscle function. 
(B) Absolute maximal tetanic force (Po) of the TA in MIN-WS and MIN-CX. (C) Force-
frequency curve of the tibialis anterior (TA) specific force measurements (Force in 
kilonewtons / calculated muscle CSA in m2) in MIN-WS and MIN-CX. Muscle force 
analysis was assessed using in situ muscle function. (D) Specific maximal tetanic force 
(sPo) of the TA in MIN-WS and MIN-CX. Values are means ± SE *Significant from MIN-
WS. ^Significant from MIN-WS. Significance was set at p<0.05. One-Way ANOVA. 
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Figure B.3 The effect of tumor burden on whole body and muscle specific fatigue. (A) 
Treadmill time to fatigue in 12-week-old ApcMin/+ mice (MIN-12), weight stable ApcMin/+ 
mice (<5% body weight loss, MIN-WS), and cachectic ApcMin/+ mice (>5% body weight 
loss, MIN-CX) compared to age-matched C57BL/6 (WT) mice. (B) In situ muscle 
fatigability shown as % of maximal tension after 2 minutes of an intermittent fatigue 
protocol. Values are means ± SE. *Significant from MIN-WS. ^Significant from WT. 
@Significant from MIN-12. Significance was set at p<0.05
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Muscle gp130 Signaling and Skeletal Muscle Function  
Skeletal muscle contractile dysfunction and disrupted metabolic homeostasis have 
been demonstrated across several chronic diseases (Sin and Man 2003; Deans and 
Wigmore 2005; Kuller et al. 2008; Vidt 2006). Recent evidence suggest that muscle 
mitochondrial dysfunction and increased fatigability can occur independent of changes to 
muscle size and strength suggesting that muscle weakness and fatigue have distinct 
etiologies (VanderVeen et al. 2018; Brown et al. 2017). Muscle fatigability, or the ability 
to sustain force over time, relies on several physiological phenomena, most notably, 
adequate ATP production by mitochondrial respiration and glycolytic pathways, while 
skeletal muscle force can be modulated by myofiber CSA (sarcomeres in parallel), percent 
non-contractile tissue (fibrosis), and MHC expression (fiber-type) (Holloszy and Booth 
1976; Fitts and Holloszy 1977; Munkvik, Lunde, and Sejersted 2009; Thompson et al. 
1992; Fitts 1994; Rutherford, Manning, and Newton 2016).  
Chronic inflammation is a broadly defined term used to describe an unrelenting 
immune response; however, several inflammatory mediators, specifically cytokines, have 
been implicated in the progression of several diseases and disease comorbidities (Deans 
and Wigmore 2005; Onesti and Guttridge 2014). IL-6 signaling through the membrane 
gp130 receptor has been implicated as a regulator of skeletal muscle mass and metabolic 
homeostasis during both physiological and pathological conditions (Carson and Baltgalvis 
2010; Bonetto et al. 2011; Hardee, Counts, et al. 2018; Gao et al. 2017; Puppa, Gao, et al. 
2014). While IL-6 overexpression in tumor-bearing mice accelerated muscle mass loss, 
whether IL-6 alone can induce body weight or muscle mass loss in tumor-free mice remains 
inconclusive (White et al. 2012; White, Baltgalvis, et al. 2011; Puppa et al. 2012). Recently, 
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the mitochondria have emerged as an intriguing target for inflammation induced skeletal 
muscle metabolic dysfunction (Boland, Chourasia, and Macleod 2013; Brown et al. 2017; 
Hardee et al. 2016; Carson, Hardee, and VanderVeen 2016). We have previously shown 
that elevated levels of circulating IL-6 was sufficient to decrease mitochondrial protein 
expression in tumor-free mice (Puppa et al. 2012); however, whether this occurs directly 
through the muscle gp130 receptor to increase muscle fatigue was not been examined. 
TNF-α alone has been eloquently shown to directly reduce skeletal muscle force 
and slow muscle contractile properties in vivo and ex vivo without any apparent effect on 
fatigue, further emphasizing that weakness and fatigue have distinct etiologies (Reid and 
Moylan 2011; Gilliam et al. 2011; Hardin et al. 2008; Reid, Lannergren, and Westerblad 
2002; Li et al. 2000). We have previously shown that chronically elevated IL-6 reduced 
mitochondrial proteins in addition to the muscle gp130 receptor regulating mitochondrial 
quality control; however, the effect of IL-6 and muscle gp130 signaling on skeletal muscle 
force and fatigue remains largely unknown. Our preliminary results suggest that two weeks 
of IL-6 over-expression is sufficient to increase plasma IL-6 (Figure 2.4 B) and induce 
skeletal muscle gp130 signaling (Figure 2.4 C). While IL-6 over-expression had no effect 
on muscle force (Figure 2.5 A), IL-6 induced submaximal and maximal contraction-
induced skeletal muscle fatigue (Figure 2.5 B, C). 
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Figure B.4 IL-6 over-expression experimental design. (A) At 10 weeks of age, male 
C57BL/6 mice were subjected to 2 weeks of systemic IL-6 overexpression. Mice were 
injected with 50 ug of IL-6 plasmid into the Quad for muscle electroporation. After 1 week 
this process was repeated. Muscle function analysis was conducted after 2 full weeks of 
IL-6 overexpression. (B) Plasma levels of IL-6 throughout the duration of the study. (C) 
Summary data of relative expression of phosphorylated muscle STAT3 (Y705) in the TA 
following 2 weeks of IL-6 over-expression. Values are means ± SEM. @ Significantly 
different from Day 0. One-way ANOVA. ^Significantly different from Vector controls. 
Significance was set at p<0.05. Students t-test. 
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Figure B.5 The effect of IL-6 over-expression of skeletal muscle function. (A) Specific 
maximal tetanic force (sPo) of the tibialis anterior (TA) two weeks following the first 
electroporation in Vector and IL-6 mice. (B) in situ muscle fatigability shown as % of 
initial tension produced by the TA after 90 seconds of a submaximal fatigue protocol. (C) 
In situ muscle fatigability shown as % of maximal tension produced by the TA after 90 
seconds of a maximal fatigue protocol. Values are means ± SEM.  ^ Significant from Vector 
controls. Significance was set at p<0.05. Students t-test. 
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2.3 – Experimental Design and Methods 
Specific Aim 1. Examine the impact of cachexia progression on the development of 
skeletal muscle fatigue in tumor-bearing mice. 
Premise 
Cachexia-induced skeletal muscle mass loss is associated with reduced ability to 
perform basic daily tasks leading to a loss of functional independence and reduced life 
quality (Vigano et al. 2000; Evans et al. 2008; Moses et al. 2004; Fearon KC 2006; Argiles 
2014; Amano et al. 2017). Additionally, regardless of significant body weight loss, cancer 
patients with reduced functional testing scores have worse chemotherapy tolerance and 
have reduced survival (O'Gorman, McMillan, and McArdle 1999; al-Majid and McCarthy 
2001a). While overall functional capacity can be impacted by the nervous (both central and 
peripheral), circulatory, and musculoskeletal systems, specific decrements to skeletal 
muscle’s contractile quality have been identified in cachectic patients and tumor bearing 
mice (Christensen et al. 2014; Gorselink et al. 2006; Murphy et al. 2012; Roberts, Frye, et 
al. 2013; Jaweed et al. 1983). The drivers of functional deficits in skeletal muscle during 
cachexia progression have not been clearly defined (Op den Kamp et al. 2012; Christensen 
et al. 2014; Biolo, Cederholm, and Muscaritoli 2014). 
 
Aim 1.1 Experimental Design 
The purpose of aim 1.1 was to determine the functional properties of skeletal 
muscle during the progression of cancer cachexia in MIN mice. We hypothesized that 
cachectic skeletal muscle would exhibit a decreased in force production and increased 
fatigability when compared to weight stable and healthy controls. To test this hypothesis, 
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male MIN mice were stratified by percent body weight (BW) loss ([End BW - Peak 
BW]/Peak BW) into weight stable (MIN-WS; <5% BW loss) or cachectic (MIN-CX; >5% 
BW loss). This delineation is a clinically relevant classification and has previously used to 
describe the progression of cachexia in the male MIN mouse (Fearon 2008; White, Baynes, 
et al. 2011). Age-matched male WT mice served as healthy non-tumor bearing controls. 
The TA was stimulated in situ and analyzed for several properties of muscle function.  
 
Aim 1.1 Primary outcomes 
Skeletal Muscle Contractile Properties:  
The contractile properties on the TA were assessed using in situ skeletal muscle 
function analysis. The sciatic nerve was stimulated to elicit a single action potential which 
subsequently causes a single muscle twitch. Once the optimal length (Lo) of the muscle 
was determined by generating a twitch length-tension curve, the TPT and 1/2 RT was 
measured and recorded. The muscle was then stimulated with increased frequencies (10-
300 hz) to generate a force-frequency curve. The relative increase in force (% of maximal 
tetanic force) was calculated. Lastly, the rate of muscle contraction and relaxation from 
maximal tension (+dP/dt and -dP/dt, respectively) was calculated from a 200 hz 
stimulation. Collectively, these outcomes have been classically used to describe the 
contractile properties of skeletal muscle.  
Skeletal Muscle Force Production: 
Skeletal muscle’s force production capacity was measured in the TA using in situ 
skeletal muscle function analysis. Maximal tetanic force (Po) was recorded as the greatest 
absolute force (millinewtons, mN) of the muscle at Lo generated during a force-frequency 
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curve. sPo was assessed by dividing the Po by the calculated muscle CSA. Muscle CSA was 
calculated by muscle mass/(Lf x 1.06), where Lf represents the fiber length determined by 
multiplying the Lo by 0.6, the predetermined TA muscle length to fiber length ratio, and 
1.06 represents the skeletal muscle density (Brooks and Faulkner 1988).  
Skeletal Muscle Fatigability:  
Skeletal muscle’s fatigue properties were measured in the TA using in situ skeletal 
muscle function analysis. The TA was rested for 5-minutes at Lo before being subjected to 
an intermittent fatigue protocol. The TA was subjected to a 4-minute intermittent fatigue 
protocol consisting of a 1 second long maximal contraction (250 hz) every 5 seconds (1 
second on, 4 seconds rest) (Murphy et al. 2012). The force production of the TA was 
measured at each contraction. Fatigue was determined by the calculating the relative force 
production (% of the initial, time 0, contraction) of the TA throughout the duration of the 
fatigue protocol. A significantly lower relative force production was classified as an 
increase in muscle fatigability and/or accelerated fatigue. 
 
Aim 1.1 Statistical analysis 
Determining Statistical Significance:  
Given the purpose and hypothesis of the study was to determine the effect of 
cachexia progression on muscle function, mice were separated into 3 groups for statistical 
analysis, WT, MIN-WS and MIN-CX. Initially, a Bartlett’s test was performed to 
determine if there is a statistical difference in the groups standard deviations (SD). If there 
was no significant difference in groups SD a one-way ANOVA assuming Gaussian 
distribution was performed to appropriately test for significant differences in our primary 
 240 
outcomes between the 3 groups. If a significant difference in group SD was observed, a 
Kruskal-Wallis test was performed to appropriately test for significant differences in our 
primary outcomes between the 3 groups. All statistical analysis was performed using 
GraphPad Prism 7. Values were presented as means plus / minus SEM (standard error of 
the mean). Significance will be set at p<0.05. 
Power analysis:  
A power analysis was performed to determine the sample size needed to observe 
statistical significance using a one-way ANOVA. Power (1-β) was set to 0.8 and error of 
probability (α) was set at 0.05. Based on previously published results and our preliminary 
data, to achieve significance for an estimated 15 ± 5 % difference between groups, a sample 
size of 9 is needed for each group.  
 
Aim 1.2 Experimental Design 
The purpose of aim 1.2 was to determine the relationship between systemic 
inflammatory markers, muscle gp130 signaling, body weight loss, and properties of 
skeletal muscle function in during the progression of cachexia in MIN mice. We 
hypothesized that there would be a negative linear relationship between several indices of 
cachexia and the properties of skeletal muscle function in MIN mice. To test this 
hypothesis, analysis of several properties of skeletal muscle function was conducted in 
male MIN mice with varying degrees of cachexia (0-25% Body Weight loss). Immediately 
following muscle function analysis and prior to sacrifice, each mouse’s tissues were 
excised and snap frozen in liquid nitrogen. Protein and mRNA expression of muscle gp130 
signaling was examined in the contralateral TA. Following data collection, the relationship 
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between several cachexia indices and the properties of skeletal muscle function correlations 
was examined. 
 
Aim 1.2 Primary outcomes  
Skeletal Muscle Contractile Properties: See aim 1.1 
Skeletal Muscle Force Production: See aim 1.1 
Skeletal Muscle Fatigability: See aim 1.1 
Indices of Cachexia:  
The progression of cachexia in the male MIN mouse has been well described. Body 
weight was measured weekly throughout the early and mid-stages of adulthood of the mice 
to determine the relative loss of body weight in individual mice. The muscle and tissue 
weights of each mouse was determined prior to sacrifice. Blood was collected immediately 
prior to sacrifice and Plasma IL-6 levels will be examined using an ELISA. 
Skeletal Muscle Inflammatory Signaling:  
Phosphorylated and total protein expression of direct (STAT3 (Y705) and ERK1/2 
(T202/Y204)0 and indirect (NFκB (S536) and P38 (Y182)) downstream gp130 targets 
were measured in the proximal TA using Western blot techniques. The phosphorylated to 
total ratio of these proteins was used to determine the activation of each respective protein. 
Additionally, mRNA expression of gp130 signaling associated transcriptional targets, IL-
6, SOCS3, TNFα were measured using RT-PCR. 
Relationship Between Indices of Cachexia and Skeletal Muscle Function:  
Pearson’s correlations and stepwise linear regression models were performed 
analyzing the cachexia indices (BW, % BW Loss, muscle mass, plasma IL-6, and muscle 
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inflammatory signaling) as the independent variable and the properties of skeletal muscle 
function (1/2 RT, TPT, +dP/dt, -dP/dt, Po, sPo, and fatigue) as the dependent variable.   
 
Aim 1.2 Statistical analysis 
Determining Statistical Significance:  
See aim 1.1. A Pearson’s correlation was used to determine correlations between 
inflammatory genes and proteins with muscle function properties in MIN mice. Stepwise 
linear regression models were used to identify predictors (cachexia indices) of the 8 
measured outcomes related to skeletal muscle function. Significance was set at p<0.05. 
Power analysis: See aim 1.1 
 
Aim 1.3 Experimental Design 
The purpose of aim 1.3 was to determine the relationship between skeletal muscle 
oxidative and glycolytic metabolism with skeletal muscle fatigue in MIN mice. We 
hypothesized that there would be a direct relationship between skeletal muscle fatigability 
and mitochondrial content, and mitochondrial and glycolytic gene expression. To test this 
hypothesis, analysis of several properties of skeletal muscle function was conducted in 
male MIN mice with varying degrees of cachexia (0-25% Body Weight loss). Immediately 
following muscle function analysis and prior to sacrifice, each mouse’s tissues was excised 
and snap frozen in liquid nitrogen. mRNA expression of key mitochondrial and glycolytic 
targets in addition to EDL COX activity was determined from the contra-lateral TA to 
determine relationships to muscle function.  
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Aim 1.3 Primary outcomes  
Skeletal Muscle Contractile Properties: See aim 1.1 
Skeletal Muscle Force Production: See aim 1.1 
Skeletal Muscle Fatigability: See aim 1.1 
Skeletal Muscle Metabolic Gene Expression:  
mRNA expression of mitochondrial content and quality control, PGC-1α, FIS1, 
MFN1 and 2, and COXIV, as well as key glycolytic metabolism genes, hexokinase and 
phosphofructokinase, were measured using RT-PCR.  
Relationship Between Skeletal Muscle Metabolic Gene Expression and Skeletal Muscle 
Function: 
Pearson’s correlations and stepwise linear regression models were performed 
analyzing the mRNA expression of metabolism (PGC-1α, FIS1, MFN1 and 2, COXIV, 
hexokinase, and phosphofructokinase) as the independent variable and the properties of 
skeletal muscle function (1/2 RT, TPT, +dP/dt, -dP/dt, Po, sPo, and fatigue) as the dependent 
variable. 
 
Aim 1.3 Statistical analysis 
Determining Statistical Significance: See aim 1.1 
Power analysis: See aim 1.1 
Relationship Between Muscle Metabolism and Skeletal Muscle Function: See aim 1.2 
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Specific Aim 1 Research Methods 
Animals 
Male WT and MIN mice were purchased from Jackson Laboratories and were bred 
at the University of South Carolina’s Animal Resources Facility. All animals were group 
housed and kept on a 12:12-h light-dark cycle. Body weights were measured weekly, and 
animals were monitored for signs of distress. Animals were given food and water ad libitum 
throughout the duration of the study. All animals were fasted 5 hours prior to tissue 
collection. Mice were anesthetized with a ketamine-xylazine-acepromazine cocktail, and 
hindlimb muscles and select organs were carefully dissected and snap frozen in liquid 
nitrogen and stored at -80⁰C until further analysis. The University of South Carolina’s 
Institutional Animal Care and Use Committee approved all animal experiments. 
Analysis of Muscle Function 
At ~20 weeks of age, mice were anesthetized with 2% isoflurane inhalation and 
kept anesthetized at 1.5 % isoflurane throughout the duration of the procedure (~1 hour). 
Muscle function analysis of the TA in situ, which maintains the host nerve and blood 
supply, has been previously described (Murphy et al. 2012; Bonetto, Andersson, and 
Waning 2015; Dellorusso et al. 2001). Briefly, the distal tendon of the left TA was isolated 
and tied to a force transducer (Aurora Scientific, Ontario, Canada) using 5-0 silk sutures. 
The mouse was place on the apparatus maintained at 37C throughout the entirety of the 
procedure (Bonetto, Andersson, and Waning 2015). The sciatic nerve was exposed 
proximal to the knee and maintained using warmed mineral oil. The sciatic nerve was then 
subjected to a single stimulus to determine Lo. Once Lo was obtained, a force-frequency 
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curve was generated, and maximal tetanic force was determined. After a 5-minute rest the 
TA was subjected to a 4-minute intermittent fatigue protocol consisting of 1 second 
maximal stimulation every 4 seconds (Murphy et al. 2012). Maximal tension was again 
measured 5 and 10 minutes after completion of the fatigue protocol. Specific tension was 
determined using TA muscle CSA calculated by muscle mass/(Lf x 1.06), where Lf 
represents fiber length determined by multiplying Lo by 0.6, the predetermined TA muscle 
length to fiber length ratio, and 1.06 represents the skeletal muscle density (Brooks and 
Faulkner 1988). 
Western blot analysis 
Western blot analysis was performed as described previously (Puppa, Gao, et al. 
2014). Briefly, the right proximal TA was homogenized, and protein concentration was 
determined using the standard Bradford protein assay. Homogenates were fractionated on 
7-10% SDS-polyacrylamide gels and transferred to a polyvinylidene difluoride membrane. 
Primary antibodies for phosphorylated (p) and total (t) P65, STAT3, P38, and Erk1/2 (Cell 
Signaling Technology) were incubated 1:1000 overnight at 4⁰C in 5% TBST milk. Anti-
rabbit IgG-conjugated secondary antibodies (cell signaling) were incubated 1:2000 for 1 
hour at room temperature in 5% TBST milk. Enhanced Chemiluminescence was used to 
visualize antibody-antigen interaction and captured using the Syngene: G-Box. Blots were 
analyzed by determining the integrated optical density of each band using ImageJ (NIH 
software). 
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RNA isolation and RT-PCR 
RNA isolation, cDNA synthesis, and RT-PCR were performed as previously 
described (Narsale et al. 2016) using reagents from Applied Biosystems (Foster City, CA, 
USA). Primers for GAPDH, IL-6, IL-1, TNF-, SOCS3, PGC1, FIS1, MFN 1 and 2, 
Hexokinase II, and Phophofructokinase will purchased from IDT (Coralville, Iowa, USA) 
and run using SYBR green PCR buffer (Narsale et al. 2016). Data were analyzed using the 
2-ΔΔCT method.  
Cytochrome C Oxidase Activity  
EDL muscle samples will be homogenized in extraction buffer (0.1 M 
KH2P04/Na2HP04, 2 mM EDTA, pH 7.2). Cytochrome-c oxidase (COX) activity was 
determined by measuring the rate of oxidation of fully reduced cytochrome c at 550nm 
using (CYTOCOX1) Sigma Aldrich Kit and spectrophotometer (Eppendorf) (Iqbal and 
Hood 2015).  
Statistical analysis 
Values are presented as means ± standard error of the mean (SEM).  Student t-tests 
were performed to determine differences between genotypes. A one-way ANOVA was 
used to determine differences in muscle function and inflammatory signaling when MIN 
mice were stratified by age or body weight loss. Post hoc analyses were performed with 
student Newman-Keuls methods. A Bartlett’s test was used to determine significantly 
different standard deviations (p<0.05). If a significant difference was observed between 
group standard deviations, a non-parametric Kruskal-Wallis one-way ANOVA was used. 
A Pearson correlation was used to determine correlations between inflammatory genes and 
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proteins with muscle function properties in MIN mice. Stepwise linear regression models 
were used to identify predictors (cachexia indices) of the 8 measured outcomes related to 
skeletal muscle function. Significance was set at p<0.05. 
 
Specific Aim 2. Determine the role of muscle gp130 signaling in skeletal muscle fatigue 
during the progression of cachexia.  
Premise 
Skeletal muscle contractile dysfunction and disrupted metabolic homeostasis have 
been demonstrated across several chronic diseases (Sin and Man 2003; Deans and 
Wigmore 2005; Kuller et al. 2008; Vidt 2006). Recent evidence suggests that muscle 
mitochondrial dysfunction and increased fatigability can occur independent of changes to 
muscle size and strength demonstrating that muscle weakness and fatigue have distinct 
etiologies (VanderVeen et al. 2018; Brown et al. 2017). IL-6 signaling through the 
membrane gp130 receptor has been implicated as a regulator of skeletal muscle mass and 
metabolic homeostasis during both physiological and pathological conditions (Carson and 
Baltgalvis 2010; Bonetto et al. 2011; Hardee, Counts, et al. 2018; Gao et al. 2017; Puppa, 
Gao, et al. 2014). Furthermore, the mitochondria have emerged as an intriguing target for 
inflammation induced skeletal muscle metabolic dysfunction (Boland, Chourasia, and 
Macleod 2013; Brown et al. 2017; Hardee et al. 2016; Carson, Hardee, and VanderVeen 
2016). We have previously shown that elevated levels of circulating IL-6 was sufficient to 
decrease mitochondrial protein expression in tumor-free mice (Puppa et al. 2012); 
however, whether this occurs directly through the muscle gp130 receptor to increase 
muscle fatigue was not been examined. Furthermore, the muscle gp130 receptor has 
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recently been shown to play a role in skeletal muscle mitochondrial quality control; 
however, the effects of IL-6 and gp130 signaling on skeletal muscle fatigue has not been 
examined.  
Both systemic inflammation and muscle inflammatory signaling have been 
extensively examined for their regulation of muscle wasting with cancer (Tisdale 2002; 
Evans et al. 2008; Carson and Baltgalvis 2010; VanderVeen, Fix, and Carson 2017; Argiles 
et al. 2009; Argiles 2014; Deans and Wigmore 2005; Sandri 2008; Onesti and Guttridge 
2014). Chronic inflammation has been undoubtably linked to disrupted muscle protein 
turnover and oxidative metabolism, which are both integral to the pathology of muscle 
mass loss during cachexia progression (White, Baltgalvis, et al. 2011; Carson, Hardee, and 
VanderVeen 2016; Argiles et al. 2009; White, Baynes, et al. 2011; Deans and Wigmore 
2005; Seto, Kandarian, and Jackman 2015; Cannon TY 2007; Onesti and Guttridge 2014; 
Fearon, Glass, and Guttridge 2012). Systemic overexpression of IL-6 in the MIN mouse is 
sufficient to accelerate the cachectic phenotype, while IL-6 null MIN mice had no 
significant muscle mass loss; however, global manipulation of IL-6 is shown to directly 
modulate tumor-burden (Baltgalvis et al. 2008). To this end, LLC tumor-bearing gp130 
muscle specific knockout (KO) mice demonstrated an attenuation muscle mass loss 
compared to intact controls, associated with suppressed STAT3 and p38; however, whether 
gp130 loss improved skeletal muscle function remains unknown  (Puppa, Gao, et al. 2014). 
 
Aim 2.1 Experimental Design  
The purpose of aim 2.1 was to determine if elevated skeletal muscle gp130 
signaling is sufficient to induce skeletal muscle fatigue in tumor-free mice. We 
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hypothesized that elevating circulating levels of IL-6 would induce fatigue through the 
activation of skeletal muscle gp130 signaling. To test this hypothesis, male WT and skeletal 
muscle specific gp130 knockout (skm gp130 KO) mice were electroporated with an IL-6 
plasmid to increased plasma IL-6. Control WT and skm gp130 KO mice were given an 
empty vector. After two weeks of elevated IL-6, several properties of skeletal muscle 
function were assessed in situ.  
  
Aim 2.1 Primary outcomes  
Skeletal Muscle Inflammatory Signaling: See aim 1.2 
Skeletal Muscle Contractile Properties:  
The contractile properties on the TA will be assessed using in situ skeletal muscle 
function analysis. The sciatic nerve was stimulated to elicit a single action potential which 
subsequently caused a single muscle twitch. Once Lo of the muscle was determined by 
generating a twitch length-tension curve, the TPT and 1/2 RT were measured and recorded. 
The muscle was then stimulated with increased frequencies (10-200 hz) to generate a force-
frequency curve. The relative increase in force (% of maximal tetanic force) was calculated. 
Lastly, the rate of muscle rise and relaxation from maximal tension (+dP/dt and -dP/dt, 
respectively) was calculated from a 200 hz stimulation.  
Skeletal Muscle Force Production:  
Skeletal muscle’s force production capacity was measured in the TA using in situ 
skeletal muscle function analysis. Po was recorded as the greatest absolute force 
(millinewtons) of the muscle at Lo generated during a force-frequency curve. sPo was 
assessed by dividing the Po by muscle CSA. Muscle CSA was calculated by muscle 
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mass/(Lf x 1.06), where Lf represents the fiber length determined by multiplying the Lo by 
0.6, the predetermined TA muscle length to fiber length ratio, and 1.06 represents the 
skeletal muscle density (Brooks and Faulkner 1988).  
Skeletal Muscle Fatigability:  
Skeletal muscle’s fatigue properties were measured in the TA using in situ skeletal 
muscle function analysis. The TA was rested for 5-minutes at Lo before being subjected to 
an intermittent fatigue protocol. The TA was subjected to a 5-minute submaximal fatigue 
protocol consisting of a 0.5-second-long contraction (50 hz) every second. After 
completion of the submaximal fatigue protocol, the TA was subjected to an additional 5-
minute maximal fatigue protocol consisting of a 0.5-second-long contraction (200 hz) 
every second. The force production of the TA was measured at each contraction. Fatigue 
was determined by the calculating the relative force production (% of the initial, time 0, 
contraction) of the TA throughout the duration of each fatigue protocol. The two protocols 
were analyzed separately. A significantly lower relative force production was classified as 
an increase in submaximal and/or maximal muscle fatigability. 
 
Aim 2.1 Statistical analysis 
Determining Statistical Significance:  
Given the purpose and hypothesis of the study was to determine if elevated skeletal 
muscle gp130 signaling was sufficient to induce skeletal muscle fatigue in tumor-free mice, 
4 groups of mice were used, WT Vector or IL-6, and skm gp130 KO Vector or IL-6. 
Initially, a Bartlett’s test was performed to determine if there is a statistical difference in 
the groups SD. If there was no significant difference in groups SD a standard two-way 
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ANOVA was performed to appropriately test for significant differences between 
treatments and genotypes. If an interaction was observed, a Tukey’s multiple comparison 
was performed to determine changes within a treatment and/or genotype. All statistical 
analysis was performed using GraphPad Prism 7. Values are presented as means plus / 
minus SEM (standard error of the mean). Significance will be set at p<0.05. 
Power analysis:  
A power analysis was performed to determine the sample size needed to observe 
statistical significance using a two-way ANOVA. Power (1-β) was set to 0.8 and error of 
probability (α) was set at 0.05. Based on previously published results and our preliminary 
data, to achieve significance difference between groups for an estimated effect size of 1.2, 
a sample size of 9 is needed for each group.  
 
Aim 2.2 Experimental Design 
The purpose of Aim 2.2 was to determine the effect of elevated skeletal muscle 
gp130 signaling on skeletal muscle oxidative and glycolytic metabolism. We hypothesized 
that elevating circulating levels of IL-6 would induce mitochondrial dysfunction through 
the activation of skeletal muscle gp130 signaling. To test this hypothesis, male WT and 
skm gp130 KO mice were electroporated with an IL-6 plasmid to increased plasma IL-6. 
Control WT and skm gp130 KO mice were given an empty vector. After two weeks of 
elevated L-6, the TA was analyzed for several indices of mitochondrial content, quality, 
and function. 
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Aim 2.2 Primary outcomes 
Respiratory Control Ratio: 
Mitochondrial respiration was measured polarographically in a respiration chamber 
(Hansatech Instruments) maintained at 37°C as previously described (Kwon et al. 2015). 
A randomly selected cohort of mice from each treatment group were used for analysis of 
mitochondrial function. A 7-10 mg piece of TA muscle was mechanically tweezed with 
forceps under a dissecting microscope in ice-cold buffer X (60 mM K-MES, 35 mM KCl, 
7.23 mM K2EGTA, 2.77 mM CaK2EGTA, 20 mM imidazole, 0.5 mM DTT, 20 mM 
taurine, 5.7 mM ATP, 15 mM phosphocreatine, and 6.56 mM MgCl2, pH 7.1). The fiber 
bundle was then incubated in 50uM saponin for 30 minutes and washed 3 times for 5 
minutes in respiration buffer (105mM K-MES, 3mM KCl, 1mM EGTA, 10mM K2HPO4, 
5mM MgCl2, 0.005mM Glutamate, 0.002mM Malate, 0.05% BSA, 20mM Creatine, pH 
7.1). Fiber bundles were then placed into the oxygraph machine in 20mM creatine 
respiration buffer at 37 degrees and provided with 5mM of pyruvate and 2mM of malate. 
Two minutes following pyruvate and malate, 0.25mM of ADP was injected into the 
chamber to induce STATE 3 respiration for a duration of 5 minutes. 10ug/mL of 
Oligomycin was then injected to induce steady state 4 respiration for a duration of 10 
minutes. Respiratory Control Ratio (RCR) was calculated by dividing state 3 by state 4 
respirations. 
Mitochondrial Content and Quality Control:  
The distal TA was sectioned to examine succinate dehydrogenase (SDH) enzyme 
activity histologically. Thresholds corresponding to high SDH enzyme activity will set 
manually and uniformly across all images, and myofibers will be classified as having high 
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or low SDH enzyme activities. All muscle regions were included in analysis, and the 
percentage of high SDH enzyme activity myofibers is expressed as the percentage per total 
number of myofibers. 
See aim 1.3 for gene expression.  
 
Aim 2.2 Statistical analysis 
Determining Statistical Significance: See aim 2.1 and 1.3 
Power analysis: See aim 2.1 
 
Aim 2.3 Experimental Design 
The purpose of aim 2.3 was to determine the role of skeletal muscle gp130 signaling 
in cancer induced skeletal muscle fatigue in MIN mice. We hypothesized that loss of 
muscle gp130 signaling would attenuate the skeletal muscle fatigue progression in MIN 
mice that have initiated cachexia. To test this hypothesis, skeletal muscle specific (HSA 
cre/+) gp130 inducible knock out (iKO) mice will be crossed with MIN mice to produce 
the MIN iKO. Floxed gp130 wildtype and MIN mice will serve as their respective controls. 
All groups will be administered tamoxifen for 5 days at 12 weeks of age. Following a 1-
week washout period the mice will be tracked and monitored for 4 weeks. At ~17 weeks 
of age, the functional properties of skeletal muscle will be assessed in situ. 
 
Aim 2.3 Primary outcomes 
Skeletal Muscle Inflammatory Signaling: See aim 1.2 
Skeletal Muscle Contractile Properties: See aim 1.1 
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Skeletal Muscle Force Production: See aim 1.1 
Skeletal Muscle Fatigability: See aim 2.1 
Respiratory Control Ratio: See aim 2.2 
Mitochondrial Content and Quality Control: See aim 2.2 
 
Aim 2.2 Statistical analysis 
Determining Statistical Significance: See aim 2.1 
Power analysis: See aim 2.1 
 
Specific Aim 2 Research Methods 
Animals 
For experiments in aims 2.1 and 2.2, male mice on a C57BL/6 background were 
bred with gp130fl/fl mice provided by Dr. Colin Stewart's laboratory [Laboratory of Cancer 
and Developmental Biology, National Cancer Institute, U.S. National Institutes of Health 
(NIH), Frederick, MD, USA] in collaboration with Dr. Lothar Hennighausen (Laboratory 
of Genetics and Physiology, National Institute of Diabetes and Digestive and Kidney 
Diseases, NIH, Bethesda, MD, USA). gp130fl/fl male mice were bred with Cre-expressing 
mice driven by myosin light chain (MLC), from Dr. Steven Burden (New York University, 
New York, NY, USA). The resulting fl/fl cre/+ (KO) mice have a skeletal muscle deletion 
of gp130. Offspring were genotyped by using tail snips to obtain Cre recombinase 
(forward, 5′-AGCCCTGACCCTTTAGATTCCATTT-3′, and reverse, 5′-
AAAACGCCTGGCGATCCCTGAAC-3′; and wild type 5′-
GCGGGCTTCTTCACGTCTTTCTTT-3′) and floxed gp130 (forward, 5′-
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ACGTCACAGAGCTGAGTGATGCAC-3′, and reverse, 5′-
GGCTTTTCCTCTGGTTCTTG-3′).  
For experiments in aims 2.3, gp130fl/fl mice were crossed with inducible Cre-
expressing mice driven by human alpha skeletal actin (HSAcre/+) to develop an inducible 
gp130 KO mouse (iKO). Simultaneously, gp130fl/fl mice were crossed with MIN to 
produce a gp130 fl/fl MIN (gp130 fl/fl MIN). The resulting gp130 iKO and gp130fl/fl MIN 
were crossed to obtain an iKO-MIN mouse. Offspring were genotyped by using tail snips. 
All animals were group housed and kept on a 12:12-h light-dark cycle. Body 
weights were measured weekly, and animals were monitored for signs of distress. Animals 
were given food and water ad libitum throughout the duration of the study. All animals 
were fasted 5 hours prior to tissue collection. Mice were anesthetized with a ketamine-
xylazine-acepromazine cocktail, and hindlimb muscles and select organs were carefully 
dissected and snap frozen in liquid nitrogen and stored at -80⁰C until further analysis. All 
animal experiments were approved by the University of South Carolina’s Institutional 
Animal Care and Use Committee. 
IL-6 Overexpression 
in vivo intramuscular electroporation of an IL-6 plasmid was used to increase 
circulating IL-6 levels in mice as previously described. The quadriceps muscle was used 
as a vessel to produce IL-6 and secrete it into circulation and was not used for any analyses 
in the study. The TA muscle used in the study was not subjected to electroporation. Briefly, 
mice were injected with 50 μg of the IL-6 plasmid driven by the CMV promoter, or empty 
control vector, into the quadriceps muscle. Mice were anesthetized with a 2% mixture of 
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isoflurane and oxygen (2 l/min). The leg was shaved, and a small incision was made over 
the quadriceps muscle. Fat was dissected away from the muscle, and the plasmids were 
injected in a 50-μl volume of phosphate-buffered saline (PBS). A series of eight 50-ms, 
100-V pulses was used to promote uptake of the plasmid into myofibers, and then the 
incision was closed with a wound clip. Both vector control and IL-6 groups received the 
appropriate plasmid starting at 10 weeks of age. Mice were euthanized after 2 weeks after 
IL-6 overexpression. 
Analysis of Muscle Function 
At ~12 weeks of age, mice were anesthetized with 2% isoflurane inhalation and 
kept anesthetized at 1.5 % isoflurane for ~1hr throughout the duration of the procedure (~1 
hour). Muscle function analysis of the TA in situ, which maintains the host nerve and blood 
supply, has been previously described. Briefly, the distal tendon of the left TA was isolated 
and tied to a force transducer (Aurora Scientific, Ontario, Canada) using 5-0 silk sutures. 
The mouse was place on the apparatus maintained at 37ºC throughout the entirety of the 
procedure. The sciatic nerve was exposed proximal to the knee and maintained using 
warmed mineral oil. The sciatic nerve was then subjected to a single stimulus to determine 
the optimal length (Lo). Once Lo was obtained, a force-frequency curve was generated, and 
maximal tetanic force was determined. After a 5-minute rest the TA was subjected to an 
intermittent fatigue protocol consisting of 0.5 second submaximal stimulation (50Hz) 
every second for 5 minutes. After submaximal fatigue the TA was subjected to an 
intermittent fatigue protocol consisting of 0.5 second maximal stimulation (200Hz) every 
second for 5 minutes. Specific tension was determined using TA muscle CSA calculated 
by muscle mass/(Lf x 1.06), where Lf represents fiber length determined by multiplying Lo 
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by 0.6, the predetermined TA muscle length to fiber length ratio, and 1.06 represents the 
skeletal muscle density. 
Immunohistochemistry for myosin heavy chain IIA, IIX, and IIB 
Immunohistochemistry for myosin heavy chain (MHC) type IIa, IIx, and IIb was 
performed as previously described (Goodman et al. 2012). Transverse muscle sections 
(8m) of the TA were blocked in 10% IgG Fab (Jackson Immunology) in PBS (5% BSA 
+ 5% Triton X100) for 1 h at room temperature and then incubated overnight at 4°C with 
primary antibodies [mouse IgG1 monoclonal anti-type IIa MHC (clone SC-71; 1:100) and 
mouse IgM monoclonal anti-type IIb MHC (clone BF-F3, 1:10).  All MHC antibodies were 
obtained from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, 
IA). Secondary antibodies (biotinylated anti-mouse IgG FITC, IgM AMCA; Thermo 
Fischer) were incubated with the sections for 1 hour at RT. Slides were air dried and 
covered in glycerol mounting medium containing DABCO and coverslipped. At least 8 
random, non-overlapping digital images at 20X magnification were taken, and fibers 
stained positive or absent for MHC type IIa, IIx, and IIb were tabulated using imaging 
software (ImageJ; NIH). The analyses were performed by an investigator blinded to the 
treatment groups. 
Western blot analysis 
Western blot analysis was performed as described previously. Briefly, the right 
proximal TA was homogenized, and protein concentration was determined using the 
standard Bradford protein assay. Homogenates were fractionated on 7-10% SDS-
polyacrylamide gels and transferred to a polyvinylidene difluoride membrane. Primary 
antibodies for gp130 (Santa Cruz) and phosphorylated (p) and total (t) STAT3 (Cell 
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Signaling Technology) were incubated 1:1000 overnight at 4⁰C in 5% TBST milk. Anti-
rabbit IgG-conjugated secondary antibodies (cell signaling) were incubated 1:2000 for 1 
hour at room temperature in 5% TBST milk. Enhanced Chemiluminescence was used to 
visualize antibody-antigen interaction and captured using the Syngene: G-Box. Blots were 
analyzed by determining the integrated optical density of each band using ImageJ (NIH 
software). 
Cytochrome C Oxidase Activity  
EDL muscle samples were homogenized in extraction buffer (0.1 M 
KH2P04/Na2HP04, 2 mM EDTA, pH 7.2). Cytochrome-c oxidase (COX) activity was 
determined by measuring the rate of oxidation of fully reduced cytochrome c at 550nm 
using (CYTOCOX1) Sigma Aldrich Kit and spectrophotometer (Eppendorf).  
Respiratory Control Ratio 
Mitochondrial respiration was measured polarographically in a respiration chamber 
(Hansatech Instruments) maintained at 37°C as previously described (Kwon et al. 2015). 
A randomly selected cohort of mice from each treatment group were used for analysis of 
mitochondrial function. A 7-10 mg piece of TA muscle was mechanically tweezed with 
forceps under a dissecting microscope in ice-cold buffer X (60 mM K-MES, 35 mM KCl, 
7.23 mM K2EGTA, 2.77 mM CaK2EGTA, 20 mM imidazole, 0.5 mM DTT, 20 mM 
taurine, 5.7 mM ATP, 15 mM phosphocreatine, and 6.56 mM MgCl2, pH 7.1). The fiber 
bundle was then incubated in 50uM saponin for 30 minutes and washed 3 times for 5 
minutes in respiration buffer (105mM K-MES, 3mM KCl, 1mM EGTA, 10mM K2HPO4, 
5mM MgCl2, 0.005mM Glutamate, 0.002mM Malate, 0.05% BSA, 20mM Creatine, pH 
7.1). Fiber bundles were then placed into the oxygraph machine in 20mM creatine 
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respiration buffer at 37 degrees and provided with 5mM of pyruvate and 2mM of malate. 
Two minutes following pyruvate and malate, 0.25mM of ADP was injected into the 
chamber to induce STATE 3 respiration for a duration of 5 minutes. 10ug/mL of 
Oligomycin was then injected to induce steady state 4 respiration for a duration of 10 
minutes. Respiratory Control Ratio (RCR) was calculated by dividing state 3 by state 4 
respirations. 
Statistical analysis 
Values are presented as means plus / minus standard error of the mean (SEM).  A 
Bartlett’s test was used to determine significantly different standard deviations (p<0.05). 
A Two-Way ANOVA was used to determine a difference between treatment and genotype. 
If a statistical interaction was observed, a Tukey’s multiple comparison’s test was 
performed to determine specific differences. Significance was set at p<0.05.   
 
Specific Aim 3. Determine the role of muscle use on skeletal muscle fatigue during 
cachexia progression. 
Premise 
Cancer patients with decreased functional ability and increased fatigue, regardless 
of cachexia diagnosis, experience decreased quality of life and a poorer prognosis 
(O'Gorman, McMillan, and McArdle 1999; al-Majid and McCarthy 2001a). Fatigue is the 
most frequently reported symptom by cancer patients (al-Majid and McCarthy 2001a). 
Cancer patients and preclinical cachexia models exhibit decreased volitional activity and 
increased fatigue that precedes significant weight loss (Baltgalvis 2010; Murphy et al. 
2012; Roberts, Frye, et al. 2013; Toth et al. 2016; Puppa, Gao, et al. 2014). We have 
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previously demonstrated that the MIN mouse continues normal growth and development 
up to 16 weeks of age where body weight begins to plateau. At 18 weeks of age there is 
evidence of significant body weight loss (~5-10%) that continues for 2-4 weeks (~20%). 
Interestingly, reductions in wheel activity, most notably max velocity, is reduced at 15 
weeks of age and steadily declines until they are near completely sedentary at 18 weeks 
(Baltgalvis 2010). Additionally, we have reported that 8 weeks of endurance exercise 
training prevented IL-6 induced muscle wasting in MIN mice; however, these results were 
associated with significant reductions in tumor-burden. Lastly, we have reported that 2 
weeks, 7 sessions, of repeated eccentric muscle contractions could attenuate muscle mass 
loss associated with improve SDH activity without affecting tumor burden in mice that 
initiated cachexia (~7% BW loss) (Hardee et al. 2016). Collectively, these results 
demonstrate that physical activity and skeletal muscle use can modulate cachexia 
progression; however, whether this modulation affects cancer-induced skeletal muscle 
dysfunction has not been established. 
 
Aim 3.1 Experimental Design  
The purpose of aim 3.1 was to determine the relationship between volitional activity 
and skeletal muscle fatigue during the progression of cachexia. We hypothesized that 
skeletal muscle fatigue occurs prior to significant body weight loss which would be directly 
related to reduced physical activity. To test this hypothesis, WT and MIN mice were 
monitored for daily cage activity at starting 12 weeks of age, when tumor-burden is set, 
and tracked for 5 weeks (Allen et al. 2001). MIN mice were further stratified into 2 groups 
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corresponding with high and low activity. At 17 weeks of age, the functional properties of 
skeletal muscle were assessed in situ.    
 
Aim 3.1 Primary outcomes  
Voluntary Cage Activity:  
From 12-17 weeks of age, mice were single-housed and placed in activity monitor 
cages (Opto-M3 Activity Meter, Columbus Instruments). Activity was measured for 12 
hours during the dark cycle (7PM–7AM) and 12 hours during the day cycle (7AM–7PM); 
the number of beams crossed in an X–Y plane was recorded for two consecutive nights. 
Food consumption was also recorded during this time while the mice were single-housed.  
Skeletal Muscle Contractile Properties: See aim 1.1 
Skeletal Muscle Force Production: See aim 1.1 
Skeletal Muscle Fatigability: See aim 2.1 
Indices of Cachexia: See aim 1.1 
Relationship Between Indices of Cachexia and Skeletal Muscle Function:  
Pearson’s correlations and stepwise linear regression models were performed 
analyzing the cachexia indices (BW, BW Loss, muscle mass, plasma IL-6, and muscle 
inflammatory signaling) as well as physical activity levels as the independent variable and 
the properties of skeletal muscle function (1/2 RT, TPT, +dP/dt, -dP/dt, Po, sPo, and fatigue) 
as the dependent variable.   
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Aim 3.1 Statistical analysis 
Determining Statistical Significance:  
Given the purpose of this study was to determine the relationship between volitional 
activity and skeletal muscle fatigue during the progression of cachexia, mice will be 
separated into 3 groups for statistical analysis, WT, MIN Low Activity (MIN-LA), and 
MIN High Activity (MIN-HA). Initially, a Bartlett’s test was performed to determine if 
there was a statistical difference in the groups SD. If there was no significant difference in 
groups SD a one-way ANOVA assuming Gaussian distribution was performed to 
appropriately test for significant differences in our primary outcomes between the 3 groups. 
If a significant difference in group SD was observed, a Kruskal-Wallis test was performed 
to appropriately test for significant differences in our primary outcomes between the 3 
groups. A Pearson’s correlation was used to determine correlations between volitional 
activity and skeletal muscle function properties in MIN mice. All statistical analysis was 
performed using GraphPad Prism 7. Values are presented as means plus / minus SEM 
(standard error of the mean). Significance will be set at p<0.05. 
Power analysis:  
A power analysis was performed to determine the sample size needed to observe 
statistical significance using a one-way ANOVA. Power (1-β) was set to 0.8 and error of 
probability (α) was set at 0.05. Based on previously published results, to achieve 
significance for an estimated 15 ± 5 % difference between groups, a sample size of 9 is 
needed for each group. 
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Aim 3.2 Experimental Design 
The purpose of aim 3.2 was to determine if 5 weeks of free access to a wheel prior 
to significant body weight loss can prevent the induction of skeletal muscle fatigue in MIN 
mice. We hypothesized that increased volitional activity would delay the onset of skeletal 
muscle fatigue in MIN mice. As previously described, reduced volitional activity presents 
as early as 3 weeks prior to significant body weight loss (Baltgalvis 2010). To test our 
hypothesis, WT and MIN mice were given free access to a wheel at 12 weeks of age and 
monitored until 17 weeks of age. After 5 weeks of free access to wheels, the functional 
properties of skeletal muscle will be assessed in situ.   
 
Aim 3.2 Primary outcomes 
Voluntary Wheel Activity: See aim 3.1  
Skeletal Muscle Contractile Properties: See aim 1.1 
Skeletal Muscle Force Production: See aim 1.1 
Skeletal Muscle Fatigability: See aim 2.1 
Indices of Cachexia: See aim 1.1 
Relationship Between Indices of Cachexia and Skeletal Muscle Function:  
Pearson’s correlations and stepwise linear regression models were performed 
analyzing the cachexia indices (BW, % BW Loss, muscle mass, plasma IL-6, and muscle 
inflammatory signaling) as well as physical activity levels as the independent variable and 
the properties of skeletal muscle function (1/2 RT, TPT, +dP/dt, -dP/dt, Po, sPo, and fatigue) 
as the dependent variable. 
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Aim 3.2 Statistical analysis 
Determining Statistical Significance:  
Given the purpose and hypothesis of the study was to determine if 5 weeks of free 
access to wheels prior to significant body weight loss can prevent the induction of skeletal 
muscle fatigue in MIN mice, mice were separated into 4 groups for statistical analysis, WT 
Control (WT-C), WT Wheel Access (WT-WA), MIN Control (MIN-C), MIN Wheel 
Access (MIN-WA). Initially, a Bartlett’s test was performed to determine if there was a 
statistical difference in the groups SD. If there was no significant difference in groups SD 
a two-way ANOVA assuming Gaussian distribution was performed to appropriately test 
for significant differences in our primary outcomes between the 4 groups. If a significant 
difference in group SD was observed, a Kruskal-Wallis test was performed to appropriately 
test for significant differences in our primary outcomes between the 4 groups. A Pearson’s 
correlation was used to determine correlations between volitional activity and skeletal 
muscle function properties in MIN mice. All statistical analysis was performed using 
GraphPad Prism 7. Values will be presented as means plus / minus SEM (standard error of 
the mean). Significance will be set at p<0.05. 
Power analysis:  
A power analysis was performed to determine the sample size needed to observe 
statistical significance using a two-way ANOVA. Power (1-β) was set to 0.8 and error of 
probability (α) was set at 0.05. Based on previously published results, to achieve 
significance for an estimated 15 ± 5 % difference between groups, a sample size of 9 is 
needed for each group. 
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Aim 3.3 Experimental Design 
The purpose of aim 3.3 was to determine if 5 weeks of free access to a wheel prior 
to significant body weight loss would prevent the reduction in skeletal muscle oxidative 
metabolism in MIN mice. We hypothesized that increased volitional activity would delay 
the reduction in skeletal muscle oxidative metabolism in MIN mice. As previously 
described, reduced volitional activity presents as early as 3 weeks prior to significant body 
weight loss (Baltgalvis 2010). To test our hypothesis, WT and MIN mice were given free 
access to a wheel at 12 weeks of age and monitored until 17 weeks of age. At 17 weeks of 
age the oxidative capacity of skeletal muscle was assessed using respiratory control ratio.  
 
Aim 3.3 Primary outcomes 
Voluntary Wheel Activity: See aim 3.1  
Skeletal Muscle Contractile Properties: See aim 1.1 
Skeletal Muscle Force Production: See aim 1.1 
Skeletal Muscle Fatigability: See aim 2.1 
Respiratory Control Ratio: See aim 2.2 
Relationship Between Skeletal Muscle Oxidative Metabolism and Skeletal Muscle 
Function: See aim 1.3 
 
Aim 3.3 Statistical analysis 
Determining Statistical Significance: See aim 3.2 
Power analysis: See aim 3.2 
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Specific Aim 3 Research Methods 
Animals 
Male WT and MIN mice were purchased from Jackson Laboratories and were bred 
at the University of South Carolina’s Animal Resources Facility. All animals were group 
housed and kept on a 12:12-h light-dark cycle. Body weights were measured weekly, and 
animals were monitored for signs of distress. Animals were given food and water ad libitum 
throughout the duration of the study. All animals were fasted 5 hours prior to tissue 
collection. Mice were anesthetized with a ketamine-xylazine-acepromazine cocktail, and 
hindlimb muscles and select organs were carefully dissected and snap frozen in liquid 
nitrogen and stored at -80⁰C until further analysis. All animal experiments were approved 
by the University of South Carolina’s Institutional Animal Care and Use Committee. 
Voluntary Wheel Running 
Voluntary wheel running was used as a marker of volitional physical activity and 
was performed as previously described (Baltgalvis 2010). At 12 wk of age, WT and MIN 
mice were housed individually in cages with 9.5-in.-diameter stainless steel activity wheels 
(MiniMitter, Bend, OR). Running activity was monitored daily from 12 to 17 weeks of age. 
Bicycle computers (Specialized, Morgan Hill, CA) with magnetic sensors measured 
average speed, distance, time, and maximum speed, and the data were recorded daily. Mice 
were separated into 4 groups for statistical analysis, WT-C, WT-WA, MIN-C, and MIN-
WA. 
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Analysis of Muscle Function 
At ~17 weeks of age, mice were anesthetized with 2% isoflurane inhalation and 
kept anesthetized at 1.5 % isoflurane for ~1hr throughout the duration of the procedure (~1 
hour). Muscle function analysis of the TA in situ, which maintains the host nerve and blood 
supply, has been previously described. Briefly, the distal tendon of the left TA was isolated 
and tied to a force transducer (Aurora Scientific, Ontario, Canada) using 5-0 silk sutures. 
The mouse was place on the apparatus maintained at 37ºC throughout the entirety of the 
procedure. The sciatic nerve was exposed proximal to the knee and maintained using 
warmed mineral oil. The sciatic nerve was then subjected to a single stimulus to determine 
Lo. Once Lo was obtained, a force-frequency curve was generated, and maximal tetanic 
force was determined. After a 5-minute rest the TA was subjected to an intermittent fatigue 
protocol consisting of 0.5 second submaximal stimulation (50Hz) every second for 5 
minutes. After submaximal fatigue the TA was subjected to an intermittent fatigue protocol 
consisting of 0.5 second maximal stimulation (200Hz) every second for 5 minutes. Specific 
tension was determined using TA muscle CSA calculated by muscle mass/(Lf x 1.06), 
where Lf represents fiber length determined by multiplying Lo by 0.6, the predetermined 
TA muscle length to fiber length ratio, and 1.06 represents the skeletal muscle density. 
Western blot analysis 
Western blot analysis was performed as described previously (Puppa, Gao, et al. 
2014). Briefly, the right proximal TA was homogenized, and protein concentration was 
determined using the standard Bradford protein assay. Homogenates were fractionated on 
7-10% SDS-polyacrylamide gels and transferred to a polyvinylidene difluoride membrane. 
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Primary antibodies for phosphorylated (p) and total (t) P65, STAT3, P38, and Erk1/2 (Cell 
Signaling Technology) were incubated 1:1000 overnight at 4⁰C in 5% TBST milk. Anti-
rabbit IgG-conjugated secondary antibodies (cell signaling) were incubated 1:2000 for 1 
hour at room temperature in 5% TBST milk. Enhanced Chemiluminescence was used to 
visualize antibody-antigen interaction and captured using the Syngene: G-Box. Blots were 
analyzed by determining the integrated optical density of each band using ImageJ (NIH 
software). 
RNA isolation and RT-PCR 
RNA isolation, cDNA synthesis, and real-time PCR were performed as previously 
described (Narsale et al. 2016) using reagents from Applied Biosystems (Foster City, CA, 
USA). Primers for GAPDH, IL-6, IL-1, TNF-, SOCS3, PGC1, FIS1, MFN 1 and 2, 
Hexokinase II, and Phophofructokinase will purchased from IDT (Coralville, Iowa, USA) 
and run using SYBR green PCR buffer (Narsale et al. 2016). Data were analyzed using the 
2-ΔΔCT method.  
Cytochrome C Oxidase Activity  
EDL muscle samples were homogenized in extraction buffer (0.1 M 
KH2P04/Na2HP04, 2 mM EDTA, pH 7.2). Cytochrome-c oxidase (COX) activity was 
determined by measuring the rate of oxidation of fully reduced cytochrome c at 550nm 
using (CYTOCOX1) Sigma Aldrich Kit and spectrophotometer (Eppendorf) (Iqbal and 
Hood 2015).  
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Respiratory Control Ratio 
Mitochondrial respiration was measured polarographically in a respiration chamber 
(Hansatech Instruments) maintained at 37°C as previously described (Kwon et al. 2015). 
A randomly selected cohort of 4 mice from each treatment group were used for analysis of 
mitochondrial function. A 7-10 mg piece of TA muscle was mechanically tweezed with 
forceps under a dissecting microscope in ice-cold buffer X (60 mM K-MES, 35 mM KCl, 
7.23 mM K2EGTA, 2.77 mM CaK2EGTA, 20 mM imidazole, 0.5 mM DTT, 20 mM 
taurine, 5.7 mM ATP, 15 mM phosphocreatine, and 6.56 mM MgCl2, pH 7.1). The fiber 
bundle was then incubated in 50uM saponin for 30 minutes and washed 3 times for 5 
minutes in respiration buffer (105mM K-MES, 3mM KCl, 1mM EGTA, 10mM K2HPO4, 
5mM MgCl2, 0.005mM Glutamate, 0.002mM Malate, 0.05% BSA, 20mM Creatine, pH 
7.1). Fiber bundles were then placed into the oxygraph machine in 20mM creatine 
respiration buffer at 37 degrees and provided with 5mM of pyruvate and 2mM of malate. 
Two minutes following pyruvate and malate, 0.25mM of ADP was injected into the 
chamber to induce STATE 3 respiration for a duration of 5 minutes. 10ug/mL of 
Oligomycin was then injected to induce steady state 4 respiration for a duration of 10 
minutes.  RCR was calculated by dividing state 3 by state 4 respirations. 
Statistical analysis 
Values are presented as means ± standard error of the mean (SEM).  Student t-tests 
were performed to determine differences between genotypes. A one-way ANOVA was 
used to determine differences in muscle function and inflammatory signaling when MIN 
mice were stratified by age or body weight loss. Post hoc analyses were performed with 
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student Newman-Keuls methods. A Bartlett’s test was used to determine significantly 
different standard deviations (p<0.05). If a significant difference was observed between 
group standard deviations, a non-parametric Kruskal-Wallis one-way ANOVA was used. 
A Pearson correlation was used to determine correlations between inflammatory genes and 
proteins with muscle function properties in MIN mice. Stepwise linear regression models 
were used to identify predictors (cachexia indices and activity) of the 8 measured outcomes 
related to skeletal muscle function. Significance was set at p<0.05.
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APPENDIX C
RAW DATA 
Table C.1. Characteristic data of ~20-week-old male MIN and WT mice 
 Peak 
Weight (g) 
Final 
Weight 
(g) 
% 
loss 
Hindlimb 
mass 
(mg) 
Testes 
(mg) 
Epi 
Fat 
(mg) 
Spleen 
(mg) 
Tibia 
Length 
(mm) 
WT 
28.3 28.3 0% 219 213 480 65 16.8 
26.4 26.4 0% 205 196 401 52 16.9 
29 29 0% 217 205 467 71 16.7 
27.8 27.8 0% 224 198 335 80 16.8 
24.2 24.2 0% 177 165 329 67 16.55 
25.2 25.2 0% 188 169 358 60 16.85 
27.3 27.1 -1% 207 202 418 66 16.8 
24.5 24.5 0% 192 200 370 59 16.6 
27 27 0% 219 202 455 79 16.95 
27.2 27.2 0% 210 207 346 67 16.95 
MIN-
WS 
25.9 25.3 -2% 189 190 190 594 16.9 
27.8 27.3 -2% 198 220 115 536 16.95 
25.6 25.1 -2% 194 202 214 400 16.9 
25.4 25.4 0% 211 196 267 113 17.0 
26.4 26.4 0% 184 181 167 420 16.8 
30.1 30.1 0% 223 180 274 119 16.9 
27.7 27.7 0% 207 192 257 504 17 
MIN-
CX 
24.6 19.5 -21% 149 158 0 442 16.8 
23.3 18.4 -21% 104 58 0 406 16.9 
22.4 19.3 -14% 127 142 0 479 16.7 
26.5 22.1 -17% 163 158 0 521 17.05 
24.3 20.1 -17% 153 169 0 518 16.9 
24.5 20.5 -16% 120 109 0 316 16.9 
23.7 19 -20% 107 94 0 434 16.55 
23.5 19.4 -17% 129 105 0 490 16.85 
24.5 19.3 -21% 89 72 0 472 16.65 
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Table C.2 Indices of cachexia in MIN mice 
  
Plasma 
IL-6 
(pg/ml) 
TA 
Weight 
(mg) 
 
p/t 
STAT3 
 
p/t 
P65 
 
p/t 
ERK 
1/2 
 
p/t 
P38 
 
WT 
ND 47 0.21 1.17 0.40 0.45  
ND 44 0.58 0.73 1.11 1.09  
ND 43 1.36 0.71 0.57 0.87  
ND 41 1.45 1.00 0.40 1.99  
ND 43 1.57 1.01 1.34 1.34  
ND 41 1.03 1.05 1.03 0.69  
ND 28 0.86 0.98 1.07 0.84  
ND 47 0.96 1.36 2.09 0.74  
ND 46 0.21 1.17 0.40 0.45  
ND 50 0.58 0.73 1.11 1.09  
MIN-
WS 
42.99 38 0.50 0.66 0.76 0.26  
41.01 44 0.27 1.14 0.82 0.37  
18.09 42 0.36 0.91 0.90 1.09  
ND 43 1.79 0.97 0.52 1.11  
ND 37 1.60 1.60 0.35 1.97  
ND 47 0.24 0.97 1.08 1.12  
ND 47 0.65 1.13 0.87 0.71  
MIN-
CX 
ND 31 0.78 1.32 0.72 0.68  
ND 20 13.96 1.89 2.72 1.94  
ND 27 16.93 1.38 3.18 1.89  
32.98 36 16.22 0.97 1.78 1.73  
31.15 33 7.47 1.79 0.34 1.43  
355.25 27 16.86 1.60 0.89 2.00  
936.36 25 18.81 2.56 0.79 2.35  
65.78 29 44.00 1.04 14.15 2.54  
50.99 21 7.59 1.69 2.02 2.59  
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Table C.3 Indices of cachexia in MIN mice 
  
IL-6 
mRNA 
SOCS3 
mRNA 
IL-1β 
mRNA 
TNF-α 
mRNA 
COX 
Activity 
WT 
0.89 0.74 0.63 0.82 5.38 
0.86 0.82 0.92 1.04 3.07 
1.01 0.57 0.82 1.17 4.05 
1.26 1.88 1.44 1.43 4.96 
0.50 1.68 1.73 1.09 4.53 
0.68 0.83 0.74 0.82 4.85 
1.01 1.00 1.17 0.91 5.83 
1.06 0.76 0.81 0.95 5.23 
1.73 0.73 0.74 0.79 3.99 
0.89 0.74 0.63 0.82 5.38 
MIN-
WS 
1.45 2.14 0.87 0.95 4.37 
1.16 1.77 0.28 0.82 6.51 
0.84 1.43 0.35 0.77 5.18 
1.29 1.25 0.93 0.65 4.68 
0.69 1.46 0.89 0.76 1.46 
0.86 0.70 0.81 0.69 5.33 
1.75 0.45 1.02 1.06 3.69 
MIN-
CX 
57.23 37.09 19.15 1.02 1.80 
2.44 16.31 2.23 0.76 2.31 
7.69 20.79 9.95 0.88 2.85 
1.33 7.58 2.65 1.15 1.77 
1.42 7.13 0.76 1.05 3.64 
1.83 11.58 1.57 0.94 3.53 
6.96 18.10 0.87 1.38 1.18 
0.89 5.63 3.43 1.39 1.27 
2.44 16.03 2.60 1.35 1.73 
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Table C.4 The effect of cachexia on whole body and muscle specific fatigue 
 
Time to Fatigue 
(minutes) 
 67 
 79 
WT 75.5 
 72 
 81.75 
 77 
 52.25 
MIN- 75 
12 56 
 63 
 45.33 
 47.75 
MIN- 50.5 
WS 43.17 
 21.33 
 13.33 
 13.18 
MIN- 17.33 
CX 14.67 
 8.25 
 15 
 39.5 
  
 275 
Table C.5 The effect of cachexia on whole body and muscle specific fatigue 
  
Muscle Fatigue  
(Muscle force @ 90 seconds) 
WT 
31 
33 
32 
40 
38 
24 
31 
28 
41 
33 
MIN-
WS 
32 
33 
19 
25 
46 
46 
24 
MIN-
CX 
32 
40 
30 
25 
43 
34 
6 
38 
39 
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Table C.6 The effect of cachexia on whole body and muscle specific fatigue 
 0 30 60 90 120 150 180 210 240 
 1647 1368 927 591 503 488 423 391 340 
 1390 850 650 561 464 407 362 311 271 
 1343 1102 687 455 431 398 333 284 247 
 1295 1022 776 561 513 490 471 443 421 
WT 1420 1172 943 649 546 509 483 458 436 
 1368 1141 649 415 331 286 250 228 202 
 1711 1347 884 635 533 462 400 354 309 
 1315 1045 626 441 364 323 311 282 271 
 1506 1272 1021 705 617 584 575 569 546 
 1682 1410 887 659 562 543 487 439 370 
 1586 1281 1027 719 597 519 469 436 385 
 1329 1090 720 532 445 403 369 334 303 
MIN- 1372 1152 701 555 416 377 314 264 216 
12 1381 1127 775 579 470 408 339 301 265 
 1410 1105 961 710 562 495 451 420 400 
 1431 1188 622 455 404 366 334 310 273 
 1338 1098 660 446 357 302 249 210 174 
 1443 1203 461 269 185 125 81 52 36 
MIN- 1618 1147 650 405 308 265 215 192 159 
WS 1336 1071 878 620 513 484 454 441 419 
 1545 1274 870 708 626 519 454 408 368 
 1522 1260 573 370 280 212 166 123 95 
 738 577 316 235 194 163 156 156 141 
 718 536 414 289 246 232 228 211 211 
 909 766 362 277 224 200 163 164 146 
 972 784 381 245 183 164 120 94 80 
MIN- 1157 886 696 498 401 409 386 388 384 
CX 772 604 393 262 221 202 190 187 185 
 786 574 167 48 50 67 81 93 97 
 849 676 438 322 264 229 201 183 172 
 591 472 342 233 194 180 170 157 152 
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Table C.7 The effect of cachexia on maximal tetanic force 
 10 
hz 
30 
hz 
50 
hz 
80 
hz 
100 
hz 
120 
hz 
150 
hz 
180 
hz 
200 
hz 
250 
hz 
300 
hz 
 268 271 447 1333 1477 1521 1579 1602 1620 1613 1607 
 229 271 573 1131 1391 1459 1482 1555 1525 1567 1542 
 215 246 553 1146 1262 1333 1324 1329 1349 1352 1312 
 325 392 826 1132 1204 1262 1274 1258 1290 1284 1278 
WT 342 402 903 1223 1366 1309 1382 1396 1394 1367 1350 
 348 406 943 1186 1277 1275 1269 1339 1351 1308 1298 
 310 391 820 1172 1404 1554 1619 1650 1652 1648 1599 
 263 281 506 1264 1383 1426 1462 1499 1480 1489 1399 
 271 295 493 1042 1387 1575 1586 1618 1648 1597 1544 
 370 440 952 1388 1513 1589 1642 1638 1678 1677 1600 
 331 362 854 1206 1248 1301 1355 1387 1365 1324 1102 
 243 270 471 1224 1240 1278 1314 1319 1287 1281 1256 
 305 349 657 1156 1319 1353 1343 1376 1388 1383 1362 
MIN- 207 232 404 1059 1294 1488 1548 1572 1574 1589 1574 
WS 187 201 384 869 1062 1174 1197 1199 1249 1307 1323 
 305 294 647 1416 1470 1512 1542 1542 1530 1516 1507 
 346 413 964 1322 1475 1494 1518 1539 1545 1459 1400 
 224 215 388 558 572 669 644 680 756 696 701 
 277 280 561 698 743 765 743 748 735 709 692 
 267 290 629 855 899 926 945 942 920 896 868 
 345 411 740 879 916 950 962 967 970 944 902 
MIN- 280 363 768 980 1102 1157 1182 1188 1187 1166 1117 
CX 306 395 583 656 669 698 705 610 474 323 436 
 283 382 628 746 781 803 807 799 797 783 764 
 294 421 708 854 891 899 895 860 850 835 816 
 227 245 473 565 584 581 576 583 584 563 556 
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Table C.8 The effect of cachexia on specific tetanic force 
 10 
hz 
30 
hz 
50 
hz 
80 
hz 
100 
hz 
120 
hz 
150 
hz 
180 
hz 
200 
hz 
250 
hz 
300 
hz 
 49 49 81 243 269 277 287 292 295 294 293 
 42 50 106 209 257 270 274 288 282 290 285 
 41 47 106 220 242 255 254 255 258 259 251 
 65 79 166 227 242 254 256 253 259 258 257 
WT 65 76 171 232 259 248 262 264 264 259 256 
 73 85 197 247 266 266 265 279 282 273 271 
 95 120 250 358 429 475 495 504 505 503 489 
 48 51 92 230 252 260 266 273 269 271 255 
 54 58 97 206 274 311 313 320 326 315 305 
 65 77 167 244 266 279 288 288 295 295 281 
 72 79 186 263 272 284 295 302 298 289 240 
 44 49 85 220 223 230 237 237 232 231 226 
 59 68 127 224 256 262 260 267 269 268 264 
MIN- 39 44 77 201 245 282 293 298 298 301 298 
WS 42 45 85 193 236 261 266 267 278 291 295 
 53 52 113 248 258 265 270 270 268 266 264 
 62 74 172 236 263 267 271 275 276 261 250 
 55 53 95 137 140 164 158 167 186 171 172 
 103 104 208 259 276 284 276 277 273 263 257 
 82 89 192 261 274 282 288 287 281 273 265 
 78 93 167 198 207 214 217 218 219 213 204 
MIN- 53 69 145 185 209 219 224 225 225 221 211 
CX 93 121 178 200 204 213 215 186 145 99 133 
 90 121 199 236 247 254 256 253 253 248 242 
 85 122 205 247 258 260 259 249 246 241 236 
 87 94 181 216 224 223 221 224 224 216 213 
  
 279 
Table C.9 The effect of cachexia on the muscle force rates 
 ½ 
RT 
TPT -dP/dt +dP/dt 
 8 17 17876 18391 
 8.7 18 16673 19277 
 8.8 20 15039 14413 
 10.5 21 14096 12748 
WT 10.2 21 16609 13051 
 12.4 20 14418 11599 
 12.1 21 16604 15797 
 9.4 17 25174 15538 
 7.2 18 23681 30195 
 11.2 21 15830 14945 
 11 20 15432 13868 
 9.2 21 13900 12657 
 11.5 18 15070 12414 
MIN- 8.6 18 14224 17405 
WS 7.6 17 13356 13896 
 8.3 19 13920 16166 
 11.6 20 18523 11488 
 8.4 19 10274 5531 
 12.4 19 7218 7411 
 10.1 22 12578 8008 
 11.7 24 11894 6855 
MIN- 15.4 25 9786 12659 
CX 12.4 24 10499 4652 
 12.8 24 9552 7682 
 12.6 23 9268 7655 
 11.3 22 5915 4754 
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Table C.10 The effect of cachexia on calcium handling gene expression 
 SERCA1 RyR1 Calsequestrin 
 1.4 1.0 0.5 
 1.2 1.4 1.0 
 0.7 0.7 1.9 
 0.9 0.9 1.0 
WT 0.8 0.7 1.0 
 1.1 0.9 0.8 
 0.8 1.0 0.8 
 0.8 0.8 1.0 
 1.2 1.4 0.9 
 0.8 1.1 0.7 
 1.3 1.5 1.6 
 1.0 1.1 2.3 
 1.2 1.6 1.7 
MIN- 0.8 1.2 1.9 
WS 1.2 1.4 4.0 
 1.2 1.0 1.9 
 0.9 0.8 1.6 
 1.4 1.7 2.2 
 1.7 2.0 2.1 
 1.5 1.7 4.5 
MIN- 1.5 1.5 1.4 
CX 0.9 1.1 1.8 
 1.8 1.7 1.9 
 1.0 1.4 7.6 
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Table C.11 Characteristic data of male gp130 KO and WT with elevated IL-6 
   Body Weight (g)  Plasma IL-6 (pg/mL) 
Treatment Group  Pre Mid Post 
 Pre Mid Sac 
Vector WT 
 22.3 22.8 23.2  0 0 0 
 24.1 24.5 25.2  0 0 0 
 22.8 23.6 23.1  0 0 0 
 23.8 24.5 24.1  0 0 0 
 22.5 24.3 26.1 
 0 0 0 
 20.7 21.5 22.3 
 0 0 0 
 21.9 22.7 23.5 
 0 0 0 
 21.5 22.3 23.1  0 0 0 
 22.8 23.6 24.4  0 0 0 
 22.2 23.3 24.3  0 0 0 
 25.5 26.3 27.1  0 0 0 
 26.0 26.5 29.0  0 0 0 
 26.0 26.5 27.9  0 0 0 
  24.3 25.1 25.9   0 0 0 
Vector KO 
 23.0 22.8 23.1  0 0 0 
 25.3 25.8 26.1  0 0 0 
 22.5 23.2 23.8  0 0 0 
 24.0 24.1 24.2  0 0 0 
 24.8 24.9 25.0  0 0 0 
 24.6 24.6 24.5  0 0 0 
 24.7 24.9 25.0  0 0 0 
 26.6 27.1 27.6  0 0 0 
 28.1 27.7 27.2  0 0 0 
 24.2 25.3 25.1  0 0 0 
 24.0 24.5 25.0  0 0 0 
  24.3 24.5 24.7   0 0 0 
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Table C.12 Characteristic data of male gp130 KO and WT with elevated IL-6 
   Body Weight (g)  Plasma IL-6 (pg/mL) 
Treatment Group  Pre Mid Post 
 Pre Mid Sac 
IL-6 WT 
 24.2 23.6 23.2  0 151.18 125.06 
 21.7 21.9 20.2  0 142.28 166.75 
 23.3 22.8 22.1  0 64.562 53.253 
 24.4 24.6 23.5  0 121.26 90.264 
 22.0 22.6 23.2  0 46.777 58.702 
 21.0 21.8 22.6  0 26.975 53.95 
 22.7 23.5 24.3  0 24.333 58.4 
 21.4 22.2 23.0  0 7.4286 15.6 
 21.4 22.2 23.0  0 34.341 99.589 
 23.1 23.9 24.7  0 13.778 31.69 
 
25.4 26.2 27.0 
 
0 98.1 80.29 
 27.4 28.2 29.0  0 16.1 94.395 
 21.6 22.4 23.2  0 35.52 54.32 
 23.7 24.5 25.3  0 31.025 79.775 
  24.0 24.8 25.6   0 154.53 371.03 
IL-6 KO 
  21.8 22.2 22.9   0 49.525 134.78 
 22.9 22.9 23.7  0 67.275 164.78 
 24.8 25.0 26.1  0 65.775 154.53 
 23.9 23.1 22.3  0 74.895 99.157 
 25.7 25.5 25.3  0 87.643 117.1 
 24.0 23.8 23.6  0 218 123.83 
 26.6 26.6 26.5  0 63.071 125.89 
 22.5 23.1 23.6  0 158.58 204.53 
 23.2 24.0 24.8  0 180.5 230.4 
 25.2 26.0 26.8  0 65.2 110.5 
  20.2 21.0 21.8   0 50.2 90.2 
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Table C.13 Characteristic data of male gp130 KO and WT with elevated IL-6 
   Tissue Weights (mg) 
Treatment Group  Hindlimb HL/TL 
Tibia 
Epi 
Fat Spleen 
Vector WT 
 210.5 12.31 17.10 293 86 
 214.5 12.692 16.90 292 78 
 189.5 11.28 16.80 292 56 
 214.5 12.618 17.00 382 61 
 215.5 12.639 17.05 278 72 
 181 10.904 16.6 236 54 
 187.5 11.194 16.75 349 57 
 207 12.176 17.00 295 67 
 200.5 12.115 16.55 215 58 
 197.5 11.826 16.7 360 76 
 224 13.099 17.1 385 80 
 230 13.068 17.60 573 91 
 206 11.873 17.35 742 69 
  215.5 12.676 17.00 376 86 
Vector KO 
 216 13.051 16.55 228 61 
 216 12.857 16.80 297 70 
 202 12.169 16.60 377 54 
 209 12.59 16.60 312 56 
 221.5 13.145 16.85 363 57 
 206.5 12.255 16.85 286 66 
 217.5 12.946 16.80 292 63 
 233 13.626 17.10 392 80 
 234.5 13.754 17.05 346 76 
 211 12.485 16.90 260 293 
 202.5 12.126 16.70 301 150 
  199.5 11.875 16.80 244 91 
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Table C.14 Characteristic data of male gp130 KO and WT with elevated IL-6 
   Tissue Weights (mg) 
Treatment Group  Hindlimb HL/TL 
Tibia 
Epi 
Fat Spleen 
IL-6 WT 
 204.5 12.136 16.85 314 161 
 170.5 10.333 16.50 212 141 
 204 12.179 16.75 262 138 
 211 12.522 16.85 331 147 
 204.5 12.173 16.80 270 125 
 191 11.541 16.55 200 94 
 204.5 12.029 17 124 122 
 194 11.652 16.65 362 73 
 186.5 11.201 16.65 359 122 
 196 11.737 16.7 385 98 
 205 12.202 16.80 374 143 
 222.5 13.012 17.10 497 130 
 184 11.018 16.7 314 93 
 211.5 12.703 16.65 257 92 
  216.5 12.887 16.80 434 152 
IL-6 KO 
  195.5 11.813 16.55 270 90 
 193 11.592 16.65 202 108 
 216 12.706 17.00 261 272 
 204 11.965 17.05 238 136 
 223 13.195 16.90 346 123 
 211.5 12.627 16.75 272 258 
 222.5 13.166 16.90 499 133 
 193.5 11.518 16.80 299 178 
 199.5 12.018 16.60 249 231 
 224 13.453 16.65 352 390 
  181.5 11.204 16.20 201 268 
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Table C.15. The effect of elevated IL-6 on skeletal muscle’s contractile properties 
Treatment Group TA Lo 
1/2 
RT TPT Po sPo 
-
dP/dt +dP/dt 
Vector WT 
47.0 14.0 8.6 16.6 1559 294 20337 21850 
48.0 14.0 7.1 13.6 1778 329 25300 22670 
44.5 13.0 7.4 13.9 1512 280 20153 22522 
48.0 13.5 6.2 14.1 1898 338 24396 22975 
51 14 12.4 18.8 1460 254 15050 23766 
45 13.5 10.5 16.4 1686 320 21167 20500 
45 14 9.7 16.6 1419 280 16013 22529 
51.0 14.0 9.1 14.1 1627 283 22014 21793 
51.0 14.0 9.9 16.1 1621 282 17041 22255 
44.5 14.0 8.4 16.7 1597 318 19629 23432 
51.5 14.3 9.7 17.0 1760 309 17286 25694 
55.5 14.3 7.4 14.8 1976 321 25851 26840 
47.5 14.0 7.3 14.9 1551 290 20304 22785 
47.5 14.5 7.8 16.1 1730 335 18556 25656 
Vector KO 
49.5 13.0 8.2 15.3 1329 221 11712 24776 
51.0 14.0 10.2 16.6 1622 282 20657 22264 
46.5 13.0 7.7 15.1 1566 277 15652 25807 
48.5 13.5 7.2 15.2 1787 315 24113 26244 
52.0 13.0 8.6 15.0 1635 259 17430 27858 
49.0 13.0 6.6 15.1 1681 283 19803 27645 
51.0 13.5 6.2 13.9 1690 283 15843 28451 
54.5 14.0 8.7 14.7 1795 292 20971 24416 
56.5 14.5 6.2 14.3 1862 303 19393 31552 
46.5 13.0 8.3 14.4 1595 283 23645 20631 
46.0 13.0 6.5 13.5 1364 244 21883 24011 
46.5 12.5 8.2 15.0 1613 275 17730 24173 
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Table C.16. The effect of elevated IL-6 on skeletal muscle’s contractile properties 
Treatment Group TA Lo 
1/2 
RT TPT Po sPo 
-
dP/dt +dP/dt 
IL-6 WT 
47.0 13.5 7.8 15.9 1661 302 19721 20211 
37.0 13.0 8.6 14.9 1445 322 20769 18694 
41.5 13.0 8.0 13.8 1569 311 20710 23751 
47.5 13.0 6.6 14.7 1611 279 18146 24640 
46.0 13.3 7.9 14.5 1912 349 26393 26735 
46.5 14 12.1 15.6 1618 309 18534 20450 
46.5 14.5 10.2 17.9 1408 278 15292 16911 
46.5 14.5 10.7 17.3 1555 307 13821 20412 
43 14 9.1 17 1329 274 15712 15551 
46 14 11.2 18.1 1487 287 15192 21968 
45.0 13.5 9.8 18.1 1710 325 18981 25705 
50.5 13.5 8.8 17.8 1644 279 14340 25411 
46.5 14.5 8.9 15.8 1568 310 20118 23066 
49.5 13.5 8.5 16.4 1707 295 20657 22279 
51 14 7.3 15 1558 271 21581 27546 
IL-6 KO 
47.0 14.0 8.7 16.3 1495 282 18106 21183 
46.5 13.5 6.8 15.5 1494 275 19835 23759 
52.0 13.5 7.4 15.0 1650 271 23558 24921 
48.5 13.0 12.3 17.3 1513 257 17982 22403 
53.0 13.5 7.7 13.3 1676 270 21985 27387 
47.5 13.3 7.6 14.9 1602 283 20548 26482 
53.0 13.0 6.8 15.0 1703 265 20870 25545 
50.5 14.0 9.2 15.5 1400 246 19648 24620 
46.0 14.0 6.4 14.2 1581 305 17360 26922 
52.0 13.5 6.3 15.0 1655 272 20893 26514 
40.5 12.5 6.2 13.8 1423 278 19711 22061 
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Table C.17. The effect of elevated IL-6 on muscle fiber-type distribution 
Treatment Group Type IIa Type IIx Type IIb 
Vector WT 
16.4 31.2 52.4 
8 47 45 
8.9 34.6 56.5 
15.4 45.1 39.4 
6 34 60 
IL-6 WT 
9 35 55 
6 44 50 
10 43 48 
8 44 48 
23 37 40 
Vector KO 
16.7 45.1 38.4 
5.4 36.5 58.1 
9.6 46 44.4 
15 40 46 
1 27 72 
IL-6 KO 
11 35 54 
9 50 41 
4 28 69 
4 37 59 
6 27 67 
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Table C.18 Animal characteristics of male skeletal muscle specific gp130 KO ApcMin/+ 
mice 
Geno  Age Peak BW BW 
% BW 
Loss 
  18.4 24.2 24.2 0% 
  15.3 24.6 24.6 0% 
  17.0 30.2 30.2 0% 
Flox  16.4 24.8 24.8 0% 
  16.4 24.4 24.4 0% 
  19.3 27.9 27.9 0% 
  19.0 26.2 26.2 0% 
  17.4 27.3 27.3 0% 
  16.0 25.6 25.1 2% 
  17.3 21.1 20.1 5% 
MIN  16.4 23.9 22.4 6% 
Flox  17.4 27.5 25.6 7% 
  18.4 25.6 23.6 8% 
  16.0 25.6 20.6 20% 
  16.7 22.6 22.6 0% 
  17.3 26.7 26.7 0% 
  17.6 27.5 27.5 0% 
MIN  18.4 28.8 28.8 0% 
KO  18.4 28.2 28.2 0% 
  18.4 25.9 24.4 6% 
  17.6 25.0 23.5 6% 
  18.0 26.0 22.5 13% 
  16.7 23.0 20.1 13% 
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Table C.19. Animal characteristics of male skeletal muscle specific gp130 KO ApcMin/+ 
mice 
Geno Hindlimb Spleen Testes 
Sem 
Ves 
Tibia 
Flox 
268 87 183 221 17.3 
298.5 61 208 220 17.45 
364 88 192 251 17.6 
284 54 201 120 17.7 
282.5 65 206 137 17.6 
283 79 189 202 17.4 
279.5 68 201 212 17.9 
MIN 
Flox 
296 374 167 163 17.65 
278 492 123 79 18.1 
232.5 301 121 40 17.3 
249.5 460 53 58 17.5 
263.5 425 170 102 17.95 
262 376 192 54 17.5 
245 358 119 33 17.7 
MIN 
KO 
255 369 215 141 17.45 
320.5 261 167 144 17.9 
314.5 341 185 153 17.5 
333 158 215 165 18.35 
312 378 220 142 18.5 
256 366 150 45 18.3 
245 462 144 37 17.8 
229.5 595 160 64 17.2 
230 345 106 43 17.55 
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Table C.20. The role of the muscle gp130 receptor in cancer-induced skeletal muscle 
contractile dysfunction 
Geno TA Lo 1/2 RT TPT -dP/dt +dP/dt 
Flox 
45.0 14.0 10.9 17.4 23365 26493 
53.0 13.5 8.0 15.1 17125 22257 
57.5 14.0 8.7 14.9 13010 31413 
48.0 14.0 8.5 14.9 21518 26694 
47.0 13.5 8.9 14.3 19058 24114 
45.0 14.0 9.8 16.2 20348 27972 
49.5 14.0 5.2 14.0 18201 30673 
MIN 
Flox 
48.5 14.0 5.5 14.4 18591 23197 
45.5 14.5 5.6 12.8 13591 24740 
39.0 13.5 7.5 17.0 11925 24505 
35.5 13.0 13.8 18.9 10076 12940 
44.5 14.0 10.7 14.6 6502 24146 
46.0 13.5 9.5 14.3 11079 23075 
40.5 13.0 10.4 16.2 12184 19127 
MIN 
KO 
43.0 14.5 8.2 15.0 19778 22511 
53.5 15.0 6.6 15.8 11439 27366 
53.5 14.5 13.5 16.2 9164 22607 
56.5 16.0 7.7 15.1 15707 29273 
52.0 15.5 7.5 15.3 15446 26247 
43.0 14.0 7.8 16.0 11265 18924 
42.0 14.0 8.6 16.3 9389 26257 
38.0 15.0 14.4 17.8 6727 16305 
39.5 14.0 7.2 14.1 18385 17604 
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Table C.21. The effect of IL-6 on muscle mitochondrial content 
Treatment Geno 
COX 
Activity 
Complex 
I 
Complex 
II 
Complex 
III 
Complex 
IV 
Complex 
V 
Vector WT 
6.19 1.16 1.06 1.28 1.38 1.13 
6.85 1.14 1.22 1.17 0.83 1.05 
5.41 1.00 1.10 1.15 0.98 1.05 
5.28 0.97 0.85 0.87 0.98 0.91 
5.67 0.84 0.81 0.79 0.89 0.97 
5.26 0.90 0.96 0.74 0.95 0.89 
5.72 - - - - - 
5.61 - - - - - 
5.57 - - - - - 
5.53 - - - - - 
Vector KO 
6.18 1.11 0.90 1.30 0.73 1.02 
5.78 1.06 0.88 1.13 0.90 1.08 
6.28 0.61 0.55 0.66 0.58 0.87 
6.43 0.86 0.96 1.26 0.91 0.94 
5.29 0.95 0.85 1.30 1.13 1.00 
5.38 1.15 1.27 1.40 0.81 1.06 
5.62 - - - - - 
IL-6 WT 
3.49 0.94 0.64 0.80 0.67 0.85 
1.44 0.76 0.70 1.15 0.68 1.04 
3.78 0.56 0.52 0.87 0.70 0.79 
2.48 0.77 0.43 0.99 0.60 0.89 
5.15 0.83 0.50 0.99 0.60 0.91 
3.53 0.51 0.23 0.72 0.45 0.76 
3.45 - - - - - 
IL-6 KO 
4.05 1.10 1.15 1.23 0.82 1.04 
6.17 1.03 1.00 1.11 0.85 0.95 
6.04 1.13 1.28 1.18 0.71 1.06 
5.69 1.15 1.29 1.44 1.15 1.10 
4.65 0.95 0.88 1.18 0.70 1.01 
6.04 0.85 0.48 1.38 0.89 1.12 
5.77 - - - - - 
4.75 - - - - - 
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Table C.22. The effect of IL-6 on skeletal muscle force production 
Treat
ment Geno 10 30 50 80 100 120 150 180 200 
Vector WT 
342 373 595 1269 1393 1445 1513 1559 1538 
343 318 430 1290 1528 1629 1704 1703 1778 
240 268 446 983 1331 1417 1468 1488 1504 
352 340 487 1126 1460 1606 1688 1832 1893 
398 482 870 1255 1344 1413 1430 1460 1437 
323 385 737 1292 1415 1499 1623 1667 1684 
364 360 688 1093 1211 1247 1300 1366 1401 
285 346 557 1112 1307 1345 1524 1514 1595 
304 336 546 1100 1382 1477 1519 1539 1601 
327 328 588 1248 1430 1505 1576 1597 1584 
389 550 902 1400 1522 1640 1722 1760 1664 
349 358 541 1221 1554 1706 1787 1818 1912 
269 281 397 1143 1335 1415 1478 1507 1539 
324 384 557 1031 1134 1517 1563 1671 1718 
Vector KO 
349 338 433 984 1119 1135 1319 1329 1267 
426 473 714 1332 1529 1602 1622 1618 1600 
324 329 477 1316 1450 1497 1528 1540 1559 
405 424 570 1238 1415 1567 1666 1725 1775 
361 506 565 1404 1617 1559 1539 1593 1602 
339 352 477 1362 1545 1602 1602 1653 1676 
318 333 428 1281 1514 1649 1690 1605 1630 
384 382 514 1334 1556 1661 1751 1795 1784 
388 411 511 1422 1564 1542 1817 1826 1862 
327 376 469 1233 1427 1495 1567 1586 1581 
280 339 410 1049 1218 1290 1337 1353 1356 
315 331 451 1120 1385 1485 1547 1579 1601 
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Table C.23. The effect of IL-6 on skeletal muscle force production 
Treat
ment Geno 10 30 50 80 100 120 150 180 200 
IL-6 WT 
339 388 510 1287 1465 1542 1601 1640 1658 
255 283 450 1064 1223 1310 1393 1422 1445 
298 303 567 1329 1470 1509 1539 1551 1547 
268 288 438 1108 1390 1487 1537 1557 1496 
375 405 494 1365 1614 1721 1816 1868 1893 
321 350 525 1212 1414 1523 1584 1608 1618 
322 287 629 1056 1077 1304 1353 1383 1408 
324 361 643 1191 1449 1551 1555 1484 1454 
305 363 561 1081 1253 1301 1329 1326 1284 
319 410 813 1216 1340 1416 1473 1487 1473 
397 432 758 1220 1348 1397 1447 1650 1647 
287 321 600 1311 1504 1548 1618 1644 1624 
307 338 536 1177 1356 1456 1528 1523 1549 
319 354 623 1166 1486 1628 1687 1707 1688 
313 325 533 1009 1333 1446 1487 1550 1558 
IL-6 KO 
325 357 568 1052 1208 1352 1412 1441 1455 
360 370 571 1145 1309 1370 1435 1469 1494 
393 384 613 1005 1417 1481 1526 1603 1648 
370 552 644 1100 1299 1481 1498 1510 1465 
357 318 493 1134 1382 1588 1650 1622 1676 
367 363 557 1166 1398 1468 1538 1576 1602 
360 321 536 1301 1563 1642 1603 1627 1685 
391 392 503 1061 1226 1278 1355 1369 1400 
294 299 487 1134 1299 1377 1496 1542 1554 
302 355 498 974 1259 1273 1546 1655 1649 
281 292 384 941 1049 1106 1203 1372 1372 
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Table C.24. The effect of IL-6 on skeletal muscle force production 
Treat
ment Geno 10 30 50 80 100 120 150 180 200 
Vector WT 
65 70 112 240 263 273 286 294 290 
63 59 79 238 282 301 315 315 329 
44 50 83 182 246 262 272 275 278 
63 61 87 201 260 286 301 326 337 
69 84 151 218 234 246 249 254 250 
61 73 140 246 269 285 309 317 320 
72 71 136 215 239 246 256 269 276 
50 60 97 193 227 234 265 263 277 
53 58 95 191 240 257 264 268 278 
65 65 117 249 285 300 314 318 316 
68 96 158 245 267 287 302 309 292 
57 58 88 199 253 278 291 296 311 
50 52 74 213 249 264 276 281 287 
63 74 108 199 219 293 302 323 332 
Vector KO 
58 56 72 164 186 189 220 221 211 
74 82 124 232 266 279 282 281 278 
57 58 84 233 257 265 271 273 276 
71 75 100 218 250 276 294 304 313 
57 80 89 222 256 247 244 252 254 
57 59 80 229 260 269 269 278 282 
53 56 72 215 254 277 283 269 273 
63 62 84 217 253 270 285 292 290 
63 67 83 231 254 251 295 297 303 
58 67 83 218 253 265 278 281 280 
50 61 73 188 218 231 239 242 243 
54 56 77 191 236 253 263 269 273 
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Table C.25. The effect of IL-6 on skeletal muscle force production 
Treat
ment Geno 10 30 50 80 100 120 150 180 200 
IL-6 WT 
62 71 93 234 267 281 291 298 302 
57 63 100 237 272 292 310 317 322 
59 60 113 264 292 299 305 308 307 
46 50 76 192 241 258 267 270 259 
68 74 90 249 295 314 331 341 346 
61 67 100 231 270 291 302 307 309 
64 57 124 209 213 258 267 273 278 
64 71 127 235 286 306 307 293 287 
63 75 116 223 259 268 274 273 265 
62 79 157 235 258 273 284 287 284 
75 82 144 232 256 265 275 314 313 
49 54 102 222 255 262 274 279 275 
61 67 106 233 268 288 302 301 306 
55 61 108 202 257 281 291 295 292 
54 56 93 176 232 251 259 270 271 
IL-6 KO 
61 67 107 199 228 255 266 272 275 
66 68 105 211 241 252 264 270 275 
65 63 101 165 233 244 251 264 271 
63 94 109 187 221 252 254 256 249 
58 51 80 183 223 256 266 262 270 
65 64 98 206 247 259 272 278 283 
56 50 83 202 243 255 249 253 262 
69 69 88 186 215 224 238 240 246 
57 58 94 219 251 266 288 297 300 
50 58 82 160 207 209 254 272 271 
55 57 75 184 205 216 235 268 268 
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Table C.26. The effect of IL-6 on submaximal contraction-induced skeletal muscle 
fatigability 
Treat
ment Geno 0 5 10 15 20 25 30 35 40 45 50 
Vector WT 
500 350 382 491 571 631 672 706 726 728 722 
456 377 454 565 635 685 716 747 772 793 801 
388 292 332 425 503 544 580 603 624 638 644 
514 411 445 542 638 682 717 749 782 804 818 
795 718 797 847 873 882 886 887 892 895 894 
648 427 537 608 654 680 698 714 733 737 750 
569 460 550 608 649 681 700 709 713 709 699 
361 314 411 541 621 645 658 671 675 688 698 
573 458 573 635 671 691 709 734 736 749 761 
649 490 641 733 791 825 847 860 866 870 869 
478 377 455 576 645 685 702 711 705 712 710 
548 432 471 506 611 655 697 719 738 756 759 
374 302 334 420 518 575 608 640 661 673 671 
562 529 697 765 809 816 844 844 839 832 816 
Vector KO 
361 301 410 201 517 536 540 540 529 504 479 
603 493 600 680 718 726 753 753 744 735 728 
408 352 414 552 636 676 687 694 691 686 670 
542 413 448 516 622 681 719 747 767 771 771 
348 322 366 418 513 574 607 630 646 647 639 
387 339 390 489 597 652 676 685 689 692 685 
447 392 491 643 711 745 761 764 762 758 742 
527 415 530 648 718 757 776 786 789 786 780 
472 428 535 667 736 777 788 789 794 763 731 
416 327 355 383 403 417 425 436 442 451 451 
388 340 395 509 581 620 637 651 658 661 656 
476 379 419 455 542 585 599 613 620 625 625 
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55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 
707 686 664 642 613 582 555 525 496 474 446 431 411 395 374 
796 780 754 721 682 643 602 565 529 503 482 460 441 428 411 
643 628 607 589 556 520 467 431 395 369 345 337 323 320 294 
812 803 784 754 731 699 666 635 597 566 540 519 497 478 463 
888 876 856 854 776 729 678 627 588 551 526 500 483 468 454 
754 752 747 735 719 696 671 639 605 571 537 506 476 450 426 
686 666 634 601 561 522 488 458 438 424 404 384 372 354 347 
698 695 683 664 639 610 576 544 511 478 453 427 403 381 364 
762 761 756 744 728 708 683 659 633 608 577 546 524 496 476 
860 837 801 755 704 636 601 567 524 492 469 460 428 424 419 
704 695 675 648 622 588 553 518 483 452 426 401 376 359 344 
749 728 703 676 668 620 598 557 531 502 477 446 420 398 373 
672 654 635 606 572 537 500 463 430 406 386 366 350 335 325 
798 768 696 678 623 571 501 474 440 413 377 370 359 344 332 
455 437 426 417 407 402 391 371 355 344 332 327 317 313 307 
712 677 659 619 608 574 542 540 523 496 501 473 468 449 440 
641 603 558 515 480 453 428 414 401 390 380 376 370 366 361 
745 721 695 666 635 602 571 540 512 487 466 448 429 417 402 
607 573 529 491 452 429 404 387 380 358 352 336 324 314 307 
665 631 579 526 476 436 406 384 363 351 339 326 317 311 305 
716 677 641 592 552 516 486 462 450 435 426 423 416 411 407 
768 755 735 710 683 659 631 612 590 568 551 535 520 506 492 
689 655 620 605 551 522 509 483 472 459 453 454 447 432 424 
446 443 433 423 411 397 383 366 347 346 319 303 321 291 281 
647 629 603 573 544 514 494 477 465 453 445 432 425 421 416 
619 609 589 563 528 488 450 413 386 366 350 337 326 316 308 
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130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 
359 349 330 320 304 291 283 268 259 251 246 244 235 227 225 
399 388 376 371 362 352 347 341 335 330 328 317 312 306 302 
283 274 266 259 251 260 238 234 224 221 233 215 209 209 205 
448 432 422 412 402 392 382 374 366 358 352 346 338 332 325 
441 431 420 415 407 401 394 393 388 383 378 379 373 369 367 
406 392 375 363 351 342 334 327 320 319 308 302 299 292 284 
341 328 320 313 300 297 296 291 288 284 282 277 276 273 273 
346 330 319 307 296 290 299 298 293 280 267 255 252 246 243 
458 439 423 411 397 384 370 362 354 345 340 329 323 317 312 
410 400 401 396 376 368 368 366 366 361 351 346 347 346 346 
326 315 298 291 282 278 270 265 263 258 259 256 258 254 252 
357 347 341 319 316 309 306 306 290 307 291 284 279 279 285 
320 313 308 303 299 285 289 279 275 273 275 264 259 255 249 
328 320 313 292 299 294 287 277 260 271 267 256 258 251 250 
318 297 296 294 291 289 309 283 284 278 280 277 274 275 275 
435 419 415 419 398 388 391 376 370 367 364 354 352 347 342 
359 358 354 349 348 345 342 340 335 333 331 329 324 321 318 
391 383 371 359 347 342 333 325 318 309 307 296 289 281 276 
304 293 287 275 267 273 260 258 250 246 240 234 234 230 224 
301 293 290 286 282 279 271 265 259 256 252 246 244 235 233 
402 397 396 393 389 387 384 384 378 379 374 373 369 365 360 
478 470 459 452 443 436 429 422 416 410 401 396 391 385 382 
422 415 411 381 402 400 393 392 387 385 381 375 370 367 406 
297 276 271 265 266 259 285 261 246 243 240 235 227 231 229 
407 402 394 390 385 381 375 367 364 362 357 355 349 344 341 
302 293 283 280 275 262 256 254 247 239 236 231 226 221 218 
  
 299 
205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 
220 221 229 222 225 226 210 205 218 207 206 203 201 200 199 
296 291 286 281 277 271 268 268 263 262 259 254 254 253 249 
202 201 203 198 188 188 210 190 207 186 189 184 179 184 176 
321 313 308 305 303 300 298 297 297 294 288 285 288 287 287 
360 359 355 356 351 350 346 344 342 343 337 338 338 338 334 
282 275 269 266 261 256 254 250 248 244 246 249 242 238 231 
269 270 263 261 255 256 255 254 251 252 243 242 244 240 239 
234 231 226 222 224 218 220 219 213 213 212 210 208 210 207 
309 302 298 294 287 285 280 274 270 270 264 263 253 248 247 
337 340 329 326 320 317 315 316 310 295 304 301 302 299 293 
258 255 255 250 246 236 241 243 239 236 235 234 229 229 231 
279 269 272 264 264 258 254 253 256 251 245 241 242 236 235 
248 250 244 236 231 232 230 226 222 220 218 213 212 210 206 
235 243 239 235 198 229 223 216 208 205 216 206 198 201 204 
269 268 270 271 282 265 278 259 256 256 254 264 252 250 256 
356 337 331 330 331 325 320 320 315 313 313 308 304 306 303 
315 312 306 304 299 294 295 291 285 282 280 277 267 268 267 
273 272 267 263 271 259 255 251 250 249 256 241 251 234 233 
216 224 216 215 215 211 200 213 197 195 193 194 188 199 187 
227 219 218 216 210 213 207 206 203 203 199 198 195 195 194 
359 355 352 350 348 346 344 341 339 334 331 327 325 324 323 
376 372 365 362 359 355 350 344 340 336 331 327 323 318 317 
387 365 380 347 354 352 349 349 345 340 337 337 336 332 319 
220 222 219 230 231 226 214 219 206 208 207 208 212 210 202 
336 330 329 327 322 321 315 313 307 306 307 302 299 296 293 
215 211 208 202 204 202 198 193 195 194 192 187 188 187 183 
  
 300 
280 285 290 295 300 
198 201 196 196 198 
249 245 243 242 242 
178 174 173 181 175 
284 281 275 279 270 
330 329 327 295 312 
233 233 227 225 226 
239 231 230 230 229 
206 201 206 200 199 
252 241 242 241 238 
288 284 285 290 272 
226 227 227 220 219 
240 234 236 233 228 
203 202 195 197 195 
203 198 201 194 194 
256 248 247 244 243 
305 297 295 299 301 
265 261 257 255 252 
233 241 227 226 230 
193 183 180 181 179 
190 188 188 186 185 
318 317 313 311 309 
314 308 304 300 298 
329 326 323 324 320 
194 197 193 191 197 
292 291 288 287 285 
182 181 179 177 177 
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Table C.27 The effect of IL-6 on submaximal contraction-induced skeletal muscle 
fatigability 
Treatment Geno 0 5 10 15 20 25 30 35 40 45 50 
IL-6 WT 
474 374 482 574 629 663 684 697 704 708 709 
370 266 294 365 427 461 480 490 497 502 507 
466 356 437 540 603 636 661 716 732 744 747 
412 361 393 429 506 573 610 634 652 656 654 
479 374 405 449 527 567 581 584 577 565 533 
747 563 671 734 771 794 808 818 823 825 820 
670 623 706 782 834 869 899 919 932 941 939 
617 382 448 512 562 599 633 668 694 708 713 
547 375 484 537 562 573 570 570 569 566 568 
735 668 759 799 831 841 846 852 842 841 834 
714 668 773 834 861 874 877 875 869 867 862 
856 593 790 878 924 944 954 956 955 939 926 
486 347 490 575 619 641 652 657 662 661 658 
476 347 406 511 582 622 645 659 668 666 659 
277 235 269 293 324 348 372 393 389 392 377 
IL-6 KO 
359 308 352 432 499 551 543 565 572 557 561 
435 391 532 635 676 695 698 701 691 671 628 
477 393 432 530 605 648 667 688 695 695 683 
424 349 390 516 563 596 627 644 659 670 669 
545 471 506 636 715 755 787 815 845 861 861 
506 406 446 550 638 676 693 703 708 708 703 
493 384 413 453 554 603 638 652 651 652 649 
395 340 373 424 501 550 564 586 598 610 612 
456 406 531 679 747 780 795 800 795 765 720 
351 318 354 397 469 545 588 617 623 632 638 
414 329 370 449 559 619 645 668 681 684 700 
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55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 
702 689 672 642 614 578 541 507 481 459 437 419 404 388 377 
505 501 496 486 474 456 433 410 384 366 345 327 317 304 293 
741 717 655 615 582 538 503 478 451 433 411 400 386 368 355 
641 619 587 550 509 477 447 424 402 383 368 355 342 330 320 
509 486 454 429 408 392 377 360 347 333 313 297 288 272 267 
806 787 756 717 670 622 581 551 519 495 472 456 439 432 422 
929 894 835 751 672 603 553 519 488 460 444 426 414 402 394 
705 689 663 633 602 568 535 506 482 466 446 431 418 404 396 
565 562 553 544 530 514 493 471 446 427 402 382 359 341 320 
816 779 722 655 603 547 504 467 437 419 396 382 368 357 343 
857 845 834 812 787 752 724 677 637 599 573 534 507 485 470 
907 880 831 777 729 668 596 550 527 496 469 445 435 421 405 
654 646 632 615 594 570 536 506 469 439 412 394 378 363 357 
646 623 607 583 557 537 523 497 484 466 449 438 425 409 397 
366 359 340 319 298 276 256 241 229 219 209 199 192 187 184 
557 548 530 521 499 466 442 406 383 361 337 322 305 293 284 
584 516 462 443 415 400 386 373 363 351 344 338 333 327 323 
668 642 617 587 561 532 511 491 493 460 446 433 420 410 400 
652 641 612 577 544 501 476 458 426 409 381 371 353 342 329 
854 835 798 755 703 653 603 565 533 506 486 467 454 443 433 
685 665 628 595 556 522 490 466 441 418 403 386 371 359 350 
646 634 618 592 563 535 509 476 453 426 404 382 366 353 341 
614 602 601 590 578 559 539 509 494 472 449 432 407 394 387 
669 620 577 541 511 488 469 451 441 429 416 409 402 396 390 
626 608 580 548 508 477 443 423 396 384 365 354 343 330 324 
682 662 639 610 579 539 506 481 457 436 426 420 405 403 391 
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130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 
368 360 350 344 338 334 324 320 314 312 306 303 297 294 292 
287 276 267 259 253 243 237 230 226 218 213 208 205 201 197 
345 332 331 317 309 303 298 287 282 280 275 270 265 262 256 
309 303 296 287 280 273 268 261 254 246 242 238 232 228 222 
255 244 238 234 226 224 219 216 215 212 210 205 204 201 199 
409 399 395 387 376 369 362 360 353 353 350 347 346 344 337 
384 380 374 369 370 369 373 360 356 360 356 356 349 351 353 
387 376 366 361 354 348 344 336 333 326 319 315 313 312 311 
306 291 279 265 253 245 235 227 219 211 206 197 196 189 185 
334 320 314 312 304 303 295 294 293 292 289 279 283 279 274 
442 423 411 404 383 373 364 354 342 334 328 323 314 306 301 
400 389 382 374 365 361 356 353 350 348 342 334 331 327 323 
353 340 335 333 327 324 327 316 315 308 308 305 303 299 298 
385 366 357 346 334 326 317 306 301 293 289 279 274 269 262 
176 173 172 167 167 165 158 157 147 152 153 152 151 146 148 
276 265 254 247 245 236 233 229 223 223 220 218 222 219 216 
317 311 310 306 303 300 297 293 291 280 282 289 278 276 275 
392 382 376 369 362 356 349 340 336 329 322 318 313 307 301 
322 316 308 299 293 289 283 282 275 275 264 262 262 259 253 
423 415 408 402 395 388 385 374 369 366 360 358 350 346 339 
341 335 329 322 317 311 308 303 301 296 291 287 280 276 272 
328 313 312 299 291 290 276 276 268 262 259 259 251 246 246 
376 363 354 340 340 324 316 311 311 304 298 293 282 271 269 
388 383 380 373 374 370 365 364 361 358 355 351 353 352 346 
314 309 301 293 286 275 271 269 262 271 263 262 251 252 243 
384 382 372 373 374 368 364 360 357 357 354 349 345 333 337 
  
 304 
205 210 215 220 225 230 235 240 245 250 
289 285 283 278 274 269 263 263 259 258 
193 188 184 181 179 176 174 172 171 174 
251 249 242 240 236 232 229 226 221 217 
216 212 205 201 194 191 189 184 178 175 
196 193 194 196 199 198 187 193 184 182 
335 330 325 320 315 316 314 311 304 306 
354 353 364 371 371 362 347 334 321 315 
308 307 305 303 301 303 301 294 293 291 
178 174 174 168 165 166 161 161 157 153 
277 270 269 274 269 269 267 262 261 262 
297 291 290 285 282 276 265 263 261 253 
317 317 311 309 308 304 303 303 300 296 
296 292 289 287 283 281 278 274 270 267 
259 246 247 239 238 232 226 222 220 215 
144 145 136 145 143 136 138 133 146 146 
213 217 220 217 221 225 215 216 216 210 
273 271 268 268 265 261 257 252 252 250 
296 292 287 280 276 268 263 259 255 248 
251 245 240 235 231 226 223 223 220 209 
332 326 325 320 316 309 308 301 299 296 
267 262 259 254 251 248 242 239 234 231 
248 244 244 241 238 239 237 231 230 233 
271 265 262 256 264 255 254 244 252 249 
347 346 346 343 342 336 336 331 333 329 
244 242 237 234 229 236 230 231 226 222 
334 335 330 326 322 317 312 311 309 308 
  
 305 
255 260 265 270 275 280 285 290 295 300 
252 250 247 248 242 241 235 235 233 228 
166 168 163 166 163 161 159 159 159 156 
214 208 206 202 198 196 192 190 187 187 
175 171 172 168 167 167 163 160 160 157 
180 181 182 181 179 181 180 184 181 175 
300 314 307 311 298 291 307 305 314 301 
316 314 316 317 321 311 319 321 320 315 
288 284 283 279 276 275 274 275 275 274 
153 155 154 152 149 149 148 145 141 141 
258 256 253 250 248 250 251 247 248 244 
251 246 242 241 240 236 238 231 227 223 
291 296 282 281 278 281 277 274 277 272 
266 261 266 253 251 247 243 240 237 234 
214 210 208 207 204 203 199 197 196 195 
143 147 139 145 137 133 137 134 133 136 
211 213 218 217 209 212 214 207 209 208 
242 238 237 235 232 232 229 226 223 221 
245 239 236 233 227 223 219 214 211 208 
212 202 202 199 197 193 206 196 181 190 
291 287 281 281 275 272 269 264 259 261 
227 223 221 216 213 212 208 205 203 201 
231 230 223 221 220 216 214 212 212 212 
244 229 231 236 224 228 228 232 231 227 
328 328 326 324 321 320 318 317 314 314 
224 221 214 214 211 212 208 206 204 197 
304 300 298 297 292 288 288 285 280 280 
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Table C.28. The effect of IL-6 on submaximal contraction-induced skeletal muscle 
fatigability 
Treatment Geno 
Max Force 
following 30 
contractions 
Force @ 90s of 
submaximal 
contraction 
Vector WT 
58% 34% 
62% 32% 
63% 28% 
64% 33% 
69% 43% 
66% 38% 
44% 32% 
68% 33% 
66% 41% 
62% 35% 
67% 29% 
63% 28% 
53% 30% 
55% 27% 
Vector KO 
63% 28% 
59% 33% 
54% 26% 
57% 30% 
55% 24% 
58% 23% 
58% 27% 
65% 34% 
50% 26% 
63% 23% 
66% 35% 
54% 26% 
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Table C.29. The effect of IL-6 on submaximal contraction-induced skeletal muscle 
fatigability 
Treatment Geno 
Max Force 
following 30 
contractions 
Force @ 90s of 
submaximal 
contraction 
IL-6 WT 
46 31% 
53 28% 
52 30% 
59 26% 
51 19% 
56 35% 
59 32% 
56 36% 
62 35% 
54 31% 
66 40% 
54 33% 
59 32% 
55 29% 
52 15% 
IL-6 KO 
70 27% 
52 25% 
57 30% 
57 30% 
65 34% 
58 29% 
62 28% 
64 36% 
53 29% 
58 26% 
66 34% 
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Table C.30. Indices of cachexia in gp130 KO MIN mice. 
Geno 
Plasma 
IL-6 
Total 
Polyps 
<1mm 1-2mm >2mm 
TA 
Weight 
Flox 
0 0 0 0 0 45 
0 0 0 0 0 53 
0 0 0 0 0 57.5 
0 0 0 0 0 47 
0 0 0 0 0 45 
0 0 0 0 0 48 
0 0 0 0 0 49.5 
MIN 
Flox 
7.3 48 0 25 22 48.5 
33.2 23 0 0 23 45.5 
0 78 0 13 62 39 
21.6 45 1 10 32 35.5 
23.0 80 0 20 60 44.5 
4.6 83 6 29 47 46 
64.9 88 0 37 50 40.5 
MIN 
KO 
3.6 59 14 30 12 43 
8.2 26 0 0 24 53.5 
25.2 42 0 12 28 53.5 
18.7 64 0 40 19 56.5 
10.0 39 0 2 35 52 
100.8 72 0 15 54 43 
10.0 39 0 0 37 42 
98.5 72 0 15 54 38 
21.3 64 0 40 19 39.5 
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Table C.31. Indices of cachexia in gp130 KO MIN mice 
Geno gp130 STAT3 NFKB Erk1/2 P38 
Flox 
0.91 0.89 0.80 1.14 2.24 
1.34 1.45 1.60 0.48 0.23 
1.00 1.01 0.81 1.45 1.05 
0.78 0.87 0.84 1.08 0.45 
0.95 0.79 0.95 0.86 1.02 
1.02 1.03 0.83 1.44 1.03 
0.89 0.91 0.84 1.16 2.20 
MIN 
Flox 
1.02 1.49 0.91 0.60 1.77 
0.78 3.18 0.88 2.38 9.25 
0.99 0.62 1.03 0.73 2.89 
0.88 1.58 0.94 1.07 5.90 
1.33 1.87 1.06 1.70 3.58 
0.99 20.67 0.85 1.28 1.66 
1.18 4.07 1.00 2.56 2.05 
MIN 
KO 
0.24 0.61 1.13 0.38 6.94 
0.12 2.24 1.04 0.71 7.22 
0.41 0.84 1.14 0.37 1.24 
0.14 1.52 1.04 0.30 5.03 
0.16 0.68 0.78 0.74 1.19 
0.16 1.94 0.52 0.41 1.30 
0.21 1.75 0.47 0.59 1.81 
0.12 25.32 0.70 0.59 9.51 
0.06 0.46 0.58 0.62 7.36 
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Table C.32. The role of the muscle gp130 receptor on cancer-induced muscle weakness. 
Geno 10 30 50 80 100 120 150 180 200 
Flox 
348 434 676 1259 1555 1750 1854 1898 1911 
273 265 406 1201 1520 1494 1520 1631 1589 
340 355 537 1262 1389 1503 1578 1616 1615 
285 340 417 1021 1281 1393 1548 1653 1636 
273 264 508 1311 1489 1566 1609 1602 1611 
346 358 653 1370 1533 1575 1604 1637 1690 
374 327 420 1138 1591 1695 1745 1765 1773 
MIN 
Flox 
240 250 412 1133 1362 1425 1499 1540 1536 
289 279 337 846 950 1192 1321 1415 1423 
264 287 452 1108 1223 1288 1357 1389 1397 
332 384 745 932 995 1035 1050 1035 1033 
267 269 363 718 930 1044 1106 1136 1145 
260 285 607 1142 1279 1341 1380 1390 1391 
276 425 743 1045 1113 1168 1245 1252 1260 
MIN 
KO 
239 271 365 942 1317 1470 1535 1544 1469 
240 257 391 1143 1317 1437 1486 1498 1450 
346 359 562 1282 1320 1369 1347 1355 1291 
228 237 465 1010 1371 1542 1600 1650 1619 
266 285 446 1007 1222 1370 1529 1574 1588 
288 373 646 1076 1162 1192 1184 1166 1145 
318 317 565 1031 1198 1290 1331 1332 1326 
293 328 674 858 946 989 1016 1017 1011 
271 270 394 962 1131 1222 1257 1188 1167 
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Table C.33. The role of the muscle gp130 receptor on cancer-induced muscle weakness 
Geno 10 30 50 80 100 120 150 180 200 
Flox 
69 86 133 248 307 345 365 374 377 
44 43 65 194 245 241 245 263 256 
52 55 83 195 214 232 243 249 249 
53 63 77 189 237 257 286 305 302 
50 48 92 239 271 285 293 292 293 
68 71 129 270 302 310 316 323 333 
67 59 75 204 285 304 313 316 318 
MIN 
Flox 
44 46 75 207 249 261 274 282 281 
58 56 68 171 192 241 267 286 287 
58 63 99 243 268 282 298 305 306 
77 89 173 216 231 240 244 240 240 
53 54 72 143 185 208 221 226 228 
48 53 113 212 238 249 257 258 259 
56 86 151 212 226 238 253 255 256 
MIN 
KO 
51 58 78 201 281 314 328 330 314 
43 46 70 203 234 255 264 266 258 
59 62 96 220 227 235 231 233 222 
41 42 83 181 246 277 287 296 290 
50 54 84 190 231 259 289 297 300 
59 77 133 222 240 246 244 240 236 
67 67 119 218 253 272 281 281 280 
73 82 169 215 237 247 254 254 253 
61 61 88 216 254 274 282 267 262 
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Table C.34. The role of the muscle gp130 receptor on cancer-induced muscle fatigability 
Geno 0 5 10 15 20 25 30 35 40 45 50 
Flox 
557 434 516 663 767 819 838 850 857 861 865 
433 311 412 501 552 583 598 611 622 626 634 
518 407 483 633 725 774 786 806 803 801 803 
356 304 338 359 376 416 457 485 499 503 498 
495 414 442 578 658 693 707 713 718 714 708 
359 300 341 380 427 476 509 536 568 588 601 
412 350 390 471 563 621 649 659 657 640 610 
MIN 
Flox 
285 241 267 287 304 325 348 363 374 378 380 
343 288 320 361 420 457 481 481 479 473 459 
408 361 415 506 612 647 647 625 596 558 526 
605 574 603 616 614 596 563 526 486 450 420 
300 281 319 377 406 419 418 409 395 376 353 
537 457 589 669 708 723 727 723 701 678 634 
545 449 570 648 683 681 656 613 564 519 486 
MIN 
KO 
284 208 225 241 252 262 269 278 285 290 292 
294 250 300 317 343 359 374 379 368 357 346 
239 197 221 246 264 277 288 306 300 286 273 
346 324 344 412 472 495 520 533 533 542 535 
316 279 310 357 428 486 515 517 506 496 510 
411 371 457 513 555 560 596 597 571 528 487 
445 418 559 671 691 668 614 558 515 480 452 
692 635 587 521 469 427 393 368 342 310 273 
332 227 238 250 257 262 267 272 272 275 282 
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55 60 65 70 75 80 85 90 95 100 
856 845 822 795 766 726 687 647 613 586 
630 618 599 576 537 509 474 445 419 390 
794 751 719 664 615 573 549 503 479 463 
483 465 443 417 397 377 361 345 334 323 
685 664 636 598 565 531 503 483 465 448 
609 595 589 564 538 503 465 438 411 387 
560 525 498 464 446 438 421 402 393 384 
383 380 379 370 359 348 334 321 309 296 
438 419 393 380 362 350 335 328 316 315 
499 479 463 446 436 423 411 401 389 381 
398 379 364 345 328 310 291 276 256 241 
331 307 287 273 257 244 235 223 214 207 
591 553 517 483 468 443 427 416 404 389 
459 465 416 399 386 371 356 345 334 322 
292 292 289 280 278 270 262 255 247 238 
339 336 333 325 323 317 310 305 297 295 
262 259 256 252 253 257 252 248 242 237 
516 486 472 457 433 421 411 398 393 399 
490 466 453 425 408 389 371 357 352 339 
448 415 387 363 343 322 301 284 263 258 
424 401 382 369 353 344 335 328 321 316 
243 211 191 170 154 138 132 125 118 113 
271 271 263 252 237 227 219 215 208 202 
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105 110 115 120 125 130 135 140 145 150 
559 538 523 510 500 491 483 475 466 461 
369 354 340 328 315 305 297 292 291 282 
447 427 422 409 401 405 397 398 376 360 
317 306 301 295 287 282 276 269 264 260 
436 423 416 405 394 392 384 377 377 366 
361 345 328 322 313 299 288 287 269 268 
352 370 361 354 345 333 330 320 313 309 
282 271 262 255 248 245 240 236 232 231 
311 301 300 296 314 290 287 285 284 280 
372 366 359 352 346 339 336 330 327 321 
226 211 198 187 175 165 157 149 141 135 
201 192 189 184 180 176 173 167 164 164 
385 377 368 361 356 348 349 345 343 337 
312 304 296 288 282 276 271 267 258 258 
230 223 220 216 212 207 203 195 199 194 
290 282 279 275 266 264 261 257 251 251 
234 232 227 223 220 212 209 213 215 210 
391 374 372 364 357 350 344 334 326 323 
329 331 308 286 281 281 280 275 272 270 
243 229 215 205 182 187 179 172 166 161 
313 306 304 299 295 289 288 284 282 279 
107 105 104 102 101 100 100 100 99 99 
196 191 187 186 182 179 177 173 172 169 
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155 160 165 170 175 180 185 190 195 200 
456 448 443 438 434 429 425 419 416 411 
281 274 266 262 261 252 245 240 236 234 
365 368 360 363 357 340 337 339 341 328 
253 247 244 242 238 237 237 235 234 229 
362 351 352 352 344 339 338 336 329 329 
263 254 246 247 242 238 234 229 228 227 
301 291 292 267 282 272 279 272 267 274 
229 227 225 228 224 221 220 219 220 216 
277 276 272 271 269 266 264 261 261 257 
319 316 311 309 308 303 303 299 297 294 
128 123 117 114 113 109 106 106 104 102 
159 156 153 150 147 145 144 141 139 139 
335 332 334 329 329 325 324 321 319 320 
254 251 249 243 245 242 239 238 240 235 
188 192 190 189 184 185 177 174 170 171 
243 245 237 235 232 229 221 222 221 223 
205 206 199 190 189 191 181 186 181 176 
318 316 307 304 294 301 297 289 289 286 
263 292 256 259 246 243 232 244 245 240 
156 151 149 145 140 139 135 134 131 131 
276 275 272 269 269 266 263 263 260 259 
97 97 95 97 95 94 94 94 96 93 
170 165 163 163 160 157 160 157 156 156 
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205 210 215 220 225 230 235 240 245 250 
405 401 397 392 386 384 380 376 370 368 
232 223 222 226 216 212 209 207 211 203 
338 324 324 324 322 311 312 301 306 299 
229 227 224 224 219 218 217 215 214 214 
327 322 323 318 314 312 305 311 303 298 
225 226 212 223 213 209 210 204 204 212 
263 260 259 240 259 246 230 245 233 244 
211 210 213 210 209 205 207 201 201 199 
252 251 251 248 244 241 239 238 235 229 
290 289 287 285 285 279 278 278 277 273 
101 101 101 100 102 103 103 104 102 101 
137 136 134 136 127 131 131 132 129 131 
315 316 312 310 311 308 308 306 303 303 
236 232 230 231 229 228 227 225 225 220 
171 170 167 165 165 165 160 163 161 159 
219 217 217 213 217 215 211 208 207 207 
180 172 180 170 170 169 166 165 162 163 
284 284 275 272 261 266 266 258 257 259 
230 230 214 216 208 210 215 206 200 205 
129 128 128 125 126 126 124 125 117 123 
258 257 256 253 254 250 250 249 249 246 
94 92 91 91 90 91 91 90 90 89 
154 154 153 152 151 149 149 146 147 147 
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255 260 265 270 275 280 285 290 295 300 
365 362 358 354 351 348 345 341 337 335 
200 197 202 195 189 194 188 181 184 185 
297 308 289 295 291 284 271 267 264 270 
208 208 206 206 203 203 203 200 199 197 
298 294 291 291 284 287 280 280 273 274 
202 202 211 197 195 199 200 190 186 187 
242 237 235 224 217 222 216 220 216 218 
197 195 195 193 192 191 188 188 186 186 
230 229 227 223 222 222 214 218 216 214 
273 270 268 266 265 264 263 261 258 256 
102 101 99 102 102 102 99 99 97 97 
128 129 128 127 127 130 121 130 126 126 
303 301 294 294 294 295 292 291 289 276 
222 217 218 213 214 213 210 214 213 208 
159 156 155 153 153 151 154 150 149 149 
202 202 203 200 198 192 197 193 195 236 
162 159 160 156 155 156 156 155 153 149 
253 245 246 244 246 246 240 239 243 236 
188 201 198 194 198 195 189 188 186 186 
123 123 123 121 120 119 118 120 119 119 
245 244 244 245 242 242 238 238 238 154 
89 89 86 85 84 83 83 82 80 178 
146 142 144 142 141 138 140 141 139 136 
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301 305 310 315 320 325 330 335 340 345 350 
1109 948 913 871 839 818 795 773 766 761 753 
774 772 763 747 740 720 701 687 677 670 670 
895 679 673 657 634 626 607 599 589 591 581 
1002 834 813 787 766 753 742 730 721 714 712 
981 830 826 800 768 752 729 715 698 687 677 
869 780 762 747 716 698 686 665 657 640 637 
739 590 587 560 504 526 516 524 502 494 486 
949 838 787 742 705 677 658 648 642 637 629 
849 726 710 685 669 649 640 633 625 623 619 
639 551 542 533 531 523 515 507 508 499 494 
250 181 180 177 174 173 169 171 162 158 154 
664 524 508 488 468 454 405 428 421 413 406 
600 488 489 481 476 466 468 464 461 482 449 
452 396 396 390 379 372 367 358 351 344 338 
749 667 637 609 589 573 563 558 543 544 545 
629 555 553 548 541 543 538 537 533 528 529 
406 365 364 359 362 356 352 353 351 348 348 
610 547 542 535 517 516 517 510 505 476 467 
624 502 497 482 492 482 479 452 467 455 449 
275 221 219 217 216 212 208 205 200 196 193 
458 393 395 392 387 386 384 383 382 377 378 
146 107 106 100 100 97 97 95 93 90 88 
566 540 522 496 480 478 468 463 456 449 445 
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355 360 365 370 375 380 385 390 395 400 
752 750 743 742 740 734 737 732 730 726 
662 660 658 656 652 649 647 647 650 648 
567 568 560 562 557 548 549 551 548 544 
707 702 704 701 694 696 696 695 692 697 
674 670 663 662 657 655 656 654 655 652 
634 625 615 611 613 614 611 610 603 604 
442 482 459 474 460 456 453 425 443 429 
628 629 623 622 622 626 625 622 621 618 
609 614 608 608 605 608 605 603 604 601 
494 483 481 479 477 472 467 469 471 456 
151 149 150 142 140 137 135 135 132 131 
404 398 381 393 389 387 390 385 383 385 
449 447 441 435 435 428 429 410 420 430 
331 329 324 324 323 321 322 318 318 314 
533 533 537 535 533 529 533 528 520 520 
525 520 525 521 519 518 514 512 512 510 
346 342 343 343 340 338 336 336 335 332 
482 471 475 489 472 476 476 474 459 449 
449 435 421 436 434 432 458 501 376 420 
189 187 184 182 177 178 178 175 173 174 
373 373 369 369 368 367 364 364 361 362 
86 84 81 80 80 77 76 74 71 70 
446 442 437 442 434 433 434 433 435 434 
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405 410 415 420 425 430 435 440 445 450 
729 729 724 722 721 727 722 720 718 716 
651 649 648 649 651 644 645 650 643 650 
544 539 536 533 533 528 524 529 524 529 
691 692 691 688 686 689 689 689 684 683 
652 652 648 648 642 644 640 640 639 639 
603 610 608 602 597 603 598 594 589 589 
451 427 432 412 391 416 395 397 400 397 
615 615 615 613 613 610 609 610 609 603 
597 600 598 596 595 594 595 592 591 591 
459 462 457 457 458 455 458 451 452 443 
129 129 129 126 127 126 124 124 123 123 
382 382 383 382 380 381 379 379 382 381 
398 411 407 406 419 414 405 396 389 394 
315 316 314 310 311 310 306 307 310 310 
507 516 516 515 513 513 509 508 501 502 
509 510 511 506 506 506 505 502 499 505 
332 328 329 329 327 326 321 325 322 319 
448 450 446 447 455 433 428 434 433 431 
407 423 398 399 359 384 405 508 502 487 
158 172 173 171 171 170 171 169 169 173 
363 359 359 361 359 359 358 356 359 357 
68 69 69 68 67 65 61 62 58 59 
431 428 429 430 434 426 429 427 422 424 
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455 460 465 470 475 480 485 490 495 500 
712 708 706 708 704 704 702 702 705 705 
645 640 644 640 643 643 643 644 647 656 
522 521 521 510 519 522 507 518 517 515 
683 681 679 680 678 678 678 678 678 678 
637 638 638 633 636 635 636 635 636 632 
590 577 586 585 581 580 581 567 569 580 
391 392 388 378 393 376 382 379 380 374 
606 604 606 604 600 605 602 599 589 581 
591 589 588 587 586 585 583 583 583 583 
448 447 447 446 446 445 440 441 437 441 
122 122 124 123 124 122 122 122 125 123 
381 383 383 383 383 350 382 381 378 377 
400 396 392 389 389 395 384 387 388 376 
309 310 304 310 307 305 306 305 303 302 
499 499 497 497 495 494 485 493 489 485 
501 499 497 496 497 493 495 492 492 492 
321 319 319 319 317 319 316 318 318 313 
419 421 422 418 419 427 425 411 408 402 
463 496 489 472 445 459 459 461 440 437 
174 158 172 173 171 171 170 171 169 169 
359 357 357 357 356 357 356 352 357 358 
59 56 53 54 53 56 53 54 52 52 
420 418 416 421 416 418 419 420 416 415 
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505 510 515 520 525 530 535 540 545 550 
706 707 704 703 700 698 697 696 697 698 
661 669 672 676 677 675 677 683 678 683 
513 506 505 504 508 507 509 500 505 501 
678 678 678 678 678 678 678 678 678 678 
629 633 634 634 633 633 636 630 631 629 
566 564 571 562 566 565 560 561 562 562 
378 382 381 379 376 374 368 373 372 373 
576 572 571 571 572 578 576 578 582 578 
583 582 579 580 578 580 578 578 577 576 
443 437 436 437 435 432 435 432 431 431 
123 123 123 125 124 124 124 127 126 128 
378 378 379 377 378 377 380 377 379 379 
379 383 375 374 381 372 367 372 372 366 
302 302 301 299 300 298 298 294 297 297 
488 489 479 484 485 484 483 483 482 478 
494 493 492 492 493 495 491 489 492 491 
316 315 315 313 314 313 310 312 309 310 
412 415 414 404 399 388 389 395 386 396 
459 434 408 422 502 433 443 440 429 424 
173 174 158 172 173 171 171 170 171 169 
353 351 350 351 352 349 347 353 344 345 
51 51 54 51 49 49 49 48 46 46 
414 416 419 414 416 414 412 414 406 406 
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555 560 565 570 575 580 585 590 595 600 
697 696 696 695 694 695 690 690 693 690 
679 683 680 682 683 687 694 689 689 689 
503 500 497 503 501 500 507 499 496 501 
678 678 678 678 678 678 678 678 678 678 
626 628 628 631 632 631 635 637 631 631 
561 553 550 552 555 553 564 556 554 556 
367 375 370 372 368 367 368 366 368 370 
575 576 573 570 572 566 569 566 567 568 
577 577 575 576 574 576 575 571 569 573 
429 433 427 428 430 425 427 429 426 421 
129 129 131 130 132 132 132 135 135 137 
380 379 378 379 380 379 374 377 376 378 
366 342 357 359 361 315 357 358 368 369 
291 295 289 293 293 294 289 293 292 294 
478 479 479 478 477 478 475 479 473 475 
489 489 482 482 487 483 483 483 483 480 
310 311 311 312 314 312 312 313 309 311 
391 381 389 395 375 386 387 393 382 388 
440 417 471 373 403 415 388 384 407 435 
169 173 174 158 172 173 171 171 170 171 
347 344 342 343 343 340 339 342 342 338 
44 45 44 44 45 44 45 48 43 42 
416 415 403 399 400 405 396 406 403 395 
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Table C.35. The role of the muscle gp130 receptor on cancer-induced muscle fatigability 
Geno 
Force Following 
Submax Fatigue 
Force Following Max 
Fatigue 
Flox 
1109 690 
774 689 
895 501 
1002 678 
981 631 
869 556 
739 370 
MIN 
Flox 
949 568 
849 573 
639 421 
250 137 
664 378 
600 369 
452 294 
MIN 
KO 
749 475 
629 480 
406 311 
610 388 
624 435 
275 171 
458 338 
146 42 
566 395 
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Table C.36. The effect of muscle gp130 loss on mitochondrial content, function, and 
quality control in MIN mice 
Geno APMK BNIP3 Parkin P62 PGC1 DRP1 FIS1 MFN1 COXIV 
Cyto 
C 
Flox 
1.49 0.45 1.38 1.03 0.86 1.81 0.56 0.74 2.00 0.55 
1.25 1.26 1.02 1.46 1.27 0.86 1.65 0.75 1.02 0.99 
0.81 1.08 0.85 0.99 0.97 0.96 1.04 0.89 0.43 0.91 
0.72 0.99 0.89 0.83 0.91 0.62 1.03 1.31 0.73 1.18 
0.74 1.22 0.86 0.69 0.99 0.76 0.72 1.30 0.82 1.36 
MIN 
Flox 
0.79 1.74 1.29 0.86 0.85 1.30 0.80 1.24 0.11 1.54 
0.86 0.86 1.03 0.71 0.58 1.17 0.87 1.12 0.82 1.31 
1.09 1.72 1.13 0.79 0.92 0.95 1.38 1.11 0.10 1.67 
1.24 1.17 0.87 0.89 0.61 1.65 0.77 0.90 0.25 1.67 
1.38 1.44 0.93 0.70 0.88 0.96 0.85 0.72 0.12 1.45 
1.03 0.79 1.33 0.41 0.55 1.30 0.98 0.49 0.35 1.13 
1.09 0.92 1.42 0.74 0.84 1.09 0.82 1.08 0.24 1.35 
MIN 
KO 
1.48 1.07 1.29 0.76 0.85 1.30 0.63 1.14 0.09 1.50 
0.75 0.72 0.73 0.86 0.61 1.00 0.75 1.18 1.40 1.03 
0.84 1.30 0.90 0.88 1.20 1.60 0.60 1.46 1.00 1.67 
0.45 0.93 0.84 0.87 0.83 1.15 0.25 1.63 0.99 0.80 
0.45 1.23 0.88 0.85 0.93 1.32 0.48 1.62 1.51 1.18 
8.89 1.61 0.88 0.97 1.29 1.48 0.62 1.42 1.16 1.33 
1.35 1.20 0.97 0.91 0.78 1.25 0.61 1.06 1.05 1.41 
0.71 2.68 1.01 0.65 0.83 0.73 0.46 0.96 0.13 1.64 
2.10 1.15 0.92 0.77 0.78 1.54 1.09 0.84 0.28 1.41 
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Table C.37. The effect of muscle gp130 loss on mitochondrial content, function, and 
quality control in MIN mice 
Geno RCR 
Flox 
6.1929 
7.1706 
7.2879 
7.3543 
MIN 
Flox 
5.7639 
2.9933 
3.0492 
5.7062 
3.275 
MIN 
KO 
8.9278 
7.707 
5.3497 
6.7902 
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Table C.38. Mouse body composition and behavior pre- and post-wheel access 
Treatment geno 
12 Wk 
Body 
Weight 
12 Wk 
Food 
Intake 
12 Wk 
Lean 
Mass 
12 Wk 
Fat 
mass 
12 Wk 
Fat % 
Control B6 
23.8 3.33 18.2 2.1 10.4 
23.7 3.62 17.6 3.2 15.3 
25.0 3.56 18.6 3.0 13.9 
24.0 4.00 18.1 2.7 12.9 
23.5 3.62 18.3 2.5 11.9 
23.6 3.78 18.1 2.8 13.3 
24.1 3.72 19.0 2.6 12.2 
24 3.46 17.8 2.6 12.8 
22.8 3.8 17.2 2.6 13.2 
21.5 3.76 15.7 2.5 13.8 
Wheel B6 
23.3 3.78 17.6 2.4 12.2 
23.5 3.86 18.0 2.8 13.7 
23.9 3.38 18.3 2.4 11.5 
24.8 3.98 17.9 2.7 12.9 
22.6 4.18 17.4 2.4 12.0 
23.9 3.30 18.1 2.4 11.7 
23.8 3.02 18.2 2.6 12.3 
24.5 3.74 17.5 3.5 16.6 
24.1 4.24 18.1 2.5 12.1 
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Treatment geno 
12 Wk 
Body 
Weight 
12 Wk 
Food 
Intake 
12 Wk 
Lean 
Mass 
12 Wk 
Fat 
mass 
12 Wk 
Fat % 
Control Min 
22.7 3.00 18.1 2.3 11.3 
24.2 3.07 19.3 2.8 12.6 
21.7 3.73 18.6 2.2 10.6 
21.5 3.90 15.9 2.4 13.1 
24.0 3.83 17.9 2.5 12.2 
26.6 4.39 20.3 3.4 14.3 
23.2 3.63 17.1 2.5 12.7 
23.1 3.88 17.8 2.4 11.8 
23.4 3.77 17.3 2.7 13.4 
22.4 5.13 16.9 1.8 9.8 
Wheel Min 
23.2 2.93 18.8 2.4 11.2 
20.7 3.73 16.5 2.4 12.6 
21.8 3.26 16.9 2.2 11.8 
23.5 3.74 18.3 2.5 12.0 
23.7 3.86 18.2 2.6 12.4 
23.9 4.06 19.0 2.3 10.7 
22.8 4.30 17.9 2.1 10.7 
23.5 4.25 18.1 2.4 11.7 
20.3 3.56 15.7 2.3 12.7 
22.4 3.38 16.9 2.7 13.7 
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Table C.39. Mouse body composition and behavior pre- and post-wheel access 
Treatment geno 
18 Wk 
Body 
Weight 
18 Wk 
Food 
Intake 
18 Wk 
Lean 
Mass 
18 Wk 
Fat 
Mass 
18 Wk 
Fat % 
Control B6 
25.5 3.88 19.2 3.1 14 
25.6 4.08 19 2.6 12.1 
27.8 4.24 20.4 3.4 14.3 
26.9 3.96 19.5 3.2 14.2 
26 3.20 19.6 2.9 13.1 
25.2 3.57 19.5 2.9 13 
26.0 4.35 20.2 2.5 11.1 
25.7 4.33 19.6 2.6 11.6 
24.6 4.17 18.6 2.5 12 
22.3 4.13 17.3 2.3 11.6 
Wheel B6 
24.5 4.25 19.6 2.5 11.4 
25.1 4.42 19.4 2.0 9.3 
25.3 4.53 20.0 2.1 9.7 
26.2 4.65 19.5 2.4 11.1 
24.7 5.10 19.4 2 9.5 
24.9 4.90 19.2 2.4 10.9 
24.4 4.50 19.2 2.6 12.1 
25.3 4.19 19.3 2.1 10 
26.6 4.29 20.2 2.6 11.2 
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Treatment geno 
18 Wk 
Body 
Weight 
18 Wk 
Food 
Intake 
18 Wk 
Lean 
Mass 
18 Wk 
Fat 
Mass 
18 Wk 
Fat % 
Control Min 
22.7 4.98 17 2.5 12.8 
23.9 3.80 19.5 1.8 8.6 
25.5 3.94 17.9 2.7 13.1 
23.5 3.40 17.9 2.9 13.9 
25.1 3.46 18.6 3.0 13.7 
22.7 3.75 19.5 1.8 8.3 
24.3 3.41 18.5 3.3 15.2 
25.1 3.37 18.5 3.0 13.8 
24.2 3.47 18.3 2.8 13.2 
19.9 3.10 14.7 1.4 8.7 
Wheel Min 
21.5 3.20 16.7 1.9 10.3 
23.9 3.86 17.8 3.1 14.7 
25.8 3.04 19.1 2.8 12.7 
26.6 4.10 19.7 2.5 11.1 
26.0 4.07 20.2 3.0 12.9 
26.2 4.10 22.0 2.3 9.7 
24.5 3.63 20.0 2.5 11.2 
25.5 4.50 18.9 2.9 13.5 
20.4 4.27 16.5 2.0 10.7 
23.8 4.10 20.1 2.4 10.7 
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Table C.40. Functional characteristics pre- and post-wheel access 
Treatment geno 
12 Wk 
Cage 
Activity 
12 Wk 
Time to 
Fatigue 
12 Wk 
Grip 
Strength 
12 Wk 
G.S. / 
BW 
12 Wk 
Rotorod 
Control B6 
16028.1 72 2.54 0.1090 34.83 
16624.3 56 2.64 0.1103 83.07 
16201.1 95 2.61 0.1043 64.07 
18612.1 80 2.48 0.1035 72.97 
13415.3 68 2.49 0.1065 75.90 
26947.4 88 2.41 0.1010 54.37 
22177.9 72 2.67 0.1074 62.23 
23890.0 66 2.64 0.1075 54.93 
21790.3 90 2.47 0.1073 66.3 
18841.9 92 2.26 0.1054 45.9 
Wheel B6 
23982.6 106 2.24 0.0962 79.27 
20668.1 70 2.62 0.1094 21.80 
24214.4 90 2.66 0.1104 67.67 
23861.9 77 2.63 0.1059 72.30 
21664.4 55 2.29 0.1014 67.67 
16205.1 52 2.52 0.1056 70.40 
13426.6 95 2.56 0.1062 72.50 
17209.4 82 2.65 0.1083 46.30 
15374.0 90 2.07 0.0869 60.60 
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Treatment geno 
12 Wk 
Cage 
Activity 
12 Wk 
Time to 
Fatigue 
12 Wk 
Grip 
Strength 
12 Wk 
G.S. / 
BW 
12 Wk 
Rotorod 
Control Min 
15528.6 77 2.34 0.1011 55.87 
18880.6 65 2.15 0.0894 58.87 
18014.5 70 2.29 0.1058 62.43 
14179.6 92 2.25 0.1018 46.07 
21998.7 78.8 2.51 0.1084 61.28 
13558.8 50 3.01 0.1133 45.73 
22360.8 89 2.66 0.1176 81.67 
35885.6 122 2.65 0.1158 55.53 
38872.3 90 2.62 0.1118 88.33 
20707.3 54 2.66 0.1186 57.00 
Wheel Min 
15001.1 75 2.46 0.1067 30.97 
37668.6 110 2.42 0.1167 61.97 
11359.3 78 2.08 0.0947 42.77 
21139.7 50 2.46 0.1051 58.83 
34789.3 92 2.35 0.0988 38.23 
26059.0 75 2.28 0.0962 33.93 
30596.9 85 2.23 0.0982 35.43 
16312.4 61 2.42 0.1030 57.37 
22995.6 45 2.16 0.1065 95.83 
18403.9 71 2.47 0.1090 108.4 
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Table C.41. Functional characteristics pre- and post-wheel access 
Treatment geno 
18 Wk 
Cage 
Activity 
18 Wk 
Time to 
Fatigue 
18 Wk 
Grip 
Strength 
18 Wk 
G.S. / 
BW 
18 Wk 
Rotorod 
Control B6 
22976.2 91 2.70 0.1037 60.2 
25272.5 88 2.66 0.1036 115.6 
19284.0 84 2.73 0.1002 73.3 
27680.8 82 2.88 0.1088 66.5 
31720.8 69 2.62 0.1026 81.0 
15151.7 90 2.85 0.1109 58.6 
24026.6 73 2.92 0.1131 69.7 
29384.4 86 3.14 0.1259 61.7 
32627.0 93 3.11 0.1278 87.0 
35762.0 110 3.01 0.1342 93.5 
Wheel B6 
32350.8 180 2.82 0.1133 42.6 
18435.2 165 2.95 0.1193 52.1 
39396.2 180 2.91 0.1138 77.4 
27625.7 185 2.86 0.1112 78.1 
34113.0 142 2.71 0.1107 89.0 
22130.0 175 2.83 0.1115 77.9 
37567.3 61 2.74 0.1121 104.7 
41240.0 115 2.50 0.0989 55.5 
40416.7 175 2.73 0.1027 50.5 
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Treatment geno 
18 Wk 
Cage 
Activity 
18 Wk 
Time to 
Fatigue 
18 Wk 
Grip 
Strength 
18 Wk 
G.S. / 
BW 
18 Wk 
Rotorod 
Control Min 
4292.6 19 2.46 0.1069 120.7 
2762.4 24 2.27 0.0935 53.8 
16894.0 49 2.63 0.1030 68.5 
24144.8 87 2.59 0.1073 89.3 
3561.4 46 2.52 0.1033 33.9 
3203.0 39 2.11 0.0930 44.7 
18602.3 47 2.38 0.0974 81.6 
28991.0 37 2.51 0.1035 82.4 
23562.0 53 2.55 0.1073 94.3 
316.3 7 1.54 0.0847 21.0 
Wheel Min 
2241.2 17 2.17 0.1021 67.4 
21137.4 120 2.49 0.1072 68.9 
16875.3 72 2.67 0.1054 84.7 
12224.3 160 2.84 0.1117 61.1 
16121.3 162 2.49 0.0994 60.9 
12607.7 116 2.85 0.1105 70.2 
12463.3 90 2.92 0.1207 68.3 
19568.3 60 2.64 0.1033 67.6 
6349.7 61 2.20 0.1081 95.9 
20973.0 141 2.59 0.1051 76.8 
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Table C.42. The effect of wheel access on the characteristic data of MIN and B6 mice 
Treatment geno Age 
Peak 
Weight 
current 
weight 
Pre-
Fast 
Sac 
BW 
current 
loss 
Control B6 
18.3 25.8 25.8 25.5 -1.2% 
19.4 25.9 25.7 25.6 -1.2% 
19.7 27.6 27.3 27.8 0.7% 
19.7 26.8 26.3 26.9 0.4% 
20.7 26.0 26.0 26.0 0.0% 
19.7 25.7 25.7 25.2 -1.9% 
19.0 26.0 25.7 26.0 0.0% 
20.1 26.2 25.7 25.7 -1.9% 
19.9 24.7 24.6 24.6 -0.4% 
19.9 22.9 22.3 22.3 -2.6% 
Wheel B6 
20.3 25.4 25.2 24.5 -3.5% 
20.0 25.2 25.6 25.1 -0.4% 
20.0 26.5 25.6 25.3 -4.5% 
19.7 26.1 26.2 26.2 0.4% 
19.7 24.3 24.7 24.7 1.6% 
19.7 25.4 24.9 24.9 -2.0% 
19.7 24.5 24.8 24.8 1.2% 
19.7 25.9 25.6 25.6 -1.2% 
19.7 26.6 26.3 26.3 -1.1% 
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Treatment geno Age 
Peak 
Weight 
current 
weight 
Pre-
Fast 
Sac 
BW 
current 
loss 
Control Min 
18.7 24.3 22.7 22.5 -7.4% 
18.7 24.8 23.9 24.5 -1.2% 
18.7 25.5 25.5 25.1 -1.6% 
19.0 23.7 23.5 23.5 -0.8% 
18.6 25.1 25.1 24.5 -2.4% 
20.1 26.7 21.9 21.9 -18.0% 
20.3 24.8 24.3 25.4 2.4% 
20.3 25.1 25.1 25.2 0.4% 
18.9 24.4 24.2 24.2 -0.8% 
18.9 22.9 19.1 19.1 -16.6% 
Wheel Min 
18.4 24.6 21.2 21.5 -12.6% 
18.4 24.0 24 23.9 -0.4% 
19.4 25.8 25 25.8 0.0% 
19.0 26.6 25.9 26.6 0.0% 
19.7 26.0 26.0 26.0 0.0% 
19.7 26.6 26.6 26.2 -1.5% 
19.7 24.5 24.2 24.5 0.0% 
19.7 25.5 25.5 25.5 0.0% 
20.0 21.9 20.4 20.4 -6.8% 
20.0 25.6 24.6 23.8 -7.0% 
 
  
 337 
Table C.43. The effect of wheel access on the characteristic data of MIN and B6 mice 
Treatment Geno Tibia 
Hind
limb 
Hindlimb/T
ibia 
Epi 
Fat 
Spleen Testes 
Sem 
Ves 
Control B6 
17.05 298 17.5 264 74 185 280 
17.00 317 18.6 255 73 209 290 
17.00 353 20.8 360 80 209 331 
17.10 324 18.9 288 70 198 351 
16.80 303 18.0 309 78 187 329 
16.95 298 17.6 221 79 195 264 
17.1 316 18.5 294 73 188 298 
17.05 303 17.7 178 64 205 313 
16.95 311 18.3 187 66 183 307 
16.80 274 16.3 191 54 170 289 
Wheel B6 
16.95 302 17.8 208 76 213 285 
17.00 314 18.4 178 59 193 250 
17.15 336 19.6 197 60 193 262 
17.20 319 18.5 183 55 197 282 
17.10 318 18.6 117 103 191 233 
17.20 313 18.2 125 63 195 220 
17.10 310 18.1 245 76 203 260 
17.05 322 18.9 224 56 208 266 
17.20 340 19.7 253 66 204 290 
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Treatment Geno Tibia Hindlimb 
Hindlimb/
Tibia 
Epi 
Fat 
Spleen Testes 
Sem 
Ves 
Control Min 
16.90 242 14.3 57 353 181 124 
17.00 246 14.5 54 502 188 84 
16.60 285 17.1 220 210 190 222 
16.7 283 16.9 201 179 183 155 
16.90 300 17.8 171 372 202 196 
17.00 233 13.7 0 289 147 50 
16.75 304 18.1 288 177 200 220 
17.20 304 17.7 229 435 205 204 
16.90 298 17.6 156 315 191 225 
16.40 167 10.2 0 297 106 35 
Wheel Min 
17.00 226 13.3 0 342 149 40 
16.80 274 16.3 173 265 185 280 
16.70 308 18.4 193 199 187 343 
17.25 316 18.3 138 189 190 210 
17.10 272 15.9 185 237 201 205 
17.10 313 18.3 154 351 211 239 
16.75 295 17.6 121 383 179 164 
17.00 313 18.4 168 253 203 249 
16.40 206 12.6 42 305 137 85 
16.70 309 18.5 164 269 191 191 
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Table C.44. The effect of wheel access on skeletal muscle’s contractile properties in the 
MIN and B6 
Geno Treatment TA Lo 
1/2 
RT 
TPT -dP/dt +dP/dt 
B6 Control 
49.5 14.5 8.2 14.3 17205.9 22550.5 
52.0 14.0 7.2 15.0 16525.8 21396.6 
53.5 14.5 8.0 16.6 11816.5 25134.6 
51.0 14.0 6.7 15.4 17804.7 28989.3 
48.5 14.0 7.6 14.9 25886.2 24339.4 
46.0 14.0 7.4 14.4 18734.1 18553.0 
48.0 14.5 7.2 15.5 23102.8 24273.7 
47.5 14.5 7.7 15.4 16915.1 27002.9 
49.5 14.0 6.3 14.6 14301.7 25054.3 
44.0 14.0 6.5 14.6 13195.4 22950.6 
B6 Wheel 
45.0 13.5 7.3 15.9 12637.8 20704.8 
48.0 14.5 8.1 14.7 17758.6 18858.6 
50.5 14.0 7.4 13.3 20159.1 23443.6 
50.5 15.0 7.7 14.8 21926.7 24893.4 
46.5 14.0 7.4 14.8 19352.0 25188.1 
47.5 15.0 8.0 15.1 23074.1 25148.5 
47.0 14.5 7.6 14.7 20135.2 20113.2 
48.0 14.0 7.5 15.1 22285.3 21824.2 
53.0 14.5 6.7 14.5 19966.8 28596.2 
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Geno Treatment TA Lo 
1/2 
RT 
TPT -dP/dt +dP/dt 
Min Control 
41.0 14.5 9.1 16.6 18649.3 18754.1 
40.0 14.0 8.8 15.9 10469.5 24772.9 
45.0 14.0 8.3 16.6 16022.1 15937.7 
44 13 15.2 17.6 17445.5 20633.5 
47.5 13.5 8.4 15.2 9274.4 29960.3 
36.0 13.0 9.7 16.6 9091.8 12842.9 
44.5 14.5 8.8 14.9 15343.1 24668.5 
47 14.5 7.0 15.1 11664.6 26941.3 
48 14 6.4 14.6 12838.8 23085.8 
27.0 13.5 12.5 19.2 4576.0 8595.9 
Min Wheel 
32.0 15.0 20.2 28.5 1556.0 10377.4 
43.5 14.5 11.3 15.9 14983.3 21026.9 
48.0 14.5 8.6 16.0 13028.6 24308.5 
49.0 14.0 8.6 16.8 10720.7 28287.1 
48.5 14.5 6.8 14.6 23360.1 22856.5 
45.0 15.0 11.2 16.5 13708.2 18251.9 
44.0 14.5 7.1 14.8 13176.1 19037.7 
47.0 14.0 7.5 16.6 13501.5 25049.2 
34.0 13.5 11.7 19.8 14119.8 15440.5 
50 14.5 10.3 16.8 12746.1 25285.2 
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Table C.45 The effect of free wheel access on body weight, polyp size, and plasma IL-6 
Treat 
ment 
Geno 
11 12 13 14 15 16 17 18 19 
Control B6 
22.9 23.8 23.3 23.3 23.5 24.5 25.1 25.8 25.5 
23.7 23.7 23.5 24.0 24.5 24.8 25.1 25.9 25.7 
25.0 25.0 24.5 25.0 24.8 26.3 26.7 27.6 27.3 
24.0 24.0 24.4 24.1 24.6 25.0 25.5 26.8 26.3 
24.0 23.5 23.4 24.1 24.2 24.5 24.3 24.7 26.0 
22.5 23.6 23.6 24.1 24.4 25.0 25.7 25.1 25.7 
24.1 24.1 23.9 24.1 23.8 25.0 25.3 25.8 26.0 
24.4 24.0 23.6 24.3 23.8 24.8 24.9 26.2 25.7 
22.7 22.8 22.2 22.7 22.6 23.6 23.8 24.7 24.3 
21.3 21.5 21.2 21.8 22.0 22.1 22.2 22.9 22.4 
Wheel B6 
23.5 23.3 23.7 23.7 24.1 23.7 24.7 25.4 25.0 
24.2 23.5 24.1 24.1 24.0 24.7 25.2 25.1 25.2 
24.6 23.9 24.4 24.5 25.3 25.0 25.4 25.6 26.5 
23.9 24.3 24.5 24.1 26.1 25.1 25.7 25.3 25.3 
21.9 22.5 22.5 22.5 23.4 23.3 23.6 24.3 24.3 
22.8 23.4 23.4 23.7 24.3 24.8 25.4 25.1 25.1 
21.9 22.5 22.5 22.6 23.3 23.2 23.6 24.5 24.4 
24.2 23.5 24.1 24.3 24.1 24.7 24.2 25.9 25.3 
24.6 23.9 24.4 24.5 24.5 25.5 25.7 26.5 26.6 
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Treat 
ment 
Geno 
11 12 13 14 15 16 17 18 19 
Control Min 
23.5 22.7 22.7 22.7 24.3 24.2 23.4 22.7 22.5 
24.4 24.2 24.4 24.4 24.6 24.8 24.7 23.9 24.5 
21.3 21.7 22.0 22.0 23.5 24.5 25.1 25.5 25.1 
21.9 21.5 21.3 21.3 23.0 23.5 23.7 23.5 23.5 
23.9 24.0 24.4 24.8 25.1 24.8 22.5 25.1 24.5 
25.0 26.0 26.4 26.7 26.4 25.1 23.7 22.7 21.9 
22.5 23.2 22.6 23.1 23.0 23.4 23.8 24.4 24.8 
22.9 23.1 22.9 22.9 23.4 23.9 23.7 24.3 25.1 
23.4 23.1 22.9 22.8 23.1 23.8 24.4 24.2 24.2 
22.4 21.1 20.2 19.6 19.1 19.1 19.1 19.1 19.1 
Wheel Min 
23.7 23.2 23.3 23.3 24.6 24.5 21.9 21.2 21.5 
21.0 20.7 21.5 21.5 22.8 23.0 22.5 24.0 23.9 
22.1 21.8 22.1 23.3 23.7 24.1 24.7 25.0 25.8 
22.9 23.5 24.0 24.5 24.7 24.9 25.4 25.9 26.6 
23.0 23.7 24.0 23.9 24.9 24.5 25.1 26.0 26.0 
23.5 23.9 24.0 24.4 25.7 25.4 25.8 26.6 26.2 
22.1 22.8 23.2 23.2 24.2 24.2 24.2 24.2 24.5 
22.5 23.5 23.6 23.7 24.0 25.4 25.3 25.5 25.5 
20.2 20.3 21.0 21.3 21.0 21.9 19.2 20.2 20.4 
22.4 22.4 22.6 23.0 24.0 24.5 24.4 25.6 24.6 
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Table C.46 The effect of free wheel access on body weight, polyp size, and plasma IL-6 
  Intestines <1mm 1-2mm >2mm  
Treatment Geno Total Total Total Total Plasma IL-6 
Control Min 
103 5 23 75 11.7 
114 5 8 99 61.5 
87 17 25 44 7.8 
93 9 23 61 7.8 
99 0 13 86 7.8 
133 2 19 110 109.0 
55 0 13 42 11.8 
59 0 9 50 23.0 
72 4 11 57 14.6 
96 0 0 95 40.6 
Wheel Min 
112 2 10 98 84.4 
101 16 21 64 27.0 
95 27 26 41 7.8 
68 7 8 53 7.8 
87 8 16 62 25.0 
90 4 5 79 37.0 
101 12 11 77 7.8 
94 2 31 60 70.5 
70 0 1 67 40.1 
87 1 26 58 18.3 
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Table C.47 The effect of free wheel access on body weight, polyp size, and plasma IL-6 
  
Average Time Per Day Per Week 
    
Treatment Geno 1 2 3 4 5 
Wheel B6 
141.0 148.8 174.1 147.3 161.3 
142.6 159.0 159.3 139.8 150.1 
125.4 185.2 86.3 101.6 62.9 
106.3 145.3 150.0 235.3 236.8 
43.9 191.6 110.0 105.4 124.4 
101.1 129.7 132.8 153.1 139.4 
134.0 168.5 162.0 130.3 154.6 
156.0 168.0 201.0 139.0 160.6 
121.5 169.5 212.2 197.1 150.7 
Wheel Min 
107.0 87.9 71.4 53.1 7.6 
108.0 231.3 281.3 263.3 183.4 
58.3 41.0 67.0 106.9 70.4 
85.2 114.5 112.9 111.3 59.4 
170.6 246.8 183.3 132.0 28.6 
76.0 111.5 160.3 158.4 121.9 
126.4 151.0 134.0 132.0 87.1 
153.7 42.8 55.6 38.7 35.7 
131.0 22.4 150.0 220.8 91.3 
60.9 67.7 132.6 107.1 76.7 
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Table C.48 The effect of free wheel access on skeletal muscle force production in the 
male MIN 
Geno 
Treat 
ment 
10 30 50 80 100 120 150 180 200 
B6 Control 
291 291 428 1008 1287 1443 1508 1504 1477 
311 342 481 1067 1258 1289 1379 1335 1404 
305 330 501 1140 1288 1280 1400 1335 1375 
298 334 472 1140 1481 1613 1649 1631 1621 
330 364 517 1162 1407 1645 1582 1702 1727 
274 288 431 990 1287 1298 1388 1443 1360 
336 416 649 1254 1535 1559 1705 1744 1733 
333 519 492 1156 1411 1510 1528 1654 1655 
256 265 478 1032 1320 1429 1507 1541 1513 
282 261 371 1017 1225 1358 1321 1373 1310 
B6 Wheel 
279 340 436 1071 1217 1326 1355 1439 1462 
302 385 570 1022 1302 1523 1605 1511 1437 
267 282 375 1082 1353 1449 1522 1404 1538 
376 440 579 1312 1575 1676 1670 1667 1785 
261 322 569 1115 1429 1555 1640 1661 1678 
342 479 645 1166 1388 1573 1666 1733 1781 
199 247 344 920 1211 1452 1526 1545 1554 
273 334 472 974 1238 1330 1456 1649 1676 
305 318 597 1093 1324 1484 1668 1687 1747 
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Geno 
Treat 
ment 
10 30 50 80 100 120 150 180 200 
Min Control 
298 349 569 1109 1297 1359 1350 1455 1453 
323 312 476 830 882 1197 1270 1294 1306 
204 266 303 728 1180 1252 1289 1360 1221 
346 437 547 981 1193 1308 1389 1410 1354 
321 345 557 1202 1324 1384 1401 1423 1417 
292 298 600 842 896 925 972 961 920 
300 420 655 1195 1369 1499 1492 1583 1606 
294 477 687 1031 1144 1282 1444 1486 1455 
233 352 439 944 1155 1235 1290 1297 1284 
241 364 558 634 662 687 671 635 535 
Min Wheel 
302 570 744 788 769 777 744 742 741 
265 311 370 898 1084 1148 1253 1295 1272 
317 356 501 1271 1445 1550 1575 1590 1592 
314 368 538 1152 1345 1425 1494 1524 1508 
295 366 487 1084 1340 1471 1621 1713 1759 
290 255 348 813 1149 1131 1187 1218 1217 
232 263 411 949 1038 1105 1202 1207 1247 
299 328 504 1119 1362 1444 1467 1395 1390 
171 217 345 767 973 1066 1104 1146 1166 
268 358 457 1021 1244 1364 1501 1464 1403 
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Table C.49 The effect of free wheel access on skeletal muscle force production in the 
male MIN 
Geno 
Treat 
ment 
10 30 50 80 100 120 150 180 200 
B6 Control 
54 54 79 187 239 268 280 279 274 
53 58 82 182 215 220 235 228 239 
52 57 86 196 221 220 240 229 236 
52 58 82 198 258 281 287 284 282 
60 67 95 213 257 301 289 311 316 
53 56 83 191 248 250 268 278 262 
64 80 124 240 294 298 326 334 332 
64 100 95 224 273 292 296 320 320 
46 48 86 185 237 256 270 276 271 
57 53 75 205 247 274 266 277 264 
B6 Wheel 
53 65 83 204 231 252 258 274 278 
58 74 109 196 249 292 307 289 275 
47 50 66 190 238 255 267 247 270 
71 83 109 247 296 315 314 314 336 
50 61 109 213 273 297 313 317 320 
68 96 129 233 278 315 333 347 356 
39 48 67 180 237 284 298 302 304 
50 62 87 180 229 246 269 305 310 
53 55 103 189 230 257 289 292 303 
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Geno 
Treat 
ment 
10 30 50 80 100 120 150 180 200 
Min Control 
67 78 127 248 291 304 302 326 326 
72 69 106 184 196 266 282 287 290 
40 52 60 144 233 247 254 268 241 
65 82 102 184 223 245 260 264 253 
58 62 100 217 238 249 252 256 255 
67 68 137 193 205 212 222 220 210 
62 87 135 247 283 309 308 327 332 
57 93 134 201 224 251 282 291 284 
43 65 81 174 214 228 238 240 237 
76 115 177 201 210 218 213 201 169 
Min Wheel 
90 169 221 234 228 231 221 220 220 
56 66 78 190 229 242 265 273 269 
61 68 96 243 277 297 302 304 305 
57 67 97 209 244 258 271 276 273 
56 69 92 205 254 279 307 324 333 
61 54 73 172 243 239 251 257 257 
48 55 86 198 217 231 251 252 260 
56 62 95 211 257 273 277 263 262 
43 55 87 193 245 268 278 288 293 
49 66 84 188 229 251 276 269 258 
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Table C.50. The effect of free wheel access on skeletal muscle fatigability in the male 
MIN 
Geno 
Treat 
ment 0 5 10 15 20 25 30 35 40 45 50 
B6 
Contro
l 
287 241 292 376 434 401 450 499 528 541 546 
278 252 284 316 377 424 453 481 507 522 526 
392 330 385 481 513 531 551 542 542 536 511 
340 305 346 414 519 587 611 626 640 638 651 
291 260 296 308 353 387 424 460 485 497 501 
330 258 286 327 370 392 452 480 527 551 575 
505 439 482 558 636 648 675 664 689 649 649 
391 337 394 497 591 643 668 683 691 695 687 
326 245 273 296 380 398 424 437 498 555 604 
320 311 354 436 530 589 625 650 672 680 672 
B6 Wheel 
373 326 363 449 525 563 577 595 605 596 593 
366 305 376 444 489 518 537 557 543 560 552 
373 303 339 403 445 487 520 549 571 588 596 
389 342 392 457 560 625 660 686 709 730 740 
414 337 367 411 485 537 567 590 608 620 627 
417 346 400 490 566 615 658 701 736 751 752 
279 253 277 309 349 394 425 439 443 437 424 
305 262 286 325 396 472 514 550 579 594 624 
344 310 308 322 324 387 366 457 473 477 488 
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55 60 65 70 75 80 85 90 95 100 105 110 
540 527 503 476 444 406 368 339 308 286 263 246 
515 499 467 442 416 392 370 353 337 325 315 306 
481 476 433 425 403 381 361 345 339 319 316 308 
616 593 577 532 518 493 463 454 423 403 398 381 
495 487 470 445 427 406 387 370 352 335 323 308 
582 577 563 548 528 502 477 451 425 403 387 362 
635 638 585 566 545 515 473 447 416 463 385 438 
668 633 597 560 526 495 469 449 428 409 390 385 
633 635 620 595 557 515 482 447 415 391 365 349 
644 605 565 529 500 477 452 436 419 407 396 384 
583 555 526 493 463 433 412 391 377 367 354 348 
522 505 504 465 403 364 362 364 339 315 313 286 
597 593 584 567 548 523 502 482 466 454 443 436 
741 730 708 679 643 604 564 526 493 464 440 422 
621 608 581 549 510 474 441 418 395 382 367 359 
739 715 687 652 614 576 534 497 464 432 405 385 
403 376 351 328 308 291 277 259 243 238 225 221 
607 588 564 541 517 483 455 424 395 374 354 331 
463 462 428 384 393 375 356 344 321 302 286 279 
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115 120 125 130 135 140 145 150 155 160 165 170 175 
237 227 223 217 211 207 204 202 195 194 192 187 187 
294 289 277 266 264 251 246 240 233 229 223 218 216 
287 288 290 289 269 279 262 258 247 249 248 244 243 
373 364 356 351 343 335 333 326 307 304 292 287 284 
295 283 274 264 255 246 243 236 231 228 223 219 218 
348 328 311 305 292 279 272 266 264 256 259 245 242 
375 367 372 354 376 351 348 343 327 339 319 311 310 
372 367 362 353 353 341 343 341 337 337 331 330 323 
335 324 317 308 300 295 289 281 271 267 259 257 251 
374 369 360 353 348 343 337 334 328 327 320 323 318 
342 336 331 325 321 317 314 309 306 303 300 298 294 
287 274 276 275 269 260 259 247 241 233 229 218 216 
425 424 415 410 403 400 395 390 386 381 378 372 367 
406 395 380 373 362 355 348 338 333 325 319 311 307 
348 340 331 323 315 310 304 297 291 287 281 274 273 
365 347 334 318 307 299 289 282 275 267 261 256 251 
220 203 196 194 190 182 180 171 170 168 163 161 158 
319 302 289 279 270 258 252 245 237 233 225 222 221 
269 252 241 216 229 218 233 212 209 198 214 205 184 
 
  
 352 
180 185 190 195 200 205 210 215 220 225 230 235 240 
182 180 180 177 178 174 171 169 168 164 165 162 160 
215 209 208 210 202 203 205 198 195 197 197 193 189 
239 256 234 223 233 226 223 218 218 216 216 214 205 
291 276 278 273 266 262 259 249 252 256 252 243 241 
216 214 209 207 206 204 201 199 199 194 195 193 189 
247 243 240 226 238 227 226 226 219 225 220 213 224 
299 297 294 293 286 280 278 275 269 263 255 259 254 
321 319 315 310 308 304 300 295 295 292 286 285 283 
244 240 236 232 224 220 217 208 208 204 201 198 194 
317 311 306 303 300 296 294 287 291 290 286 285 280 
294 288 289 285 281 280 275 274 271 269 262 261 258 
206 202 199 210 192 194 201 197 198 189 183 180 180 
363 361 357 355 348 345 343 339 336 335 327 324 326 
299 294 288 282 278 274 267 262 260 254 249 246 240 
269 263 257 251 246 242 238 231 229 224 222 216 214 
247 241 235 234 232 231 226 226 225 223 223 220 218 
191 155 154 151 155 155 145 146 146 141 142 146 138 
211 211 209 206 210 202 209 199 201 199 201 198 196 
187 239 227 197 236 236 233 229 229 227 211 230 204 
 
  
 353 
245 250 255 260 265 270 275 280 285 290 295 300 
158 156 154 155 153 151 148 149 146 149 145 139 
192 186 185 186 186 180 178 181 179 179 175 171 
211 207 206 202 202 200 198 194 192 192 189 188 
232 236 226 236 216 220 217 213 214 227 204 205 
191 189 187 183 187 184 183 177 178 175 174 172 
210 211 210 206 207 219 206 208 214 200 214 210 
264 249 241 244 236 235 231 232 231 236 222 231 
276 268 268 266 262 268 264 258 257 250 245 244 
191 190 184 184 180 179 174 175 172 171 170 169 
281 279 277 273 270 269 266 264 262 258 257 256 
257 255 253 258 254 244 243 240 236 236 234 232 
180 179 169 177 175 176 175 177 175 169 173 169 
316 308 313 310 301 295 303 290 294 280 284 275 
237 234 231 226 224 223 223 219 217 217 212 214 
215 211 211 211 207 207 207 202 201 201 201 199 
217 217 216 217 222 213 212 210 209 210 208 208 
138 140 142 137 139 138 135 135 133 133 133 136 
197 196 190 190 189 186 188 184 184 183 181 181 
228 225 225 220 215 218 216 215 209 209 209 191 
 
  
 354 
300 305 310 315 320 325 330 335 340 345 350 355 360 
552 445 428 423 416 412 398 400 396 390 387 382 382 
762 697 681 669 653 648 640 635 633 631 623 627 624 
625 529 511 510 470 498 497 484 480 470 466 470 462 
811 701 689 667 665 653 646 628 623 626 624 604 620 
929 889 831 798 782 768 747 739 728 724 719 716 712 
895 836 746 713 694 668 664 659 655 656 646 640 636 
851 735 692 662 655 634 920 897 877 862 843 815 806 
794 685 670 659 645 641 637 627 624 621 618 618 606 
795 697 685 677 668 652 646 640 635 632 622 619 615 
744 673 666 655 648 637 629 626 615 611 601 602 595 
730 646 635 624 611 590 591 588 582 576 584 577 577 
690 627 599 594 572 558 556 551 544 537 542 534 535 
912 826 793 782 753 739 728 715 710 703 695 689 689 
1060 925 893 865 840 815 803 789 780 771 763 756 755 
1006 837 804 781 752 738 711 702 694 680 675 669 668 
1050 916 871 824 798 777 762 747 743 727 728 722 718 
649 562 540 521 501 490 479 474 467 460 454 454 453 
973 857 819 784 754 736 721 709 701 695 687 685 677 
923 766 731 688 597 728 583 571 548 620 542 613 604 
 
  
 355 
365 370 375 380 385 390 395 400 405 410 415 420 425 
373 373 367 375 374 371 363 366 362 338 359 354 355 
618 622 616 615 615 611 615 613 606 610 609 607 609 
460 461 446 454 459 459 465 440 449 455 458 457 441 
617 603 608 599 615 604 602 599 606 602 599 595 580 
712 709 703 706 707 707 706 704 704 702 703 702 700 
637 635 641 633 633 636 634 634 634 635 636 633 639 
773 755 610 632 635 810 621 607 610 611 613 627 658 
608 611 616 605 616 610 607 602 615 612 604 606 605 
610 609 605 605 596 593 595 592 591 591 587 586 584 
590 583 580 578 572 574 574 566 567 564 564 552 560 
573 574 564 563 559 569 553 555 556 552 550 551 552 
529 529 528 529 529 528 538 522 523 523 523 522 518 
683 689 675 674 668 663 661 663 663 663 656 659 656 
749 749 744 742 738 738 736 741 735 729 729 728 726 
661 663 657 653 651 645 646 643 642 642 635 638 635 
712 715 716 715 703 705 705 704 703 703 706 706 706 
448 447 449 451 448 446 444 442 439 443 443 435 440 
676 677 678 673 673 671 670 665 667 666 664 659 660 
595 592 583 581 566 561 564 566 568 555 552 566 553 
 
  
 356 
430 435 440 445 450 455 460 465 470 475 480 485 490 
351 359 346 347 347 335 333 331 329 342 326 321 329 
597 602 604 600 598 600 598 595 596 596 596 592 594 
451 448 450 450 441 436 434 444 434 442 407 436 431 
585 588 588 591 577 588 587 598 588 585 587 578 583 
698 694 697 695 694 693 692 692 691 690 690 687 688 
638 637 631 637 634 640 639 638 634 635 636 637 638 
655 656 624 626 634 638 639 620 655 622 634 631 603 
604 601 605 601 594 599 602 606 598 603 597 596 595 
584 576 577 574 577 578 574 571 571 570 571 569 567 
558 563 560 558 559 560 558 558 559 555 554 555 554 
550 549 550 549 546 547 542 541 538 540 538 544 542 
517 516 516 516 511 517 510 510 514 511 509 510 510 
655 657 658 648 646 651 650 649 643 655 640 637 637 
725 719 725 722 714 716 715 716 713 714 714 711 715 
637 639 634 632 629 629 630 633 631 632 630 633 647 
702 702 702 700 700 700 695 697 689 693 696 691 690 
443 436 435 443 438 434 439 434 432 432 434 436 430 
653 655 656 655 653 652 652 651 651 652 649 646 650 
556 549 556 549 539 547 536 541 530 527 526 520 524 
 
  
 357 
495 500 505 510 515 520 525 530 535 540 545 550 555 
319 322 322 319 319 318 323 314 316 313 310 307 310 
598 588 589 591 593 587 591 592 587 588 590 591 581 
439 437 440 434 431 438 437 427 421 416 425 429 430 
580 578 584 582 575 582 586 571 584 589 578 587 574 
688 694 692 690 690 691 691 688 688 688 686 687 687 
638 638 640 637 641 635 632 635 635 633 631 637 632 
632 636 638 631 607 639 613 616 610 607 611 599 597 
604 600 596 595 600 594 593 598 593 599 586 589 590 
569 567 564 566 568 569 563 567 564 564 564 558 564 
547 549 551 548 548 547 544 544 543 541 544 544 545 
539 540 541 530 531 531 531 532 535 535 532 532 531 
509 513 511 508 507 510 506 507 505 501 509 506 503 
639 635 634 633 630 629 627 631 626 626 623 625 631 
712 708 706 707 707 705 701 707 704 703 701 702 697 
632 631 632 643 640 635 631 632 627 628 628 631 631 
692 682 692 689 690 687 688 686 686 682 682 682 680 
436 430 430 431 431 433 431 432 431 432 432 432 434 
647 644 648 646 645 643 644 643 639 640 636 635 634 
519 517 522 508 504 512 456 495 505 492 500 482 480 
 
  
 358 
560 565 570 575 580 585 590 595 600 
310 309 307 305 305 307 305 305 305 
588 582 588 580 581 582 584 579 585 
425 315 422 426 433 427 424 432 431 
563 574 565 575 570 566 577 568 575 
684 683 682 680 681 680 679 680 682 
637 638 637 632 634 631 632 635 632 
608 769 618 612 615 607 626 615 606 
594 581 582 584 587 583 584 589 585 
563 559 561 558 557 559 555 558 554 
535 539 536 542 543 541 540 540 539 
530 520 530 522 525 521 525 525 521 
508 503 505 500 504 502 503 504 498 
629 627 632 630 631 632 642 635 630 
699 696 694 692 696 696 696 690 689 
634 631 634 628 635 622 630 629 626 
683 679 680 681 680 680 679 677 676 
429 434 432 427 429 422 427 436 433 
639 638 638 640 640 635 638 639 636 
478 495 498 490 477 491 472 475 470 
 
  
 359 
 
Geno 
Treat 
ment 0 5 10 15 20 25 30 35 40 45 50 
Min Control 
513 404 504 593 641 670 685 685 685 685 681 
560 490 626 693 704 691 667 632 601 561 531 
313 222 240 264 266 298 305 336 336 338 357 
224 177 195 217 232 255 286 297 308 315 321 
494 442 462 493 503 493 475 442 413 373 352 
443 480 479 449 410 373 342 318 299 282 268 
444 323 356 423 515 576 610 629 644 657 662 
458 387 453 571 617 625 623 604 582 555 527 
376 306 344 410 476 505 515 514 510 499 480 
251 225 204 213 203 195 192 154 161 148 150 
Min Wheel 
690 673 658 637 620 587 559 515 475 438 407 
322 273 326 410 473 480 507 512 515 517 504 
394 331 365 455 515 525 551 554 545 531 531 
443 339 401 493 546 563 582 586 580 568 559 
400 307 330 346 362 385 419 448 473 494 503 
382 282 316 386 418 449 461 460 475 467 464 
374 272 298 366 428 466 486 497 504 507 505 
492 346 437 530 576 601 614 619 616 605 586 
329 259 282 343 399 428 443 462 481 495 501 
402 319 346 403 465 472 472 466 461 447 432 
 
  
 360 
55 60 65 70 75 80 85 90 95 100 105 110 115 
665 650 629 604 575 545 516 488 471 446 432 422 409 
503 482 460 443 424 408 395 383 372 361 352 341 334 
354 341 340 343 326 315 320 293 288 270 275 260 258 
320 314 312 306 295 288 275 264 253 244 233 226 217 
332 320 304 298 281 268 266 256 248 241 242 238 231 
256 240 228 218 208 204 203 199 194 188 185 182 178 
662 647 627 597 561 523 492 460 432 403 388 368 351 
494 473 454 432 417 400 384 375 366 352 344 338 336 
468 450 430 414 395 380 362 353 339 329 321 312 304 
141 126 130 123 117 106 106 93 82 80 73 63 58 
380 359 342 329 313 300 284 270 261 250 240 234 224 
471 451 431 404 398 381 360 360 345 345 337 328 341 
499 460 440 422 414 385 360 363 351 341 338 336 331 
529 546 471 448 431 406 385 379 369 361 356 352 347 
496 487 470 447 426 404 386 367 352 336 326 311 298 
466 452 444 419 415 385 354 354 326 307 297 274 275 
494 484 461 451 443 423 413 401 391 377 367 357 351 
560 631 502 474 447 426 410 395 387 381 373 368 364 
502 498 488 475 460 442 421 400 384 367 349 333 316 
413 398 383 372 362 355 353 346 344 338 339 336 332 
 
  
 361 
120 125 130 135 140 145 150 155 160 165 170 175 180 
400 394 389 386 382 376 375 372 369 365 362 356 355 
328 320 316 312 307 303 301 297 293 292 289 285 284 
235 234 237 224 223 224 223 215 211 202 210 209 194 
210 202 188 186 181 171 169 162 159 154 150 148 147 
227 224 220 210 208 218 215 206 212 213 205 205 203 
174 172 169 163 156 151 154 156 157 157 156 147 142 
340 328 316 307 298 290 282 278 269 267 261 258 252 
329 325 318 317 313 315 310 305 309 303 307 306 300 
298 290 284 280 278 275 270 268 265 262 259 256 253 
53 54 46 46 40 39 38 48 38 42 42 40 35 
217 208 201 194 188 180 175 167 160 153 146 143 138 
327 318 318 311 306 306 300 301 293 292 287 284 281 
326 324 318 319 314 314 309 309 306 300 304 298 299 
343 339 333 333 329 326 322 320 317 313 313 308 306 
285 275 265 254 259 252 248 244 238 236 229 227 226 
265 260 270 244 242 245 225 220 219 219 209 227 206 
342 335 329 328 317 314 311 308 303 300 298 295 293 
359 355 348 347 343 339 335 331 327 326 322 318 314 
305 294 291 278 269 264 259 261 250 250 241 241 238 
332 328 326 323 320 318 315 314 310 308 304 302 300 
 
  
 362 
185 190 195 200 205 210 215 220 225 230 235 240 245 
348 345 339 333 329 324 321 315 310 307 302 297 294 
280 279 277 276 274 273 271 267 266 267 264 263 259 
192 189 182 191 182 181 177 175 176 172 173 187 171 
146 142 139 136 134 131 130 128 126 125 119 120 118 
202 204 198 200 195 197 195 189 190 187 187 177 184 
147 148 150 151 150 150 144 141 144 145 139 140 142 
248 244 237 235 230 226 225 221 220 216 213 210 206 
303 296 297 293 292 289 289 300 285 285 282 280 279 
251 247 244 241 239 237 234 233 229 227 219 221 219 
38 38 37 29 32 31 27 28 27 26 26 28 19 
131 130 126 123 123 120 118 116 113 112 109 108 106 
277 282 272 269 265 275 272 277 263 252 250 249 248 
301 297 299 297 291 293 289 288 291 284 286 284 282 
306 302 302 300 295 295 291 289 288 284 283 280 277 
222 220 216 216 210 213 205 204 201 204 199 200 199 
197 199 200 195 191 189 183 185 185 184 175 177 175 
290 289 279 286 279 274 273 270 266 264 266 262 256 
311 307 306 304 300 297 292 289 285 283 279 276 273 
236 231 227 222 220 215 210 204 200 196 198 192 189 
297 294 290 288 285 283 279 276 274 273 272 267 263 
 
  
 363 
250 255 260 265 270 275 280 285 290 295 300 
291 286 282 280 276 274 271 268 266 264 261 
261 260 261 257 256 253 252 253 252 249 247 
169 168 167 166 162 162 177 161 157 156 154 
119 115 116 113 113 112 110 108 107 106 106 
181 193 187 185 186 179 177 178 176 172 175 
135 132 134 133 131 134 138 139 138 140 139 
204 203 201 197 195 191 188 186 185 182 181 
278 279 276 276 273 268 271 264 263 267 269 
217 216 212 213 210 207 204 202 201 201 199 
21 24 19 24 20 20 18 18 16 16 15 
106 103 102 102 101 101 101 102 102 102 102 
245 241 243 239 247 235 231 240 231 231 228 
278 266 267 276 272 272 270 270 266 269 265 
274 265 264 268 264 263 260 258 255 256 252 
198 197 194 192 194 192 191 189 186 185 187 
181 177 175 172 169 164 171 165 166 166 155 
256 252 247 246 250 245 242 240 238 236 238 
269 265 262 259 256 253 251 247 244 243 239 
184 182 180 183 180 177 173 166 168 164 164 
261 259 256 255 251 248 245 245 242 239 237 
 
  
 364 
300 305 310 315 320 325 330 335 340 345 350 355 360 
861 743 688 644 611 593 570 563 550 542 539 532 527 
576 494 489 476 470 464 457 451 443 439 432 431 428 
703 636 636 594 579 566 561 550 538 530 525 536 527 
576 498 454 436 431 405 393 396 381 374 373 368 365 
415 336 324 329 317 311 311 263 265 262 260 270 271 
405 347 334 311 295 302 302 301 301 302 300 299 286 
940 754 728 693 664 641 621 601 583 571 565 550 544 
597 501 497 489 482 479 474 470 466 468 457 453 454 
684 581 570 550 536 524 513 509 502 495 494 484 481 
16 16 16 16 16 15 15 15 15 14 14 14 14 
147 108 106 105 105 102 102 103 109 109 113 115 114 
644 558 549 520 527 510 496 489 497 483 470 470 472 
574 518 511 501 502 493 501 479 492 488 449 441 456 
589 520 513 501 496 489 489 479 481 478 456 452 459 
968 865 808 778 752 733 723 708 703 698 694 695 691 
621 551 523 512 491 483 462 474 448 440 463 451 424 
758 681 663 637 621 602 591 584 571 563 564 555 564 
604 522 515 501 491 486 478 478 469 468 463 463 463 
793 700 663 630 593 569 546 533 525 512 507 503 502 
638 601 583 583 571 567 568 567 558 556 552 547 551 
 
  
 365 
365 370 375 380 385 390 395 400 405 410 415 420 425 
523 521 527 525 515 523 532 518 518 518 514 513 517 
424 420 417 413 414 409 405 407 403 402 400 401 396 
530 520 520 524 524 517 518 544 516 509 512 499 511 
369 351 343 357 335 344 342 355 348 341 326 348 345 
261 258 261 260 248 252 251 264 252 250 242 261 243 
277 295 298 282 277 287 295 292 294 277 295 295 292 
540 538 540 534 536 532 527 522 524 526 522 520 516 
451 443 444 438 438 438 435 433 432 431 431 428 429 
483 472 473 468 472 469 465 467 464 465 461 461 460 
13 13 13 13 13 12 12 12 12 11 11 11 11 
120 121 120 123 127 126 127 121 125 128 130 132 134 
460 464 467 458 455 454 458 455 458 456 466 446 456 
444 458 461 468 465 442 454 452 446 442 450 451 439 
452 458 457 461 458 445 450 448 445 441 444 445 439 
691 693 690 690 685 687 684 685 687 685 682 686 682 
440 426 434 438 430 413 424 426 420 423 416 428 425 
550 547 549 544 542 543 547 548 547 545 535 554 537 
460 457 454 453 450 448 446 444 444 439 439 439 438 
498 501 508 497 497 496 494 493 492 497 497 494 490 
545 541 539 634 543 541 542 537 532 529 534 533 531 
 
  
 366 
430 435 440 445 450 455 460 465 470 475 480 485 490 
514 512 511 510 515 511 507 506 506 511 508 509 511 
398 395 396 395 397 395 396 396 394 395 392 395 393 
501 493 505 474 505 501 486 508 468 492 496 473 482 
346 323 322 337 317 334 344 344 325 340 341 314 322 
258 250 241 263 250 263 255 244 251 247 256 247 246 
272 267 283 288 288 286 287 290 278 275 271 283 283 
517 521 516 518 513 516 513 510 510 510 510 502 512 
431 427 427 427 426 426 424 426 423 420 420 420 419 
460 462 459 461 455 460 462 456 458 460 457 454 458 
11 10 10 10 10 9 9 9 9 9 8 8 8 
134 135 138 138 138 137 135 137 140 137 138 137 138 
460 460 460 467 455 458 459 456 453 449 457 458 457 
454 453 448 440 413 452 437 436 443 437 442 421 433 
446 445 442 437 423 442 434 434 436 433 435 425 431 
679 684 680 678 682 676 671 675 680 678 673 672 671 
425 419 423 416 422 422 412 409 406 408 414 408 402 
538 536 534 535 530 528 525 525 530 529 534 533 534 
439 437 437 434 433 433 431 433 429 429 428 429 429 
492 492 488 488 488 488 489 495 489 483 484 480 482 
543 529 534 538 537 538 535 537 537 533 533 536 529 
 
  
 367 
495 500 505 510 515 520 525 530 535 540 545 550 555 
512 510 515 502 502 502 501 513 502 502 505 500 500 
390 393 392 389 390 388 387 388 388 388 385 387 387 
496 509 485 508 491 497 495 499 504 499 471 481 479 
334 340 321 334 336 326 329 329 342 330 334 336 335 
242 235 235 237 229 242 235 237 233 241 236 239 231 
284 286 284 273 267 274 275 279 279 278 261 272 276 
504 502 503 499 501 500 504 499 494 495 494 494 492 
416 419 414 416 416 415 413 415 414 415 414 414 413 
444 451 453 453 453 457 454 453 452 451 454 453 450 
8 7 7 7 7 7 6 6 6 6 5 5 5 
135 137 136 134 135 136 136 135 135 138 137 139 141 
443 449 447 448 447 456 447 453 461 456 457 454 447 
424 439 425 427 431 408 416 434 427 426 418 407 406 
425 433 425 426 428 415 420 428 425 424 420 414 413 
673 675 668 670 667 665 667 665 668 670 663 669 664 
418 416 408 406 409 398 403 406 415 400 405 393 395 
529 530 523 525 523 521 521 530 522 520 522 520 518 
427 427 426 425 424 423 424 422 422 422 423 420 420 
478 481 480 478 480 477 478 478 477 480 477 479 483 
530 511 532 531 523 526 518 510 514 514 518 509 518 
 
  
 368 
560 565 570 575 580 585 590 595 600 
496 499 498 495 498 497 495 500 495 
388 384 387 385 386 387 382 387 383 
486 473 489 472 492 476 468 494 486 
329 331 330 332 328 326 322 329 326 
233 230 226 230 229 241 228 219 233 
257 263 268 270 252 242 241 260 264 
489 490 492 487 490 491 486 486 485 
411 408 413 395 396 402 406 410 406 
451 448 450 434 450 446 432 445 444 
5 4 4 4 4 4 3 3 3 
139 141 140 144 142 144 144 144 140 
445 447 457 442 451 457 452 455 458 
412 399 406 397 399 396 395 398 395 
415 408 412 406 408 407 404 407 405 
664 668 667 664 665 664 654 660 655 
410 403 393 390 402 402 398 393 404 
515 516 510 514 517 516 512 511 514 
419 417 417 416 417 417 412 415 414 
478 478 474 477 475 483 475 477 476 
515 512 508 513 512 510 510 511 516 
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Table C.51 The effect of free wheel access on skeletal muscle fatigability in the male 
MIN 
Geno Treatment 
Max Force 
Following Submax 
Fatigue 
Max Force 
Following Max 
Fatigue 
Max Force 
Following 5 
Minute Recovery 
B6 Control 
552.49 305.24 836.23 
762.10 585.24 1147.55 
624.54 430.60 868.33 
810.52 574.72 1273.52 
929.07 682.00 1259.63 
895.44 631.79 1167.07 
919.82 606.10 1393.51 
794.42 585.11 1411.95 
795.39 553.95 1152.90 
743.77 539.07 1178.19 
B6 Wheel 
730.15 520.84 1115.08 
689.67 498.47 1121.65 
911.76 630.17 1355.84 
1059.93 689.32 1572.38 
1006.09 626.08 1409.83 
1049.59 676.24 1470.08 
649.25 432.59 1134.33 
973.17 636.39 1333.95 
923.43 469.77 1119.74 
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Geno Treatment 
Max Force 
Following 
Submax Fatigue 
Max Force 
Following 
Max Fatigue 
Max Force 
Following 5 Minute 
Recovery 
Min Control 
861.16 495.33 1153.65 
576.28 382.86 923.54 
703.31 486.47 1011.98 
576.14 325.64 721.79 
415.12 233.32 643.82 
404.65 264.37 559.15 
939.92 484.73 1389.07 
596.73 406.21 1058.49 
684.21 444.31 1071.63 
16.40 2.90 16.67 
Min Wheel 
147.08 140.42 582.52 
643.73 458.17 1050.29 
573.75 395.02 871.31 
588.66 404.63 954.02 
967.72 654.52 1249.10 
620.79 403.62 871.03 
757.87 513.70 1006.68 
603.57 414.25 1036.73 
792.78 476.33 990.90 
638.20 515.69 1158.58 
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Table C.52 The effect of wheel access on skeletal muscle mitochondrial content in 
isolated skeletal muscle mitochondria in the male MIN. 
     Mitochondrial Complex 
Treat 
ment 
Geno 
State 
3 
State 
4 
RCR I II III IV V 
Control B6 
7.14 2.00 3.57 0.86 0.80 0.87 0.74 1.03 
10.13 1.81 5.59 0.93 0.67 0.84 0.70 0.79 
9.12 2.26 4.04 1.41 1.94 1.22 1.49 1.15 
9.29 2.06 4.51 1.27 1.43 1.14 1.05 1.05 
10.57 2.03 5.22 0.83 0.63 0.98 1.20 0.97 
6.75 1.16 5.82 0.69 0.54 0.95 0.83 1.01 
Wheel B6 
8.22 1.52 5.41 1.21 2.09 1.49 1.27 1.20 
9.48 2.09 4.54 1.26 1.85 1.45 1.31 1.26 
8.23 1.62 5.07 1.39 1.94 1.37 1.20 1.20 
10.16 1.95 5.22 1.32 2.12 1.38 1.24 1.21 
9.68 2.01 4.82 1.37 2.39 1.53 1.34 1.34 
7.12 1.78 4.00 1.37 1.68 1.31 1.09 1.29 
Control Min 
9.00 1.47 6.14 0.95 0.55 0.81 0.69 1.02 
7.54 1.16 6.52 0.57 0.30 0.64 0.51 0.92 
7.71 1.75 4.40 0.89 0.66 0.86 0.60 1.05 
8.54 1.32 6.49 1.33 0.95 1.05 0.83 1.16 
5.38 2.22 2.43 1.17 0.54 0.76 0.54 1.05 
9.47 2.18 4.35 1.32 0.80 0.92 0.68 1.21 
Wheel Min 
8.25 2.23 3.70 1.33 0.74 0.94 0.62 1.25 
9.84 1.91 5.15 1.41 1.01 1.06 0.66 1.18 
8.52 1.29 6.61 1.39 1.25 0.98 0.68 1.10 
10.97 2.79 3.93 1.32 1.19 0.96 0.63 1.10 
7.10 1.98 3.59 1.37 1.56 1.02 0.70 1.15 
10.47 2.02 5.18 1.27 1.37 0.94 0.71 1.22 
 
